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Abstract 
Blood brain barrier dysfunction and breakdown is increasingly implicated in 
neurodegenerative disease (NDD) pathogenesis. Recently, the blood borne protein 
fibrinogen and the cleaved form fibrin were shown to be involved in neuroinflammatory 
pathways in animal models of NDDs, with microglia, the immune cells of the central 
nervous system playing a central role. Studies have identified binding sites on microglia 
for fibrinogen and induction of an activated phenotype has been reported. Studies 
performed here using primary microglial and cerebellar granule cell (CGC) cultures 
aimed to elucidate the signalling pathways induced in microglia by fibrinogen and fibrin, 
and specifically how these signals affected neuronal integrity. Fibrin induced microglial 
death after prolonged exposure with both fibrinogen and fibrin capable of inducing 
significant release of the pro-inflammatory cytokines TNFα and IL-6. However, this was 
dependent on culture serum conditions, which also affected iNOS expression after 
treatment with fibrinogen. Non-apoptotic induction of caspase-3/7 expression in 
microglia was also proposed after treatment with fibrinogen. Characterisation of the 
CGCs identified the presence of a population of microglia and development of a 
microglial depletion technique suggested the observed population was involved in 
fibrinogen- and fibrin-mediated neuronal death. Further manipulation using 
pharmacology, microglial depletion and conditioned medium suggested that microglial 
TNFα release and caspase activation were specifically involved in fibrinogen- and 
fibrin-mediated neuronal death. Endoplasmic reticulum stress and calcium 
dyshomeostasis in the form of calpain activation were coupled to the microglial 
activation pathway as well as being associated with neuronal death after fibrinogen 
exposure. Neuroprotection from fibrinogen and fibrin treatment was found by co-
activating specific metabotropic glutamate receptors on either microglia or neurons. 
Finally, translation of specific findings to a human phagocyte culture model provides 
strong support for the induction of the same pathways in humans.  
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Abbreviations 
° C  - Degrees Celsius 
-veCTR - Negative control 
A260 - Absorbance at 260 nm 
A280 - Absorbance at 280 nm 
Aβ - Amyloid-β 
AD - Alzheimer’s Disease 
AFU ‐ Arbitrary fluorescence units 
ALS - Amyotrophic lateral sclerosis 
AMPA - (2-amino-3-(5-methyl-3-oxo-1,2- 
oxazol-4-yl)propanoic acid) 
AMT‐HCl - 2-Amino-5,6-dihydro-6-methyl-
4H-1,3-thiazine hydrochloride 
ANOVA - Analysis of variance 
APO - Apocynin 
APP - Amyloid precursor protein 
APS ‐ Ammonium persulphate 
AraC ‐ Cytosine arabinosuranoside 
ATF6 - Activating transcription factor 6 
ATP - Adenosine triphosphate 
BAPTA-AM - 1,2-Bis(2-
aminophenoxy)ethane-N,N,N',N'-tetraacetic 
acid tetrakis(acetoxymethyl ester) 
BBB ‐ Blood‐brain barrier 
BCL-2 - B-cell lymphoma 2 
BSA ‐ bovine serum albumin 
Ca2+ - Calcium Ion 
CAA - Cerebral amyloid angiopathy 
Cal - Calpastatin 
CD11b - MAC-1 Integrin receptor 
cDNA - transcribed DNA 
CDPPB - 3-Cyano-N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamide 
CgA - Chromogranin A 
CGC ‐ Cerebellar granule cell 
CNS ‐ Central nervous system 
CO2 - Carbon dioxide 
CSF - Cerebrospinal fluid 
CTR ‐ Control 
Cy3 - Cyanine-3 
DAPI ‐ 4',6‐diamidino‐2‐phenylindole 
DCGIV ‐ (2S,2'R,3'R)-2-(2',3'-
dicarboxycyclopropyl) glycine 
ddH2O ‐ Endotoxin free pure distilled water 
DHE - Dihydroethidium 
DHPG ‐ (S)-3,5-dihydroxyphenylglycine 
DIV ‐ Days in vitro 
DMEM ‐ Dulbecco’s modified eagle medium 
DMSO ‐ Dimethyl sulfoxide 
DNA ‐ Deoxyribonucleic acid 
EAE ‐ Experimental autoimmune encephalitis 
EBSS ‐ Earle’s balanced salts solution 
EC50 - 50% of effective concentration 
ECL ‐ Enhanced chemiluminescence 
EDTA - Ethylene diamine tetraacetic acid 
EGF - Epidermal growth factor 
EGTA ‐ Ethylene glycol tetraacetic acid 
eIF2α - Eukaryotic translation initiation factor 2α 
ELISA ‐ Enzyme‐linked immunosorbent assay 
ER ‐ endoplasmic reticulum 
ERK1/2 - Extracellular signal-regulated 
kinase1/2 
FACs - Fluorescence activated cell sorting 
FALS - Familial amyotrophic lateral sclerosis 
FAM-DEVD-FMK - Carboxyfluorescein-labelled 
caspase-3/7 inhibitor 
FasL ‐ Fas ligand 
FBS ‐ Foetal bovine serum 
FG ‐ Fibrinogen 
FITC ‐ Fluorescein isothiocyanate 
FITC-ATAD-FMK - Carboxyfluorescein-labelled 
caspase-12 inhibitor 
fMRI - functional Magnetic resonance imaging 
FN ‐ Fibrin 
Fu - Fucoidan 
g ‐ acceleration due to gravity 
g ‐ gram MAPK ‐ mitogen‐activated protein kinase 
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GABA - gamma amino butyric acid  
GAPDH -  Glyceraldehyde 3-phosphate 
dehydrogenase 
GFAP ‐ glial fibrillary acidic protein 
GM-CSF - Granulocyte-Macrophage Colony 
Stimulating Factor 
GPCR - G-protein coupled receptor 
h ‐ hour 
HEPES ‐ 4‐(2‐hydroxyethyl)‐1‐ 
piperazineethanesulfonic acid 
Hi - Hirudin 
hMΦ - human Monocyte-derived 
macrophages 
Hoechst-33342 - 2´-(4-Ethoxyphenyl)-5-(4-
methyl-1-piperazinyl)-2,5´-bi-1H-
benzimidazole 
HRP ‐ Horse radish peroxidise 
I‐B4 ‐ Bandeiraea simplicifolia isolectin B4 
ICC - Immunocytochemistry 
IFNγ ‐ Interferon‐γ 
IgG - Immunoglobulin G 
IL ‐ interleukin 
iNOS ‐ inducible nitric oxide synthase 
Ion - Ionomycin 
IP3 - Inositol trisphosphate 
IRE1α - Inositol-requiring 1 homologue 
JNK - c-Jun N-terminal kinase 
K+ - Potassium ions 
KCl - Potassium Chloride 
kDa ‐ kiloDalton 
L ‐ litre 
L-AP4 ‐ L-(+)-2-amino-4-phosphonobutyric 
acid 
LDH - Lactate dehydrogenase 
LME - L-Leucine methyl ester 
LOAD - Late onset Alzheimer’s disease 
LPS ‐ Lipopolysaccharide 
M ‐ molar 
PAMP ‐ pathogen‐associated molecular 
pattern 
MEM ‐ minimum essential medium  
MG ‐ microglia 
mg ‐ milligrams 
MGCM ‐ microglial‐conditioned medium 
mGluR ‐ metabotropic glutamate receptor 
MHC - Major histocompatibility complex 
min ‐ minute 
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 mRNA ‐ messenger ribonucleic acid  
MS ‐ multiple sclerosis 
MTEP - 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine 
mV - milliVolt 
MW ‐ molecular weight 
µg ‐ microgram 
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Na+ - Sodium Ions 
NAAG ‐ N‐acetylaspartylglutamate 
NADPH ‐ nicotinamide adenine dinucleotide 
phosphate 
NDD - Neurodegenerative disease 
NFκB ‐ nuclear factor kappa-lightchain-enhancer 
of activated B cells 
ng ‐ nanogram 
NGS ‐ normal goat serum 
nM ‐ nanomolar 
NMDA - N-Methyl-D-aspartic acid 
nNOS ‐ neuronal nitric oxide synthase 
NO ‐ nitric oxide 
NRbS - Normal Rabbit serum 
ns ‐ not statistically significant 
O2•־  - Superoxide 
ONOO־ - Peroxynitrite 
OPC ‐ oligodendrocyte precursor cell 
p ‐ probability value 
PAGE ‐ polyacrylamide gel electrophoresis 
TGFβ - Transforming growth factor β 
Th ‐ Thapsigargin 
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PBMCs - Peripheral blood mononuclear cells 
PBS ‐ Phosphate buffered saline 
PD ‐ Parkinson’s Disease 
PDL ‐ Poly‐D‐lysine 
PERK - Protein kinase R-like endoplasmic 
reticulum kinase 
pg ‐ picogram 
pH ‐ Hydrogen ion concentration 
PI ‐ Propidium iodide 
PI3K - Phosphoinositide 3-kinase 
PKC - Protein kinase C 
PMA - Phorbol 12-myristate 13-acetate 
PMSF - Phenylmethylsulfonyl fluoride 
PMX ‐ polymyxin B 
PNS - Peripheral nervous system 
PRR - Pattern recognition receptors 
PS1 - Presenilin-1 
ROS ‐ Reactive oxygen species 
rpm ‐ Revolutions per minute 
RT ‐ Room temperature 
RT-PCR ‐ Reverse transcription-Polymerase 
chain reaction 
Sal - Salubrinal 
SBTI - Soy bean trypsin inhibitor 
SC - serum-containing 
SDS-PAGE - Sodium dodecyl sulphate-
Polyacrylamide gel electrophoresis 
SEM ‐ standard error of the mean 
SF - serum-free 
SOD1 ‐ Superoxide dismutase 1 
siRNA - Short interfering ribonucleic acid 
SR-A - Scavenger receptor-A 
SR-B1 -  Scavenger receptor-B1 
STS - Staurosporine  
TA - Annealing temperature 
TEMED ‐ N, N, N’, N’‐
tetramethylethylenediamine 
Thal ‐ Thalidomide 
TLR ‐ Toll‐like receptor 
TM - Melting temperature 
TNFα ‐ Tumour necrosis factor α 
TNFR ‐ Tumour necrosis factor receptor 
tPA ‐ Tissue-type plasminogen activator 
TRITC ‐ Tetramethyl rhodamine isothiocyanate 
TTBS ‐ Tween‐20 Tris-buffered saline 
Tu ‐ Tunicamycin 
uPA - Urokinase-type plasminogen activator  
UPR - Unfolded protein response 
Wort - Wortmannin 
w/v ‐ weight/volume 
z-ATAD-FMK - carbobenzoxy -Ala-Thr-Ala-
Asp(OME)-fluoromethylketone 
z-VAD-FMK - carbobenzoxy-Val-Ala-Asp(OME)-
fluoromethylketone 
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1. Introduction 
1.1. Cells of the Central Nervous System 
It is estimated that the human mammalian brain contains 85 billion neurons supported, 
maintained and protected by a further 85 billion non-neuronal cells including glia. It is 
becoming increasingly evident that elucidation of the neuron-glial connections and 
interactions will not only play a key role in our future understanding of the human 
nervous system but also our understanding of neurodegenerative disease progression.  
1.1.1. Neurons 
Neurons are specialised cells in the nervous system responsible for the sending and 
receiving of chemically mediated electrical signals. The nature of the signals and 
whether they are excitatory or inhibitory depends on the ratio of neurotransmitter 
released (Seal & Edwards 2006).  
The morphological diversity of neuronal morphology at first glance would suggest a 
particularly heterogeneous population however, these structural characteristics have a 
great dependence on the relative cellular location, and basic neuronal anatomy and 
physiology tends to be relatively uniform. A typical neuron consists of the cell body, or 
soma, that contains the nucleus, branched cellular extensions known as dendrites that 
receive the vast majority of the cells excitatory or inhibitory input, and the axon, an 
extension from the axon hillock responsible for neuronal signal output (Figure 1.1.1). 
Signalling between neurons depends primarily on ion exchange in the axon which is 
mediated through voltage-gated ion channels and ion pumps including the 
Na+/K+‐ATPase transversing the plasma membrane. Broadly, neurons have a negative 
resting membrane potential of -70 mV due to the specific permeability of neuronal 
membranes to K+, leading to extracellular leakage. Transmission of a neural signal 
occurs when the membrane potential reaches a voltage-dependent threshold upon 
which time an action potential is fired leading to a brief depolarisation of the cell, 
 normally to a value of approximately +40 mV, followed by repolarisation and a 
refractory period, all of which occurs
The action potential is chemically propagated to other neurons via specialised 
structures called synapses composed of the pre
terminal, the synaptic cleft and glial terminals. Upon neuronal depolarisation
known as neurotransmitters are released from the pre
synaptic cleft, ligating relevant neurotransmitter receptors on 
leading to propagation of
 
 Figure 1.1.1. Basic neuronal anatomy
Classic anatomy of a neuron including the main extracellular connections such as 
afferent nerves (purple) synapsing with the dendritic tree surrounding the cell body 
and the tripartite synapse showing the involvement of astrocytes during synaptic 
transmission induced through the firing of an efferent action potential, after supra
threshold stimulation, down the axon (black arrow and graph). 
 in under 1 ms (Purves 2008)
-synaptic terminal, th
-synaptic nerve terminal into the 
the post
 the excitatory or inhibitory signals. 
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1.1.1.1. The cerebellum and cerebellar granule neurons 
The cerebellum is generally considered as the motor element of the brain, maintaining 
equilibrium and coordinating muscle contractions, ensuring appropriate muscle 
contraction occurs at the appropriate time. More recent studies however, suggest the 
cerebellum additionally contributes to cognitive and sensory functions (Strick et al. 
2009; Timmann et al. 2010). The gross anatomy of the cerebellum consists of a cortex, 
of gray matter contained in transverse folds or folia and a central region of white matter 
(Figure 1.1.2), providing the distinctive and unmistakable anatomy. There are four 
pairs of intrinsic central nuclei (dentate, globose, emboliform and fastigial) embedded in 
the cerebellar white matter and three pairs of central peduncles (superior, middle and 
inferior) connecting the cerebellum with the midbrain, pons and medulla, respectively 
(Kiernan 2009). 
More than 90% of the cerebellum is composed of granule neurons, or CGCs, and they 
constitute the largest homogenous neuronal population in the mammalian brain 
(Contestabile 2002). Neurogenesis of granule cells is largely postnatal, which led to the 
idea that explanted cerebella could provide an uncomplicated source of primary 
neurons, in vitro, and since the development of the culture nearly 40 years ago (Gallo 
et al. 1982), hundreds of labs have utilised it for all nature of neuronal experimental 
models. Furthermore, CGCs are glutamatergic neurons, the most prevalent neuronal 
type in the mammalian brain and in culture they mature and express synaptic 
connections and a wide range of receptors including the NMDA receptor, the primary 
receptor implicated in excitotoxicity, a phenomena linked to acute and chronic 
neurodegenerative disease processes (Salińska et al. 2005; Lau & Tymianski 2010). 
Also, recent studies (Kaushal & Schlichter 2008) using embryonic cortical neurons 
have replicated previous studies in our laboratory performed on CGCs (Taylor et al. 
2005), supporting the physiological similarities of differing neuronal subtypes in culture. 
  
 `
Figure 1.1.2. Rat cerebellar anatomy
A multi-photon fluorescence image of rat cerebellum in which the Purkinje cells were 
labelled green (anti
quantum dots), glia were marked red (anti
selenide/zinc sulphide quantum dots) and cell nuclei marked blue (using Hoechst 
DNA stain). Permission to use the image was granted b
the National Centre for Microscopy and Imaging Research
University of California San Diego (UCSD).
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1.1.1.2. Circuitry of the cerebellum 
The cerebellum is organised into three distinct layers as shown in Figure 1.1.2 and 
1.1.3. There is a Purkinje cell layer consisting of a single row of Purkinje cell bodies 
which project their dendrites superficially into a synaptic zone known as the molecular 
layer. Finally there is the granule cell layer, the deepest layer of the cerebellum, 
consisting of densely packed interneurons with axons that extend into the molecular 
layer. Other cerebellar interneurons such as Basket cells and Golgi cells have their cell 
bodies in the molecular and granule layers (Kiernan 2009). With respect to afferent 
fibres into the cerebellum, climbing fibres originate in the inferior olivary complex of 
nuclei and synapse with proximal elements of the Purkinje cell dendritic trees in the 
molecular layer. Other afferent fibres, not originating from the inferior olivary nuclei are 
known as mossy fibres and synapse with neurons in the granule layer (Figure 1.1.3) 
(Kiernan 2009).         
  
Mossy fibre
Go
P
Gr
Ba
Climbing fibre
To a central nucleus 
of the cerebellum
-
-
+
-
+ +
+
-
++
Molecular layer
Purkinje cell layer
Granule cell layer
Figure 1.1.3. Cerebellar circuitry 
A longitudinal representation of the neurons of the cerebellar cortex, showing excitatory 
(+) and inhibitory (-) synapses. Purkinje cell (P), Granule cell (Gr), Golgi cell (Go), 
Basket cell (Ba). Adapted from Kiernan (2009). 
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1.1.2. Astrocytes 
Astrocytes, or astroglia, are the most numerous and diverse glial cell population in the 
CNS. The ‘true’ astrocytes have a unique ‘astro/stellate’ morphology due to the 
arrangement of intermediate filament proteins (Figure 1.1.4), including glial fibrillary 
acidic protein (GFAP; used as an astrocytic marker in immunofluorescence) and 
vimentin (Verkhratsky & Butt 2007). Astrocytes can be further sub-classified based on 
location. Proteoplasmic astrocytes are located in the grey matter and fibrillary or fibrous 
astrocytes located in the white matter, and it is therefore not surprising, based on their 
locations, that they associate with neuronal cell bodies and synapses or with axons, 
respectively.   
Radial glia, another population of astrocytes, are bipolar cells with an ovoid cell body 
and elongated processes. They are involved in the formation of the neurovascular unit 
and produce two main processes with one forming astrocytic end-feet (Section 1.2.1) 
on ventricular walls and the other at the pial surface (Verkhratsky & Butt 2007). These 
cells also form scaffold to assist neuronal migration during early embryonic stages of 
development and also contribute to the oligodendrocyte progenitor cell (OPC) 
population (Nishiyama et al. 2009). After CNS maturation, radial glia generally 
disappear from the majority of brain regions, transforming into stellate astrocytes. 
However, in certain brain regions some do remain, such as the Müller cells of the retina 
and Bergmann glia, the most abundant astrocyte of the cerebellum (Haydon 2001). 
Other smaller populations of specialised astrocytes also exist after maturation including 
velate astrocytes in cerebellum and tanycytes in periventricular organs and raphe part 
of spinal cord (Verkhratsky & Butt 2007). 
  
 Astrocytes tile the entire CNS in an essentially non
communicating with each other distally through gap
2010). These individual 
neuronal synapses formed between many different neurons
significant involvement of astrocytes in neuronal function. Astrocytic involvement in 
neuronal activity was supported by studies identifying the expression of potassium and 
sodium ion channels and that they exhibit evoked inward currents suggesting 
excitability yet, they do not fire or propagate action potentials 
does not however make them excitably redundant with the discovery that regulated 
changes in intracellular calcium represent astrocytic excitability 
1990; Charles et al. 1991)
astrocyte-astrocyte and astrocyte
oscillations resulting from intracellular calcium store release that propagate over large 
Figure 1.1.4. Astrocyte morphology
A standard fluorescence image of 
classical stellate astrocytic morphology using immunofluorescent tagging of the 
astrocyte-specific marker glial fibrillary acid protein 
Cy3; red) and cell nuclei 
-overlapping orderly manner 
-junctions 
region-specific astrocytes are in contact with thousands of 
, prompting the idea of 
(Lalo et al. 2006)
. These regulated changes are functionally significant in 
-neuronal communication and occur as intrinsic 
 
primary rat astrocyte cultures showing the 
(anti-GFAP
(DAPI; blue). Scale bar = 15 µm. 
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distances (Sofroniew & Vinters 2010). Furthermore, via expressed neurotransmitter 
receptors, changes in astrocytic intracellular calcium concentrations can be triggered 
by neurotransmitter release from neurons at the synapse inducing the release of 
neuroactive substances from the astrocytes, which in turn signal back to the neurons 
creating a feedback loop that either enhances or inhibits neuronal activity (Haydon 
2001; Barres 2008).  
The integral importance of astrocytes in the development and regulation of neuronal 
activity was first alluded to by Pfieger and Barres (1997). Retinal ganglion neurons can 
be highly purified and cultured in serum-free medium with a high survival rate in the 
total absence of glia. Pfieger and Barres used these cultures to identify the significance 
of astrocytes in relation to neuronal firing. The cultured neurons had dendrites and 
axons and were electrically excitable but little spontaneous synaptic activity was 
observed. However, if these neurons were co-cultured with astrocytes, or conditioned 
medium from astrocyte cultures was administered, the frequency and amplitude of 
spontaneous postsynaptic currents were significantly enhanced (Pfrieger & Barres 
1997). These data suggested that developing neurons in culture formed inefficient 
synapses requiring glial signals to become fully functional, and following on from these 
studies it is now widely accepted that astrocytes are intrinsically involved in modulating 
synaptic transmission (Perea & Araque 2010), to the extent that, anatomically, the 
synapse is now termed the tri-partite synapse, which includes the pre- and post-
synaptic clefts and an astrocytic element. 
Astrocytes maintain tight control of local ion and pH homeostasis, deliver glucose, 
provide metabolic substrates, and clear neuronal waste (Nedergaard et al. 2003). 
Through two-photon-imaging of calcium signals, studies also show that astrocytes 
regulate blood flow with respect to neuronal activity (Schummers et al. 2008), further 
identifying the fundamental involvement of these cells in normal brain function. 
However, this integral involvement in normal function suggests that in dysfunctional 
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conditions astrocytes would also be significantly affected. Reactive astrocytes termed 
astrogliosis is a common pathological hallmark of dysfunctional and diseased CNS 
tissue where the astrocytes demarcate the injury site from healthy tissue by forming a 
glial scar (Schachtrup et al. 2010), and it has been suggested that dysfunctions in 
astrogliosis or scar formation could contribute to, or be the primary cause of, CNS 
disease mechanisms (Sofroniew & Vinters 2010). 
1.1.3. Oligodendrocytes 
This population of glia have few processes, hence the prefix ‘oligo’, their main function 
being the myelination of axons between the nodes of Ranvier for electrical insulation 
and saltatory nerve conduction. The population was initially described by Del Rio 
Hortega in 1928 who classified them into four phenotypes dependent on morphology 
and location, descriptions of which are given below: 
Type I:  Have a small rounded cell body with four to six primary 
processes that branch and myelinate 10-30 thin (<2 µm 
diameter) axons. Each secondary process forms a single 
internodal myelin segment approximately 100-200 µm in length. 
Present in forebrain, cerebellum and spinal cord 
Type II: Morphologically similar to type I but are only present in the white 
matter, for example, the optic nerve.    
Type III: Have a much larger cell body than types I and II, with several 
thick primary processes with the ability to myelinate up to five 
thick axons (4 -15 µm diameter). These cells produce sheaths 
that range from 200 - 500 µm in internodal length. Present in 
medulla oblongata and spinal cord 
Type IV: Have no processes and form a single long myelin sheath up to 
1000 µm in internodal length around the largest diameter axons. 
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These are present almost exclusively around the nerve root 
entrances into the CNS 
The four morphological phenotypes are likely to originate from common 
oligodendrocyte progenitor cells (OPCs), which have been shown to derive in particular 
areas of the CNS including the ventral ventricular zone of the spinal cord, the ventral 
forebrain, and the ganglionic eminences (Bradl & Lassmann 2010). Differentiation of 
OPCs into oligodendrocytes is dependent on the Notch 1 receptor (Genoud et al. 
2002), γ-secretase and astrocytes (Watkins et al. 2008). Also, their ability to myelinate 
axons is regulated by neuronal activity (Gyllensten & Malmfors 1963) and is brief, 
occurring early during differentiation (Watkins et al. 2008). As previously mentioned, 
oligodendrocytes myelinate the axons to provide electrical insulation, however they 
also induce sodium channel clustering at the nodes of Ranvier, an important 
requirement for saltatory nerve conduction (Kaplan et al. 1997; Kaplan et al. 2001).  
Oligodendrocyte death and subsequent demyelination occurs in multiple sclerosis 
leading to some of the characteristic symptoms associated with the disease (Section 
1.3.2). The cells also express AMPA, kainite and NMDA receptors, exposing them to 
glutamate toxicity, a pathological mechanism associated with a number of 
neurodegenerative diseases, and also the purinergic P2X7 receptor that exposes them 
to potential damage from high extracellular concentrations of ATP (Bradl & Lassmann 
2010).      
1.1.4. NG2-positive cells or Polydendrocytes 
NG2-positive cells were the most recent major glial population to be discovered in the 
CNS and are defined as CNS parenchymal cells expressing the NG2 proteoglycan. 
They are classically known as oligodendrocyte progenitor cells (OPCs) however the 
name polydendrocyte has recently been proposed due to their multi-processed 
morphology, lineal relationship to oligodendrocytes and observations that they are in 
fact multi-potential progenitors (Nishiyama et al. 2009).  
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Reports from in vitro studies suggested these cells could differentiate into 
oligodendrocytes and astrocytes if serum was absent or present, respectively (Raff et 
al. 1983), and were thus initially proposed as bipotential progenitors. At first these 
studies were alluded to as in vitro artefacts however studies in vivo showed a purified 
OPC cell line (CG-4) could differentiate into oligodendrocytes and astrocytes when 
transplanted into a glial-depleted environment (Franklin et al. 1995). Although this 
supported the bipotentiality of these cells, a heterogeneous population consisting of 
distinct committed progenitor cells of oligodendrocyte and astrocyte lineage or cellular 
changes due to the artificial immortality of the cell line can’t be ruled out.  
Further observations suggested the polydendrocytes were multi-potential progenitors 
with the generation of neurons from OPCs excised from postnatal rat optic nerve and 
treated with bone morphogenetic protein 2 (BMP2) and platelet derived growth factor 
AA (PDGF AA). This led to the generation of multi-potent neural stem cell-like cells that 
were capable of generating neurons, astrocytes and oligodendrocytes (Kondo & Raff 
2000). 
Distinctive physiological properties for polydendrocytes have been observed using 
electrophysiology on hippocampal slice preparations identifying these cells as distinct 
from mature astrocytes (Nishiyama et al. 2009). These cells are also able to generate 
ionotropic glutamate and GABA receptor currents, again discovered using slice 
preparations (Berger et al. 1992). Further studies led to the concept of neuron-
polydendrocyte synapses, which in the hippocampus have been shown to undergo 
long term potentiation demonstrated by increasing excitatory post-synaptic current 
amplitudes (Ge et al. 2006). These neuron-glia synapses have also been identified in 
the molecular layer of the cerebellum, where the polydendrocytes were shown to 
respond to multiple climbing fibre inputs with coordination of the response with Purkinje 
cells (Lin et al. 2005). 
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The complete functional significance of these cells is still being intensely researched, 
with the synaptic involvement a very hot topic. The general suggestion at present is 
that these neuronal synaptic inputs are involved in the classical functions attributed to 
the OPCs, such as proliferation, differentiation into mature glia and migration to 
demyelinated regions (Nishiyama et al. 2009). 
1.1.5. Microglia 
Microglia as a single population was first introduced by Pio del Rio-Hortega in 1932 
after development of a silver carbonate staining technique provided the first high quality 
images of these cells (Rio-Hortega 1932). Limited breakthroughs in the physiology of 
microglia occurred until the development of the facial nerve lesion model (Blinzinger & 
Kreutzberg 1968), which enabled the study of microglial responses to injury in CNS 
tissue with an intact blood brain barrier.  
Microglia are the innate immune cells of the CNS, are of mononuclear phagocyte 
lineage and their underlying role is to monitor the environment and act to maintain 
homeostasis (Perry et al. 2007; Kettenmann et al. 2011). They are derived mainly from 
leptomeningeal mesenchymal cells, which enter the brain during development and 
transform into microglia (Bechmann et al. 2007). Elegant studies with rat bone marrow 
chimeras demonstrated that a subset of microglia, termed ‘perivascular’ microglia was 
derived from bone marrow (Hickey & Kimura 1988). It is assumed that in the healthy 
brain, microglia exist as a stable population however, after axonal degeneration and 
blood brain barrier disruption it has been shown that a subpopulation of monocytes can 
infiltrate the CNS and transform into microglia (Bechmann et al. 2005; Mildner et al. 
2007).  
The varying derivations of microglia could contribute to the observed heterogeneity of 
the population with studies suggesting regional differences in microglia in situ and in 
culture, demonstrated by selective expression of mRNAs or proteins (including TNFα, 
IL-6, integrins and iNOS) or differences in proliferative potential (Kettenmann et al. 
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2011). Furthermore, variations in neurotransmitter exposure and proximity to blood 
vessels could also be contributing to the heterogeneity.  
1.1.5.1. Phenotypes 
The resting phenotype of microglia is characterised by ramified morphology displaying 
a small cell body, long slender processes with secondary fine cellular branching 
(Figure 1.1.5). Little is known about the mechanism by which the infiltrating progenitors 
morphologically change to this state however, some experiments suggest purines 
including ATP and adenosine and certain unknown astrocytic factors induce the resting 
phenotype (Wollmer et al. 2001). 
Until recently this ‘resting’ phenotype was considered quiescent however in vivo 
imaging studies have shown the fine cellular processes are highly dynamic, suggesting 
constant surveillance is performed by the microglia (Nimmerjahn et al. 2005; Davalos 
et al. 2005). This observation coupled with the idea that the little known general daily 
functions of microglia in healthy subjects are likely to involve restrained activation due 
to sub-inflammatory threshold changes in brain homeostasis, there is now a general 
consensus that microglia have shifts in activation states from a surveillance mode to 
other states dependent on the intensity of the inflammatory insult (Kettenmann et al. 
2011).  
  
Classical ‘full’ activation seen during infection, trauma, ischemia and 
neurodegenerative disorders can be characterised by an increase in cell volume, an 
amoeboid-like morphology, and the increased expression of  cell
including CD14, maj
receptors, that are involved in a broad range of inflammatory responses from antigen
presentation to cell migration 
with chemokine gradients creates motile microglia that are able to migrate to immune
compromised and damaged areas 
homeostasis. This congregation of microglia to the injured area of the CNS is termed 
microgliosis and is seen during neuroinflammation 
chronic neurodegeneration 
Activated microglia are the phagocytes of the CNS and engulf tissue debris and dead 
cells in an attempt to return homeostasis, as well as being involved in the phenomenon 
Figure 1.1.5. Changes in microglial morphology
Standard immunofluorescence imag
microglia presenting with small cell bodies and slender processes identified as a 
‘resting’ morphology (arrow; 
morphology identified by large cell bodies with amoeboid characteristics (
Immunofluorescence was performed with an IB
microglia (green), anti
(marked with anti-Cy3; red) and 
or histocompatibility complex (MHC) molecules and chemokine 
(Block et al 2007). The amoeboid morphology coupled 
of the CNS and actively attempt to return 
(Carbonell et al. 2005)
(Ladeby et al. 2005). 
 
ing of primary rat microglial cultures with 
A) or presenting with the classic activated 
4-FITC conjugation to label 
-iNOS to label activated microglia after LPS 
cell nuclei (DAPI; blue). Scale bars = 10 µm.
35 
 
-surface molecules 
-
-
 and in 
B). 
treatment 
 
36 
 
of ‘synaptic stripping’ (Graeber et al. 1993; Schiefer et al. 1999), a mechanism by 
which the synapses of injured neurons are pruned from their cell bodies in an attempt 
to promote growth and survival, although a recent review argues against microglial 
involvement (Perry & O’Connor 2010). In the presence of immobilised fibrinogen and 
fibrin deposits in models of MS and AD, microglia are activated to a phagocytic 
phenotype (Adams et al. 2007a; Paul et al. 2007) and have also been shown to 
phagocytose myelin (Pinteaux-Jones et al. 2008) and β-amyloid (Aβ) deposits (Fiala et 
al. 2007). With a focus on AD, a specific cell surface receptor complex (CD36/α6β1 
integrin/CD47) has been identified that mediates phagocytosis of fibrous Aβ by 
microglia, in vitro, that differs from the complex used by the classical phagocytic 
receptors, i.e. the immunoglobulin or complement receptors (Koenigsknecht & 
Landreth 2004). Interestingly, recent studies have suggested that this observed 
microglial-mediated phagocytosis of fibrous Aβ can be inhibited if oligomeric Aβ is 
present suggesting a further enhancement of inflammation (Pan et al. 2011). 
1.1.5.2. Signalling – Receptors and released factors 
Microglia express a vast array of receptors and channels ranging from ion channels 
and receptors involved with inflammatory responses, to neuropeptide and classical 
neurotransmitter receptors. This section will focus on the receptors relevant to this 
thesis, which includes a subset of the receptors involved in inflammatory and 
phagocytic mechanisms and the metabotropic glutamate receptors (mGluRs). This will 
be followed by an overview of classical inflammatory responses after microglial 
activation. 
1.1.5.2.1. Pattern recognition receptors 
The evolution of microglia to express multiple, diverse membrane receptors that 
identify and bind pathogen-associated molecular patterns (PAMPS) known as pattern 
recognition receptors (PRR) allows them to be activated by a diverse array of stimuli. 
However, activation of these receptors can have unwanted effects. In the case of 
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microglial-mediated neurotoxicity, PRRs responsible for host defence and phagocytosis 
have often been observed mediating neuronal damage in the absence of a known 
pathogen, suggesting that non-pathogenic stimuli could be misinterpreted with 
neurotoxic consequences (Block et al 2007).  
Toll-like receptors (TLRs) are the most studied group of PRRs. Microglia regulate the 
expression of TLRs throughout development and in response to pathogens (McKimmie 
& Fazakerley 2005). TLRs initiate innate immune responses on interaction with 
infectious agents but have also been implicated in detrimental microglial activation and 
neurotoxicity through the induction and release of neurotoxic factors (Block et al 2007). 
The recognition of particular PAMPs by particular TLRs leads to transcriptional 
upregulation of distinct genes, dependent on the TLRs and cell types involved, with 
differing signalling cascades dependent on the adaptor molecules recruited. Generally 
speaking TLR signalling can be divided into usage of either the MyD88 or TRIF adaptor 
molecules (Takeuchi & Akira 2010).  
Microglia are reported to express TLRs 1-9 (Jack et al. 2005) and it is generally 
accepted that TLR4 is the primary lipopolysaccharide (LPS) receptor (Lien et al. 2000) 
reported to be a crucial contributor to the microglial response to LPS, mediating LPS-
induced neurodegeneration in vitro (Lehnardt et al. 2003). LPS is a major constituent 
on the outer membrane of Gram-negative bacteria. It acts as a potent endotoxin and 
elicits strong immune responses in mammals making it an excellent tool to induce 
microglial activation (Section 1.1.5.2.4). Upon ligand stimulation, TLR4 recruits the 
adapter protein MyD88 which subsequently forms a complex leading to the 
translocation of the transcription factor NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) to the nucleus driving cytokine production. 
Simultaneously, MAPK cascades are activated leading to activation of nuclear AP-1 
which is also critical for the induction of cytokine genes (Takeuchi & Akira 2010). TLR4 
has been shown to be upregulated during brain inflammation (Bsibsi et al. 2002) 
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however the receptor has also been implicated in beneficial repair processes including 
improved remyelination and cerebral tissue protection (Glezer et al. 2006). 
Recently, non-apoptotic, orderly activation of caspase-8 and -3/7 via a protein kinase C 
(PKC)-δ-dependent pathway has been shown to specifically regulate microglial 
activation after treatment with LPS and other inflammogens including lipoteichoic acid 
(LTA, TLR2 agonist) and PamC3sk4 (synthetic lipopeptide TLR1/2 agonist) (Burguillos 
et al. 2011). These data further elucidate TLR-associated activation pathways providing 
interesting evidence for intracellular pathway convergence in microglia after diverse 
extrinsic pathogen exposure.   
Interestingly, fibrinogen-(FG)-mediated secretion of macrophage inflammatory protein-
1α, (MIP-1α), MIP-1β, MIP-2, and monocyte chemoattractant protein-1 from a 
macrophage cell line as well as primary murine peritoneal macrophages, has been 
shown to be dependent on TLR4 signalling (Smiley et al. 2001). This suggests that 
LPS and FG could have a similar evolutionary conserved binding motif for TLR4, 
potentially explaining the involvement of FG in inflammatory responses (Adams et al. 
2007b). 
1.1.5.2.2. Integrin and Scavenger receptors 
The integrin family of molecules have roles in cell adhesion, tissue specific homing and 
cellular trafficking during development and infection. The four β2-integrin members of 
this family are best known for their roles in leukocyte trafficking during inflammation 
and contributing to leukocyte activation in immune responses and phagocytosis (Ley et 
al. 2007). The β2-integrins are heterodimeric receptors that share a common β-chain 
(CD18) and are known as CD11a/CD18 (αLβ2, LFA-1), CD11b/CD18 (αMβ2, Mac-1, 
CR3), CD11c/CD18 (αXβ2, p150,95, CR4) and CD11d (αDβ2). The α and β chains are 
composed of multiple protein domains that contribute to ligand binding and subsequent 
signalling. In the inactive state, these protein domains are masked by a ‘folded’ 
conformation inhibiting any interactions with ligands however upon activation by 
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cytokines or other inflammatory factors the intracellular domains are exposed after 
conformational changes to an open, active state, allowing ligand-receptor interactions 
(Abram & Lowell 2009; Hu et al. 2010). 
Activation tends to induce rapid multimerisation of the receptors followed by assembly 
of an intracellular signalling platform resulting in gene expression modulation via Akt, 
ERK and/or JNK signalling pathways. Cytoskeletal rearrangements also occur upon 
activation with dependence on Rap-GTPases (Abram & Lowell 2009). 
CD11b is one of the more characterised members of the β2-integrin sub-family and has 
been shown to participate in signalling cascades that result in the transmigration of 
leukocytes into lymphoid organs and to sites of infection and inflammation as well as 
involvement in complement-mediated phagocytosis (Hu et al. 2010). The β2-integrins 
have been identified on human brain microglia, and have been shown to be 
upregulated during AD (Akiyama & McGeer 1990). Interestingly, soluble fibrinogen has 
been shown to interact with CD11b in a competitive manner (Benimetskaya et al. 
1997). Furthermore, ‘immobilised’ fibrinogen has been shown to induce a phagocytic 
microglial phenotype that was dependent on CD11b binding, with competitive inhibitory 
binding significantly attenuating EAE disease progression (Adams et al. 2007a).  
The scavenger receptors are another group of microglial-associated receptors that 
mediate cell adhesion to, and endocytosis of, various native and pathologically 
modified substances (Husemann et al. 2002). The group can be pooled with other 
‘multi-ligand receptors’ such as the receptor for advanced glycation end products 
(RAGE) and the LDL-like receptor related protein (LRP), but the classical scavenger 
receptor members are scavenger receptor class A (SR-A, CD204), scavenger receptor 
class B type I (SR-BI) and CD36. Here, the emphasis will be on SR-A, the scavenger 
receptor that was investigated in this thesis. 
SR-A and SR-BI seem to be developmentally regulated with observable expression in 
neonatal microglia but little or no expression in the adult brain (Husemann & Silverstein 
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2001). However, during AD pathogenesis, a significant increase in microglial-
associated SR-A expression is observed (Christie et al. 1996; Honda et al. 1998) with 
in vitro studies suggesting microglial SR-A mediates adhesion and endocytosis of 
fibrillar Aβ by microglia (El Khoury et al. 1996). Interestingly, studies have shown that 
fibrillar Aβ activates signal transduction in microglia via two parallel pathways involving 
either p38 MAPK or ERK1/2 (McDonald et al. 1998). However, activation of scavenger 
receptors failed to induce these pathways, suggesting fibrillar Aβ interactions with SR-A 
induce an alternative pathway although performing simple competitive binding assays 
would have provided stronger evidence for this differential SR-A activation.  
Inflammation also seems to modulate scavenger receptor expression with studies 
showing an increase in SR-A mRNA and protein in microglia after treatment with LPS, 
IFNγ and IL-1α, but not with TGF-β1, in vitro (Grewal et al. 1997). Furthermore, SR-A 
ligands including fucoidan and polyinosinic acid have been shown to block 
chromogranin-A-(CgA)-mediated responses in MG including iNOS expression, 
mitochondrial depolarisation, glutamate release and apoptosis, as well as attenuating 
CgA-induced microglial-mediated neurotoxicity (Hooper et al. 2009a). 
Interestingly, the use of animal models of AD, identified that SR-A expression was 
localised to microglia associated with parenchymal and vascular deposits of Aβ 
(Bornemann et al. 2001), suggesting roles for the receptor in AD pathology. However, it 
was shown previously using SR-A-/- human APP mice that the receptor was not 
required for development of AD-like pathology in these mice (Huang et al. 1999), 
suggesting possible compensatory effects by other family members. A complete 
knockout of the three known members would provide greater insight into the role of 
these receptors in AD pathogenesis.    
Briefly, CD36 has been shown to be present in microglia throughout CNS development 
with variable expression observed in a number of neurodegenerative diseases 
including high expression in the microglia of AD patients. Furthermore it has been 
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shown to mediate ROS production from microglia in response to fibrillar Aβ (Coraci et 
al. 2002)       
1.1.5.2.3. Neurotransmitter receptors – focus on mGluRs 
Studies identifying the expression of neurotransmitter receptors on microglia, coupled 
with the proposal of volume transmission as a signalling mechanism in parallel with the 
classical wiring transmission (Agnati et al. 1995), brought about the idea that neuron-
microglial communication could occur through these receptors. Microglia express many 
groups of neurotransmitter receptors including metabotropic and ionotropic glutamate 
receptors, GABA, purinergic and dopaminergic to name a few (Pocock & Kettenmann 
2007; Kettenmann et al. 2011). Here, the focus will be on the metabotropic glutamate 
receptors (mGluRs) and their involvement in microglial activation and subsequent 
neurotoxicity or protection.  
The mGluRs are members of the g-protein coupled receptor (GPCR) superfamily, 
which is the most abundant receptor gene family in the human genome. They are 
membrane bound proteins with seven transmembrane domains that are activated by 
extracellular ligands, which in turn transduce intracellular signals via interactions with g-
proteins (a heterotrimeric complex of α, β and γ subunits) with subsequent modulation 
of various effector molecules such as enzymes, ion channels and transcription factors 
(Niswender & Conn 2010). The mGluRs are sub-classified into three groups based on 
sequence homology, g-protein coupling and ligand selectivity.    
Group I mGluRs (mGluR1 and 5) are predominantly coupled to Gq/G11 proteins and 
activate phospholipase Cβ, resulting in the hydrolysis of phosphotinositides and 
generation of inositol 1,4,5-trisphosphate (IP3) and diacylglycerol, which leads to 
calcium mobilisation and activation of protein kinase C (Niswender & Conn 2010). Two 
independent studies have suggested that only mGluR5 from group I is expressed in 
microglia (Biber et al. 1999; Byrnes et al. 2009a). The latter study further suggested 
that agonism of mGluR5 could attenuate LPS-mediated microglial activation with 
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significant decreases in nitric oxide, reactive oxygen species, TNFα and galectin-3 
observed (Byrnes et al. 2009a). Furthermore, this specific activation of microglial 
mGluR5 was able to attenuate microglial-mediated neurotoxicity after LPS treatment, 
suggesting a neuroprotective role through microglial mGluR5 activation (Byrnes et al. 
2009a). This was further alluded to by the same group using rat spinal cord injury 
models in vivo to show mGluR5 activation downregulated ED-1, Iba-1 and Galectin-3 
expression with decreases in NADPH oxidase components, TNF release and iNOS 
expression also shown (Byrnes et al. 2009b). Further studies by the same group using 
siRNA techniques identified that the mGluR5-mediated decrease in microglial reactivity 
and subsequent neurotoxicity was due to NADPH oxidase inhibition (Loane et al. 
2009).     
Group II (mGluR2 and 3) and group III (mGluR4, 6, 7 and 8) are predominantly coupled 
to Gi/o proteins, which are classically coupled to the inhibition of adenylyl cyclase with a 
subsequent decrease in cAMP levels (Niswender & Conn 2010). Work completed and 
ongoing in our laboratory has provided and continues provide insight into the 
differential roles of group II and III mGluRs on microglia, ranging from direct and 
indirect toxicity to the induction of neuroprotective phenotypes (Kingham et al. 1999; 
Taylor et al. 2002; Taylor et al. 2003; Taylor et al. 2005; Pinteaux-Jones et al. 2008). 
Initial studies by Kingham et al (1999) identified that the microglial apoptosis induced 
by chromogranin A (CgA), a peptide associated with AD senile plaques, could be 
significantly attenuated by broad antagonism of group II and III mGluRs, suggesting a 
role for this class of receptor in regulating the toxicity of disease-associated deposits 
(Kingham et al. 1999).  
These findings were taken forward by subsequent studies firstly identifying the 
functional expression of both group II mGluRs on microglia, activation of which induced 
significant microglial death whereas antagonism attenuated microglial-mediated 
neurotoxicity after treatment with CgA (Taylor et al. 2002). Secondly, Taylor et al 
(2003) identified functional group III (mGluR4, 6 and 8 but not mGluR7) mGluRs on 
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microglia, which when activated attenuated CgA and LPS-mediated microglial 
activation, the opposite to that observed after group II activation. Furthermore, specific 
activation of the group III receptors on microglia was able to attenuate microglial-
mediated neurotoxicity after treatment with CgA or LPS (Taylor et al. 2003). Finally, it 
was identified that mGluR2 activation, and not mGluR3 of the group II receptors was 
responsible for the observed microglial-mediated toxicity. Microglial mGluR2-mediated 
TNFα release was shown to be responsible for the observed neurotoxicity, in concert 
with the pro-apoptotic factor Fas ligand (Taylor et al. 2005).  
Support for the detrimental activation of microglial group II mGluRs was observed in an 
in vitro model of stroke penumbra. Glutamate released from oxygen and glucose 
deprived stressed embryonic rat neurons stimulated co-cultured microglial group II 
mGluRs triggering the activation and induction of neurotoxicity mediated through 
microglial release of TNFα (Kaushal & Schlichter 2008). This mechanism could also be 
mimicked by administration of a group II mGluR agonist. Interestingly, the mGluR-
dependent microglial activation involved NFκB signalling, but in contrast to LPS-
induced microglial activation, no MAPK signalling or NO production and release was 
observed (Kaushal & Schlichter 2008). 
The old view of neurotransmitters as molecules solely for communication between 
synapses is being tested with discoveries showing receptors present on non-neuronal 
cells with diverse functionality. Further studies into the roles and functions of these 
neurotransmitter receptors on microglia will help us to understand the seemingly vast 
signalling capacity these cells have, which could lead to further breakthroughs in our 
understanding of neuron-glial relationships.  
1.1.5.2.4. Microglial-mediated cytokine and ROS signalling 
The final subsection will focus on the factors released from microglia during activation. 
This is a vast and complicated subject, some of which has already been covered in 
previous sections. Therefore, this will be an overview of the inflammatory factors 
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released after classical LPS-mediated microglial activation and those associated with 
Alzheimer’s disease pathogenesis.  
For over twenty years, microglial activation has been modelled in vitro with LPS, a 
component of gram-negative bacteria (Hetier et al. 1988). It is now widely accepted 
that chronic microglial activation results in deleterious & neurotoxic consequences with 
contributions from the chronic release of pro-inflammatory factors that can lead to 
neuronal toxicity and death (Block et al. 2007). In vitro, LPS exposure induces 
prolonged classic (M1) microglial activation (Porcheray et al. 2005), characterised by 
the release of pro-inflammatory factors, which is used to mimic the chronic activation 
identified to be detrimental in vivo. These studies have enabled researchers to identify 
the profile of released factors that could potentially drive disease pathogenesis.  
The most intensely studied group of factors shown to be released from microglia during 
activation is the cytokines. These are small proteins ranging in size from 8 – 40 kDa 
that are able to be synthesised by nearly all nucleated cells. Interestingly, there is no 
obvious amino acid sequence motif or 3D structural similarities linking this family, it is 
rather their biological activities that provide the sub-classification into either pro- or anti-
inflammatory, based on the evoked ligand-receptor signalling and subsequent up- or 
down-regulation of pro- or anti-inflammatory gene products (Dinarello 2000). As 
described in section 1.1.5.2.1, microglia, upon activation with LPS via TLR4, mediate 
signalling through the MyD88 adapter system complex that activates downstream 
kinases such as IκB and MAPKs, which in turn control the activities of signal-
dependent transcription factors such as NFκB that regulate hundreds of genes, 
including cytokines (Glass et al. 2010). LPS has been shown to induce microglial 
release of pro-inflammatory cytokines including TNFα, IL-1α, IL-1β and IL-6 (Hetier et 
al. 1988; Lee et al. 1993), on numerous occasions. In support of the in vitro modelling 
of LPS-induced microglial activation, the cytokine release profile has been shown to 
translate to AD pathology where microglia surrounding AD plaques stained positive for 
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TNFα, IL-1β and IL-6, as well as monocyte chemotactic protein-1 (MCP-1, CCL2), a 
pro-inflammatory chemokine (Akiyama et al. 2000). Interestingly, fibrinogen and fibrin 
have also been shown to induce the production of pro-inflammatory cytokines including 
IL-1β, IL-6 and TNFα from human monocytes, in vitro (Perez et al. 1999; Jensen et al. 
2007).  
Focussing on TNFα, the pro-inflammatory cytokine is a member of the TNF superfamily 
of ligands, many of which promote inflammatory signalling (Wajant et al. 2003). TNFα 
is synthesised as a monomeric transmembrane protein (tmTNFα) that is inserted into 
the membrane as homotrimers, cleavage of which releases the 51 kDa soluble TNFα 
trimer (solTNFα) that circulates during an inflammatory response. Both forms of TNFα 
are biologically active and synthesis can occur in microglia, astrocytes, and some 
populations of neurons (McCoy & Tansey 2008). Cell signalling with TNFα occurs via 
TNFR1 and TNFR2 with solTNFα preferentially binding to TNFR1 leading to 
subsequent activation of a number of signal transduction pathways, including ERK, 
NFκB, p38 MAPK and c-Jun N-terminal kinase (JNK) (McCoy & Tansey 2008). 
Activation of these various pathways leads to an array of outcomes, ranging from pro-
survival to apoptosis with dependence thought to derive from acute or chronic TNFα-
induced JNK activation (Sato et al. 2005; Tobiume et al. 2001). 
TNFR2 is not as widely expressed as TNFR1 and does not couple to an intracellular 
death domain. The transmembrane form of TNFα is the preferential ligand for TNFR2 
activation, which can lead to pro-inflammatory and pro-survival signalling pathways 
through recruitment of adapter proteins and activation of the NFκB pathway. TNFR2 
signal transduction has been shown to promote neuronal survival via activation of 
phosphatidylinositol-3-kinase-(PI3K)-dependent signalling (McCoy & Tansey 2008). 
Also, it has been suggested that the primary contribution of TNFR2 to TNFα-mediated 
signal transduction is through the promotion of TNFR1 signalling by enhancement of 
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the solTNFα binding affinity for TNFR1, a mechanism known as ‘ligand passing’ 
(Tartaglia et al. 1993). 
Finally, as well as microglial-induced paracrine signalling of TNFα through the 
described receptors, microglial-mediated TNFα release has been shown to act in an 
autocrine fashion through activation of TNF receptors on microglia contributing to self-
perpetuating microglial activation (Kuno et al. 2005; Kettenmann et al. 2011) (Figure 
1.1.6). Furthermore, microglial-mediated TNFα release can activate astrocytes leading 
to the release of astrocytic factors that can lead to further microglial activation (Saijo et 
al. 2009). 
With respect to modelling microglial activation in rodent models, it is now well 
established that activation promotes expression of the inducible nitric oxide synthase 
(iNOS) enzyme. However, there is still a debate over whether human cells utilise the 
enzyme as prominently as their rodent counterparts (Peterson et al. 1994; Ding et al. 
1997; Panaro et al. 2003). Expression of iNOS occurs in response to inflammatory 
cytokines and promotes the production of nitric oxide (NO), a pleiotropic cell signalling 
molecule and free radical released from microglia that combats pathogen invasion. It 
has been consistently shown that NO release from microglia is mediated by the p38 
and p42/44 MAPK pathways resulting in NFκB-mediated transcription of the iNOS gene 
(Bhat et al. 1998). Nitric oxide interacts with superoxide (O2•־) free radicals to form 
peroxynitrite (ONOO-), a potent toxin that can cause DNA breakage, lipid peroxidation 
and protein nitration (Pacher et al. 2007). However, NO has also been shown to protect 
neurons from excitotoxicity by downregulating NMDA receptor activity through 
nitrosylation of the receptors redox groups and it is in fact the conversion of NO to 
ONOO- that induces the significant neurotoxicity, implicating another enzyme called 
NADPH oxidase (Pacher et al. 2007). NADPH oxidase is a multi-subunit protein 
involved in the production of reactive oxygen species (ROS) through catalysis of the 
formation of O2•־ from oxygen which in turn can lead to the production of ONOO- and 
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hydrogen peroxide (H2O2) through reactions involving NO. Glial NADPH oxidase has 
been implicated in NDDs with microglial NADPH oxidase shown to be involved in AD-
associated oxidative stress (Wilkinson & Landreth 2006). Furthermore, Aβ-mediated 
microglial activation has been shown to involve TNFα-dependent expression of iNOS, 
subsequently leading to neuronal death (Combs et al. 2001).  
It must not be forgotten that first and foremost the microglial population is present to 
maintain CNS homeostasis. Microglia are not auto-aggressive cells, with their main 
function being to protect damaged neurons and not cause damage themselves (Streit 
2004). For example, anti-inflammatory cytokines such as TGFβ and IL-10 that can 
suppress NO or O2•־ radical generation are also released from microglia during 
inflammatory responses to counteract the inflammation (Gebicke-Haerter 2001).Thus, it 
is likely that the combination of chronic inflammation, microglial senescence, genetic 
and epigenetic factors lead to microglial dysfunction including a loss of pro- and anti-
inflammatory factor equilibrium, which contributes to neurodegenerative disease 
progression.    
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Figure 1.1.6. Activated microglia in self-perpetuating neurotoxicity 
The mechanism through which microglia are activated is either via a direct 
stimulus or inflammatory trigger such as LPS or due to neuronal damage from 
toxins such as MPTP and the release of neuronal-derived microglial activators 
such as α-synucelin leading to reactive microgliosis. This can also induce the 
subsequent release microglial-derived neurotoxic factors including cytokines and 
reactive oxygen and nitrogen species. In chronic neurodegeneration these 
mechanisms could lead to self-perpetuating neurotoxicity through sustained 
activation of microglia. 
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1.2. The blood brain barrier – structure, function and dysfunction 
The bacteriologist Paul Ehrlich was first to touch on the concept of a barrier separating 
the brain from the rest of the body in the early 20th century. He noticed that after intra-
venous injection of a range of dyes, staining was observed in all tissues except for the 
brain. However at first he assumed the reason for lack of staining was due to a low 
affinity for the dyes in CNS tissue (Ehrlich 1904). It was not until a student of Ehrlich’s, 
Edwin Goldmann, injected the same dyes into the cerebrospinal spinal fluid and 
observed the opposite to Erhlich’s conclusions that the concept of the barrier was 
proposed (Goldmann 1913).  
1.2.1. Structure and Function 
Today the blood brain barrier (BBB) can be defined by its functions of limiting the entry 
of plasma components, red blood cells and leukocytes into the CNS, and maintaining 
the chemical composition of the neuronal environment, which is required for the proper 
functioning of neuronal circuits, synaptic transmission, angiogenesis, and neurogenesis 
in the adult brain (Zlokovic 2008). The human brain receives approximately 20% of 
cardiac output and if cerebral blood flow stops or slows, brain functions can stop in 
seconds leading to neuronal damage occurring within minutes (Girouard & Iadecola 
2006). Thus neuronal-vascular relationships are critical for normal brain function.  
In simplistic terms the BBB is composed of a tightly sealed monolayer of brain 
endothelia, which precludes free exchange of solutes between the blood and brain and 
visa versa (Abbott et al. 2006; Zlokovic 2008). Brain endothelial cells are functionally 
different from peripheral vascular endothelial cells. They contain an increased number 
of mitochondria, lack fenestrations, have minimal pinocytotic activity, and very 
importantly, form tight junctions (Desai et al. 2007) with proteins such as occludins and 
claudins, which confer the low paracellular permeability and high electrical resistance 
of the barrier (Zlokovic 2008). Transport across the barrier is therefore via active rather 
than passive mechanisms, which can be classified into 5 main categories: carrier-
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mediated transport, ion transport, active efflux transport, receptor-mediated transport 
and caveolae-mediated transport. These mechanisms transport nutrients and ions, 
expel metabolites, transport large proteins, and regulate endocytosis, respectively. 
In partnership with the monolayer of brain endothelia, neurons, pericytes, astrocytes 
and microglia form a functional unit referred to as the neurovascular unit (Figure 1.2.1) 
creating an interface between the brain and vasculature (Bell & Zlokovic 2009). 
Pericytes are from vascular smooth muscle lineage (Zlokovic 2008). Their processes 
wrap the brain endothelium and communicate directly through the specialized synapse-
like “peg-socket” contacts (Bell & Zlokovic 2009), contributing to the stability of the 
microvessels (von Tell et al. 2006). These cells regulate endothelial growth and 
migration through release of growth factors and angiogenic molecules such as TGFβ 
(Desai et al. 2007; Dore-Duffy & LaManna 2007). Recent studies have suggested 
pericytes are vital for the formation of the BBB, regulating functional aspects including 
the formation of tight junctions between the brain endothelia (Daneman et al. 2010).  
Astrocytes communicate with other cells of the neurovascular unit through ‘end feet’ 
which contact the capillary surface providing the brain with physical support, with an 
important role in regulating brain water-electrolyte metabolism (Zlokovic 2008). Factors 
released from the astrocytes such as TGFβ and IL-6 enhance expression of endothelial 
signalling proteins and tight junction proteins leading to improved BBB function (Desai 
et al. 2007). Furthermore, astrocytes contribute to brain communication pathways, for 
example by modulating synaptic transmission (Newman 2003).  
Microglia under inflammatory conditions release cytokines and chemokines that enable 
recruitment to the CNS of peripheral mononuclear cells that are able to penetrate the 
healthy BBB by a process of diapedesis directly through the cytoplasm of the brain 
endothelia cells and not via a paracellular route (Abbott et al. 2010). Microglia also form 
end feet connections with the brain endothelia and along with the astrocytic end feet 
are termed the glia limitans. This part of the barrier coupled with the basement 
 membrane forms the final obstacle for the mononuclear cell entry into the brain 
al. 2007). Finally, the basement membrane separates the brain endothelium from the 
pericytes and astrocytes in the neurovascular unit 
extracellular matrix proteins including 
proteoglycans, laminin and 
neurovascular unit (Desai et al. 2007)
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1.2.2. Dysfunction  
Dysfunction and disruption of the BBB and trans-endothelial migration of activated 
leukocytes are among the earliest pathological hallmarks seen in MS brains, with 
release of pro-inflammatory cytokines and chemokines contributing to the observed 
BBB disruption (Kermode et al. 1990; Minagar & Alexander 2003). With the use of EAE 
animal models of MS, it has been shown that auto-aggressive CD4+ T lymphocytes are 
activated outside the CNS and accumulate in the CNS by crossing the BBB due to 
cytokine signalling (Ransohoff et al. 2003) contributing to neuronal death. Furthermore 
using the same animal models, decreased expression of claudin-3 was observed, 
suggesting either breakdown or rearrangement of tight junctions (Wolburg et al. 2003) 
potentially contributing to the loss of BBB integrity. Finally, blood borne proteins 
including fibrinogen, normally excluded from the CNS parenchyma, have been 
localised to lesion sites in MS apparently prior to significant cerebral tissue injury and 
demyelination (Akassoglou et al. 2004) further supporting early significant breakdown 
of the BBB in MS. These data have been supported in house by immunohistochemical 
studies performed on EAE spinal cord tissue, showing significant extravascular 
fibrinogen staining (Figure 1.2.2).     
 In AD pathology, the role of BBB dysfunction is relatively novel in comparison to MS. A 
commonly accepted view, until discoveries with functional magnetic resonance imaging 
(fMRI) (Drake & Iadecola 2007), was that the barrier was in fact intact in AD patients 
when compared with ‘non-demented’ elderly (Alafuzoff et al. 1987). Now, it is widely 
accepted, as a result of information obtained from brain imaging studies in humans and 
animal models, that cerebrovascular dysfunction may precede cognitive decline and 
the onset of neurodegenerative changes in human AD and animal AD models (Bell & 
Zlokovic 2009). Changes in the brain capillary unit, degeneration of the brain 
capillaries, reduction in resting cerebral blood flow (CBF), or a combination of the 
aforementioned, may be the first indications of a disease process prior to the better 
 characterized neuronal changes and 
that vascular dysfunction has a critical role in Alzheimer’s disease and is discussed in 
further detail in section 1.3.1
brain parenchyma can cause a decrease in CBF 
affects the synthesis of proteins required for memory and learning, and could 
eventually lead to neuronal injury or death 
Figure 1.2.2. Fibrinogen extravasation in an animal model of blood brain barrier 
breakdown 
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Expression of the major Aβ-influx transporter, RAGE, has been shown to increase in 
affected cerebral vessels, microglia and neurons, suggesting peripheral Aβ could be 
transported back into the CNS. Furthermore, expression of low-density lipoprotein 
receptor related protein-1 (LRP), a key Aβ clearance receptor at the BBB and along the 
cerebrovascular system, is suppressed early in AD (Zlokovic 2008; Bell & Zlokovic 
2009), with decreased  expression of the major efflux transporter p-glycoprotein also 
observed (Lee & Bendayan 2004). Other changes in the expression of key vascular 
genes and receptors in brain capillaries and small cerebral arteries are also likely to 
compromise BBB functionality, causing an increase in Aβ accumulation and a 
neuroinflammatory response (Zlokovic 2008; Abbott et al. 2010). The 
neuroinflammatory hallmark of AD is likely to have an impact on barrier integrity and 
function, with pro-inflammatory cytokines TNFα and IL-1β, both elevated in AD, being 
well-known disruptors of BBB integrity in sepsis (Desai et al. 2007). 
Other functional abnormalities likely to have an effect on BBB integrity in AD are 
changes in the organization and expression of tight junction proteins after Aβ 
deposition (Marco & Skaper 2006). Furthermore, studies on institutional and 
ambulatory patients with AD have shown an increase in serum proteins within the CSF, 
suggesting increased permeability of the BBB (Elovaara et al. 1985; Kalaria & Kroon 
1992). The detrimental impact of this increase in serum proteins in the CNS has been 
studied in animal models of AD, where significant deposition of fibrinogen accelerated 
neurovascular damage and enhanced neuroinflammation (Paul et al. 2007).  
Limited data has been published on BBB dysfunction in Parkinson’s disease (PD) 
however it has been suggested that absorption and metabolism of putative PD toxins 
and faulty elimination of these toxins from the CNS, across the BBB, may play a role in 
disease pathogenesis (Zlokovic 2008). Interestingly, studies suggesting a 
polymorphism in the p-glycoprotein efflux transporter gene MDR1 may predispose 
carriers to damaging effects of pesticides leading to a PD-like phenotype (Droździk et 
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al. 2003). Further studies expanded the number of polymorphisms in the MDR1 gene 
found to be associated with the risk of developing PD in a Chinese population (Lee et 
al. 2004a). Functional support for this genetic risk factor was provided by PET studies 
that indirectly observed a decrease in the p-glycoprotein efflux transporter in the 
midbrain of people at a risk of developing PD (Kortekaas et al. 2005). However, further 
studies identified limited changes in p-glycoprotein expression in early PD (Bartels et 
al. 2008a), although significant decreases were observed in later stages of the disease 
(Bartels et al. 2008b), suggesting loss of the p-glycoprotein efflux transporter is not a 
primary event in the pathogenesis of PD. 
The occurrence of BBB disruption in ALS was initially suggested due to studies that 
observed abnormally high levels of IgG and albumin in the CSF of ALS patients 
(Leonardi et al. 1984). These studies were supported by subsequent observations of 
an increased level of IgG in the spinal cord of ALS patients (Engelhardt & Appel 1990). 
Furthermore, the same group showed IgG from the sera of ALS patients could induce 
death in an in vitro culture of the motor neuron cell line VSC4.1 (Smith et al. 1994).  
The use of G93A SOD1 mutation mice as a model of ALS has showed functional 
impairment of the BBB, demonstrated by Evans blue extravasation into the spinal cord 
at the early stages of disease onset (Garbuzova-Davis et al. 2007). Furthermore this 
study observed significant decreases in the expression of glutamate transporter-1 and 
CD146, which suggested endothelia damage or loss. These observations were 
subsequently supported by Zhong et al (2008), in a number of animal models of ALS, 
who also detected significant decreases in tight junction proteins that preceded 
significant expression of inflammatory markers and disease onset, suggesting pre-
symptomatic BBB dysfunction occurs very early in ALS disease progression (Zhong et 
al. 2008).  
The decrease in tight junction proteins was translated to the human disease with 
studies quantifying mRNA levels of the proteins in post-mortem samples (Henkel et al. 
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2009). These abnormalities in tight junction protein expression were confirmed by 
studies on post mortem human spinal cord from ALS patients (Miyazaki et al. 2011) 
with further observations including changes in basement membrane component levels 
and a significantly higher dissociation of astrocytic end feet from the neurovascular 
unit, supporting a loss of BBB integrity in ALS. 
BBB dysfunction in neurodegeneration is clearly an extremely important pathological 
event. It seems the loss of integrity observed in the disorders described can be divided 
into three general areas: 
• The inefficient clearance of toxins 
• Increased transport of auto-aggressive immunocompetent cells across the BBB 
• A physical loss of barrier integrity partly due to loss of tight junctions   
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1.3. Neurodegenerative diseases – focussing on inflammation and 
microglial involvement 
Inflammation is an underlying component of a diverse range of neurodegenerative 
diseases (NDDs) and their associated neuropathology and it is believed by many that 
microglia are a causative factor in this process (Block et al 2007). Here, descriptions of 
the main NDDs focussed on in this thesis will be provided with an emphasis on the 
involvement of inflammation and microglia.    
1.3.1. Alzheimer’s disease 
Alzheimer’s disease (AD) can be broadly characterised by progressive cognitive 
decline associated with neurovascular dysfunction (Iadecola 2004; Zlokovic 2005), 
accumulation of neurotoxic Aβ in vasculature and the brain parenchyma (Hardy 2006), 
and intraneuronal fibrillar tangles (Santacruz et al. 2005; Qiang et al. 2011).  
Aβ has been at the centre of Alzheimer’s disease research since the proposal of the 
amyloid cascade hypothesis (Hardy & Allsop 1991) due to the discovery of a mutation 
in the amyloid precursor protein gene in familial AD patients (Goate et al. 1991). 
Furthermore, levels of Aβ have been shown to be increased in the interstitial fluid of 
familial and sporadic AD sufferers, leading to the formation of neurotoxic Aβ oligomers 
(Haass & Selkoe 2007).  
Only around 1% of AD cases are familial with approximately 99% of AD patients 
presenting with sporadic late onset AD (LOAD), which is defined as being over the age 
of 65 years with no evidence of Mendelian genetic transmission (Tanzi & Bertram 
2005). Twin studies into genetic risk factors for the development of LOAD have 
however shown sporadic AD to be highly heritable with genes involved in more than 
60% of disease susceptibility with mutations in the APOE gene accounting for as much 
as 50% of this genetic susceptibility (Gatz et al. 2006).  
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Familial mutations in APP have been shown to increase the production of Aβ42 
compared with the shorter Aβ40 (Suzuki et al. 1994). This longer form more readily 
forms insoluble amyloid fibrils suggesting a possible mechanism for enhanced Aβ 
deposition. Interestingly however, no increase in Aβ production is observed in LOAD 
and current concepts suggest that Aβ accumulates in the sporadic form due to faulty 
clearance (Tanzi et al. 2004), contributing to neurovascular accumulation and vascular 
deposition of Aβ leading cerebral amyloid angiopathy (CAA) (Greenberg et al. 2004), a 
significant risk factor in dementia (Zlokovic 2008) and a prominent feature in the 
alternative vascular hypothesis of AD (de la Torre 2004). Furthermore, recent studies 
have identified that fibrinogen contributes to this faulty clearance of Aβ (Cortes-Canteli 
et al. 2010). Recent data has identified new genetic risk factors for LOAD, namely 
clusterin and complement receptor 1 (CLU and CR1, respectively) (Harold et al. 2009; 
Lambert et al. 2009). The protein products of these genes are associated with cellular 
clearance pathways, with clusterin previously being shown to be involved in the 
regulation of microglial-mediated phagocytosis of Aβ (Cole & Ard 2000). 
Extensive evidence has been published suggesting that Aβ deposition provokes 
microglial-mediated inflammatory responses that significantly contribute to cell loss and 
cognitive decline (Akiyama et al. 2000). Levels of the pro-inflammatory cytokine TNFα 
are shown to increase in the brains and plasma of AD patients (Fillit et al. 1991; 
Tarkowski et al. 1999). Furthermore TNFα has been shown to induce neuronal death 
(Venters et al. 1999; Taylor et al. 2005), with in vitro studies identifying microglial 
signalling pathways induced by Aβ subsequently lead to the release of this pro-
inflammatory cytokine (Combs et al. 2000; Combs et al. 2001).  
Chromogranin A (CgA) is an AD plaque-associated peptide. Studies published from our 
laboratory have identified CgA-mediated toxicity of both microglia and neurons 
(Kingham et al. 1999; Kingham & Pocock 2000; Taylor et al. 2002; Taylor et al. 2003; 
Hooper & Pocock 2007). Recent studies have also identified the microglial scavenger 
receptor class A (SR-A) as the putative receptor for the observed CgA-mediated 
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neurotoxicity (Hooper et al. 2009a) with regulation by the transcription factor p53 also 
observed (Davenport et al. 2010).    
Further in vitro studies coupled with in vivo studies have identified the CD11b (MAC-1, 
CR3, αMβ2 integrin) receptor and PI3K pathway to be essential in fibrillar Aβ-mediated 
microglial activation leading to superoxide production and neuronal loss (Zhang et al. 
2011)      
Clinical data to identify the role of microglia in AD has been advanced with PET studies 
using 11C-R-PK11195, a marker for activated microglia (Banati 2002). Initial studies 
suggest that the 11C-R-PK11195 signal is significantly enhanced in particular areas of 
the brain in AD patients when compared with controls, mostly correlating with a 
significant increase in amyloid load. Interestingly, along with the microglial association 
with amyloid deposition, a negative correlation between microglial activation and Mini 
Mental State Examination (MMSE) test results was observed, suggesting microglial 
activation in an attempt to decrease the amyloid burden could be contributing to 
neuronal dysfunction and cognitive deficits (Edison et al. 2008). 
Epidemiological studies have demonstrated that people prescribed non-steroidal anti-
inflammatory drugs (NSAIDs) for relatively long periods of time were less inclined to 
develop AD (Etminan et al. 2003; Vlad et al. 2008), and limited evidence suggests that 
they may attenuate AD progression (Weggen et al. 2007). Although clinical trials with 
NSAIDs failed to show any significant efficacy in AD (possibly due to inhibition of only 
one inflammatory pathway in microglia), the epidemiological studies coupled with new 
genetic risk factor data support a prominent role for inflammation in AD, which would 
subsequently involve the immune-competent cells of the CNS. With this in mind, any 
significant breakthrough in our understanding of how microglia are involved in the 
cognitive decline observed in AD could provide a leap forward in our therapeutic 
strategies for this disease.  
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1.3.2. Multiple sclerosis 
Multiple sclerosis (MS) involves the chronic destruction of the protective myelin sheath 
around nerve axons via degradation of its cellular components, (oligodendrocytes in 
the CNS, Schwann cells in the PNS) and subsequent loss of neuronal functionality. 
Symptoms can vary significantly from patient to patient but include: visual disturbances, 
muscle weakness, co-ordination and balance issues, numbness and prickling 
sensations and cognitive issues. The majority of patients (80%) suffer from relapsing-
remitting MS where symptoms typically evolve over a period of several days, stabilise 
and then often improve, either spontaneously or after administration of corticosteroids, 
within weeks. It typically begins in the 2nd – 3rd decade of life with a female 
predominance of 2:1 (Noseworthy et al. 2000). Secondary progressive MS occurs in 
patients suffering from the relapsing-remitting disease and is identified by persistent 
signs of CNS dysfunction developing after a relapse, with disease progression 
occurring between relapses. Finally, the other 20% of patients suffer from primary 
progressive MS, which is characterised by a gradually progressive clinical score.  
The pathological hallmark of chronic MS is the demyelinated plaque which can be 
characterised by a hypocellular region due to demyelination, relative preservation of 
neurons and astrocytic scars (Compston et al. 2005). It is broadly believed to be an 
immune-mediated disorder that occurs in genetically susceptible people (Noseworthy 
et al. 2000). However, despite the obvious immunological features of the disorder other 
researchers believe it is primarily a neurodegenerative disease (Hemmer et al. 2002; 
Chaudhuri & Behan 2004) arguing amongst other things that many NDDs have 
immunological elements. Given the considerable clinical, genetic, MRI and pathological 
heterogeneity of the disease, it is most likely that more than one molecular mechanism 
contributes to the significant tissue injury observed (Noseworthy et al. 2000).     
Along with infiltrating lymphocytes, microglia play important roles throughout the 
pathogenesis of MS. In the early stages of disease, prior to significant BBB disruption 
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or myelin sheath degradation activated microglia have been observed in MS lesion 
tissue (Gay et al. 1997), and along with the oligodendrocytes have been proposed to 
drive MS pathology with identification in pre-active lesions (van der Valk & Amor 2009). 
Furthermore, activated microglia have been shown adhering to damaged myelin 
sheaths and axons in acute MS lesions, suggesting a role for these cells in the 
destructive process (Trapp et al. 1998). Finally, laser confocal microscopy of post-
mortem MS patient tissue showed significant iNOS expressing cells in chronically 
active lesions with a sub-population identified as microglia (Hill et al. 2004).  
In an EAE model of MS, dendritic microglia have been demonstrated to present myelin 
antigens to infiltrating T cells within the brain suggestive of  a critical role in driving the 
progression observed in this model (Miller et al. 2007). Furthermore, studies using in 
vivo pharmacogenetic and bone marrow chimera techniques identified that microglial 
paralysis could substantially repress the development of EAE disease progression 
(Heppner et al. 2005).  
The ability of microglia to phagocytose myelin has been demonstrated in vitro. Initial 
studies found human microglia-mediated phagocytosis of myelin induced significant 
release of IL-1, IL-6 and TNFα after 12 – 24 hours (Williams et al. 1994). Interestingly, 
earlier studies suggest that peritoneal macrophage-mediated myelin phagocytosis was 
dependent on the MAC-1 receptor, with increased TNFα concentrations significantly 
reducing the cells’ ability to phagocytose myelin (Brück et al. 1992). Later studies 
suggest microglia are more efficient than peritoneal macrophages at phagocytosing 
myelin (Mosley & Cuzner 1996). Furthermore, myelin-mediated microglial activation 
has been shown to lead to neurotoxicity, in vitro (Pinteaux-Jones et al. 2008). 
Microglia are clearly actively involved throughout MS disease progression. Their roles 
in pre-active lesions with oligodendrocytes, as antigen-presenting cells within the CNS, 
in initiating and propagating immune responses, in phagocytosis of myelin debris and 
apoptotic cells, and in the production of pro-inflammatory factors potentially 
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exacerbating tissue injury, suggests manipulation of microglia could provide an avenue 
of therapeutic benefit. 
1.3.3. Parkinson’s disease 
Parkinson’s disease (PD) is a chronic movement disorder affecting the dopaminergic 
neurons, specifically in the substantia nigra and locus coeruleus, with one hypothesis 
suggesting an initial locus in the dorsal motor nucleus of the vagus nerve (Braak et al. 
2006). The neuronal loss is accompanied by three distinctive intraneuronal inclusions: 
the Lewy body, the pale body, and the Lewy neurite, with the main component of Lewy 
bodies being the aggregated form of the presynaptic protein α-synuclein (Lees et al. 
2009). Typically PD sufferers have lost over 80% of their dopaminergic neurons before 
symptoms appear which include tremors, rigidity, slow movement (bradykinesia), 
balance issues and the Parkinsonism gait. 
PD is generally considered as a sporadic disease with ageing as the major risk factor. 
Incidence of the disease rises steeply from 17.4 in 100,000 between the ages of 50 
and 59 years to 93.1 in 100,000 between the ages of 70 – 79 years, with a total lifetime 
risk of 1.5% (Lees et al. 2009). However, approximately 10% of cases develop before 
the age of 45. Due to the sporadic nature of the disease, environmental factors are 
assumed to take a prominent role. To date, certain environmental toxins have been 
identified including 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), cyanide, 
rotenone and toluene, which can produce a similar but not identical models of the 
disorder (Tanner & Aston 2000).  
Investigations into genetic factors have identified a number of genes with mutations 
associated with Parkinsonism or PD, including α-synuclein, LRRK-2, GBA, MAPT, 
HLA-DRA, Parkin, PINK1, DJ-1 and ATP13A2 (Lees et al. 2009; Simón-Sánchez et al. 
2009; Hamza et al. 2010). The most interesting risk factor with respect to inflammation 
and microglia in PD is the latest factor to be identified, HLA-DRA (Hamza et al. 2010), 
a gene that partly codes for the class II HLA-DR antigen protein expressed by antigen-
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presenting cells such as microglia, enabling interaction with inflammatory T cells 
(Kreutzberg 1996). Interestingly, mutations in this gene have also been associated with 
multiple sclerosis (Noseworthy et al. 2000). 
Microglial inflammation is thought to underpin the tissue damage in PD (Halliday & 
Stevens 2011) with a neuroprotective phenotype in early PD followed by a switch to a 
neurotoxic phenotype as the disease progresses (Sawada et al. 2006), although this 
hypothesis has been brought into question (Graeber & Streit 2009). Modelling 
dopaminergic neuronal loss with the neurotoxin MPTP has identified microglial 
activation as a contributing factor to MPTP-mediated toxicity. MPTP induces its 
neurotoxic effects after conversion to MPP+, catalysed by the mostly astrocytic enzyme 
monoamine oxidase B (Lobsiger & Cleveland 2007). In MPTP-treated mouse models of 
PD, significant microgliosis and enhancement of iNOS expression in microglia has 
been observed after treatment. Furthermore iNOS-/- mice were shown to be more 
resistant to MPP+ toxicity (Liberatore et al. 1999), and therefore, taken with the 
microglial-associated iNOS expression, these data suggest an important mechanistic 
contribution from microglia in the MPP+-mediated toxicity. In vivo studies and in vitro 
co-cultures have provided support for the inflammatory microglial involvement in MPP+-
mediated neurotoxicity. Studies using the inflammatory modulator minocycline reduced 
MPP+-mediated iNOS expression in BV2 microglia and MPP+ induced neurotoxicity 
could only be attenuated by minocycline if glia were present (Du et al. 2001).  
The major constituent of Lewy bodies, mutated α-synuclein, has been shown to more 
potently stimulate microglia to a pro-inflammatory phenotype than the normally folded 
protein, with increased levels of IL-1β and TNFα observed (Klegeris et al. 2008). 
Recently, wildtype α-synuclein has been shown to alter TLR expression on microglia 
(Béraud et al. 2011), suggesting the protein contains a pathogen-associated molecular 
pattern (PAMP), required for recognition by TLRs (Section 1.5.1.2.1). 
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These models specifically target one aspect of PD pathology, whether it’s neuronal loss 
or Lewy body constituents. The development of more comprehensive models utilising 
α-synuclein mutants in conjunction with chemically induced loss of neurons, or the use 
of rotenone, another dopaminergic neurotoxin which also aggregates α-synuclein 
(Betarbet et al. 2000; Sherer et al. 2003) would, in my view, provide more relevant data 
to the human disorder, some of which is starting to appear (Mount et al. 2007).  
1.3.4. Amyotrophic lateral sclerosis  
Motor neurone disease or amyotrophic lateral sclerosis (ALS) is a chronic 
neurodegenerative disorder of vulnerable motor neurons in the brain, brainstem and 
spinal cord. Symptoms include fasciculation, muscle wasting and weakness, increased 
spasticity, hyper-reflexia and respiratory complications, which usually occur in 
advanced disease causing death through paralysis of the respiratory muscles and 
diaphragm after 2 – 5 years from disease onset (Boillée et al. 2006a; Glass et al. 
2010). The majority (90%) of patients suffer from sporadic ALS, whereas the remaining 
10% suffer from familial ALS, a quarter of which are associated with genetic mutations 
in superoxide dismutase-1 (SOD-1), an enzyme involved in the destruction of the 
reactive oxygen species, superoxide (O2•־). To date over 115 disease-associated 
mutations have been found in the SOD-1 gene and the emerging general consensus 
suggests that the disease results from a toxic gain of function in the mutant protein, not 
loss of enzymatic activity (Lobsiger & Cleveland 2007). In support of this, complete 
absence of functional SOD-1 does not compromise life-span in mice or promote motor 
neurone disease (Boillée et al. 2006a). 
Studies have suggested that SOD-1 is a central contributor to disease initiation but not 
disease progression. The use of short interfering RNA (siRNA) to specifically silence 
mutant SOD-1 in motor neurons substantially delayed disease onset but did not 
significantly delay progression after onset (Ralph et al. 2005), suggesting other non-cell 
autonomous mechanisms are involved. Thus, the observed role for inflammation in 
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ALS could provide answers to this mechanistic shortfall. Both ALS animal models and 
patients develop prominent features of neuroinflammation including astrogliosis and 
microgliosis (Boillée et al. 2006a; Lobsiger & Cleveland 2007). Interestingly however, 
treatment of ALS mutant mice with minocycline significantly extended survival by 
delaying disease onset (Zhu et al. 2002), suggesting a prominent role for inflammation, 
as well at mutant SOD-1, in disease initiation. 
Later more elegant studies strongly suggested that microglia were significantly involved 
in ALS disease progression. Boillée and colleagues (2006) used a CD11b-promoter 
driven Cre transgene to specifically knockdown mutant SOD-1 in cells of the myeloid 
lineage (including microglia) in a LoxSOD1G37R mouse model of ALS. These animals 
showed no delay in disease onset, suggesting a microglial SOD-1-independent 
mechanism in disease initiation. However survival was greatly enhanced due to 
slowing of disease progression (Boillée et al. 2006b), suggesting microglial-specific 
mutant SOD-1 contributes significantly to ALS progression. A similar outcome was 
observed in another study using differing techniques. Using a double mutant mouse 
SOD1G93A/PU.1-/- (PU.1 is a transcription factor vital for production of myeloid derived 
cells) bone marrow transplantation was performed to provide a donor-derived microglial 
population (Beers et al. 2006). If SOD1G93A/PU.1-/- mutants received wild-type donor-
derived microglia after bone marrow transplantation, motor neuron loss was 
significantly slowed and disease duration was prolonged, when compared with mice 
receiving SOD1G93A donor-derived microglia (Beers et al. 2006). 
A number of microglial associated inflammatory factors have been proposed as key 
mediators in this motor neuron loss including TNFα, enhanced synthesis of which has 
been shown by SODG93A mutant microglia (Weydt et al. 2004). However, deletion of the 
TNFα gene did not affect the lifespan or the extent of motor neuron loss in either 
SODG93A or SOD1G37R ALS mouse models (Gowing et al. 2006), suggesting other 
inflammatory mediators are involved. NADPH oxidase-dependent reactive oxygen 
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species were found to be the likely component of the microglial-mediated non-cell 
autonomous ALS progression. Studies showing genetic knockdown of the gp91phox 
catalytic subunit of the NADPH oxidase significantly extended survival in SODG93A ALS 
models, although like previous studies (Zhu et al. 2002), this seems to be due to delay 
of disease onset rather than slowing disease progression, suggesting little correlation 
can be made here with the mutant microglial-ablation studies (Boillée et al. 2006b; 
Beers et al. 2006). 
In each of the diseases described, distinct pathways are involved in the generation of 
the inducers of inflammation, such as Aβ, myelin, α-synuclein or SOD-1, that occurs in 
distinct brain regions. However, once these disease-associated inducers of 
inflammation are present, remarkable convergence in the effector mechanisms is 
observed leading to the amplification of inflammation and subsequent neurotoxicity and 
neuronal death, with activation of microglia as the universal component. Attenuating 
neuroinflammation may not prevent disease initiation or alter the underlying cause, but 
by specifically targeting microglial-mediated release of neurotoxic factors there are 
suggestions that progression could be slowed, potentially providing a clinical benefit.    
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1.4. Cell Death 
Cell death is defined as irreversible loss of plasma membrane integrity (Kroemer et al. 
2009). In broad terms, there are three specific types of cell death that have been 
characterised extensively based on morphological criteria. The first type of cell death 
termed apoptosis by Kerr and colleagues in 1972 can be morphologically identified by 
characteristic changes in nuclear morphology, including chromatin condensation 
(pyknosis) and fragmentation (karyorrhexis), minor changes in cytoplasmic organelles, 
and overall cell shrinkage, blebbing of the plasma membrane and formation of 
apoptotic bodies that contain nuclear or cytoplasmic material (Kroemer et al. 2009), 
with these changes occurring prior to loss of plasma membrane integrity. The second 
type of cell death is characterized by the presence of large autophagic vacuoles in the 
cytoplasm, hence the commonly used nomenclature, autophagy-mediated cell death. 
The final form of cell death termed necrosis is often defined as an unregulated form of 
cellular destruction. Necrosis is determined morphologically by early plasma membrane 
rupture and dilatation of cytoplasmic organelles, in particular mitochondria and nuclei 
(Kroemer et al. 2009). In recent years a regulated form of necrosis has been suggested 
with data proposing death receptor activation can occur in apoptotic-‘deficient’ 
conditions, termed necroptosis (Hitomi et al. 2008). 
This thesis focuses on mainly characterising apoptotic cell death in cell cultures after 
exposure to fibrinogen and fibrin, therefore the focus of this chapter will be on apoptotic 
pathways, with particular attention paid to ER stress-mediated apoptosis. 
1.4.1. Apoptosis 
Apoptosis is an evolutionary conserved form of cell death. As previously stated it is 
characterised morphologically by nuclear and cytoplasmic condensation, nuclear 
membrane breakdown, DNA cleavage, plasma membrane blebbing and creation of 
apoptotic bodies (Kerr et al. 1972). Apoptosis occurs via two execution programs 
downstream of a death signal. The first is via caspase pathways and the second is due 
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to organelle dysfunction, such as mitochondrial or endoplasmic reticulum dysfunction 
(Danial & Korsmeyer 2004), with some convergence of the two pathways usually 
occurring. The process is highly regulated by members of the B-cell 
leukaemia/lymphoma-2 (Bcl-2) family (Pettmann & Henderson 1998) preventing 
uncontrolled apoptosis from occurring. Within the central nervous system it follows a 
specialized highly ordered sequence of signalling cascades. These cascades can be 
initiated by intrinsic factors such as calcium dyshomeostasis or chronic production of 
reactive oxygen species (ROS) (Benn & Woolf 2004). Induction can also occur via an 
extrinsic pathway involving death receptors and pro-inflammatory cytokines (Degterev 
& Yuan 2008).  
1.4.1.1. The role of the caspases 
Caspases are a family of cysteine protease enzymes that are triggered in response to 
pro-apoptotic signals and result in the cleavage of protein substrates, causing 
disassembly of the cell (Gross et al. 1999). With respect to apoptosis, they are divided 
into two sub-groups named initiator caspases and executioner caspases. They are 
synthesised as catalytically inactive zymogens that require proteolytic activation to 
induce apoptosis (Shi 2002). Caspases have a cysteine residue at the active site and 
are cleaved after aspartic acid (Asp) residues, hence the name, C-ASP-ase. As 
summarised in Figure 1.4.1, procaspases contain an N-terminal prodomain, as well as 
sequences that encode the large (p20) and small (p10) subunit of the activated 
protease. These subunits form a heterodimer, with two such dimers assembling to for 
the active tetramer (Alberts 2008).  The initiator caspases can be characterised by a 
long prodomain (>90 amino acids), containing a caspase recruitment domain (CARD) 
that serves as a platform for the recruitment of activating adapter proteins, such as 
Apaf-1 (Kurokawa & Kornbluth 2009) inducing activation and the subsequent 
amplifying, irreversible caspase cascade (Figure 1.4.2). 
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Caspase-1, or mammalian interleukin-1β-converting enzyme (ICE), was the first 
caspase hypothesized to be involved in apoptosis because of the enzyme’s homology 
with CED-3, the product of a gene (ced-3) required for death in the nematode C-
elegans (Slee et al. 1999). It has now been identified that caspase-1 is primarily 
involved in the induction of inflammation (Yuan et al. 1993). However, caspase-1 
involvement in chromogranin-A-induced microglial apoptosis has been observed in our 
laboratory (Kingham et al. 1999; Kingham & Pocock 2000) 
As well as caspase-1, other homologues of the C- elegans protein CED-3 in mammals 
have been characterized including caspase-3, and caspase-9, which have been 
identified as major components in mammalian cell death cascades (Thornberry 1998). 
To date 14 distinct mammalian caspases have been identified, eight of which have 
been found to be involved in apoptosis (Shi 2002).  
The use of C- elegans also identified homologues in mammals of the genes ced-4 and 
ced-9 as Apaf-1 and members of the Bcl-2 family, respectively (Danial & Korsmeyer 
2004). The adaptor protein Apaf-1 has been shown to interact with cytochrome c, 
released from mitochondria during initiation of the intrinsic pathways of apoptosis, 
forming a heptomeric mega-complex called the ‘apoptosome’, which in turn induces 
cleavage of initiator caspases, such as procaspase-9 (Shi 2002) with subsequent 
activation of executioner caspases (Figure 1.4.3 & 1.4.4). The requirement for multi-
component complexes to proteolytically cleave initiator caspases is a good example of 
the tight regulation of caspase activation.  
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Figure 1.4.1. The main protein domains of the regulators of apoptosis 
Caspases contain three main domains: a prodomain and large (p20) and small 
(p10) catalytic domains. The large domain contains the active Cys residue with 
activation of caspases involving proteolytic cleavage including the removal of 
the prodomain and separation of the p20 and p10 subunits. 
 BCL-2 family proteins are sub-divided into three classes based on domain 
homology: anti-apoptotic (such as Bcl-2 and BclXL), multidomain pro-apoptotic 
(BAX and BAK) and BH3-only (such as BIM, BID, BAD, PUMA). 
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1.4.1.1.1. Emerging non-apoptotic roles for caspases 
In the last few years, caspases have been shown to be involved in non-apoptotic 
cellular processes. These range from a vital requirement for caspase-3 in long term 
depression (Li et al. 2010), and synaptic pruning and internalisation of AMPA receptors 
leading to early synaptic dysfunction in AD models (D’Amelio et al. 2011). Caspase-3 
has also been shown to be involved in Aβ1-42-mediated inhibition of long term 
potentiation (Jo et al. 2011). However, most interestingly with respect to this thesis, 
caspase-8 and -3/7 have now been shown to be intrinsic in LPS-mediated microglial 
activation (Burguillos et al. 2011; Venero et al. 2011). These new findings will be taken 
into consideration when critically analysing the data presented here.  
1.4.1.2. The intrinsic pathway of apoptosis 
The intrinsic pathway of apoptosis can be initiated by DNA damage, loss of cell 
adherence, or ER stress (Lindsten et al. 2005), to name a few. It involves caspase 
CLEAVAGE
COOH
NH2
COOH
NH2
Cleavage 
Sites
Active Tetramer 
CLEAVAGE
Discarded prodomains
Caspase Cascade - AmplificationProteolytic cleavage of caspases
APOPTOSIS
Figure 1.4.2. Classical activation of caspase zymogens during the apoptotic 
cascade 
After discarding of the caspase prodomain, the p20 (orange) p10 (purple) domains 
are cleaved and form an active caspase tetramer with two other domains. The 
initiator caspases, once cleaved, can themselves activate many executioner 
caspases leading to an amplification of the signal transduction. The executioner 
caspases can then cleave a variety of key proteins in the cell leading to programmed 
cell death. Adapted from Alberts 2008. 
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cascade activation and is tightly regulated by the Bcl-2 family of proteins. The family, 
consisting of anti- and pro-apoptotic members, is divided into three main subclasses 
based on the homology shared within four conserved domains termed ‘Bcl-2 homology 
(BH) 1-4 domains (Danial & Korsmeyer 2004) (Figure 1.4.1). The families namesake, 
Bcl-2, was the first member to be discovered. It was shown to block cell death following 
treatment with an array of physiological and pathological stimuli and was therefore the 
first of the anti-apoptotic members of the family to be discovered. Bax was the first pro-
apoptotic member to be discovered (Oltvai et al. 1993) after interactions with Bcl-2 
were observed. The inactive form of Bax resides in the cytosol or loosely anchored to 
membranes. On induction of a death signal the protein complexes into 
homooligomerised multimers that form pores in the outer mitochondrial membrane 
allowing efflux into the cytosol of cytochrome c (Lauber et al. 2001), leading to 
apoptosome formation and subsequent cellular breakdown. Upstream of these signals 
lay the BH3-only members of the Bcl-2 family. These proteins selectively respond to 
specific death/survival signals, serving as cellular sentinels (Figure 1.4.3).   
Focussing on neurodegenerative disease, the exact mechanisms of mitochondrial 
injury is relatively unknown; however it is likely to include input from reactive oxygen 
species (ROS), excitotoxins and/or toxic proteins. Intracellular Ca2+ is of the utmost 
importance for many neuronal functions including cell death and it has been shown that 
changes in the calcium homeostasis within cells can initiate intrinsic pathways leading 
to apoptosis. When intracellular levels of calcium exceed physiological levels, neuronal 
death can occur (Degterev et al. 2001). Furthermore, with the endoplasmic reticulum 
being the largest store of calcium in the mammalian cell, much emphasis is now 
focussed on the involvement of the ER-associated activation of the intrinsic pathway of 
apoptosis in neurodegenerative disorders, which will be discussed in more detail in 
section 1.4.1.4.  
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1.4.1.3. The extrinsic pathway of apoptosis 
The extrinsic pathway is initiated through activation of death receptors on the cell 
surface. These contain a ligand binding domain, a single transmembrane domain, and 
an intracellular death domain. The receptors are homotrimers and belong to the TNF 
receptor family. The ligands that activate the death receptors are also structurally 
related homotrimers that belong to the TNF family of signal proteins (Alberts 2008). 
The receptors include FAS-Receptor (FAS-R; also known as Apoptosis antigen-1), 
tumour necrosis factor receptor 1 (TNFR1), TNFR2, and TNF-related-apoptosis 
inducing ligand receptor 1 (TRAILR1). Activation of these receptors, particularly TNFR1 
and FAS-R can cause apoptosis independently or the cascades can converge with 
intrinsic pathways at the mitochondria (Cecconi et al. 1998), via the recruitment of BH3-
only proteins (Danial & Korsmeyer 2004)  . 
FAS-R is a major death receptor in apoptosis relating to neurological disorders. Under 
normal physiological conditions FAS expression is relatively low; however during 
BH3-only
Anti-apoptotic 
Bcl-2 family
Multi domain 
pro-apoptotic
BAD
BID
BIM
PUMA
BAX
BAK
Bcl-2
Bcl-XL
Mitochondrion
Endoplasmic 
reticulum
Apoptosome Effector Caspases
Ca2+ release
Cytochrome c
release
BAX
BAX
Apaf-1
Caspase-9
Cytochrome c
Figure 1.4.3. The intrinsic pathway of apoptosis 
Initiation of the intrinsic pathway of apoptosis occurs after DNA damage, loss of 
cell adherence or ER stress. BH3-only Bcl-2 proteins activate the multi-domain 
pro-apoptotic family of Bcl-2 proteins leading to cytochrome c release from the 
mitochondria and ER stress-mediated Ca2+ dyshomeostasis. Cytochrome c 
completes the apoptosome which initiates effector/executioner caspase-
mediated apoptosis Adapted from Degterev and Yuan 2008. 
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chronic neurodegenerative disorders, such as AD, expression is significantly enhanced 
(Lukiw 2004). Taylor et al. 2005 reported that TNF-α required the presence of the Fas 
receptor ligand, FasL, to induce neurotoxicity after activation of the microglial 
metabotropic glutamate receptor 2 (mGluR2) with the group I agonist DCGIV. 
The FAS-FASL interaction, extracellularly, can lead to cell death by recruitment of the 
Fas-associated death domain (FADD), which complexes with caspase-8 inducing 
activation (Benn & Woolf 2004). This complex is known as the death inducing signalling 
complex (DISC) (Figure 1.4.4). Caspase-8 in turn can stimulate downstream caspase-
3 activation via an apoptosome-independent mechanism and/or initiate intrinsic 
apoptotic pathways via association with the BH3-only protein Bid (Danial & Korsmeyer 
2004). 
TNFα, a pro-inflammatory cytokine associated with microglial activation and 
neurodegenerative disorders can bind and activate death receptors including TNFR1 
and TNFR2. Activation of TNFR1 initiates recruitment to the intracellular complex of 
TNF receptor associated death domain (TRADD). TRADD functions as a platform for 
the binding of two mediators, FADD and receptor interacting protein (RIP-1) (Micheau 
& Tschopp 2003). The addition of these proteins to the complex defines whether a 
death or survival pathway is initiated, respectively (Figure 1.4.4). Interestingly, RIP-1 
has also been identified in another type of cell death termed necroptosis, a regulated 
form of necrosis (Holler et al. 2000; Hitomi et al. 2008).  As suggested for FAS-R-
associated extrinsic apoptosis, FADD recruitment to the DISC can induce activation of 
procaspase-8 which in turn can trigger amplification of downstream caspase cascades 
(Benn & Woolf 2004).  
The cytokine TNFα not only has the capacity to directly kill cells via receptor-mediated 
activation of caspases, but also indirectly via the upregulation of apoptotic factors such 
as nitric oxide and α-chemokines (Benn & Woolf 2004). However, TNFα activation and 
the subsequent pathways do not always end with programmed cell death. 
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Observations have shown a TNFα pro-survival pathway via NFκB and activation of 
TNFR2 (Benn & Woolf 2004). 
 
  
Figure 1.4.4. An overview of the extrinsic and ER stress-mediated pathways of 
apoptosis 
Initiation of the extrinsic pathway of apoptosis occurs through death receptors such as 
TNFR1, FAS and TRAIL. This activation leads to intracellular recruitment of death 
domain proteins such as RIP, TRADD, FADD, TRAF2 and ASK1 that form a death 
inducing signalling complex (DISC). This in turn can activate caspases including 
caspase-8 and-10 that amplify the signal transduction either through the apoptosome, 
which includes caspase-9 and APAF-1 and cytochrome c, or through convergence 
with the intrinsic pathway of apoptosis via the BH3-only protein, Bid. Bid translocates 
to the mitochondria upon activation where it can regulate the release of cytochrome c, 
thus inducing formation of the apoptosome and subsequent apoptosis via caspase-3, -
6, and -7 activation. ER stress-mediated apoptosis can occur through the PERK-
eIF2α-ATF4-CHOP axis that leads to activation of caspase-3, -6, and -7. ER stress 
can also induce apoptosis via an IRE1α-ASK-p53 depedent pathway that leads to the 
BCL-2 protein Bax translocating to the mitochondria leading to release of cytochrome c 
and subsequent apoptosome formation. Furthermore caspase-12-dependent ER 
stress mediates its effects after calcium dyshomestasis and cleavage by m-calpain, via 
convergence with the apoptosome or by translocation to the nucleus. Finally, BH3-only 
proteins Bim and Bik have been identified as mediators of crosstalk between the 
mitochondria and the ER during apoptosis, with Bim translocating from the 
mitochondria to the ER and Bik translocating in the opposite direction.      
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1.4.1.4. ER stress and it’s role in apoptosis 
Interest in the role of the endoplasmic reticulum (ER) in apoptosis after cell stress 
induction has increased over the last decade with the identification of ER-localised 
caspases (caspase-12 and -4), involved in Aβ-mediated neurotoxicity in mouse models 
(Nakagawa et al. 2000; Hitomi et al. 2004). Also, identification of a pro-apoptotic Bcl-2 
family protein, Bik, shown to be localised to the ER whilst having pro-apoptotic effects 
on the mitochondria (Germain et al. 2002) further supported ER involvement in some 
forms of cellular apoptosis. Another pro-apoptotic member of the Bcl-2 family, Bim, has 
also been shown to translocate to the ER membrane and is important for ER stress-
mediated cell death (Puthalakath et al. 2007).  
The ER is a subcellular organelle with a luminal volume equating to approximately 10% 
of total cell volume. Under normal physiological conditions, the ER is the cellular area 
where the majority of secretory and transmembrane proteins are glycosylated and 
correctly folded (Alberts 2008). A number of stresses can disturb ER homeostatic 
functions including calcium dyshomeostasis, hypoxic or ischaemic conditions, the loss 
of an oxidising environment and protein overload (Szegezdi et al. 2003). These 
conditions can promote accumulation of unfolded proteins, leading to an induction of 
the unfolded protein response (UPR). 
Upon activation, the UPR essentially shuts down protein manufacture in the ER 
allowing an ER-associated protein degradation system (ERAD) to remove any 
accumulated mis-folded proteins. The UPR is mediated by three molecules known as 
the inositol-requiring-1 homologue (IRE1α), activating transcription factor 6 (ATF6), and 
protein kinase R-like endoplasmic reticulum kinase (PERK). These molecules are 
localised in the ER membrane and sense protein aggregation, triggering the UPR 
(Szegezdi et al. 2003). During acute dyshomeostasis, induction of the UPR is a pro-
survival mechanism. However, with chronic ER stress the UPR is able to initiate 
apoptosis. Of the three main arms of the UPR, it is generally thought that ER-mediated 
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apoptosis can occur via the IRE1α-associated branch and the PERK-associated 
branch (Benn & Woolf 2004) (Figure 1.4.4). A third, caspase-associated, pathway can 
also be activated in cells undergoing ER stress-mediated apoptosis via cleavage and 
processing of caspase-12 (Nakagawa et al. 2000; Szegezdi et al. 2003).  
1.4.1.4.1. CHOP and Caspase-12 in ER stress-mediated apoptosis 
CHOP (or GADD153) is a 29 kDa protein with 169 amino-acid residues, expression of 
which is mainly regulated at the transcriptional level (Oyadomari & Mori 2003). During 
ER stress all arms of the UPR induce transcription of CHOP. However, for CHOP 
protein translation to occur, the PERK-eIF2α-ATF4 branch of the UPR is essential 
(Szegezdi et al. 2006). Previous studies have shown that over expression of CHOP 
can lead to growth arrest and apoptosis (Kawahara et al. 2001). Also, CHOP-/- 
fibroblasts have shown resistance to ER stress mediated death (Oyadomari et al. 
2001). Furthermore, inhibition of eIF2α dephosphorylation by salubrinal protects 
against excitotoxic neuronal death (Sokka et al. 2007). These data suggest a strong 
association between the PERK-eIF2α-ATF4 branch of the UPR, CHOP expression and 
ER stress-induced apoptosis. Limited association of ER stress with microglial activation 
has been published. Depletion of microglial calcium stores by increased levels of nitric 
oxide has been shown to induce CHOP-associated stress responses leading to 
apoptosis (Kawahara et al. 2001). Further support for CHOP-associated microglial 
apoptosis was observed in our laboratory, with published data suggesting a correlation 
between an increase in CHOP expression after treatment of primary microglial cultures 
with LPS, chromogranin A or Aβ peptide, and subsequent microglial apoptosis 
(Davenport et al. 2010).  
Caspase-12 is a member of the group I family of ‘ICE’-like caspases, initially 
suggesting an inflammatory role. However, identification and localisation of caspase-12 
to the ER and its subsequent involvement in ER stress-mediated apoptosis identified 
an alternative pathway to the ER transcription factor-mediated death pathways 
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(Nakagawa et al. 2000). More recent studies have shed controversy on the role of 
caspase-12 in humans. Of the 9 different, alternatively spliced mRNA species for 
caspases-12, all have acquired frame shift mutations and premature stop codons, 
potentially inhibiting translation of a fully functional protein (Fischer et al. 2002). 
However, mRNA editing and post-translational modifications enabling synthesis of a 
functional protein cannot be ruled out. This hypothesis is supported by data from a 
variety of disease models, including  cancer (Mandic et al. 2003), Prion disease (Hetz 
et al. 2003), and recently Alzheimer’s disease (Lee et al. 2010) suggesting involvement 
of a functional human caspase-12 protein in ER stress-mediated apoptosis. Proposals 
have also been made for human caspase-4 as the direct homolog of rodent caspase-
12. It has been localised to the ER and is involved in Aβ-mediated neurotoxicity using 
human cell lines (Hitomi et al. 2004)  
With regards to the execution of apoptosis by caspase-12, differing mechanisms have 
been published. A mitochondrial-independent mechanism for caspase-12 induction has 
been proposed by Morishima and colleagues (2002). They show caspase-12 
translocates from the ER to the cytosol directly cleaving procaspase-9 which turn 
cleaves procaspase-3 (Morishima et al. 2002). These data have been supported by 
studies using Apaf-/- mouse fibroblasts, which were still able to undergo ER stress-
mediated apoptosis (Rao et al. 2002). Conversely, other laboratories have suggested 
close links between the ER & mitochondria, in particular, with respect to calcium 
dyshomeostasis and downstream cascades (Nakamura et al. 2000) with regulation of 
cytosolic calcium homeostasis from ER stores shown to utilise mitochondrial 
associated Bcl-2 family proteins (Bcl-2 and Bcl-xL to inhibit release, and Bax and Bak to 
promote release) via ER located calcium channels such as IP3R (Lindholm et al. 2006). 
Further involvement of calcium in caspase-12-mediated apoptosis has been suggested 
through crosstalk between the calcium activated cysteine proteases, the calpains, and 
caspase-12 in Aβ-mediated apoptosis (Nakagawa & Yuan 2000). Nakagawa and 
colleagues show calcium dyshomeostasis due to Aβ exposure leads to m-calpain-
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dependent processing of caspase-12 into the p10 and p20 subunits leading to an 
executioner caspase cascade via procaspase-9.    
1.4.1.4.2. ER stress in neurodegeneration 
The accumulation of mis-folded proteins is a pathological hallmark of many 
neurodegenerative disorders, for example Alzheimer’s disease, where there is an 
association with the pathological accumulation of Aβ aggregates. Significant induction 
in PERK and eIF2α expression has been observed in AD patients, however no 
significant increase in these immediate response ER stress markers was observed in 
Prion diseases, unless neurofibrillary tangle pathology was also present (Unterberger 
et al. 2006). Interestingly, Lee and colleagues (2010) also found significant 
upregulation of markers associated with ER stress-mediated cell death in AD patient 
samples. However, no significant induction was observed in samples taken from the 
aged transgenic AD mouse model, Tg2576 (Lee et al. 2010), which has significant 
plaque burden but no tangle pathology (Richardson & Burns 2002). These data 
suggest a prominent role for neurofibrillary tangles in transcription factor-associated ER 
stress, with limited involvement from Prion protein or Aβ aggregates. Interestingly, 
caspase-12- and caspase-4-associated ER stress pathways in rodents and humans, 
respectively, seems to be responsible for inducing Aβ-mediated apoptosis in neurons 
(Nakagawa et al. 2000; Hitomi et al. 2004), suggestiing that differential ER stress 
pathways are activated by differing pathologies. This is further supported with respect 
to Prion diseases with studies suggesting Prion protein toxicity is dependent on 
caspase-12 activity (Hetz et al. 2003).  
Finally, with respect to AD and ER stress, the presenilin-1 (PS1) protein potentially 
links ER stress to pathogenesis of the disease. PS1 is an ER transmembrane protein, 
mutations in which are present in cases of autosomal dominant familial Alzheimer's 
disease (FAD) (Berezovska et al. 2005). PS1 and its homolog PS2 are part of the 
multiprotein γ-secretase complex that mediates cleavage of amyloid precursor protein 
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(APP). Mutations in PS1 have been shown to alter APP processing leading to an 
increased ratio of toxic Aβ42 to Aβ40 (Lindholm et al. 2006), leading to plaque burden 
and early age of onset. Cells with PS1 mutations have been shown to have altered 
calcium homeostasis and an enhanced sensitivity to ER stress-mediated apoptosis. 
Furthermore, mutant PS1 inhibits IRE1α, suppressing UPR activation, causing a 
decrease in the cells sensitivity to ER stress (Lindholm et al. 2006). 
Again using genetic models of neurodegenerative diseases, the study of rare familial 
forms of Parkinson’s disease (PD) has provided elucidation of cellular pathways and 
mechanisms suggested to be important in disease progression. Of the genetic risk 
factors identified, the ubiquitin ligase, Parkin, has been of most interest with respect to 
ER stress pathways evoked in PD pathogenesis (Lindholm et al. 2006). Parkin is 
frequently mutated in early onset PD (Imai & Takahashi 2004) with loss of function 
mutations shown to be responsible for the majority of autosomal recessive 
Parkinsonism cases (Lindholm et al. 2006). Functional Parkin suppresses ER stress-
mediated death (Imai et al. 2000), whereas loss of Parkin has been shown to cause ER 
stress via accumulation of cytotoxic fibrils and protein aggregates (Imai & Takahashi 
2004). Recently, studies by Bouman and colleagues showed functional Parkin to be 
stress protective with a role in interorganellar crosstalk between the ER and 
mitochondria, promoting survival in cells undergoing stress (Bouman et al. 2011). 
These data further support the idea that ER stress could contribute to the pathogenesis 
of Parkinson’s disease. Finally, the use of compounds to model the selective loss of 
dopaminergic neurons observed in PD (such as 6-hydroxy-dopamine (6-OHDA) and N-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)), shows a significant induction of 
ER stress in cell cultures of dopaminergic neurons leading to increases in CHOP 
expression and phosphorylation of PERK and IRE1α (Ryu et al. 2002).  
Studies into motor neurone disease pathogenesis have suggested roles for ER stress 
mediated neuronal death, in particular in familial amyotrophic lateral sclerosis (FALS) 
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(Atkin et al. 2006) where significant expression of ER stress related markers were 
observed. Further support for a role for ER stress in ALS was provided by Nagata and 
colleagues (2007) who also found a significant induction in ER stress-related markers 
in lysates from lumbar spinal cord of transgenic mice carrying a mutation (G93A) in the 
SOD1 gene. The paper suggests that due to an observed disproportionate increase in 
pro-apoptotic markers in comparison to anti-apoptotic markers, such as GRP78, an 
imbalance occurs leading to ER stress prone cells (Nagata et al. 2007). Following on 
from these suggestions interesting studies into motor neurone disease using three 
separate mouse models of FALS show a subset of ‘vulnerable’ motor neurons are 
more susceptible to ER stress, showing an upregulation of ER stress markers from 
birth. Inhibition of ER stress using salubrinal attenuated disease and it is suggested 
that these vulnerable neurons, susceptible to ER stress, influence progressive 
manifestations of weakening and paralysis (Saxena et al. 2009). 
Finally, very limited data has been published on the role of ER stress in multiple 
sclerosis (MS) lesions. However, increased expression of ER stress markers including 
CHOP, XBP-1 and BiP has been observed in oligodendrocytes, astrocytes and 
microglia in active MS lesions (Mháille et al. 2008; Cunnea et al. 2011).  
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1.5. Fibrinogen and Fibrin – structure and evidence for prominent 
roles in neurodegenerative disease pathogenesis 
The role fibrinogen and fibrin in the progression of NDDs has received increasing 
attention since BBB barrier dysfunction and vascular abnormalities were shown to be 
common features of some NDDs. Elevated levels of fibrinogen in blood plasma have 
been shown to correlate with an increased risk for Alzheimer’s disease (AD) and 
dementia (van Oijen et al. 2005; Xu et al. 2008). Furthermore, in the pursuit for 
biomarkers to enable early diagnosis of Alzheimer’s disease, the level of fibrinogen-γ-A 
chain precursor was shown to be raised in the cerebrospinal fluid of AD patients when 
compared with aged matched controls (Lee et al. 2007).  
Separate from classical involvement in the coagulation cascade, fibrinogen and fibrin 
can bind and activate mononuclear cells, including microglia, with increased cytokine 
release observed (Fan & Edgington 1993; Perez & Roman 1995; Perez et al. 1999; 
Smiley et al. 2001; Adams et al. 2007a; Jensen et al. 2007; Hodgkinson et al. 2008), 
supporting a role for the protein in the inflammatory responses now considered key to 
the pathogenesis of many NDDs. Furthermore, detrimental association with classical 
NDD peptides such as Aβ (Cortes-Canteli et al. 2010) only promotes further evidence 
of an involvement in progressive neurodegeneration. Here, the structure of fibrinogen 
and the cleavage product fibrin will be briefly described, followed by published 
evidence on the significant contributions from these blood borne protein products in 
NDDs, in particular AD and MS. An emphasis on studies suggesting fibrinogen-
mediated activation of microglia will be presented. 
1.5.1. Structure of fibrinogen and its cleaved product fibrin 
Fibrinogen (FG) is a 340 kDa soluble glycoprotein synthesized by hepatocytes which 
under normal physiological conditions circulates at a concentration of approximately 3 
mg/ml (Schachtrup et al. 2007). FG molecules are 45 nm elongated protein dimers, 
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which consist of two outer D-domains connected to a central E-domain by coiled coil 
segments (Figure 1.5.1) (Mosesson 2005). The domains consist of duplicate Aα-, Bβ- 
and γ-chains derived from separate genes coupled by multiple disulphide bridges 
primarily at the N-terminals in the ‘E’ domain of the molecule (Figure 1.5.1). Each Aα 
chain contains an N-terminal fibrinopeptide A sequence that is cleaved by the protease 
thrombin, initiating assembly of fibrin (FN) (Mosesson 2005).  
The cleavage of FG by thrombin exposes polymerisation sites that have affinity for 
complementary binding pockets located in the γ-chains present in the D domain of 
neighbouring FG molecules. This initially creates staggered overlapping protein 
binding, generating double stranded fibrils, known as fibrinogen polymers (Adams et al. 
2007a). These polymers are further stabilised and cross-linked by Factor XIII 
(transglutaminase) of the coagulation cascade, leading to creation of an insoluble FN 
clot. When no longer required, the clot is degraded and cleared via proteolysis by the 
enzyme plasmin (East et al. 2008). Plasmin is produced from cleavage of the precursor 
protein plasminogen with regulation by either tissue-type plasminogen activator (tPA) 
or urokinase-type (uPA) (Akassoglou & Strickland 2002). The tPA has been shown to 
be constitutively expressed in the rodent brain (Sappino et al. 1993), and microglia 
have been shown to express uPA (Cunningham et al. 2009). Furthermore, both 
activators have been shown to be over-expressed in microglia after brain injury 
(Dietzmann et al. 2000). 
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1.5.2. The functions of fibrinogen and fibrin in chronic neurodegenerative disease 
pathogenesis 
Vascular pathology has been identified as an important factor in Alzheimer’s disease. 
Cerebral amyloid angiopathy (CAA) is the deposition of Aβ peptide in the vasculature 
and is important in the severity of AD disease pathology (Cortes-Canteli et al. 2010). 
CAA has been shown to promote degradation of vessel wall components, negatively 
affect cerebral blood flow leading to chronic brain hypoperfusion and enhance cognitive 
decline (Greenberg et al. 2004; de la Torre 2006; Thal et al. 2008). Epidemiological 
studies provide further evidence for a strong vascular component in AD, with vascular 
diseases such as stroke, atherosclerosis and hypertension associated with an 
increased risk for dementia and AD (de la Torre 2002). Moreover, neuronal loss and 
memory deficits have also been proposed as secondary to the vascular component in 
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Figure 1.5.1. The structure of fibrinogen 
Fibrinogen molecules are composed of elongated protein dimers consisting of 
duplicate Aα-, Bβ- and γ-chains derived from separate genes coupled by multiple 
disulphide bridges (A). The molecule is segregated into two outer D-domains 
connected to a central E-domain by coiled coil segments (B). 
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AD (Cortes-Canteli et al. 2010).  
FN deposition is observed in the vessels and CNS parenchyma of AD mice (Cortes-
Canteli et al. 2010; Paul et al. 2007). Furthermore FG has been shown to accumulate 
in the extravascular space in AD patients (Fiala et al. 2002; Ryu & McLarnon 2009). 
Inhibition of plasmin fibrinolytic activity, increased levels of prothrombotic molecules 
(Arai et al. 2006) and BBB dysfunction present in AD brains have been proposed as 
contributors to this FG accumulation and subsequent FN deposition (Zlokovic 2008; 
Cortes-Canteli et al. 2010). As previously described in section 1.2, BBB dysfunction 
has been shown to occur in many neurodegenerative disorders, including acute events 
such as ischaemic stroke (Sandoval & Witt 2008), and chronic diseases such as AD, 
PD, ALS and MS (Zlokovic 2008; Quaegebeur et al. 2011). This dysfunction enables 
FG and other components of blood to extravasate into the CNS parenchyma with 
subsequent haemorrhage and neuronal damage occurring (Adams et al. 2004). 
Interestingly some blood borne molecules have been shown not to cross into the 
parenchyma in AD (Sagare et al. 2007) suggesting specific interactions are still 
required to permit extravasation of FG into the CNS.  
Paul and colleagues (2007) have shown fibrin deposition in animal models of AD 
accelerated neurovascular damage. Inhibition of plasmin, thus preventing FN clot 
degradation, significantly enhanced the extravasation of Evans blue into the CNS, 
which could be attenuated if prior depletion of fibrinogen was performed (Paul et al. 
2007). Furthermore the paper shows a positive correlation between blood brain barrier 
damage induced by inhibition of FN clot degradation, and microgliosis, which could 
again be attenuated if prior depletion of FG was performed, suggesting FN deposition 
enhances neuroinflammation in these models (Paul et al. 2007). 
Studies by Cortes-Canteli and colleagues (2010) propose a direct link between FG, Aβ 
and CAA-associated physiology. In vitro and in vivo experiments showed FN clots 
formed in the presence of Aβ peptide were structurally abnormal and resistant to 
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degradation. Interestingly, stereotactic administration of FG into the CNS parenchyma 
of 6 month old AD mice was not cleared efficiently, when compared with younger 
transgenics or wildtype mice of the same age, suggesting a negative correlation 
between FG clearance and Aβ plaque burden. Furthermore, this delayed clearance 
seemed to be specific to FG as bovine serum albumin (BSA) administration was 
cleared with no significant loss of efficiency when plaque burdened AD mice and 
wildtype litter mates were compared (Cortes-Canteli et al. 2010). Finally, the paper 
provides physiological evidence to suggest the presence of FG contributes to CAA-
associated cognitive decline in AD mouse models. Together these data provide 
significant evidence that FG extravasation and FN deposition in the CNS, and FN 
deposition in the vasculature, contributes to AD disease pathogenesis.        
One of the earliest events coupled to the observed BBB dysfunction in MS (van 
Horssen et al. 2007) is the leakage of FG into the CNS resulting in perivascular 
deposition of FN (Adams et al. 2007a). A significant  volume of research, utilising in 
vitro and in vivo models, suggests a link between MS disease severity, FG and the 
subsequent FN deposition (Kwon & Prineas 1994; Akassoglou et al. 2000; Akassoglou 
et al. 2002; Akassoglou et al. 2004; East et al. 2005; Adams et al. 2007a; Adams et al. 
2007b; East et al. 2008; Yang et al. 2011a).  
In animal models of MS, genetic knockdown or pharmacological depletion of FG was 
shown to decrease inflammation and delay demyelination (Akassoglou et al. 2004; 
Yang et al. 2011a). An indirect correlation between FN deposition and aggressiveness 
of MS disease progression can also be taken from studies performed by East and 
colleagues. Induction of experimental allergic encephalomyelitis (EAE), an animal 
model for MS, in tPA genetic knockout mice (tPA-/-) was performed in parallel with EAE 
induction in wildtype mice. The tPA-/- EAE mice showed an enhanced, early and more 
severe onset of acute disease with an incomplete recovery when compared with the 
wild-type controls (East et al. 2005), suggesting a decrease in FN clot degradation 
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efficiency can enhance disease severity, again implicating FG and FN in disease 
pathogenesis. However, although enhanced FN accumulation was observed in these 
mice, a tPA-dependent mechanism independent of FN could be responsible and 
should not be overlooked. Interestingly, increases in tPA expression observed in MS 
studies are matched by a significant increase in the tPA inhibitor, plasminogen activator 
inhibitor-1 (PAI-1), suggesting inefficient clearance of fibrin would still occur (East et al. 
2008). 
Limited data has been published on involvement of FG in PD. One study shows no 
significant increase in circulating FG levels, used as a biomarker for inflammation 
(Chen et al. 2008). However, it must be noted that the sample size was very small (84 
cases, compared with 165 matched controls), and a later, larger study (>8000 
participants) showed an association between increased FG levels and prevalence of 
PD in patients over 75 years of age (Wong et al. 2010). This epidemiological study 
suggests possible involvement of FG in late stage PD but no in vitro or in vivo animal 
model studies have been performed to identify whether FG has any specific signalling 
capacity in the observed dopaminergic neuron degeneration, either directly or via 
inflammation.  
Similarly, little evidence has been published for FG involvement in ALS. One study to 
date has shown significantly enhanced serum FG levels in 80 ALS patients compared 
with age-matched controls (Keizman et al. 2009) but no specific involvement in motor 
neuron weakening or paralysis has been suggested.   
1.5.3. Cellular interactions and signalling with fibrin and fibrinogen 
Fibrin(ogen) has been shown to have a vast signalling capacity with involvement in 
inflammatory mechanisms of a wide range of disorders including rheumatoid arthritis, 
sepsis, myocardial infarction, infection and MS (Adams et al. 2007b). Aside from the 
well-documented role in the coagulation cascade, FG can mediate leukocyte 
88 
 
proliferation and inhibit apoptosis (Whitlock et al. 2000). Furthermore FG and FN can 
induce the release of pro-inflammatory cytokines from a human monocytic cell line 
(Perez et al. 1999) or primary human isolated peripheral blood monocytes (Fan & 
Edgington 1993; Jensen et al. 2007). 
As previously described (Section 1.1.5.2.2), the CD11b/CD18 (αMβ2, MAC-1, CR3) 
receptor is a member of the β-integrin family of receptors and orchestrates the innate 
immune response by regulating phagocyte adhesion, migration and engulfment of 
potentially harmful factors (Ehlers 2000). The receptor is expressed on microglia cells, 
and upregulation has been observed in AD brains post mortem (Akiyama & McGeer 
1990). The receptor has also been shown to mediate LPS-induced production of 
superoxide in microglia (Pei et al. 2007). FG association with CD11b/CD18 on many 
immune cells suggests an important role for the receptor in FG-induced inflammatory 
responses. FG-mediated TNFα release in isolated peripheral blood mononuclear cells 
(PBMCs) was dependent on CD11b (Fan & Edgington 1993). Furthermore, FG 
treatment of the human monocytic cell line U937 induced significant IL-1β expression 
via CD11b and NFκB signalling (Perez et al. 1999).  
To date, only one in vitro signalling paper has been published identifying FG-mediated 
activation of microglia (Adams et al. 2007a). FG was shown to induce a phagocytic 
phenotype in microglia via a CD11b signalling pathway dependent on PI3K and RhoA, 
two major downstream signals from CD11b that mediate cytoskeletal rearrangements 
associated with changes in cell morphology (Adams et al. 2007). Interestingly, the 
paper uses what they term ‘immobilised’ FG to induce this interaction. This is due to 
studies undertaken into the mechanism of fibrinogen ligation to CD11b. These studies 
suggested that FG contains a masked, cryptic binding site in the γ-chains that is not 
able to associate with CD11b until the protein has become immobilised, i.e. in a 
polymerised form (Lishko et al. 2002). However, as previously shown, soluble FG can 
induce cytokine release from PBMCs (Perez & Roman 1995; Perez et al. 1999; Jensen 
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et al. 2007) including human macrophages (Hodgkinson et al. 2008), and subsequently 
the same group involved in the identification of the cryptic binding site in FG published 
further data suggesting multiple binding domains in the FG molecule with an ability to 
ligate CD11b (Lishko et al. 2004). 
Another integrin receptor CD11c/CD18, associated with dendritic cells, has been 
shown to interact with FG inducing activation (Ugarova & Yakubenko 2001). Moreover, 
FG has been associated with the αvβ3 integrin receptor on CGCs causing inhibition of 
neurite outgrowth via phosphorylation of the epidermal growth factor (EGF) receptor 
(Schachtrup et al. 2007). Studies using the RAW264.7 mouse macrophage-like cell line 
and primary peritoneal macrophages, have also shown FG can induce chemokine 
secretion with dependence on toll-like receptor 4 (TLR4) (Smiley et al. 2001).  
Finally, FG has been shown to serve as an early signal in glial scar formation via the 
TGFβ/Smad signalling pathway in astrocytes. It was shown that FG can act as a carrier 
of latent TGFβ and induces phosphorylation of Smad2 in astrocytes leading to an 
inhibition of cortical neurite outgrowth potentially due to FG-mediated release of the 
chondroitin sulphate proteoglycan, neurocan, from astrocytes (Schachtrup et al. 2010).  
Together these data show the capabilities of the FG molecule through interactions with 
an array of receptors on differing cell types as well as providing a pool of TGFβ to 
induce inhibitory signalling. This broad receptor signalling capacity leads to differential 
induction of cytokines and chemokines suggesting FG may be able to promote diverse 
responses during different stages of inflammation as well as having a role in the 
inhibition of adult neurogenesis.  
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1.6. Aims and Objectives 
The role of microglia in neurodegeneration is an increasing area of research and roles 
for blood borne proteins in CNS disease progression are being continually implicated. 
Little research has been performed to identify how microglia respond in the presence of 
fibrinogen and fibrin at a molecular level. Here, the main aim was to try and elucidate 
members of signalling cascades involved in fibrinogen and fibrin-mediated microglial 
activation. This was performed using in vitro culture models with pharmacological 
manipulation where required. The research for this thesis was performed to identify 
answers to the following questions: 
• How do microglia respond to the presence of soluble fibrinogen and 
insoluble fibrin? 
• Is there a difference in microglial response to these factors and if so, 
how do the profiles differ? 
• Can fibrinogen and/or fibrin interact directly with neurons, in vitro? 
• Is it possible to manipulate observed responses with pharmacological 
interaction? 
• Do these data translate to human models?    
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2. Materials and Methods 
2.1. Materials 
Sprague Dawley pups for primary cultures were obtained from Central Biological 
Services, UCL, London, UK. The BV2 cell line was a kind gift from Dr Claudie Hooper 
(MRC Centre for Neurodegenerative Research, Institute of Psychiatry, Kings College 
London, UK). CO2 gas cylinders were obtained from BOC gases (Guilford, UK). Foetal 
bovine serum (FBS), Dulbecco's Modified Eagle's Medium (DMEM) powder 
(52100‐039), Minimum Essential Medium (MEM) powder (11700‐077), RPMI culture 
medium (21875-091), Earle’s balanced salts solution (EBSS) (14155-048), 
Neurobasal® medium (21103-049), B27® neuronal supplement (17504-044) and 
Trizol® reagent (15596018) were obtained from Invitrogen (Paisley, UK). MACS® 
multistand with QuadroMACS™ (130-091-051), MACS® LS columns (130-042-401) 
and human anti-CD14 MicroBeads (magnetic beads conjugated to monoclonal human 
CD14 antibodies; 130-050-201) were kindly provided by Professor Sarah Tabrizi 
(Department of Neurodegeneration, UCL Institute of Neurology) and were originally 
purchased from Miltenyi Biotec Ltd (Surrey, UK).  
Tissue culture plasticware were obtained from Appleton Woods (Buckinghamshire, UK) 
or VWR (Leicestershire, UK) and 13 mm coverslips (MIC3336) were obtained from 
Scientific Laboratory Supplies (Nottingham, UK). N,N,N',N'‐tetramethylethylenediamine 
(TEMED, 20‐3000‐25) and 30% w/v acrylamide (20‐2100‐05) were obtained from 
Severn Biotech (Worcestershire, UK). ECL Plus™ Western Blotting Reagents 
(RPN2106) and Amersham™ Hyperfilm ECL (28‐9068‐37) were purchased from GE 
Healthcare (Buckinghamshire, UK) and Immobilion® P polyvinylidene difluoride (PVDF) 
membranes (IPVH00010) were from Millipore (Watford, UK).  
FITC-ATAD-FMK caspase-12 staining kit (PK-CA577-K172-100), z-ATAD-FMK 
(caspase-12 inhibitor; PK-CA577-1079) and z-VAD-FMK (caspase-3 inhibitor; PK-
CA577-1010) were purchased from Promokine (Heidelberg, Germany) and 
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CaspaTag™ FAM-DEVD-FMK caspase-3/7 staining kit (APT423) was purchased from 
Millipore (Watford, UK). Annexin V-FITC apoptosis detection kit (ab140585) was 
procured from AbCam (Cambridge, UK).   
 N‐(2,6‐dioxo‐3‐piperidinyl)phthalimide (Thalidomide, #0652), 
2‐Amino‐5,6‐dihydro‐6‐methyl‐4H‐1,3‐thiazine hydrochloride (AMT‐HCl, #0871), 
(S)‐3,5‐Dihydroxyphenylglycine (DHPG, #0805), 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-
5-yl)benzamide (CDPPB, #3235), 3-((2-Methyl-1,3-thiazol-4-yl)ethynyl)pyridine 
hydrochloride (MTEP, #2921), (2S,2'R,3'R)‐2‐(2',3'‐Dicarboxycyclopropyl) glycine 
(DCGIV, #0975), L‐(+)‐2‐Amino‐4‐phosphonobutyric acid (L‐AP4, #0103), Thapsigargin 
(#1138), PD98059 (#1213) SB203580 (#1202), Ionomycin (#1704), BAPTA-AM 
(#2787), and Calpastatin (#2950) were purchased from Tocris Bioscience (Bristol, UK). 
Salubrinal (ALX-270-428) was procured from Enzo Life Sciences (Exeter, UK) and 
apocynin (178385), Suc-Leu-Tyr-AMC (fluorogenic calpain substrate, 208731) and m-
calpain (208718) were from Calbiochem (Merck, Middlesex, UK). 
TNF‐α (RTA00) and IL-6 (R6000B) Quantikine® ELISA kits, human recombinant GM-
CSF (215-GM) and IFNγ (585IF) were purchased from R&D Systems (Oxford, UK). 
GoTaq® DNA polymerase kits (M3175) were purchased from Promega (Southampton, 
UK) and Superscript® II Reverse Transcriptase kits (18064-014) were purchased from 
Invitrogen (Paisley, UK). A broad-range protein molecular weight marker (2-212 kDa, 
P7702) and a Quick-Load® 100 bp DNA ladder (N0464) were purchased from New 
England BioLabs (Hertfordshire, UK). 
Goat anti-TNFα (sc1351), mouse anti-GADD153 (CHOP; sc7351), rabbit anti-total-p38 
MAPK (sc535), donkey anti-goat-IgG-HRP (sc2020) and goat anti‐mouse‐IgG-HRP 
(sc2055) were purchased from Santa Cruz Biotechnology (Heidelberg, Germany). 
Mouse anti‐ED1 (MCA341) and mouse anti‐CD11b (MCA275EL) were obtained from 
AbD Serotec (Oxford, UK). Rabbit anti-iNOS (610333) and rabbit anti-bNOS (N31030) 
were obtained from BD Transduction Lab (Oxford, UK). Rabbit anti-phospho-p38 
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MAPK (9211), mouse anti‐phospho‐p42/44 MAPK (9106), rabbit anti-total-p42/44 
MAPK (9102) and rabbit anti-cleaved caspase-3 (9664) antibodies were obtained from 
Cell Signaling Technology (New England BioLabs, Hertfordshire, UK). Rabbit anti-
caspase-12 (ab18766), goat anti-mouse-FITC (ab6785) and rat IgG serotype control 
(ab37361) were purchased from AbCam (Cambridge, UK) and goat anti-rabbit-Cy3 
(A10520) was from Invitrogen (Paisley, UK). Mouse anti-NeuN (MAB377) was from 
Millipore (Watford, UK), mouse anti-CD68 (clone EBM11; M0718) was from DAKO 
(Ely, UK) and goat anti-rat-fibrinogen-HRP (GARa-Fbg-HRP) was from Source 
Bioscience (Nottingham, UK). TRITC-conjugated calnexin was kindly provided by Dr 
Adamantios Mamais (Department of Molecular Neuroscience, UCL Institute of 
Neurology). Mouse anti-βIII-tubulin (T5076), mouse anti‐β‐actin clone AC‐15 (A5441), 
rabbit anti-GFAP, (G4546), goat anti-rabbit-TRITC (T6778), and goat anti-rabbit-IgG-
HRP (A0545) were purchased from Sigma-Aldrich (Dorset, UK). 
Finally, Dulbecco’s Phosphate buffered saline without CaCl2 or MgCl2 (PBS; D5652) 
powder, LPS (Lipopolysaccharides from Escherichia coli; serotype 026:B6; L2762), 
fibrinogen (F4883), fibrin (F5386), Phenylmethylsulfonyl fluoride (PMSF, P7626), L-
glutamine (G3126), Leucine-methyl-ester (LME, L1002), N‐acetylaspartylglutamate 
(NAAG, A5930), Bradford protein assay reagent (B6916), Tween‐20 (P7949), 
ammonium persulphate (APS, A3678), photographic developer (P7042) and fixer 
(P7167), polymyxin B (PMX, P4932), Hirudin (94581), Fucoidan (F5631), 
Staurosporine (STS, 54400), Phorbol 12-myristate 13-acetate (PMA, P1585), 
Wortmannin (W1628), Tunicamycin (T7765), 4',6‐diamidino‐2‐phenylindole (DAPI, 
D8417), 2´‐(4‐Ethoxyphenyl)‐5‐(4‐methyl‐1‐piperazinyl)‐2,5´‐bi‐1H benzimidazole 
(Hoechst-33342, B2261), propidium iodide (P4170), FITC‐isolectin-B4 (L2895), 
DNAase (D5025), soybean trypsin inhibitor (T9003), bovine trypsin (T9935), cytosine 
arabinofuranoside (Ara-C, C1768), poly‐D‐lysine (PDL, P1149), freezing medium 
(C6164), 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid (HEPES, H0891), 
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ampicillin (A2804), gentamicin (G1397), penicillin‐streptomycin solution (P4333), 
ACCUSPIN™ System-Histopaque®-1077 tubes (A7054), and all bench grade 
chemicals were obtained from Sigma-Aldrich (Dorset, UK). 
2.2. BV2 cell culture and maintenance 
Limited studies were performed using the BV2 murine microglial cell line, generated by 
infecting primary microglial cell cultures with the v‐raf/v‐myc oncogene carrying 
retrovirus J2 (Blasi et al., 1990). The cells exhibit similar morphological, phenotypical 
and functional properties to primary microglia, however some studies have shown 
significant differences in activation, in particular with respect to cytokine release profiles 
(Horvath et al. 2008). Even so, the BV2 cell line is an extremely useful tool for in vitro 
microglia researchers, in particular as primary microglia culture yield is generally quite 
limited.  
BV2 microglia were maintained in T175 culture flasks in Dulbecco's modified Eagle's 
medium (DMEM) with 10% foetal bovine serum (FBS), supplemented with 2 mM L-
glutamine, 100 U/ml penicillin and 100 mg/ml streptomycin at 37°C in a humidified 
atmosphere with 6% CO2. Cryopreservation of cells was routinely performed to 
increase longevity of the cell line. The BV2 microglia, at a density of 1 x 106/ml were 
suspended in Sigma freezing medium (DMEM, 20% foetal bovine serum (FBS), 2 mM 
L-glutamine, 100 U/ml penicillin, and 10% DMSO – to prevent membrane rupture) and 
stored at ‐80°C. Once required, a frozen vial of cells was tha wed and added to pre-
warmed BV2 medium in a T25 culture flask. The cells were maintained at 37°C in a 
humidified atmosphere with 6% CO2 and medium was replaced at 1 day in vitro (DIV) 
to remove the cytotoxic components of the freezing medium. 
For experimental procedures and passaging, BV2 microglia were harvested from the 
culture flasks enzymatically by incubation for 5 minutes at 37°C with ~ 10 ml of 0.5 
mg/ml trypsin (1:10 dilution of 5 mg/ml stock). Neutralisation of trypsin was performed 
by adding at least an equal volume of medium to the flask. The cells were then pelleted 
by centrifugation at 3645 g for 5 minutes at room temperature (Eppendorf Centrifuge 
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5804R) and resuspended in 5 ml of fresh warm medium. For quantification of cell 
number, 20 µl of the cell suspension was administered to a haemocytometer, and cells 
in four quadrants were counted, which equated to the number of cells present in 0.1 µl 
of the suspension volume. 
The BV2 cell line was utilised for Western blotting (section 2.7) and calpain activity 
assay (section 2.9) lysates. The cells were plated on 6 well plates at a density of 1 x 
105/well. With respect to the preparation of Western blotting lysates, at least two hours 
prior to activation, serum-containing (SC) medium was replaced with serum-free (SF) 
medium (DMEM, 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin), 
this was due to observations made previously in the laboratory that the cultures 
appeared more ramified and responded better to stimuli in SF conditions. 
2.3. Primary cell cultures 
The majority of the studies performed in this thesis used primary cell cultures. Whilst 
these cultures are much more sensitive to technique, the data produced represents a 
more physiological picture in an in vitro setting when compared with an immortalised 
cell line.    
2.3.1 Rat microglia 
Primary microglia were isolated from 5-6 day old Sprague Dawley rat pups as 
previously described (Kingham et al. 1999). Rats were killed by cervical dislocation and 
decapitation in accordance with the United Kingdom Animals (Scientific Procedures) 
Act, 1986. Whole brains, minus the cerebellum, which was required for neuronal 
culture preparation (Section 2.3.3), were dissected and placed into to a phosphate 
buffered saline solution, on ice, (137 mM NaCl, 5.37 mM KCl, 5.65 mM NaH2PO4.H2O, 
13.3 mM Na2HPO4.7H2O), supplemented with 11.1 mM D-glucose, 0.02% bovine 
serum albumin (BSA), 100 units/ml penicillin, 100 µg/ml streptomycin, and 3 µg/ml 
ampicillin. The solution was prepared using filtered, UV-treated, autoclaved dH2O, pH 
7.4. Brains were then gently homogenised using 10 – 15 strokes of a Potter-Elvehjem 
tissue grinder with a Teflon pestle (VWR, Leicester, UK). The smooth homogenate was 
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halved and transferred to two 50 ml tubes (no more than the equivalent of 4 brains per 
tube) and centrifuged at 500 g for 5 min (Eppendorf Centrifuge 5804R). The resulting 
supernatant was discarded and the pellet was resuspended in 10 ml 70% Percoll. A 
gradient was then produced by overlaying the cell containing 70% Percoll solution with 
10 ml of 30% Percoll solution, followed by 10 ml of sterile PBS (Figure 2.3.1). Addition 
of each overlaying solution took place with the upmost care, so as not to disturb the 
layer below. The Percoll gradient was then centrifuged at 1250 g (Eppendorf Centrifuge 
5804R), with no acceleration or braking, for 50 min to allow dissociation of the microglia 
from the other brain tissue, which could be collected at the 70%/30% Percoll gradient 
interface (Figure 2.3.1 B). 
Microglia were collected and washed in 50 ml of sterile PBS to dilute the Percoll 
concentration. The solution was then centrifuged at 500 g with medium acceleration 
and brake (Eppendorf Centrifuge 5804R) for 5 min. The resulting ‘microglia’ pellet was 
resuspended in 1 ml of pre-warmed medium (Minimal Essential Medium (MEM) 
supplemented with 10% FBS, 20 mM KCl, 30 mM D-glucose, 2 mM L-glutamine, 25 
mM NaHCO4, 50 U/ml penicillin, 50 µg/ml streptomycin, and 6 µg/ml ampicillin) and 
were quantified using a haemocytometer as previously described (See BV2 method). It 
is worth noting that microglia were cultured in the same medium as the cerebellar 
70% Percoll cell suspension 
30% Percoll solution
1 x PBS solution
Myelin
Microglia
Centrifuge  @ 1250 g
50 minutes
No acceleration
No brake 
A. B.
Figure 2.3.1. Graphical representation of the Percoll gradient preparation 
A. Creation of the Percoll gradient was performed by addition of 70 % Percoll 
solution containing the tissue homogenate that was overlaid by 30% Percoll 
solution followed by 1 x PBS solution. B. Following centrifugation, myelin collected 
at the 30%/PBS interface was removed and discarded, and microglia were 
collected from the 70%/30% gradient interface. 
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granule cell (CGCs) cultures to enable microglial conditioned medium (MGCM) to be 
added to the CGCs as a treatment.  
It was previously observed in the laboratory that primary microglia did not adhere well 
to tissue culture plastic. Therefore, cells were always plated on sterile 13 mm glass 
coverslips at a density of 5x104/well in 24 well plates. Cell density per well was 
calculated so that the microglia were initially plated in a volume of 100 µl to provide 
optimum adherence conditions. After 30 minutes incubation at 37°C in a humidified 
atmosphere with 6% CO2, culture medium well volume was increased to 500 µl and 
plates were returned to the incubator and left for approximately 24 h before being 
washed 3 times in pre-warmed medium to remove debris. Finally, cultures were 
exposed to SF medium (MEM supplemented with  20 mM KCl, 30 mM D-glucose, 2 
mM L-glutamine, 25 mM NaHCO4, 50 U/ml penicillin, 50 µg/ml streptomycin, and 6 
µg/ml ampicillin) and left to rest for a further 3 h before treatment. Microglia were 
always used within 48 h of isolation.  
Microglia were characterised following the Percoll method of isolation. Staining using 
the microglial specific marker isolectin-B4 (Figure 2.3.2) and OX-42 have shown that 
cultures routinely contain >90% microglia (Kingham et al. 1999). Furthermore, previous 
studies in our laboratory, as well as my own showed that at 2 DIV only ~20% of 
microglia stain positive for ED-1 (Morgan et al. 2004). This suggests basal activation in 
the microglial cultures used here is relatively low.  
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DAPI
Isolectin-B4
Figure 2.3.2. Characterisation of primary microglial cultures with Isolection-B4 
Live cell staining of primary microglial cultures with the microglia marker Isolectin-B4 
(IB4; Streit 1990) shows a highly pure culture, with >90% of cells positively stained. 
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2.3.2 Rat mixed glia 
To obtain primary astrocytic cultures, a modified shaking method was performed 
(McCarthy & De Vellis 1980). The method was optimised for the isolation of microglia 
as well as oligodendrocytes from the astrocytic layer, which were required by other 
members of the laboratory. To acquire a relatively pure astrocyte culture, 2 shaking 
steps were performed on the mixed glia cultures. Initially, 5‐6 day old Sprague‐Dawley 
rat pups were killed by cervical dislocation and decapitation in accordance with the 
United Kingdom Animals (Scientific Procedures) Act, 1986. Brains were dissected and 
placed into a sterile Petri dish containing minimum essential medium (MEM) with 25 
mM 4‐(2‐hydroxyethyl)‐1‐piperazineethanesulfonic acid (HEPES), 100 U/ml penicillin, 
and 100 mg/ml streptomycin (HEPES-MEM). Cortical hemispheres were dissected and 
placed into a new Petri dish with fresh HEPES-MEM and homogenised by trituration 
through syringe needles of decreasing gauge (19-, 23‐ and 25‐gauge, respectively) 
until full dissociation of the tissue had occurred. The tissue homogenate was then 
transferred to a tube containing 45 ml HEPES-MEM and centrifuged at 230 g for 10 
minutes (Eppendorf Centrifuge 5804R). The resulting pellet was resuspended in pre-
warmed medium (DMEM, 10% FBS, 1 mM sodium pyruvate, 25 mg/ml gentamycin) 
and the suspension was seeded into a T175 tissue culture flask pre-coated with 100 
mg/ml poly-D-lysine (PDL) and maintained in an incubator at 37°C in a humidified 
atmosphere with 6% CO2. The suspension seeded in each flask was a volume 
equivalent to two brains. The medium was replaced with fresh, pre-warmed medium 
every 3 DIV, being extremely careful not to disturb the growing surface. After at least 
10 days DIV a confluent astrocytic monolayer was present on the growth surface, with 
easily distinguishable microglia and cell clusters identified as oligodendrocytes 
precursor cells (OPCs). Initially, microglia were shaken off by particular lab members 
for their personal use followed by the OPCs. This left an enriched astrocytic monolayer, 
which was utilised purely for optimisation of the leucine-methyl-ester (LME) microglia 
depletion technique (Section 2.5). The astrocytes were enzymatically dissociated from 
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the growth surface using 0.5 mg/ml trypsin (1:10 dilution of 5 mg/ml stock) and 
quantified, as described previously (Section 2.2). The cells were plated on sterile 13 
mm glass coverslips in 24 well plates at a density of 1 x 105/well and treated after a 
further 3 DIV. 
2.3.3 Rat cerebellar granule neurons 
Cerebellar granule cells (CGCs), are excitatory neurons found within the granular layer 
of the cerebellum (Section 1.1.1.1 and 1.1.1.2) and receive excitatory input from 
mossy fibres (Kiernan 2009), express excitatory amino acid receptors such as N-
methyl-D-aspartate (NMDA) receptors and release glutamate (D'Mello et al. 1993). 
Survival in culture was limited until the discovery by Gallo and colleagues that the cells 
require high extracellular concentrations of potassium (K+), i.e. depolarising 
concentrations, to survive (Gallo et al. 1987). Experimental procedures suggested that 
the requirement of these depolarising concentrations in vitro mimicked physiological 
stimulation of NMDA receptors, involving Ca2+ entry, in vivo, if one was to compare the 
timing of the differentiation and innervations of the post-mitotic granule cells (Gallo et 
al. 1987).  
CGCs were cultured from the cerebella of 5‐6 day old Sprague‐Dawley rat pups, as 
previously described (Kingham et al. 1999). As previously stated, pups were killed by 
cervical dislocation and decapitation in accordance with the United Kingdom Animals 
(Scientific Procedures) Act, 1986. The cerebella were dissected and placed into a 
sterile Petri dish containing ice cold 100 mM phosphate buffer saline (PBS), 0.3 % 
bovine serum albumin (BSA), 10 mM D-glucose and 0.38% MgSO4.7H2O. This solution 
was referred to as solution B (BASE) and was, as the name suggests used to prepare 
all subsequent solutions needed for the CGC preparation. After collection, the tissue 
was mechanically diced with a sterile razor blade. The resulting suspension was then 
enzymatically dissociated further by addition of 10 ml of solution B containing 0.5 
mg/ml trypsin (Solution T). The tissue was incubated in a water bath at 37°C for 5 
minutes with gentle agitation every 1-2 minutes to enhance the enzymatic reaction. 
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Neutralisation of the extracellular matrix digestion by trypsin was then performed by 
administration of 20 ml solution B containing 8 units/ml DNAase and 8 µg/ml soybean 
trypsin inhibitor (SBTI). Several inversions were performed to fully neutralise the 
enzyme then the suspension was centrifuged at 65 g for 5 minutes at room 
temperature. The supernatant was discarded and the pelleted cells were resuspended 
in 4 ml of solution B containing 50 units/ml DNAase and 50 µg/ml SBTI by trituration 
with three fire‐polished Pasteur pipettes of decreasing diameter, forming a 
homogeneous suspension. Perikarya were then collected by underlying the suspension 
with 5 ml 4% BSA in Ca2+-free Earle’s Balanced Salts Solution (EBSS) and centrifuging 
for 5 min at 100 g. The resulting soft pellet of enriched perikarya was then resuspended 
in 1 ml of culture medium consisting of minimum essential medium (MEM) with 10% 
FBS, 20 mM KCl, 25 mM NaHCO3, 30 mM D-glucose, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 µg/ml streptomycin and 6 µg/ml ampicillin. Quantification of cell number 
was then performed using a 1:20 dilution of the 1 ml suspension, as described in 
previous cell culture methods (Section 2.2). Cells (100 µl in volume) were plated onto 
sterile PDL (100 µg/ml) coated 13 mm coverslips at a density of 8 x 105/coverslip. After 
1 hour in the incubator at 37°C in a humidified atm osphere with 6% CO2, to allow 
adherence to the coverslip, 500 µl of pre-warmed culture medium was carefully 
administered. The cultures were returned to the incubator and after 1 DIV the cells 
were washed and half the culture medium was replaced with fresh medium 
supplemented with 10 µM cytosine arabinofuranoside (Ara-C), an anti-mitotic (Politis & 
Houle 1985), to prevent glial cell proliferation. Treatment of CGCs was performed from 
6 DIV. 
2.3.3.1. Serum-free Neuronal Medium 
Where serum-free neuronal culture conditions were required (Section 3.3.9), the CGC 
preparation was performed in an identical manner as described above but the neuronal 
medium was composed of Neurobasal® medium supplemented with  2% B27® 
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neuronal supplement, 20 mM KCl, 30 mM D-Glucose, 2 mM L-Glutamine, 50 U/ml 
penicillin, and 50 µg/ml streptomycin. 
2.3.4 Human monocyte-derived-macrophages (hMΦ) 
To translate findings from the BV2 cell line and primary rat culture data to a human in 
vitro model, culturing of human macrophages was performed. It has been suggested 
that peripheral blood monocytes are a valuable model for investigating the innate 
immune dysfunction in AD (Fiala et al. 2007; Schulz et al. 2007), and previous studies 
have utilized hMΦ alongside primary rat or human microglia to strengthen their findings 
(Vegeto et al. 2001; Coraci et al. 2002). Furthermore, early studies identified that hMΦ 
share similar morphological and immunological features with microglia, including ruffled 
cell membrane and the expression of MHC class II and complement receptor 3 (CR3; 
MAC-1, CD11b) (Bauer et al. 1991). 
Initially, monocytes were isolated from healthy human volunteers as previously 
described (Björkqvist et al. 2008). All human experiments were performed in 
accordance with the declaration of Helsinki (2008) and approved by University College 
London (UCL)/UCL Hospitals Joint Research Ethics Committee. All subjects gave 
informed written consent. 
Phlebotomy was performed within the National Hospital for Neurology and 
Neurosurgery (Queen Square) with 50 ml of blood being taken from each subject into 
Heparin treated tubes. The blood tubes were then transferred to the laboratory. The 
isolation of mononuclear cells was performed by transferring blood to ACCUSPIN™ 
System-Histopaque®-1077 tubes (Sigma-Aldrich, Dorset, UK) that had been warmed 
to room temperature (RT). Initially, the empty tubes were centrifuged at 1000 g for 1 
minute at RT, followed by transfer of the blood to the tubes (25 ml/tube) and further 
centrifugation at 1000 g for 10 minute at RT to separate the blood components (Figure 
2.3.3 A). The peripheral blood mononuclear cell (PBMC) layer was transferred to a 
sterile 50 ml tube and washed with sterile PBS by dilution to a volume of 50 ml. The 
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tube containing the PBMCs was then centrifuged at 300 g for 5 minutes at 4°C, and the 
resulting pellet was resuspended in 10 ml of PBS and quantified using a 
haemocytometer, as previously described (Section 2.2), to determine the volume of 
antibody required in the following steps. The suspension was centrifuged at 300 g for 5 
minutes at 4°C and the supernatant was discarded. T he pellet was resuspended in a 
volume of MACS® buffer (1 x PBS supplemented with 0.5% BSA and 2 mM EDTA, pH 
7.4) containing magnetic anti-CD14 beads, dependent on cell density (i.e. 90 µl of 
MACS® buffer and 10 µl of magnetic anti-CD14 beads was required per 1 x 107 cells). 
The suspension was incubated in a fridge at 4°C (no t on ice) for 15 minutes, during 
which time the column apparatus for CD14+ cell separation was assembled (Figure 
2.3.3 Bi). After the incubation, cells were washed by dilution in 4 ml of MACS ® buffer, 
followed by centrifugation at 300 g for 5 minutes at 4°C, and finally resuspended in 5 00 
µl of MACS® buffer. Each column used in the apparatus setup was initially washed 
through with 500 µl of MACS® buffer prior to the addition of the cell suspension 
containing cell-bound magnetic-CD14 antibody (Figure 2.3.3 Bii). After the samples 
had been filtered the column was washed through three times with 500 µl of MACS® 
buffer to remove any contaminants. Finally, each column was removed from the 
apparatus setup (and the magnetic field) and 2 ml of MACS® buffer was added. A 
plunger was then applied to each column to remove the CD14-positive cells (Figure 
2.3.3 Biii).   
The cell density of the suspension was again quantified and an aliquot containing 1 x 
106 cells was collected to allow monocyte purity to be calculated by FACs analysis 
using a FACs Calibur high speed cell sorter and CellQuestPro software (BD 
Biosciences). This was kindly performed by Ulrike Traeger in Professor Sarah Tabrizi’s 
Laboratory and after analysis using FlowJo software (Treestar Inc., San Carlos, CA), 
the preparations of monocytes were shown to be 90-95% pure, consistent with 
previously reported data (Björkqvist et al. 2008) (Figure 2.3.4 A). 
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The monocytes were seeded at a density of 2 x 106/ well in sterile 6 well plates for 
gene expression experiments, or at 7.5 x 104 cells/well on sterile 13 mm glass 
coverslips in 24 well plates for ICC experiments in RPMI culture medium supplemented 
with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 µg/ml streptomycin.To 
induce differentiation of the monocytes to macrophages, cell medium was 
supplemented with 20 ng/ml GM-CSF (Martinez et al., 2006), and replaced at 3 DIV. 
Macrophages were viable for use at 7 DIV, when medium was changed to serum-free, 
prior to treatment. Macrophage purity (CD14+/CD206+ cells) by FACs analysis was 
again kindly performed by Ulrike Traeger and cultures were shown to be 95-99% pure, 
suggesting near complete differentiation (Figure 2.3.4 B). 
Plasma
Mononuclear cells
ErthyrocytesHistopaque
Porous high-density 
polyethlyene barrier
Blood
Centrifuge  @ 1000 g
10 minutes
Room temperature
Ai. Aii.
Magnet Magnet
Waste collection
Filtration column
Bi. Bii. Biii.
Magnetic anti-CD14
CD14 presenting cells
Non-CD14 presenting cells
Magnet Magnet
Collection of CD14+
cells
Plunger
Figure 2.3.3. Schematic representation of specific steps in the human 
macrophage cell culture preparation 
A. Blood was transferred to a histopaque-containing tube (Ai). After centrifugation 
the layer of mononuclear cells could be collected (Aii). B. Filtration of the sample 
to remove non-CD14+ cells with the initial apparatus setup shown in Bi. CD14+-
cells bound to the magneticly tagged anti-CD14 antibodies were retained in the 
column whilst non-CD14 presenting cells filtered out and discarded (Bii). The 
column was then removed from the magnetic field and the CD14+ cells 
(monocytes) were collected (Biii). 
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Ai. Ai.
B.
Figure 2.3.4. FACs analyses of monocytes and differentiated macrophages 
Representative plots of FACs analysis performed on monocyte and macrophage 
preparations. Ai. Cell sorting by size and granularity was initially performed using 
front and side scatter analysis. This initial gated area was deemed to contain cells 
corresponding to the size and granularity associated with mononuclear cells. Aii. 
Further purity calculations were performed using two fluorescent probes, anti-
CD14-APC and anti-CCR2-PE, specific for monocytes, in this specific instance 
showing over 98% purity, with respect to CD14 staining. CCR2 staining shown 
here is low, which can occur as monocytes express viable levels of this chemokine 
receptor. Gating of these analyses was performed with respect to a negative 
control population of T and B cells that are CD14-negative.  B. Following 
differentiation in culture to macrophages, the cell preparation purity was calculated 
using anti-CD14-APC and CD206-PE probes. Here the culture purity is shown as 
>90%. 
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2.4. Cell Treatments 
2.4.1. Direct treatment of cultures 
Primary microglia and the BV2-microglial cell line were routinely plated 24 hours prior 
to treatment with substitution of the cell medium to serum-free medium at least 3 hours 
before treatment, unless otherwise stated. Microglia and CGC cultures were activated 
with LPS alone, or in combination with IFNγ, fibrinogen and fibrin for 1 – 48 hours. For 
inhibition of endotoxin-mediated responses cultures were treated with PMX 1 hour 
before activation. Depletion of microglia was performed by administration of LME 24 
hours before activation, described in detail in section 2.5.2. Thrombin catalysis was 
inhibited by pre-treating cultures with Hirudin, 1 hour before activation. For TNFα 
synthesis inhibition prior to activation, cultures were pre-treated with thalidomide (Thal), 
1 hour before. Inhibition of iNOS activity was performed in the same manner by pre-
treating cultures 1 hour before activation with AMT-HCl. Inhibition of scavenger 
receptor A was performed by administration of fucoidan to cultures 1 hour prior to 
activation. Induction of cellular apoptosis was performed by administering 
staurosporine (STS) to cultures for 4 – 8 hours. Anti-CD11b and rat-IgG were 
administered to CGC cultures 12 hours before activation. 
Superoxide induction via NADPH oxidase was induced by administration of PMA to 
CGC cultures for 24 hours. Inhibition of this induction was performed by co-treatment of 
cultures with apocynin. Inhibition of p38, p42/44 (ERK1/2) and PI3K MAPK pathways 
was performed by pre-treating cultures 1 hour before activation with SB203580, 
PD98059 and Wortmannin, respectively. 
For induction of ER stress, CGC cultures were treated with thapsigargin (Th) or 
tunicamycin (Tu) for 1 – 24 hours. Inhibition of ER stress was performed by pre-treating 
cultures with salubrinal (Sal), 1 hour before induction. Inhibition of pan-caspase 
activation was performed by pre-treating cultures with z-VAD-FMK 12 hours before 
induction. For specific inhibition of caspase-12 activation, z-ATAD-FMK was 
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administered to cultures 12 hours before activation was performed.  For release of 
intracellular calcium from BV2 microglia, Ionomycin (Ion) was administered for 0.25 – 1 
hours. Chelation of calcium in primary microglial cultures was performed with BAPTA-
AM (BAPTA) for 24 hours alone or co-treated with activators shown above. Inhibition of 
calpains was performed by administration of calpastatin 1 hour prior to activation. All 
compounds and antibodies with concentrations used to treat cultures are provided in 
Table 2.4.1. The concentrations selected are justified in the corresponding result 
chapters and were either selected based on previous studies or selected following 
titration of the proteins or inhibitors used. 
Agonists and antagonists of metabotropic glutamate receptors (mGluRs) were used 
alone or as a co-treatment with the above activators. All the mGluR agonists and 
antagonists used are listed in Table 2.4.2. The concentrations of the mGluR agonists 
or antagonists used in this study were based on previous studies on the effect of 
mGluR manipulation on microglia or published EC50 values (Macek et al. 1996; Taylor 
et al. 2003; Taylor et al. 2005; Stauffer 2011). 
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Compound Description Concentration Catalogue 
Number 
LPS Gram-negative bacterial wall 
component: microglial activator 
1 µg/ml Sigma L2762 
Serotype: 
026:B6 
IFNγ Pro-inflammatory cytokine: 
microglial activator 
100 U/ml R&D systems 
585IF 
Fibrinogen Blood borne protein 0.1 – 2.5 mg/ml Sigma F4843 
Fibrin Insoluble matrix of fibrinogen 0.05 – 1 mg/ml Sigma F5386 
LME Lysosomatropic agent that depletes microglia 5 – 75 mM Sigma L1002 
Hirudin Thrombin inhibitor 50 U/ml Sigma 94581 
Polymyxin B Endotoxin inhibitor 100 nM Sigma P4932 
Fucoidan Scavenger receptor A ligand 100 µg/ml Sigma F5631 
Anti-CD11b CD11b receptor blocking 
antibody 10 µg/ml 
Serotec 
MCA27EL 
Thalidomide TNFα synthesis inhibitor 10 µg/ml Tocris 0652 
AMT-HCl iNOS activity inhibitor 150 nM Tocris 0871 
Staurosporine Apoptotic inducer 0.5 µM Sigma 54400 
PMA NADPH oxidase  10 ng/ml Sigma P1585 
Apocynin NADPH oxidase inhibitor 10 µM Calbiochem 178385 
PD98059 ERK1/2 inhibitor 10 µM Tocris 1213 
SB203580 p38-MAPK inhibitor 10 µM Tocris 1202 
Wortmannin PI3K inhibitor 100 nM Sigma W1628 
Thapsigargin ER stress inducer  2 µM Tocris 1138 
Tuncamycin ER stress inducer 1 µg/ml Sigma T7765 
Salubrinal ER stress inhibitor 100 nM 
Enzo Life 
Sciences  
ALX-270-428 
z-VAD-FMK Pan-caspase inhibitor 1 µg/ml Promokine  PK-CA577-1010 
z-ATAD-FMK Caspase-12 inhibitor 1 µg/ml Promokine  PK-CA577-1079 
Ionomycin Calcium ionophore 2 µM Tocris 1704 
BAPTA-AM Calcium chelator 5 – 10,000 nM Tocris 2787 
Calpastatin Calpain inhibitor 1 – 10,000 nM Tocris 2950 
  Table 2.4.1. Compounds and antibodies used to treat cultures 
Abbreviations: LPS, lipopolysaccharide; IFNγ, interferon-gamma; LME, leucine-
methyl-ester; AMT-HCl, 2-Amino-5,6-dihydro-6-methyl-4H-1,3-thiazine hydrochloride; 
PMA, phorbol 12-myristate 13-acetate; PD98059, 2-(2-Amino-3-methoxyphenyl)-4H-
1-benzopyran-4-one; SB203580, 4-[5-(4-Fluorophenyl)-2-[4-(methylsulfonyl)phenyl]-
1H-imidazol-4-yl]pyridine; z-VAD-FMK, carbobenzoxy-Val-Ala-Asp(OME)-
fluoromethylketone; z-ATAD-FMK, carbobenzoxy -Ala-Thr-Ala-Asp(OME)-
fluoromethylketone; BAPTA-AM, 1,2-Bis(2-aminophenoxy)ethane-N,N,N',N'-
tetraacetic acid tetrakis(acetoxymethyl ester). 
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Compound Description Concentration Catalogue Number 
DHPG Selective Group I mGluR 
agonist (mGluR1/5) 100 µM Tocris 0805 
CDPPB Selective mGluR5 agonist  100 nM Tocris 3235 
MTEP Selective mGluR5 
antagonist 100 µM Tocris 2921 
DCGIV Selective Group II mGluR 
agonist (mGluR2/3) 500 nM Tocris 0975 
NAAG Selective mGluR3 agonist 50 µM Sigma A5930 
L-AP4 Selective Group III mGluR 
agonist (mGluR4/6/7/8) 100 µM Tocris 0103 
  
Table 2.4.2. Metabotropic glutamate receptor agonists and antagonists 
used to treat cultures 
Abbreviations: DHPG, (S)-3,5-Dihydroxyphenylglycine; CDPPB, 3-Cyano-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide; MTEP, 3-((2-Methyl-1,3-thiazol-4-
yl)ethynyl)pyridine hydrochloride; DCGIV, (2S,2'R,3'R)-2-(2',3'-
Dicarboxycyclopropyl)glycine; NAAG, N-Acetyl-L-aspartyl-L-glutamic acid; L-AP4, 
L-(+)-2-Amino-4-phosphonobutyric acid. 
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2.4.2. Microglial conditioned medium administration to neuronal cultures 
Microglial cultures were treated as required and incubated for 24 hours. Medium was 
then classed as microglial conditioned medium (MGCM) and collected into 1500 µl 
Eppendorf tubes and placed immediately on ice. MGCM was centrifuged (Eppendorf 
5415R benchtop centrifuge) at 15,800 g at 4°C for 5 minutes to remove debris and 
immediately snap frozen with dry ice, followed by storage at -20°C. Administration of 
MGCM to CGC cultures was performed after depletion of microglia from the cultures 
with LME as shown in Section 2.5.2. Half the CGC medium (250 µl) was removed, 
discarded and replaced with the relevant MGCM and incubated at 37°C.  
In the case of fibrinogen-treated MGCM, to identify if resulting observations were due 
to factors released from microglia or cross-transfer of fibrinogen in the medium an 
experiment was performed using concentrated MGCM. Initially, MGCM from FG 
treated cultures (FG-MGCM) was concentrated using centrifugal filter units (Amicon 
Ultra, Millipore, Watford, UK) that allowed removal of media components below a 
molecular weight of 10 kDa. FG-MGCM was concentrated in the spin columns by 
centrifugation (Eppendorf 5415R benchtop centrifuge) at 4 °C for 15 minutes at 14000 
g resulting in a concentrated solution (~ 15 µl), which was collected by centrifugation at 
4°C for 5 minutes at 1000 g. The concentrated sample was resolved through a 10% gel 
(Table 2.7.2) and Western blotting (Section 2.7) with anti-FG conjugated to HRP was 
performed to identify the presence of FG in MGCM, controlled with known 
concentrations (Figure 2.4.1). As expected, a strong concentration dependent 
expression was observed when known concentrations were resolved. Concentrated 
MGCM however showed much lower expression of FG at concentrations lower than 
those able induce significant toxicity (require >100 µg/ml; E. East unpublished 
observations), suggesting any cross transfer was limited and not able to induce 
significant toxicity alone.         
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Figure 2.4.1. Only low level transfer of FG occurs in MGCM experiments 
Western blot analysis was performed on concentrated MGCM from cultures 
treated with FG, with comparison to known masses of FG. Limited transfer of FG 
was observed in MGCM, when compared with the known masses, suggesting only 
low levels of FG remain in MGCM after 24 hours of treatment. Lane 1 contains 
overflow from lane containing 4 µg FG (lane 2). Anti-FG-HRP (1:500) was 
incubated with membranes for 2 hours at RT.  
4 2 0.4 
FG (µg) 
FG MGCM 
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2.5. Development and optimisation of microglia depletion from 
neuronal cultures 
Due to the observation that LPS treatment could induce significant toxicity in neuronal 
cultures, it was hypothesised that a small population of microglia present in the cultures 
was responsible. Therefore, a protocol to selectively deplete microglia from the CGC 
cultures was optimised, guided by previously published methodology (Giulian et al. 
1993; Morgan et al. 2004; Hamby et al. 2006). Initially the methodology followed 
previously published studies from our laboratory (Morgan et al. 2004), however this 
protocol required further adaption to increase neuronal survival, and methodology that 
was shown previously to deplete microglia from astrocyte cultures (Hamby et al. 2006) 
was modified for use on the CGC cultures used here.  
2.5.1. Initial optimisation 
Following previously described methodology (Morgan et al. 2004), depletion of 
microglia from CGC cultures was initially attempted using L-leucine-methyl-ester (LME) 
treatment for 24 h. LME is a lysosomatropic agent originally employed to selectively 
deplete macrophages (Thiele et al. 1983), however a number of research groups have 
used it to selectively deplete microglia from astrocyte or oligodendrocytes cultures 
(Giulian et al. 1993; Hewett et al. 1999; Hamby et al 2006). Previous studies suggested 
a concentration range of 1 – 10 mM LME could significantly deplete microglia from 
neural cultures. Therefore, at 6 DIV culture medium on CGCs was changed to medium 
containing 1 – 10 mM LME and cultures were fixed and analysed after 24 h. To 
quantify microglia and apoptosis, cultures were stained with Isolectin-B4 (IB4) and DAPI 
(See section 2.6.5), respectively. 
Only treatment with medium containing 10 mM LME could significantly decrease 
microglia number in the CGC cultures. However, significant apoptosis also occurred, 
that was concluded to be due to LME treatment rather than the cell culture media 
change, as no significant difference was observed between control cultures +/- a media 
change (Figure 3.3.4). Furthermore, it had been suggested that this concentration 
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range and exposure time to LME was optimal in low density cultures (Hamby et al. 
2006). CGC cultures are at high density, so a differing approach was performed using 
higher concentrations of LME coupled with a shorter exposure time. 
 At 6 DIV, CGCs were treated with LME but this time using a concentration range of 25 
– 75 mM for 1 h. Initially, LME was dissolved in culture medium, pH was returned to 7.4 
using 1 M sodium hydroxide (NaOH), followed by filter sterilisation. The LME 
concentration dissolved in the medium was equal to twice the concentration required (2 
x LME). Half the culture medium was removed from each CGC-containing well and 
retained at 37°C, followed by administration of 2 x  LME to the CGC-containing wells, 
i.e. diluted 1:1 giving the desired concentration. The cultures were then incubated at 
37°C in a humidified atmosphere with 6% CO 2 for 1 h. LME was removed from the 
cultures following two washes with pre-warmed fresh CGC medium. The retained cell 
medium plus an equal volume of fresh CGC medium was then added to the 
corresponding wells. Cultures were left to rest for 24 h then fixed and analysed as 
previously described with IB4 and DAPI staining. Control cultures were treated in an 
identical fashion but CGC medium without LME was used instead. The highest LME 
concentrations tested (50 -75 mM), deemed necessary to deplete microglia in astrocyte 
cultures (Hamby et al. 2006), significantly depleted microglia in the CGC cultures used 
here, but also significantly increased observed toxicity (Figure 3.3.5). Treatment with 
25 mM LME, significantly decreased microglia number without a significant increase in 
toxicity being observed in the CGC cultures (Figures 3.3.5). Further characterisation of 
this concentration, showed neuronal and astrocytic morphology was not significantly 
altered (Figure 3.3.6 and 3.3.7). Therefore this concentration was utilised for all future 
LME experiments following the protocol provided in section 2.5.2. 
2.5.2. Optimised protocol 
CGC cultures were treated with 25 mM LME for 1 h after 6 DIV. A fresh stock 
concentration of LME (150 mM) was produced in CGC medium prior to each 
experiment. The pH of the LME stock solution was return to 7.4 and the solution filter 
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sterilised using a 28 mm Polyether Sulfone (PES) 0.2 µm syringe filter (Corning, Bucks, 
UK). The stock was then diluted to a concentration of 50 mM (2 x LME) in CGC 
medium and warmed in a waterbath set to 37°C for 10  minutes. Half the culture 
medium (250 µl) was removed from each CGC-containing well and retained at 37°C. 
Wells were then treated with CGC medium containing 2 x LME (250 µl), i.e. diluted 1:1 
giving a well concentration of 25 mM, or with pre-warmed CGC medium without LME 
(250 µl) for control cultures. Cultures were incubated at 37°C in a humidified 
atmosphere with 6% CO2 for 1 h. Wells were then washed twice in fresh pre-warmed 
CGC medium to remove LME-containing media followed by the addition of the retained 
culture medium and an equal volume of fresh pre-warmed CGC medium to the 
corresponding wells. Cultures were then returned to the incubator (humidified with 6% 
CO2 at 37°C) and left to rest for 24 h before any furth er treatment. 
2.6. Fluorescence microscopy 
2.6.1. The fluorescence microscope 
A Zeiss Axioskop 2 fluorescence microscope (Oberkochen, Germany) was used to 
obtain images from immunocytochemistry (ICC) to identify protein expression and live 
and fixed cellular staining to assess caspase activation, superoxide production and cell 
death. In all cases, cells were viewed with x20 and x40 Neofluar objectives or x100 
Neofluar oil immersion objective. Images were captured using a Zeiss AxioCam HRc 
camera and analysed using Zeiss Axiovision 4.8 software.  
2.6.2. Measurement and quantification of apoptotic morphology in cultures 
Apoptosis is programmed cell death. When cells are chronically stressed, deprived of 
nutrients or injured, apoptosis can occur to induce death. The term apoptosis was 
proposed for programmed cell death with classic morphological features including 
membrane blebbing and bright pyknotic nuclei, due to chromatin condensation (Kerr et 
al. 1972). These morphological features can be simply identified in PFA fixed cultures 
using the nuclear stain   2´-(4-Ethoxyphenyl)-5-(4-methyl-1-piperazinyl)-2,5´-bi-1H-
benzimidazole (Hoechst-33342) or with 4',6-Diamidino-2-Phenylindole (DAPI) in ICC 
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experiments. Hoechst-33342 is lipophilic, readily crosses plasma membranes, and 
binds DNA allowing for quantification of cells displaying apoptotic morphology. 
Cultures were plated on 13 mm coverslips in 24 well cell culture plates, treated as 
required, fixed for 30 minutes in 4% PFA then stored until use at 4°C in PBS. Hoechst-
33342 (final concentration of 4 µg.ml־1) was administered directly to the PBS and 
incubated at room temperature in the dark for 15 minutes. Coverslips were then 
removed from plates and gently rinsed in PBS before mounting on a slide with a drop 
of PBS being used as the mountant. Hoechst-33342 stained nuclei were excited with 
light at a wavelength of 365 nm, with emission over 490 nm, to visualise Hoechst-
33342 staining. At least three fields from each coverslip were captured using the 
fluorescence microscope, with treatments being performed in duplicate or triplicate, 
and experiments repeated three times to allow for statistical analysis. Quantification 
was performed without blinding of the treatments. However, in an attempt to avoid 
objectivity, random datasets were quantified in parallel by other members of the lab 
that were blinded to the treatments. These quality control measures were performed in 
all of the large quantified datasets including the fixed and live cell staining and ICC. 
2.6.3. Live cell staining for the determination of cellular death, caspase activation 
and superoxide production 
Methods for quantifying cell death with less objectivity are desirable. This can be 
performed with the use of specific markers of death in parallel with Hoechst-33342 
staining. For example, the use of propidium iodide, a nuclear stain, that can only bind 
DNA if there is loss of membrane integrity due to the compounds lipophobicity, allows 
for quantification of total cell death. Staining of cultures with FITC-conjugated annexin 
V can be used to quantify cells in the early stages of apoptosis. This is due to a 
published observation that soon after initiating apoptosis, cells ‘flip’ phosphatidylserine 
(PS) from the inner face of the plasma membrane to the extracellular surface as a 
phagocytic signal to macrophages and microglia (Fadok et al. 1992). Once PS is on the 
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extracellular surface it can be detected by staining with FITC-conjugated annexin V, a 
protein with a strong, natural affinity for PS (Zhang et al. 1997). 
As described in section 1.4.1.1, caspase activation occurs during classical apoptosis. 
Therefore, the use of fluorescently tagged peptides that covalently bind to the activated 
form of specific caspases, allows for quantification of cells undergoing apoptosis. 
However recent studies suggesting non-apoptotic roles for caspases (Li et al. 2010; Jo 
et al. 2011; D’Amelio et al. 2011; Burguillos et al. 2011) suggests this staining should 
be undertaken in parallel with other markers of cell death. Finally, quantification of 
superoxide production in microglia present in the CGCs also provides a good marker 
for microglial activity. 
Cultures were plated on 13 mm coverslips in cell culture plates, treated as required, 
then incubated with fluorescent dyes for varying times (Table 2.6.1) at 37°C in the 
dark. Coverslips were then mounted on slides in warmed basic medium (153 mM NaCl, 
3.5 mM KCl, 0.4 mM KH2PO4, 20 mM N-Tris(hydroxymethyl)methyl-2-
aminoethanesulphonic acid (TES), 5 mM NaHCO3, 1.2 mM Na2SO4, 1.2 mM MgCl2, 2.6 
mM CaCl2, 5 mM glucose) and viewed immediately. For dye excitation and emission 
wavelengths, see Table 2.6.1. Initially, Hoechst-33342 staining of cell nuclei was 
captured to focus on a particular plane of cells, followed by other fluorescent markers. 
At least three fields from each coverslip were captured, with treatments being 
performed in duplicate or triplicate, and experiments repeated three times to allow for 
statistical analysis  
2.6.4. Immunocytochemistry 
Primary rat microglia or human monocyte-derived macrophages (hMΦ) were cultured 
on 13 mm glass coverslips and treated as required. The cultures were fixed with 4% 
paraformaldehyde (PFA) in phosphate-buffered saline (PBS; 154 mM NaCl, 1.84 mM 
KH2PO4, 9.81 mM K2HPO4.3H2O, pH adjusted to 7.4 with further addition of 
KH2PO4/K2HPO4.3H2O as necessary) for at least 30 minutes at room temperature. 
Cultures were then washed three times with PBS and permeabilised in 100% ice cold  
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Fluorescent Dye Target Excitation (nm) 
Emission 
(nm)  
Final 
Concentration 
Incubation 
times 
(min) 
Hoechst-33342 Total Nuclei 365 490 4 µg/ml 15 
Propidium Iodide 
(PI) Dead Nuclei 541 572 1 µg/ml 30 
Annexin V-FITC 
Early apoptotic – 
phosphatidylserine 
‘flip’  
485 530 5 µg/ml 60 
FAM-DEVD-FMK Active caspase-3/7 485 530 1 µg/ml 60 
FITC-ATAD-FMK Active caspase-12 485 530 1 µg/ml 60 
Dihydroethidium 
(DHE) 
Produced 
Superoxide  541 572 5 µM 45 
Fluorescently 
conjugated 
antibody 
Target Excitation (nm) 
Emission 
(nm)   
Incubation 
times 
(min) 
Goat anti-Rb-
TRITC 
1°Abs raised in 
Rabbit 541 572 1:500 120 
Goat anti-Rb-Cy3 1°Abs raised in Rabbit 541 572 1:500 120 
Goat anti-Ms-FITC 1°Abs raised in Mouse 485 530 1:1000 120 
Isolectin-B4-FITC 
Microglial-specific 
lectins  485 530 2 µg/ml 120 
pAb-Calnexin-
TRITC Cellular Calnexin 541 572 2 µg/ml 120 
Table 2.6.1. Summary of fluorescent markers and fluorescently tagged 
antibodies 
Fluorescent markers and antibodies used in fixed and live cell staining and 
immunocytochemistry experiments. Excitation and Emission wavelengths, final well 
concentrations and relative incubation times are also provided.  
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methanol for 20 minutes at -20ºC or 0.1% Triton-X100 for 10 minutes at room 
temperature (NeuN staining only) followed by three further washes with PBS. Cells 
were then blocked with 4% normal goat serum (NGS) for 30 minutes at room 
temperature. The choice of block was due to the species the secondary antibodies 
were raised in, i.e. the secondary antibodies used were raised in goat. The use of 
species-specific serum combats non-specific binding of the secondary antibody. 
Following the block of non-specific binding, 200 µl of a primary antibody diluted in PBS 
(Table 2.6.2) was incubated with the cultures overnight at 4°C in a dark, humidified 
atmosphere. Negative controls were performed in all experiments where the primary 
antibody was omitted and replaced with PBS to identify any non-specific secondary 
antibody binding. Cultures were then washed three times with PBS and incubated with 
200 µl of a relevant secondary antibody-conjugated to fluorescein isothiocyanate 
(FITC), tetramethylrhodamine-5-(and 6)-isothiocyanate (TRITC) or Cyanine-3 (Cy3) 
(Table 2.6.1) diluted in PBS for 2 hours in the dark at room temperature. If microglia 
identification and quantification was required, FITC-conjugated lectin from Griffonia 
simplicifolia (I-B4) (Streit 1990) was administered at the secondary antibody stage.  
Cultures were then again washed with PBS in the dark and incubated with 200 µl of 
1:1000 4',6-Diamidino-2-Phenylindole (DAPI; final concentration 300 ng/ml) in PBS for 
1 minute in the dark at room temperature to identify nuclear morphology. Finally 
cultures were washed once more with PBS, rinsed with ddH2O and mounted on a glass 
slide with Vectashield mountant. The edges of each coverslip were sealed to prevent 
the cells drying out and slides were stored in the dark at -20°C until viewing on the 
Zeiss Axioskop 2 fluorescence microscope. Brightness, contrast and colour balance 
were adjusted identically across treatments to allow quantification. 
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Antibody Species Relevant Reactivity Target Dilution 
pAb-iNOS Rabbit Rat Inducible nitric oxide 
synthase 1:250  
mAb-bNOS Mouse Rat Neuronal nitric oxide 
synthase 1:250 
mAb-ED-1 Mouse Rat 
Lysosomal-
glycoprotein in 
microglia 
1:500 
pAb-Cleaved caspase-3 Rabbit Rat, Human Activated caspase-3 1:500 
mAb-NeuN Mouse Rat Neuronal specific protein 1:200 
mAb-GADD153/CHOP Mouse Rat 
ER stress-
associated 
transcription factor 
1:250 
mAb-CD68 Mouse Human Human homologue 
of ED-1 1:100 
mAb-CD11b Mouse Rat 
MAC-1 integrin 
receptor on 
microglia 
1:100 
mAb-β-III-tubulin Mouse Rat Neuron-specific 
microtubule protein 1:100 
pAb-GFAP Rabbit Rat 
Astrocyte-Glial 
fibrillary acidic 
protein 
1:100 
  
Table 2.6.2. Summary of primary antibodies used in ICC experiments  
Host species, relevant reactivity, target information and relative dilutions are 
provided. 
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2.7. Western blotting 
The development of a method that allowed transfer of resolved proteins to a membrane 
enabling detection of small quantities of protein in a sample occurred in two separate 
labs around the same time (Towbin et al., 1979; Burnette et al., 1981). However, it was 
Burnette and colleagues’ more simple methodology that went on to be named Western 
blotting, a play on the name of the molecular genetics tool, Southern blotting, that 
allows for the immobilisation of electrophoretically fractionated DNA onto nitrocellulose 
filters (Burnette et al., 1981).   
Proteins in a prepared sample are separated using gel electrophoresis. The most 
common type of gel electrophoresis is sodium dodecyl sulphate polyacrylamide gel 
electrophoresis, or SDS-PAGE. The proteins are stabilised in a denatured state with 
the application of strong reducing agents, normally present in the initial lysis buffer. The 
resulting polypeptides are coated in the negatively charged SDS present in the protocol 
buffers, allowing migration through the acrylamide gel mesh towards a positive 
electrode in the gel tank. The lower the molecular weight, the faster the polypeptides 
migrate through the mesh, yielding separation on the basis of size. The following steps 
involve transfer of the resolved proteins in the gel to a membrane, again using an 
electric field, which then allows semi-quantification of proteins using specific antibodies 
targeted at the protein of interest and visualised using chemiluminescence.  
Western blotting was used to identify changes in cytosolic protein expression in cell 
lines and primary cultures, after treatment. 
2.7.1. Sample collection and preparation 
BV2s, primary microglia, and neuronal cultures (density ranging from 3 x 105 – 2.4 x 
106) were harvested into lysis buffer (30 – 45 µl, dependent on density) and incubated 
on ice for at least 20 minutes. Lysis buffer (pH 7.4) composition and relative component 
function is given in Table 2.7.1. Cell lysates were centrifuged at 15,800 g to pellet 
nuclear and membrane fractions, as well as cellular debris. All identified proteins of 
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interest were cytosolic so the resulting cytoplasmic fraction in the supernatant was 
collected and stored at - 20°C until use. 
2.7.2. Determination of protein concentration 
The protein concentration of the cytoplasmic fraction was determined by the Bradford 
protein assay (Bradford 1976) using bovine serum albumin (BSA) as a standard. To a 
96 well plate, 1 µl of each cytoplasmic lysate was added in triplicate, alongside a BSA 
standard curve. To this, 200 ml of Bradford reagent was added and mixed using an 
EASIA orbital shaker (Medgenix Diagnostics, Fleurus, Belgium) set to 60 rpm for 5 
minutes. The absorbance was measured on a GeniOS™ plate reader (Tecan Group, 
Reading, UK) at a wavelength of 595 nm.  The acidic environment of the Bradford 
reagent induces protein binding to the Coomassie dye present in the reagent. This 
causes a spectral shift in absorbance from the brown form of the dye to the blue form 
of the dye, i.e. the more protein present, the more intense to shift from brown to blue. 
Figure 2.7.1 shows a representative BSA standard curve that allowed analysis of 
protein concentration in the lysed samples, by plotting known BSA concentrations 
against sample absorbance at 595 nm. 
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Figure 2.7.1. Example standard curve generated for Bradford 
identification of the protein concentration in cell lysates 
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2.7.3. Pouring acrylamide gels 
Acrylamide gels for SDS-PAGE were prepared using mini gel apparatus (Bio-Rad, 
Hertfordshire, UK). The compositions of the protein resolving gels and protein stacking 
gel are provided in Table 2.7.2. Depending on the molecular weight of the targeted 
protein, the percentage of acrylamide in the resolving gel was altered. To target high 
molecular weight proteins (>100 kDa; e.g. iNOS and ED-1), 10% acrylamide gels were 
used, and to target lower molecular weight proteins (<100 kDa; e.g. Caspase-12 and 
TNFα), 12% acrylamide gels were used. The resolver gel was poured between two 
100% ethanol washed glass plates to a level 2.5 cm below the top of the front plate, 
and covered with 100% ethanol until the acrylamide had polymerised. The ethanol was 
removed and the stacker gel (4% acrylamide) was then poured onto the resolver gel, 
and a lane comb inserted. 
2.7.4. SDS-PAGE electrophoresis 
The volume of protein lysate sample equivalent to 30-45 µg of protein was diluted 1:1 
in sample buffer (2% SDS, 10% glycerol, 2.5% β-mercaptoethanol, 125 mM Tris-Base 
(pH 6.8) and bromophenol blue crystals) (Laemmli 1970) and boiled for 5 minutes to 
further denature the proteins. The samples were mixed, centrifuged at 1000 rpm for 15 
seconds, and loaded into the stacker gel wells submerged in a Bio-Rad mini gel tank 
filled with running buffer (125 mM Tris-Base, 1 M glycine, 0.01% SDS). Where 
possible, protein of interest standards and a broad-range protein molecular weight 
marker (2-212 kDa, New England BioLabs, Hertfordshire, UK) were loaded on the gel. 
The protein samples were then electrophoresed using a voltage of 130-165 V, until the 
‘gel front’ (a combination of contaminating cell media and bromophenol blue) and the 
molecular weight marker had reached the bottom of the resolver gel. 
2.7.5. Transfer of resolved proteins to membrane using electrophoresis 
The gel was carefully removed from the glass plates and equilibrated in ice-cold 
transfer buffer for 20 minutes (25 mM Tris-Base, 192 mM glycine, 20% methanol, 
0.01% SDS). During this time Immobilon-P-polyvinylidene difluoride (PVDF) membrane 
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was cut to the shape of the gel, activated in ice-cold 100% methanol for 1 minute, 
washed in ddH2O for 5 minutes, and equilibrated in ice-cold transfer buffer for 15 
minutes. A sandwich of transfer buffer soaked fibre pads, 3MM Chromatography paper 
(Whatman, Kent, UK), the gel and the PVDF membrane was constructed on a cassette 
as shown in Figure 2.7.2. After rolling out any trapped air-bubbles, the cassettes were 
placed in the Bio-Rad mini gel transfer apparatus with an ice pack and magnetic stirrer, 
making sure the sandwich was inserted in the correct orientation. The proteins were 
transferred to the PVDF membrane with 80 V of electricity for 1 hour. 
 
  
Cassette (top/front)
Cassette (bottom/back)
Sponge
3MM paper
PVDF membrne
Polyacrylamide gel
Figure 2.7.2. Setup of the gel/membrane sandwich required for transfer of 
resolved proteins to a membrane using electrophoresis 
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2.7.6. Immuno-blotting 
Membranes were removed from the cassette and washed with Tween 20-Tris-buffered 
saline (T-TBS; 10 mM Tris-Base, 150 mM NaCl, and 0.5% Tween 20, pH 7.4) for 10 
minutes and blocked for at least 1 h at room temperature (RT) in blocking buffer (T-TBS 
plus 5% non-fat dried milk or 1% BSA). Membranes were then incubated with the 
primary antibody diluted in blocking buffer for either 2 hours at room temperature or 
overnight at 4°, dependent on the antibody manufact urer’s recommendations (Table 
2.7.3). After 3 x 10 minute washes with T-TBS, the membranes were incubated for 1 
hour at RT with HRP-conjugated secondary antibodies with specificity for the primary 
antibody in question (Table 2.7.3), followed by 3 x 10 minute washes with T-TBS. The 
membranes were then gently blotted and incubated for 1 minute in a 1:1 solution of 
reconstituted ECL (enhanced chemiluminescence solutions 1 and 2). The membranes 
were lightly blotted again, wrapped in thin transparent film (Saran Wrap) and secured in 
an X-ray film cassette. In the dark room membranes were exposed to photographic film 
(Amersham™ Hyperfilm) for 1-30 minutes depending on signal intensity, immersed in 
developing solution followed by fixing solution, and finally washed in H2O. After being 
air-dried, the banded films were subjected to densitometry using MacBioPhotonics 
Image J software (NIH Image, Bethesda, USA) for semi-quantification of relative 
protein expression. Standard blots for caspase-12 induction using lysates from CGCs 
treated with positive controls are shown in Figure 2.7.3. In most cases, treatments and 
conditions were replicated 3 times and quantified for statistical analysis. 
  
125 
 
  
158
97.2
66.4
55.6
42.7
34.6
27
MW (kDa) Th Tu
Procaspase-12 (55 kDa)
Cleaved caspase-12 (36 kDa)
Non-specifc bands
Figure 2.7.3. Sample Caspase-12 blots with MW marker 
Western blot analysis of caspase-12 expression in CGC lysates treated with 
thapsigargin (Th; 2 µM) or Tunicamycin (Tu; 1 µg/ml). The molecular weight marker 
provides identification of the large band associated with pro-caspase-12 at 
approximately 55 kDa and the cleaved active form at approximately 36 kDa. Non-
specific banding is also observed.   
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2.7.7. Checking secondary antibody specificity 
Observations were made that suggested the secondary antibody used to identify 
caspase-12 expression by Western blotting could be directly binding to transferred 
fibrinogen. Therefore control experiments were performed using a combination of 
standard Western blotting technique and Coomassie blue membrane staining. 
Initially, Coomassie blue experiments were performed on gels loaded with 4 µg of 
fibrinogen (from fresh and frozen stocks) prepared in standard Western blotting lysis 
buffer. This provided identification of the molecular weights of relative subunits of 
fibrinogen in the preparations used here. An 8% resolver gel (Table 2.7.2) was set-up 
and the fresh or frozen preparations of fibrinogen were loaded into a standard stacker 
gel, resolved for 1 h at 165 V and transferred onto PVDF membrane as previously 
described.  
In line with a previously published protocol (Houen et al. 1997), transferred membranes 
were blocked in a 1% Tween-20 solution for 30 minutes. Membranes were then stained 
by immersion in a 0.01% Coomassie blue solution for 10 – 20 minutes and air-dried. 
Figure 2.7.4 A shows both fresh and frozen stocks of fibrinogen give the same banding 
pattern with a main band showing at a molecular weight of ~ 56 kDa, corresponding to 
the β-chain. Other bands above and below correspond to the α-chain (63 kDa) and γ-
chain (47 kDa), respectively. 
To control for secondary antibody binding to resolved fibrinogen transferred from the 
cell lysates, another experiment was performed using a range of fibrinogen 
concentrations (4 ng – 400 µg) prepared in lysis buffer. Fibrinogen was loaded into an 
8% resolver gel alongside a 4% Normal Rabbit Serum (NRbS) positive control lane. 
Protein was resolved and transferred as previously described and the goat anti-rabbit-
HRP secondary antibody was incubated with the membrane in 5% blocking buffer (T-
TBS plus 5% non-fat dried milk) for 1 h at room temperature. Chemiluminescence was 
performed and Figure 2.7.4 Bi shows the antibody bound only to NRbS and not to any 
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of the fibrinogen concentrations tested, shown to be present using the Coomassie blue 
protocol Figure 2.7.4 Bii. 
  
NRbS4 ng4 µg400 µg
Fibrinogen (4 µg)
FreshFrozen
Fibrinogen
66.4
55.6
42.7
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A. Bi.
Bii.
Figure 2.7.4. Questioning secondary 
antibody specificity  
A. Coomassie blue staining of denatured 
fibrinogen (4 µg) showing a banding pattern 
consistent with α, β, and γ chains molecular 
weights. Bi. Western blot analysis to identify 
if goat anti-rabbit-HRP non-specifcally 
bound to fibrinogen, with normal rabbit 
serum (NRbS) used as a positive control. 
No significant binding was observed and 
fibrinogen was shown to be present after 
coomassie staining was performed (Bii). 
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Component Final Concentration Function 
Tris-acetate 20 mM Buffer 
Ethylene diamine tetraacetic 
acid (EDTA) 1 mM Calcium chelator  
Ethylene glycol tetraacetic acid 
(EGTA) 1 mM Magnesium chelator 
Sodium-β-glycerophosphate 10 mM False phosphatase 
substrate 
Sodium orthovanadate 1 mM 
Tyrosine phosphatase 
inhibitor 
Glycerol 5 % Cryo-protectant 
Triton X-100 1 % 
Solubilises 
membranes 
Sucrose 0.27 M 
Increases osmolarity, 
stabilises membranes 
Benzamidine 1 mM Protease inhibitor 
Leupeptin 4 µg/ml 
Lysosomal protease 
inhibitor 
Phenylmethylsulfonyl fluoride 
(PMSF)  1 mM 
Cysteine protease 
inhibitor 
Microcystin - LR 1 µM Phosphatase inhibitor 
β-mercaptoethanol 0.1 % Reducing agent 
  Table 2.7.1. Western blotting lysis buffer components  
Components of lysis buffer required for Western blotting as previously published 
(Kingham & Pocock 2000) with the addition of PMSF for caspase-specific 
studies.   
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Resolver Gel (8%) Resolver Gel (10%) 
Resolver Gel 
(12%) Stacker Gel (4 %) 
2.4 ml 30% acrylamide 3.33 ml 30% 
acrylamide 
4 ml 30% 
acrylamide 
1.33 ml 30% 
acrylamide 
2.5 ml Resolver buffer 
(1.15 M Tris‐HCl, 0.1% 
SDS, pH 8.8) 
2.5 ml 
Resolver 
buffer 
2.5 ml 
Resolver 
buffer 
2.5 ml Stacker buffer 
(0.38 M Tris‐HCl, 
0.1% SDS, pH 6.8) 
5.1 ml ddH2O 4.17 ml ddH2O 3.5 ml ddH2O 6.17 ml ddH2O 
50 µL 10 % Ammonium 
persulphate (APS) 
50 µL 10 % 
APS 
50 µL 10 % 
APS 50 µL 10 % APS 
5 µL TEMED 5 µL TEMED 5 µL TEMED 5 µL TEMED 
  Table 2.7.2. Compositions of all used protein resolving gels and protein 
stacking gel 
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Primary Antibody Host Target Dilution Blocking buffer 
pAb-iNOS Rabbit Inducible nitric oxide 
synthase 
1:5000  
 
5% non-fat 
milk 
mAb-ED-1 Mouse 
Lysosomal-
glycoprotein in 
microglia 
1:1000  
 
5% non-fat 
milk 
pAb-Cleaved caspase-3 Rabbit Activated caspase-3 
1:1000  
 
5% non-fat 
milk 
pAb-Caspase-12 Rabbit Activated caspase-12 1:1000  5% non-fat 
milk 
mAb-phospho-ERK1/2 Rabbit 
Phosphorylated 
extracellular signal-
regulated kinases-1/2 
1:1000 1% BSA 
mAb-total-ERK1/2 Mouse 
Total extracellular 
signal-regulated 
kinases-1/2 
1:2000 1% BSA 
mAb-phospho-p38 
MAPK Mouse 
Phosphorylated p38-
mitogen-activated 
protein kinase 
1:1000 5% non-fat 
milk 
pAb-total-p38 MAPK Rabbit 
Total p38-mitogen-
activated protein 
kinase 
1:1000 5% non-fat 
milk 
pAb-TNFα Goat Pro-inflammatory 
cytokine TNFα 1:500 
5% non-fat 
milk 
mAb-β-actin Mouse Cytoskeletal protein 
β-actin 1:5000 
5% non-fat 
milk 
Anti-Rb-HRP Goat 1°Abs raised for Rabbit 1:1000 
5% non-fat 
milk 
Anti-Ms-HRP Goat 1°Abs raised for Mouse 1:1000 
5% non-fat 
milk 
Anti-Gt-HRP Donkey 1°Abs raised for Goat 1:1000 5% non-fat 
milk 
Anti-Rt-FG-HRP Goat 1°Abs targeting rat fibrinogen 1:500 
5% non-fat 
milk 
Table 2.7.3. Summary of primary and HRP-conjugated secondary antibodies 
used in Western blotting experiments 
Host species, target information, relative dilutions and blocking buffer requirements 
are provided. 
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2.8. Enzyme-linked immunosorbent assay for cytokine 
quantification 
The enzyme‐linked immunosorbent assay (ELISA) is a method that allows for specific 
protein concentration quantification in a given sample. Interestingly, the assay was 
developed independently and simultaneously in 1971 by Peter Perlmann and Eva 
Engvall at Stockholm University and by Anton Schuurs and Bauke van Weemen in The 
Netherlands (Lequin 2005). The technique is extremely useful for the quantitative 
analysis of functional cytokine release, a consequence of microglia activation. 
Quantitative sandwich ELISA kits (R&D Systems) for the measurement of classical pro-
inflammatory cytokines, tumour necrosis factor-α (TNFα) (Taylor et al. 2005) and 
Interleukin-6 (IL-6) were utilised to measure the concentration of TNFα and IL-6 
released from treated and non-treated microglia and CGC cultures.  The sandwich 
ELISA is a methodological upgrade on the standard ELISA technique. In a classical 
ELISA system, the antigen binds directly to the plate surface allowing for potentially 
high levels of non-specific binding. The sandwich ELISA combats this by coating the 
plate with a monoclonal antibody to capture the antigen under investigation, almost 
completely diminishing non-specific binding (Schuurs & Van Weemen 1977) . The 
bound antigen can then be traced using a second, usually polyclonal, antigen-specific 
antibody with a HRP conjugation providing an indirect concentration-dependent signal 
that can be quantified (Figure 2.8.1). 
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2.8.1. Sample collection and preparation 
Primary microglia or CGC cultures were treated as required. Media was collected from 
the treated cultures into sterile 1500 µl Eppendorf tubes and placed immediately on ice. 
Samples were then centrifuged at 800 g in an Eppendorf 5415R benchtop centrifuge 
for 5 minutes at 4°C, to remove any debris present in the collected medium. Samples 
were then immediately snap frozen on dry ice and stored at -20°C until required. 
Sample preparation and storage was performed as quickly as possible to prevent 
significant degradation of released cytokines, furthermore, samples were used within 1 
month of collection. 
2.8.2. Tumour necrosis factor-α sandwich ELISA 
The assay was performed following the manufacturer’s instructions (RTA00, R&D 
Systems). 96 well plates pre-coated with a monoclonal rat anti‐TNFα specific antibody 
were used. To each well, 50 µl of assay diluent were added. To allow for determination 
of the concentration in the unknown samples, rat TNFα standards (50 µl) in a 
concentration range were added to a section of the plate. A TNFα internal kit control 
(50 µl; a TNFα containing sample that had to fall within a particular concentration 
HRP HRP
A. B. C. D.
Figure 2.8.1. Graphical representation of an ELISA system  
A. Plate wells are coated in an antibody specific for the antigen of interest.  
B. Antigen binds to antibody and all other factors are removed. 
C. A second HRP-conjugated antibody to the same target is added. 
D. The HRP signal is converted to an absorbance signal using a specific solution 
and read on a plate reader. The absorbance signal is converted to concentration of 
protein by use of a standard curve (Figure 2.8.2). 
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range) was also administered to a section of the plate and 50 µl of the medium 
samples were added to the final section of the plate. After gentle agitation on an EASIA 
orbital shaker (Medgenix Diagnostics, Fleurus, Belgium) set to 60 rpm for 1 minute, 
wells were incubated for 2 hours at room temperature and then washed six times with 1 
x wash buffer. A solution (100 µl) containing the second rat anti‐TNFα antibody 
(polyclonal) conjugated to horseradish peroxidise (TNFα conjugate) was then added to 
the plate and incubated for 2 hours at room temperature. After six washes with 1 x 
wash buffer, 100 µl of substrate solution was added to the wells for 30 minutes at room 
temperature in the dark. The substrate solution reacts with the HRP conjugate and 
provides a luminescent signal. Finally, 100 µl of hydrochloric acid solution (stop 
solution) was added to each well to terminate the substrate solution colour reaction. 
The plate was gently shaken at 60 rpm for 1 minute and well-specific optical density 
was measured with a microplate reader (Anthos htII, Salzburg, Austria) set to 450 nm 
with the reference filter set to 540 nm to correct for optical imperfections. The plate 
optical density was measured within 30 minutes of the stop solution reaction 
termination. The optical density readout in the cell culture medium samples was then 
converted to a released TNFα concentration using the standard curve produced from 
the same plate. Examples of typical standard curves are shown in Figure 2.8.2. 
Samples were run in duplicate from three independent experiments to allow for 
statistical analysis. 
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2.8.3. Interleukin-6 sandwich ELISA 
The IL-6 ELISAs were again performed following the manufacturer’s instructions 
(R6000B, R&D Systems). The methodology was identical to that provided for the TNFα 
ELISA, with the all corresponding additions being of the same volume and incubation 
time. 
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Figure 2.8.2. ELISA system example standard curves 
Examples of standard curves generated for TNFα (black) and IL-6 (blue) ELISA 
assays. 
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2.9. Calpain activity assay 
During cellular stress, particularly stress of the endoplasmic reticulum, a family of 
cysteine proteases called calpains are activated (Saido et al. 1994; Nakagawa & Yuan 
2000). Calpains are activated by differing calcium concentrations that occur during 
cellular stress and it has been suggested that m-calpain, a family member activated by 
millimolar concentrations of calcium,  may be responsible for procaspase-12 cleavage 
to the active form and that disturbances in intracellular calcium storage as a result of 
amyloid-β peptide cytotoxicity may induce apoptosis through calpain-mediated 
caspase-12 activation (Nakagawa & Yuan 2000). From these published observations, 
coupled with the unfortunate loss of calcium imaging equipment, it was decided that an 
assay to quantify calpain activity could be used to identify not only if these proteases 
were activated but also whether treatments induce calcium dyshomeostasis. 
2.9.1. Optimisation 
Initially, the fluorogenic calpain substrate (Suc-Leu-Tyr-AMC) was tested against pure 
calpain, using methodology previously described (Sun et al. 1999). Calpain II (m-
calpain, 5 µg/ml), alone or pre-incubated for 2 h with the calpain antagonist calpastatin 
(1 nM – 10 µM), was added to 1 ml of assay buffer (50 mM Tris-HCl, 150 mM NaCl, 5 
mM CaCl2, 1 mM DTT, and 2 mM Suc-Leu-Tyr-AMC) and incubated for 5 minutes. The 
reaction was stopped by the addition of 10 mM ethylene glycol tetraacetic acid (EGTA). 
Aliquots (100 µl) were added to a flat bottomed clear 96-well plate (NUNC) and 
fluorescence associated with calpain activity due to Suc-Leu-Tyr-AMC binding, was 
read on a microplate spectrophotometer (GeniOS™, Tecan Group, Reading, UK) with 
an excitation wavelength of 360 nm and an emission wavelength of 460 nm. Calpain II 
addition significantly increases activity associated fluorescence when compared with 
control aliquots (identically treated, minus calpain II addition). Significant inhibition of 
calpain II-associated fluorescence occurred when calpain II was pre-incubated with at 
least 1 µM calpastatin (Figure 4.4.4 A). Therefore, for experiments involving inhibition 
of calpain, 1 µM calpastatin will be administered. 
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To optimise a calpain activity assay using cell lysates, methodology previously 
published by D’Amelio et al (2011) was modified for use here. This paper utilises a 
fluorometric assay for quantification of caspase-3 activity using a caspase-3-specific 
fluorogenic substrate with an AMC-conjugation (D’Amelio et al. 2011). Therefore, the 
method was simply modified to use a calpain-specific fluorogenic substrate. To test 
whether the methodology would allow us to identify if significant calcium 
dyshomeostasis could induce calpain II activation after treatment, assay optimisation 
was performed with the calcium ionophore, ionomycin, which elevates cytoplasmic 
calcium concentrations (Pocock & Nicholls 1992). BV2 microglia were plated at a 
density of 1 x 105 and treated after 1 DIV. Cultures were treated with 2 µM ionomycin 
time dependently (0 – 2 h). Medium was aspirated and cultures were homogenised in 
assay lysis buffer (100 mM HEPES, 0.1% Chaps (wt/vol), 1 mM EDTA, 10 mM DTT 
and 1 mM PMSF). Lysis occurred by freezing in liquid nitrogen and thawing at 37°C 
three times. Lysates were centrifuged at 11,500 g for 5 minutes to pellet debris and the 
nuclear fraction. The protein concentration of each resulting supernatant was then 
determined using the Bradford analysis method previously described (Section 2.7.2) 
and an equal mass of protein was incubated with 50 µM Suc-Leu-Tyr-AMC for 1 h at 
37°C for calpain activity determination. Fluorogeni c substrate activity was then read on 
a microplate spectrophotometer (GeniOS™, Tecan Group, Reading, UK) with an 
excitation wavelength of 360 nm and an emission wavelength of 460 nm. Figure 4.4.4 
B shows calpain activity-associated fluorescence is greatest after 30 minutes of 
ionomycin treatment, therefore this incubation period will be used in future assays as a 
positive control for calcium-mediated calpain II activity. 
Finally, to optimise the signal window, the incubation period of the fluorogenic substrate 
and the well position of the fluorescence readout were tested. Cultures were treated 
with ionomycin for 30 minutes and lysed as previously described. Incubation with Suc-
Leu-Tyr-AMC was performed at 37°C for either 1 or 1 6 h, and fluorescence readouts 
were taken from the bottom and the top of each well. Incubation of the fluorogenic 
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substrate with the cell lysates for 16 h significantly increased the fluorescent signal. 
Furthermore, the signal window was at its greatest when the fluorescent readout was 
taken from the bottom of the well (Figure 4.4.4 C). Therefore all subsequent calpain 
activity assays used a 16 h incubation of the fluorogenic substrate and the fluorescent 
signal was taken from the bottom of each well. 
2.9.2. Optimised protocol 
BV2 microglia were plated at a density of 1 x 105 in sterile six well plates in BV2 
medium and treated. After the required incubation, cultures were lysed in assay lysis 
buffer (100 mM HEPES, 0.1% Chaps (wt/vol), 1 mM EDTA, 10 mM DTT and 1 mM 
PMSF). Lysis occurred using a freeze-thaw process with liquid nitrogen and thawing at 
37°C three times. Lysates were centrifuged at 11,50 0 g for 5 minutes and the protein 
concentration of the resulting supernatant was determined using Bradford analysis as 
previously described (Section 2.7.2). An equal mass of protein (50 µg) was incubated 
with 50 µM Suc-Leu-Tyr-AMC in assay lysis buffer (final volume of 100 µl) for 16 h at 
37°C in a sterile 96 well plate (NUNC). Relevant pl ate and fluorescence controls were 
also performed, i.e. protein lysate alone, Suc-Leu-Tyr-AMC alone, and pure assay lysis 
buffer. Fluorogenic substrate activity was then read on a microplate spectrophotometer 
(GeniOS™, Tecan Group, Reading, UK) with an excitation wavelength of 360 nm and 
an emission wavelength of 460 nm. Data were plotted as a percentage of non-treated 
control calpain activity, with control levels set at 100% activity.  
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2.10. Lactate dehydrogenase release assay 
The CGC cultures were tested for levels of cell stress after treatment by measurement 
of lactate dehydrogenase (LDH) activity released into the culture medium using a 
method essentially as previously described (Kim et al. 2010).  LDH is a ubiquitous 
cytoplasmic oxidoreductase which converts pyruvate to lactate in the presence of 
reduced nicotinamide adenine dinucleotide (NADH) (Figure 2.10.1) (Koh & Choi 1987). 
LDH activity was measured by monitoring the production of NAD+ from NADH during 
the conversion of pyruvate to lactate. Aliquots (50 µl) of cell culture medium were 
incubated at room temperature with 0.26 mM NADH, 2.87 mM sodium pyruvate, and 
100 mM potassium phosphate buffer (pH 7.4) in a total volume of 200 µl. The rate of 
NAD+ formation was monitored for 5 min at 2-s intervals at 340 nm using a microplate 
spectrophotometer (GeniOS™, Tecan Group, Reading, UK). The percentage of LDH 
released into medium was calculated from three separate preparations as follows: 
(treatment-induced LDH release into medium/Total LDH in medium after cell lysis with 
1% Triton-X) x 100. The concentration of Triton-X used has previously been shown to 
induce maximal cell lysis in CGCs (Yabe et al. 2001).   
  
NADH + H+ NAD+
Lactate Dehydrogenase
(LDH)
Pyruvate Lactate
Figure 2.10.1. Lactate dehydrogenase-mediated conversion of pyruvate to 
lactate 
LDH-mediated conversion of pyruvate to lactate, requiring the presence of reduced 
nicotinamide adenine dinucleotide (NADH) 
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2.11. Quantification of gene expression by evaluation of mRNA 
levels using reverse transcription-polymerase chain reaction 
Reverse transcription-polymerase chain reaction (RT-PCR) allows for the investigation 
of gene expression through quantitative analysis of mRNA expression. The method 
consists of four distinct steps:  
1.  RNA extraction and isolation from cells or tissue of interest 
2.  Reverse transcription of all isolated RNA back to complementary DNA 
(cDNA), also known as transcribed DNA and is performed using an 
RNA-dependent DNA polymerase enzyme (reverse transcriptase; EC 
2.7.7.49).  
3. PCR involving the amplification of specific cDNA using oligonucleotide 
primers complimentary to a section of the cDNA, initiating synthesis. 
The use of primers designed specifically to compliment base sequence 
existing only within the cDNA of interest makes the PCR highly specific 
for the gene of interest. 
4.  Visualisation of the amplified cDNA produced during the PCR, and 
comparison between samples. PCR products are run through an 
agarose gel containing ethidium bromide, a compound that intercalates 
into DNA and fluoresces under UV light. The densities of the bands 
correspond directly to the amount of mRNA extracted from the original 
sample, allowing for quantification of gene expression after treatments 
or differing conditions.  
The invention of the polymerase chain reaction over 23 years by Kary Mullis and Fred 
Faloona revolutionised the capture and manipulation of DNA. The theory behind PCR 
is simple and involves cyclical temperature changes optimal for DNA replication. 
Initially a denaturing or dissociation phase is performed at 92-95°C depending on the 
protocol used. As the name suggests, this separates the double stranded cDNA to 
allow the primer pairs specific for the gene of interest to anneal, also known as the 
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second phase. Annealing temperatures (TA) can vary quite substantially and is 
dependent on the relative cytosine (C)/guanine (G) and adenine (A)/thymine (T) 
nucleotide content of the primers used and is given by:  
TA = Tm - 4°C  
Where Tm is the melting temperature, given by:  
Tm = 4(G+C) + 2(T+A) °C 
The final step is the elongation of the cDNA sequence between the primer pairs. This 
utilises a DNA polymerase (EC 2.7.7.7) from Thermophilus aquaticus (Taq), a 
bacterium first discovered in thermal springs, with the ability to withstand high 
temperatures, including those used in the initial dissociation phase. The elongation 
phase is conducted at 72°C, the characterised, opti mum temperature for Taq DNA 
polymerase. A complimentary strand of cDNA is synthesised for each existing strand, 
therefore, exponential growth of the cDNA of interest occurs after each cycle of 
dissociation, annealing and elongation. This process is only slowed when consumption 
of vital reagents has occurred. 
2.11.1. Extraction of mRNA 
RNase-free consumables were used throughout and surfaces and gloves were 
frequently sprayed with RNase inhibitor. Extraction was performed using a modified 
acid guanidinium thiocyanate-phenol-chloroform extraction method (Chomczynski & 
Sacchi 1987). Medium was aspirated from cells, rinsed with PBS and then lysed into 1 
ml Trizol® using a continuous solution aspiration/explusion technique. The Trizol®-
containing cell lysate was transferred to autoclaved RNase-free safelock tubes and 
incubated at room temperature for at least 5 minutes. The nucleic acids were isolated 
by adding 200 µl of chloroform to each tube and shaking vigorously for 15 seconds 
followed by incubation at room temperature for a further 3 minutes. The tubes were 
spun at 11,600 g in an Eppendorf 5415R benchtop centrifuge for 15 minutes at 4°C 
and the clear upper aqueous phase containing the nucleic acids was transferred into 
new tubes, taking care not to contaminate with material from the lower phases. RNA 
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was precipitated from the aqueous phase by the addition of 500 µl of isopropyl alcohol 
followed by incubation at room temperature for 10 minutes. Precipitated RNA was 
pelleted by centrifugation at 11,600 g for 10 minutes at 4°C. The supernatant was 
discarded and the pelleted RNA was washed with 1 ml 75% ethanol, vortexed and 
pelleted after centrifugation at 6200 g for 5 minutes at 4°C. The supernatant was 
removed and the RNA pellet was air-dried before dissolution into an appropriate 
volume (10-50 µl, dependent on pellet size) of ddH2O treated with the nuclease 
inhibitor diethyl pyrocarbonate (DEPC). Tubes were incubated at 70°C for 10 minutes 
to aid dissolution. RNA concentration of the resulting solutions was then calculated 
using absorbance readouts at 260 nm (A260) and at 280 nm (A280) on a Pharmacia 
Biotech Ultraspec 2000 spectrophotometer. The ratio A260 / A280 indicates the purity of 
the RNA, where pure RNA gives a ratio of 2:1, respectively.  
The standard equation to calculate the concentration of RNA from the absorption at 
260 nm is Beer's law:  
A260 = e C l 
Where A260 is the measured absorption at 260 nm 
e is the extinction coefficient (25 µl.µg-1.cm-1 for RNA)  
C the RNA concentration  
and l is the pathlength (1 cm)  
Rearrangement gives: 
C = A260 / (e l) = A260 x 40 µg/ml  
However, this is the concentration of the diluted solution and the dilution factor 
needs to be taken in to account to calculate the sample concentration: 
C(sample) = C(measured) x dilution factor (for example: 303/3 = 101) 
For example, if A260 = 0.1, then C(measured) = 0.1 x 40 µg/ml = 4 µg/ml 
and C(sample) = 4 µg/ml x 101 = 404 µg/ml = 0.404 µg/ul. 
142 
 
2.11.2. Reverse transcription of mRNA 
Reverse transcription of RNA was carried out using Superscript® II Reverse 
Transcriptase (RT) developed from the polymerase (pol) gene of Moloney murine 
leukaemia virus (M-MLV). Reverse transcription of 1 µg of RNA in 10 µl of DEPC-
treated ddH2O was performed. The first reaction consisted of the RNA solution, 1 µl of 
0.25 µg/µl oligo(dT)12-18 primer, (the classic primer mix used to prime synthesis of the 
first strand cDNA by reverse transcriptase using poly A+ mRNA* as a template) and 1 
µl of 10 mM  deoxynucleotide triphosphates (dNTPs; required for elongation of 
sequence). This reaction was incubated at 65°C for 5 minutes then immediately 
quenched on ice. During this incubation a mastermix was prepared containing (per 
reaction) 4 µl of 5X buffer (supplied with Superscript® II RTase), 2 µl 0.1 M 
dithiothreitol (DTT; a reducing agent that breaks disulphide bonds disrupting the 
secondary structure of the RNA, helping to facilitate RT enzyme initiation of reverse 
transcription), and 40 units/ml (1 µl) of RNaseOUT (a ribonuclease inhibitor). Seven 
microlitres of the mastermix was added to each reaction and incubated at 42°C for 2 
minutes before final addition of 200 units of Superscript® II RTase (1 µl) for 50 minutes 
at 42°C. Reactions were terminated by heating to 70 °C for 15 minutes. Samples were 
transferred to ice and stored at -20°C. 
2.11.3. Polymerase Chain Reaction 
A PCR was run on the product of 0.1 µg reverse transcribed RNA (2 µl). To each 
sample 48 µl of a PCR mastermix was added, containing: 10 µl 5X Flexi buffer 
(supplied with the Taq polymerase enzyme), 2.5 mM MgCl2 (concentration optimised 
by previous PhD student), 2.5 µM of forward and reverse primers, 0.2 mM dNTPs, 1.25 
units Taq DNA polymerase (0.25 µl of 5 units/µl) and DEPC-treated ddH2O to make up 
to 48 µl. The reaction consisted of an initial denaturing step at 94°C for 5 minutes, 
followed by an optimised number of cycles (see Table 2.11.1) of dissociation at 94°C, 
annealing (calculated and optimised for each primer, see Table 2.11.1), and elongation 
at 72°C. All reactions were terminated after a furt her 7 minute elongation phase at 
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72°C through storage at 4°C. To control for human e rror and varying RNA 
concentrations a house keeper gene, glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) was analysed in parallel with the genes of interest. 
2.11.4. Agarose gel electrophoresis 
After reserve transcription of RNA and PCR, 15 µl of each PCR product was loaded a 
1% w/v agarose gel in Tris/borate/EDTA buffer, containing 0.5 µg/ml ethidium bromide. 
Where possible 10 µl of a Quick-Load® 100 base pair DNA ladder (New England 
BioLabs) was loaded alongside. The gel was run for approximately 1-2 hours at 80-120 
V, dependent on tank size, and then viewed under UV light using a Gel-Pro Imager 
system. Images were captured using a CoolSNAP-Pro camera and densitometry was 
subsequent performed using ImageJ software. 
Gene 
Product 
Forward Primer Sequence 
(5’-3’) 
Reverse Primer Sequence 
(5’-3’) 
Cycle 
No. 
TA (°C) 
Rat 
Prothrombin 
ATGAGGAGGGCGTGTGGT
GCTATGT 
CCGTCGATGTAGGATTCC
AGGAGCT 35 60 
Rat  
GAPDH 
TGGTGCCAAAAGGGTCAT
CATCTCC 
GCCAGCCCCAGCATCAAA
GGTG  
35 60 
Human 
iNOS 
ACCAGTACGTTTGGCAAT
GG 
TCAGCATGAAGAGCGATT
TCT 30 58 
Human 
TNFα 
CAGCCTCTTCTCCTTCCTG
AT 
GCCAGAGGGCTGATTAGA
GA 30 58 
Human 
CHOP 
CAGAGCTGGAACCTGAGG
AG 
TGGATCAGTCTGGAAAAG
CA 30 58 
Human 
GAPDH 
AGCCACATCGCTCAGACA
C 
GCCCAATACGACCAAATC
C 30 58 
 
 
  
Table 2.11.1. Primer sequences and associated PCR cycle number and 
annealing temperatures 
144 
 
2.12. Statistical Analysis 
To directly compare single treatments, two tailed un-paired Student’s t‐tests were 
performed. If comparisons were to be made between basal or control treatments with 
other treatments, one way analysis of variance (ANOVA) was used in combination with 
the Dunnett’s post hoc test. Where data are presented as percentages, statistical 
analyses were performed on the raw data and only transformed post analysis for 
presentation purposes. Throughout data are presented as mean ± standard error 
(SEM). Where data were shown to be statistically significant, p values of *<0.05, 
**<0.01 and ***<0.001 were given, non significant data (ns) was shown as p >0.05.  
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3. Initial characterisation of fibrinogen- and fibrin-mediated 
effects on microglia in different culture systems 
3.1. Introduction 
In this chapter, initial characterisation of microglia and neuronal cultures after treatment 
with fibrinogen (FG) and fibrin (FN), in vitro, was performed. The induction of death 
after treatment was investigated to identify whether the protein preparations were toxic. 
The expression and release of proteins implicated in microglial activation and toxicity 
were quantified in primary microglial cultures but also neuronal cultures, after 
treatment. Pharmacological inhibition of particular pathways was also investigated as 
potential therapeutic interventions, with the role of microglia in any significant 
observation being prioritised. 
3.1.1. Microglia activation, in vitro 
Whether in vitro models of any sort can truly mimic an in vivo, physiological setting is 
an area of intense debate. Microglia in culture have been shown to be more sensitive 
than in situ and it can be easily perceived that without down-regulatory signals from 
other neural cells, changes in homeostasis in vitro, e.g. treatment, are likely to cause 
microglial activation. However, numerous studies have shown this not to be the case 
(Taylor et al. 2005; Ifuku et al. 2007; Klintworth et al. 2009; Maezawa et al. 2011). 
Differences in ‘resting’ microglial morphology in vitro when compared with histological 
slices, including an increase in microglia presenting amoeboid/activated characteristics 
rather than the classical ramified morphology, suggest that activation observed after 
treatment could be attributed, at least in part, to the un-physiological setting the cells 
find themselves in. However, neuronal morphology in vitro can also be dissimilar to the 
morphology observed in vivo but the cultures display similar physiology to that 
observed in situ suggesting that evolutionarily conserved signalling pathways in 
microglia may not dramatically change when the cell is isolated. Furthermore, initial in 
vitro experimentation to discover parallelism with the in vivo setting can save vast 
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amounts of money and studies that pursue the identification of factors required to 
down-regulate microglia will only add to the usefulness of in vitro culturing. These 
points coupled with the fact that many cellular and molecular responses induced after 
microglial activation by pathogens or protein aggregates associated with disease, at 
present, are not accessible in vivo, makes in vitro modelling an extremely useful tool. 
3.1.2. Activation of microglia by blood-borne proteins 
Disorders involving blood brain barrier dysfunction allow infiltration of blood-borne 
proteins into the CNS parenchyma providing potential for microglia interaction. 
Previous studies have identified microglial activation in the presence of albumin 
(Hooper et al. 2009b), fibrinogen (Adams et al. 2007a; Paul et al. 2007), and thrombin 
(Möller et al. 2000; Choi et al. 2003), although, more recently, certain thrombin-
mediated activation factors, including cytokine release, have been attributed to 
unknown high molecular weight contaminants in the protein preparations (Hanisch et 
al. 2004; Möller et al. 2006).  
It is hypothesised that microglia are primarily activated to clear or phagocytose the 
infiltrating proteins, but the chronic presence of these proteins causes hyperactivity and 
the release of factors at concentrations great enough to induce toxicity, not only in 
surrounding neural cells but also in an autocrine fashion. This thesis focuses on 
fibrinogen and the insoluble matrix, fibrin that is deposited during proteolytic cleavage 
by thrombin (Adams et al. 2004). Previous studies have identified receptors on 
microglia (Adams et al. 2007a) and neurons (Schachtrup et al. 2007), that interact with 
fibrinogen, in an immobilised form, to induce a phagocytic microglia phenotype and 
inhibit neurite outgrowth, respectively. Adams et colleagues (2007a) failed to show 
effects with soluble fibrinogen, however other studies have identified significant 
macrophage activation, including cytokine release, after treatment with the soluble form 
of the protein (Kajikawa et al. 1986; Hodgkinson et al. 2008). The initial 
characterisation of primary microglia after fibrinogen and fibrin treatment supports 
activity with both soluble and insoluble forms of the protein, with the observation of 
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differential toxicity. A non-apoptotic induction of caspases was also observed, 
supporting new literature suggesting caspase-3, -7 and -8 is primarily involved in 
microglia activation after LPS treatment rather than apoptosis (Burguillos et al. 2011). 
3.1.3. Modelling microglia activation in neuronal cultures 
As previously stated, pure in vitro cultures of primary microglia are useful tools for 
elucidating signalling pathways, however models that allow manipulation of microglial 
responses in a more physiological setting, i.e. in the presence of other cell types, are 
more attractive. Characterisation of cerebellar granule cultures (Section 2.5) identified 
the presence of glia including microglia, at a density similar to that observed in situ (~ 
12%). This provided an ideal preparation to model microglial involvement in fibrinogen- 
and fibrin-mediated toxicity in a more physiological environment. Previous observations 
showing that the presence of contaminating microglia in astrocyte cultures are 
responsible for iNOS expression after LPS treatment (Saura 2007) suggests that the 
population identified in the neuronal cultures used here could also mediate 
inflammatory responses. Modification and optimisation of a protocol to specifically 
deplete microglia (Hamby et al. 2006) from the neuronal cultures (Section 2.5.2) 
allowed the study of the involvement of microglia in fibrinogen and fibrin mediated 
responses. These studies were then compared with studies involving the administration 
of microglial-conditioned medium to neuronal cultures initially depleted of microglia to 
identify whether responses were due to released soluble factors from microglia or cell-
cell contact. 
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3.2. Effects of direct exposure of primary microglial cultures to 
fibrinogen and fibrin 
To assess any obvious morphological changes in the primary microglial cultures after 
treatment with FG or FN, immunocytochemistry (ICC) with IB4 was performed. 
Treatment of cultures with FG or FN for 24 hours did not significantly increase the 
percentage of pyknotic and condensed nuclei, a classic morphological hallmark of cells 
undergoing apoptosis, when compared with control (CTR; Figure 3.2.1). Conversely, 
this morphological change was shown to be significantly increased in cultures treated 
with staurosporine (STS), when compared with control levels. Cultures treated with FN 
showed a significant increase in the percentage of enlarged nuclei, a hallmark for 
necrotic cell death, when compared with CTR. However, treatment with FG or the 
classical microglial activator, lipopolysaccharide (LPS) did not replicate these findings, 
suggesting differential effects of these treatments when compared with FN (Figure 
3.2.1).    
The MAC-1 integrin receptor (CD11b) is a marker of microglial activation and 
expression has been shown to be upregulated in AD brains (Akiyama & McGeer 1990). 
This receptor has also been shown to mediate FG-induced phagocytic activity, in vitro 
(Adams et al. 2007a). Here it is shown that treatment of primary microglial cultures with 
FG or FN for 24 hours significantly increases the microglial expression of CD11b, to a 
level similar, or in the case of FG, greater, than the increase observed after LPS 
treatment (Figure 3.2.2 A). This was quantified for statistical analysis by calculating 
fluorescence intensity/cell in each field with ImageJ software (NIH, USA) and plotted as 
an arbitrary fluorescence unit (AFU) (Figure 3.2.2 B).  
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Figure 3.2.1. FN but not FG induces cytotoxic changes in microglia 
A. Representative images of microglial cultures after treatment with STS (0.5 µM) 
for 4 hours, or FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) for 24 hours. 
Cultures were stained with DAPI for quantification of changes in nuclear 
morphology and Isolectin-B4 for microglial identification (Streit 1990), except in 
negative control cultures. Original magnification: x40, scale bar: 10 µm. B. Sample 
sections of fields of particular interest at higher resolution, including CTR cultures, 
and FN- or STS-treated cultures, with the latter two showing microglial necrosis 
and apoptosis, respectively. C. Quantification of apoptotic and necrotic nuclear 
morphology in microglial cultures after administration of treatments given above. 
Data are presented as the mean ± SEM. Treatments were in duplicate in each 
experiment and data were analysed from 3 independent experiments. Paired two-
tailed Student’s t-tests were performed between control and each treatment. 
Levels of significance were: non-significant p>0.05, ** p<0.01, *** p<0.001.    
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Figure 3.2.2. FG and FN induce significant expression of CD11b 
A. Representative images of primary microglial cultures after treatment with FG 
(2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) for 24 hours. Cultures were stained 
with DAPI for quantification of cell number and probed with anti-CD11b (green) for 
identification of microglial activation state, except in negative control cultures, 
where anti-CD11b was omitted. Original magnification: x20, scale bar: 30 µm. B. 
Quantification of relative fluorescence intensity/cell in microglial cultures after 
administration of the treatments stated above. Data are presented in arbitrary 
fluorescence units (AFU). Treatments were in duplicate in each experiment and 
data were analysed from 3 independent experiments. Paired two-tailed Student’s t-
tests were performed between control and each treatment. Levels of significance 
were: non-significant p>0.05, * p<0.05, ** p<0.01. 
154 
 
3.2.1. Fibrinogen and fibrin treatment causes TNFα release from microglia 
Activation of microglia can cause significant release of pro-inflammatory cytokines, 
which are able to induce upregulation of pro-apoptotic factors in surrounding cells as 
well as the host cell (Kingham et al. 1999; Nguyen et al. 2002; Taylor et al. 2005). 
Treatment of primary microglial cultures with FG or FN significantly induced TNFα 
release, a classical pro-inflammatory cytokine. Treatment with the positive control, 
LPS, for 8 hours induced a highly significant increase in release, compared with non-
treated control cultures (CTR). This was followed by a significant drop in release after 
16 hours, when compared with levels of release after 8 hours. After 16 hours of LPS 
treatment, TNFα release rose significantly until 48 hours, the final time-point assayed, 
with no plateau (Figure 3.2.3 A). FN treatment induced an earlier significant rise in 
release in comparison to LPS-treated cultures. This was followed by a plateau until 16 
hours from where a steady significant increase in release was observed until 48 hours 
exposure, following a similar profile to that observed in LPS-treated cultures. FG 
treatment however, showed a different profile of TNFα release. Significant release was 
still observed after 8 hours of treatment. However, unlike LPS and FN treatment, 
release peaked at 24 hours, when compared with control levels, followed by a 
significant drop in TNFα release by 48 hours, when compared with levels of release 
after 24 hours (Figure 3.2.3 A). Furthermore, the FG- and FN-mediated TNFα release 
was concentration dependent at both 24 and 48 hours (Figure 3.2.3 B and C).  
Due to the observation that LPS or FN-induced TNFα release profiles were similar, it 
was questioned whether endotoxin contamination of FN was an issue. Previously it has 
been reported that only 40 pg/ml (or 0.4 EU/ml; 10EU/ng) of endotoxin is required to 
induce microglial proliferation, NO production and cytokine release (Weinstein et al. 
2008). Therefore, cultures were pre-treated with polymyxin B (PMX), an antibiotic that 
binds to the biologically active portion of the endotoxin-(LPS)-macromolecule known as 
lipid A (Morrison & Jacobs 1976) and potently abolishes LPS responses (Jacobs & 
Morrison 1977). PMX (100 nM) pre-treatment significantly attenuated LPS-mediated 
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TNFα release after 24 hours but did not affect FG- or FN-mediated release suggesting 
insignificant or no LPS contamination in the protein preparations used here (Figure 
3.2.4). Finally, to control against false-positive ELISA readouts, cultures were pre-
treated with thalidomide, a potent inhibitor of TNFα synthesis (Lopez-Talavera et al. 
1996). Inhibition of TNFα synthesis significantly attenuated the LPS-mediated TNFα 
release. Also, thalidomide pre-treatment significantly attenuated FG- and FN-mediated 
TNFα release (Figure 3.2.4). 
In an attempt to further elucidate pathway factors upstream of TNFα release after FG 
exposure, ELISAs were performed after pre-treatment with Mitogen-activated protein 
kinase (MAPK) inhibitors. LPS-mediated TNFα release from microglia is dependent on 
activation of the p38-MAPK pathway (Nakajima et al. 2004). In addition the 
phosphoinositide 3-kinase (PI3K) pathway has been shown to be involved in microglial-
mediated neurotoxicity after Aβ treatment (Zhang et al. 2011). Both pathways were 
pharmacologically inhibited to identify possible involvement in FG-mediated TNFα 
release. Pre-treatment of microglia with the potent, cell permeable, specific inhibitor of 
p38-MAPK, SB203580 (10 µM; the EC50 value), significantly decreased FG-mediated 
TNFα release after 24 hours by approximately 50% (Figure 3.2.5), suggesting FG-
mediated TNFα release is dependent on the p38-MAPK pathway. Conversely, the PI3K 
pathway was not involved in FG-mediated TNFα release since inhibition of the PI3K 
pathway with wortmannin (100 nM), a highly selective and potent inhibitor, did not 
attenuate the FG-mediated TNFα release (Figure 3.2.5). 
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Figure 3.2.3. FG and FN induce significant TNFα release from microglia 
A. Log timecourse analysis of TNFα release using an ELISA system after 
treatment of primary microglia with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml). 
B. Analysis of TNFα release after treatment for 24 hours with FG (0.1-2.5 mg/ml), 
FN (0.05-1 mg/ml), LPS (1 µg/ml) or LPS and IFNγ (100U/ml). C. Analysis of TNFα 
release after treatment for 48 hours with FG (0.1-2.5 mg/ml), FN (0.05-1 mg/ml), 
LPS (1 µg/ml) or LPS and IFNγ (100U/ml). Treatments were in duplicate in each 
experiment and data were analysed from 3 independent experiments. For 
timecourse analysis, paired two-tailed Student’s t-tests were performed between 
specific time-points as indicated by coloured lines. In concentration dependent 
studies a one-way analysis of variance (ANOVA) was performed with Dunnett’s 
post-test. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01, 
*** p<0.001. 
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Figure 3.2.4. FG- and FN-mediated TNFα release was not due to endotoxin 
contamination 
Analysis of TNFα release was performed using an ELISA system after treatment of 
primary microglia cultures for 24 hours with FG (2.5 mg/ml), FN (1 mg/ml) or LPS 
(1 µg/ml), co-treated with either thalidomide (Thal; 10 µg/ml) or polymyxin-B (PMX; 
100 nM). Treatments were in duplicate in each experiment and data were analysed 
from 3 independent experiments. To compare induction of TNFα release in 
multiple treatments with control levels a one way ANOVA was performed with 
Dunnett’s post-test. Direct comparison of specific treatments was analysed using 
paired two-tailed Student’s t-tests. Levels of significance were: non-significant 
p>0.05, * p<0.05, ** p<0.01, *** p<0.001.    
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Figure 3.2.5. FG-mediated TNFα release was dependent on p38-MAPK 
pathway activation 
Analysis of TNFα release was performed using an ELISA system after treatment of 
primary microglia cultures for 24 hours with FG (2.5 mg/ml) and co-treated with 
either wortmannin (Wort; 100 nM) or SB203580 (SB; 10 µM). Treatments were in 
duplicate in each experiment and data were analysed from 3 independent 
experiments. To compare induction of TNFα release in multiple treatment groups 
with control levels a one way ANOVA was performed with Dunnett’s post-test. 
Direct comparison of specific treatments was analysed using paired two-tailed 
Student’s t-tests. Levels of significance were: non-significant p>0.05, * p<0.05, ** 
p<0.01, *** p<0.001.    
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3.2.2. Differential iNOS expression is observed in microglia after treatment with 
fibrinogen or fibrin 
To further assess microglial reactivity in the presence of FG or FN, iNOS expression 
was assayed using ICC. The expression of iNOS is a classic marker of activated 
microglia (Ferretti et al. 2011). These experiments were again performed in the 
presence of PMX, to control for endotoxin contamination. In serum-free conditions FG 
and FN treatment for 24 hours significantly induced expression of iNOS to a level 
similar to that observed after LPS treatment for 24 hours, when compared with control 
levels. PMX pre-treatment of FG- and FN-treated cultures had no significant effect on 
the percentage of microglia presenting iNOS expression, however LPS-mediated 
expression was significantly inhibited (Figure 3.2.6). 
Interestingly, when iNOS expression was quantified in primary microglia cultured and 
treated in medium that still contained serum, FG-induced expression disappeared. 
Expression of ED-1 however, a classical marker of activated/phagocytic microglia, was 
still significantly higher than observed in control cultures. This suggests that although 
iNOS expression was lost, the FG-treated cells were still activated in an iNOS-
independent fashion (Figure 3.2.7). Furthermore this serum-masking effect caused no 
significant difference to the iNOS expression in FN- or LPS-treated cultures, with 
significant expression above control levels being observed (Figure 3.2.7). 
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Figure 3.2.6. FG and FN induced microglial iNOS expression in serum-free 
conditions 
A. Representative images from serum-free microglial cultures after 24 hours of 
treatment with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml), and co-treatment 
with PMX (100 nM). Cultures were co-stained with DAPI for quantification of cell 
number, and probed with anti-ED1 (green) for identification of activated microglia 
and anti-iNOS (red), except in negative control cultures, where primary antibodies 
were omitted. Original magnification: x40, scale bar: 10 µm. B. Quantification of 
iNOS+ microglia after administration of treatments given above. Data are presented 
as a percentage of total microglial number. Treatments were in duplicate in each 
experiment and data were analysed from 3 independent experiments. To compare 
the expression of iNOS in multiple treatment groups with control levels a one way 
ANOVA was performed with Dunnett’s post-test. Direct comparison of specific 
treatments was analysed using paired two-tailed Student’s t-tests. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 3.2.7. FN but not FG induced microglial iNOS expression in serum-
containing conditions 
A. Representative images of serum-containing primary microglial cultures after 24 
hours of treatment with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml). Cultures 
were co-stained with DAPI for quantification of cell number, and probed with anti-
ED1 (green) for identification of activated microglia and anti-iNOS (red), except in 
negative control cultures, where primary antibodies were omitted. Some non-
treated controls were stained with isolectin-B4 (IB4, green; Streit 1990) to identify 
culture purity. Original magnification: x40, scale bar: 10 µm. B. Quantification of 
iNOS+ and ED1+ microglia after administration of treatments stated above. Data 
are presented as a percentage of total microglial number. Treatments were in 
duplicate in each experiment and data were analysed from 3 independent 
experiments. To compare the expression of iNOS or ED1 in multiple treatment 
groups to control levels a one way ANOVA was performed with Dunnett’s post-test. 
Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01. 
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3.2.3. A non-apoptotic expression of cleaved caspase-3 after fibrinogen treatment 
of microglia 
To further support the initial finding that treatment with FG or FN did not induce 
significant or observable apoptosis, ICC targeting the expression of the cleaved form of 
the classic apoptotic executioner caspase, caspase-3, was performed (Figure 3.2.8). 
As expected, treatment of cultures with STS for 8 hours induced significant expression 
of the cleaved form of caspase-3, when compared with control levels. However, 
treatment of cultures for 24 hours with LPS also induced significant cleavage of 
caspase-3, when compared with that in control cultures. This was unexpected as 
previous findings (Figure 3.2.1) suggested that LPS treatment did not induce 
significant apoptosis in primary cultures, again replicated in this experiment. Similarly, 
treatment with FG or FN for 24 hours significantly induced caspase-3 cleavage, when 
compared with control levels, and in the case of FG-treatment, no significant apoptotic 
cell death was seen, when compared with control, which again supported previous 
findings (Figure 3.2.8 B). Significant death was observed FN-treated cultures, which 
also supported previous findings. Certainly, in the case of FG or LPS, these data 
suggest that treatment can induce cleavage of caspase-3 in a non-apoptotic role. 
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Figure 3.2.8. FG induces microglial cleaved caspase-3 expression, 
independent of death 
A. Representative images of primary microglial cultures after STS treatment (0.5 
µM; 4 hours) or 24 hours of treatment with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 
µg/ml). Cultures were co-stained with DAPI for quantification of cell number, and 
probed with anti-ED1 (green) for identification of activated microglia and anti-
cleaved caspase-3 (red), except in negative control cultures, where cultures were 
treated with STS and primary antibodies were omitted. Original magnification: x40, 
scale bar: 30 µm. B. Quantification of apoptotic/necrotic (death) morphology and 
cleaved caspase-3+ microglia after administration of treatments given above. Data 
are presented as a percentage of total microglial number. Treatments were in 
duplicate in each experiment and data were analysed from 3 independent 
experiments. To compare % death or expression of cleaved caspase-3 in multiple 
treatment groups to control levels a one way ANOVA was performed with 
Dunnett’s post-test. Levels of significance were: non-significant p>0.05, * p<0.05, 
*** p<0.001. 
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3.3. Effects of direct exposure of enriched cerebellar granule cell 
cultures to fibrinogen and fibrin 
3.3.1. Characterisation of fibrinogen- and fibrin-mediated death 
To ascertain whether exposure of enriched cerebellar granule cultures (CGCs) to FG or 
FN caused any significant apoptosis, cultures were treated with either FG or FN for 24 
and 48 hours, fixed and stained with Hoechst-33342. The cultures were then observed 
under a fluorescence microscope and cells with classic apoptotic morphology, i.e. 
pyknotic nuclei showing chromatin condensation, and membrane blebbing (Kerr et al. 
1972) were quantified against total cell number/field. Staurosporine (STS) treatment for 
8 hours was used as a positive control, and as expected, caused a significant increase 
in the number of cells displaying apoptotic nuclear morphology (Figure 3.3.1 Ai & Aii). 
Interestingly, treatment with FG induced a significant increase in cell nuclei displaying 
apoptotic morphology after 24 hours, but FN-treatment for the same time period did 
not, similar to that seen after LPS treatment (Figure 3.3.1 B & D). However, after 
cultures were exposed to LPS for 48 hours significant apoptotic morphology was 
observed. The same observation was made after FG and FN exposure for 48 hours 
(Figure 3.3.1 B & D). LPS induces its neurotoxicity primarily through activation of 
microglia, with a positive correlation being observed between abundance of microglia 
and sensitivity to LPS-induced neurotoxicity (Kim et al. 2000). Therefore, it is likely that 
contaminating microglia present in these enriched neuronal cultures are responsible for 
the significant increase in LPS-mediated neuronal death after 48 hours.  
Exposure of cell cultures to charged proteins with a high molecular weight, such as FG 
can cause nuclear shrinkage due to alteration of the osmotic equilibrium. 
Administration of such a protein produces a hypertonic ‘extracellular’ culture medium 
that causes water diffusion down the gradient, in this case, intracellular to extracellular, 
causing cell shrinkage (Horie et al. 1989). Therefore, administration of proteins like FG 
could appear to induce apoptosis if quantification depended solely on morphological 
changes. Therefore, to provide support for the morphological quantification of 
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apoptosis, live cell staining using an Annexin V-FITC conjugate was performed (Figure 
3.3.1 C). Similar to the Hoechst-33342 apoptotic morphology findings significant 
Annexin V-FITC staining was observed after 24 hours treatment with FG and 48 hours 
after both FG and FN treatment, comparable to treatment of CGCs with STS for 8 
hours, supporting the original data from Hoechst-33342 quantification (Figure 3.3.1 C 
& D). 
Further support for FG- and FN-mediated neuronal apoptosis was provided with ICC 
for cleaved caspase-3 expression and live cell staining for caspase-3/7 activation in 
CGCs (Figures 3.3.2 & 3.3.3). As expected, treatment with STS for 8 hours 
significantly induced cleavage of caspase-3 in ICC (Figure 3.3.2) and caspase-3/7 in 
live cell staining experiments, shown by the significant increase in FAM-DEVD-FMK 
fluorescence, quantified using Image J (Figures 3.3.3 A & B). Treatment with FG for 
24 hours and FN and LPS for 48 hours also significantly increased the cleavage of 
caspase-3 in ICC experiments that was associated with NeuN staining, suggesting the 
apoptotic cells were neuronal (Figure 3.3.2). Live cell staining for caspase-3/7 
cleavage after the same treatments was also significantly enhanced further supporting 
the hypothesis that these protein preparations can induce neuronal toxicity and 
apoptosis (Figure 3.3.3 A & B). 
A lactate dehydrogenase (LDH) assay was also performed for biochemical analysis of 
cellular integrity. As cell death and toxicity can be evaluated by quantification of plasma 
membrane damage, the use of an assay to assess the level of damage can be 
extremely informative. The LDH assay is one of the most commonly used forms of 
membrane damage quantification assay due to LDH being present in relatively high 
abundance in all cell types. The enzyme is also rapidly released from the cell upon 
membrane damage making it an ideal candidate for sensitive quantification of toxicity. 
As expected, treatment of the CGC cultures with STS significantly increased LDH 
release from membrane compromised cells into the culture medium after 8 hours 
(Figure 3.3.3 C). Treatment with FG for 24 hours also significantly increased the 
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release of LDH, when compared with non-treated control cultures. Furthermore, 
treatment for 48 hours with FN also significantly increased LDH release, again similar 
to the release induced by LPS treatment for 48 hours. 
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  Figure 3.3.1. FG and FN induce significant death in CGC cultures 
Ai. Representative images of CGC cultures after STS treatment (0.5 µM; 8 hours). 
Inset shows classic apoptotic morphology, indicated throughout the figure with 
arrowheads. Cultures were fixed, stained with Hoechst-33342 and apoptotic 
morphology was quantified (Aii). B. Representative images of CGC cultures after 
FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) treatment for 24 and 48 hours. As 
above, cultures were fixed, stained with Hoechst-33342 and apoptotic morphology 
quantified. C. Representative images of CGC cultures, treated as outlined in B, 
with LPS being substituted for STS (8 hours), and subjected to live cell staining 
with Hoechst-33342 and Annexin-V-FITC (green). D. Quantification of B (black, 24 
hours; grey, 48 hours, Hoechst-33342) and C (blue, 24 hours; green, 48 hours, 
Annexin-V). E. Sample fields of interest from the Hoechst-33342 fixed cell staining 
experiments at higher resolution for easier identification of FG and FN-mediated 
apoptosis in the CGC cultures when presented on the printed page. Data are 
presented as a percentage of total death in the CGC culture. All images were 
captured using x40 magnification, and all scale bars = 40 µm. Treatments were in 
triplicate in each experiment and data were analysed from 3 independent 
experiments. To compare death at each time-point in both protocols between 
control levels and treatments, a one way ANOVA was performed with Dunnett’s 
post-test. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01, 
*** p<0.001.  
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Figure 3.3.2. FG and FN treatment induces neuronal caspase-3 cleavage 
Representative images from ICC experiments on CGC cultures after STS (0.5 µM; 
8 hours), FG (2.5 mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or LPS (1 µg/ml; 48 
hours) treatment are shown. Cultures were co-stained with DAPI for nuclear 
identification, and probed with anti-NeuN (green) for identification of neurons and 
anti-cleaved caspase-3 (red), except in negative control cultures, where primary 
antibodies were omitted. All images were captured using x100 magnification, and 
scale bar = 10 µm. Treatments were in duplicate. 
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Figure 3.3.3. FG and FN induce caspase-3/7 cleavage and LDH release in 
CGC cultures 
A. Panel of representative images of live cell staining experiments in CGC cultures 
after treatment with STS (0.5 µM; 8 hours), FG (2.5 mg/ml; 24 hours), FN (1 
mg/ml; 48 hours) or LPS (1 µg/ml; 48 hours). Live cell staining was performed with 
Hoechst-33342 for nuclear identification, propidium iodide (PI; red) for total cell 
death, and FAM-DEVD-FMK (green) for active caspase-3/7. Original magnification: 
x40, scale bar: 40 µm. B. Quantification of the relative active caspase-3/7 
fluorescence intensity/cell in CGC cultures after administration of treatments stated 
above. Data are presented in arbitrary fluorescence units (AFU). C. LDH release 
assay after treatment of CGCs as stated above. Data are presented as a 
percentage of total LDH release provided by cell lysis. Treatments were in triplicate 
for both live cell staining experiments and LDH assays, and data were analysed 
from 3 independent experiments. To compare AFU or LDH release between 
control levels and treatments, a one way ANOVA was performed with Dunnett’s 
post-test. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01, 
*** p<0.001.  
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3.3.2. Differential involvement of microglia in fibrinogen- and fibrin-mediated 
neuronal death  
Due to the observation that LPS could induce neuronal death in the CGCs after 48 
hours of exposure, a method to specifically ablate microglia present in the cultures was 
optimised (Section 2.5.2; Figure 3.3.4 – 3.3.7). The use of leucine-methyl-ester (LME) 
as a phagocyte-specific executioner has been previously published for use on 
microglial (Morgan et al. 2004) and astrocyte (Hamby et al. 2006) cultures, and an 
adaptation of these methods were optimised for use on the neuronal cultures used 
here. 
As shown previously, CGC cultures exposed to LPS for 48 hours present a significant 
increase in cells displaying apoptotic morphology, when compared with non-treated 
controls (Figure 3.3.8 Aii & B). However, cultures pre-treated with LME then exposed 
to LPS for 48 hours did not show the same significant increase in apoptotic morphology 
(Figure 3.3.8 Aii & B), supporting the essential role of microglia in LPS-mediated 
neurotoxicity. Interestingly, the observed increase in apoptotic morphology seen after 
24 hours exposure of the cultures to FG was also attenuated to control levels after 
microglia depletion. This also suggests a significant role for microglia in FG-mediated 
neuronal apoptosis, after 24 hours (Figure 3.3.8 Ai & B). By 48 hours however, 
cultures exposed to FG had a significant number of cells with apoptotic morphology 
even if microglia had been depleted from the cultures. This suggests either FG has 
direct neurotoxic capabilities, or that the protein is cleaved in culture to FN (Section 
3.3.4), which in turn could have direct neurotoxic effects.   
When microglia were depleted from cultures exposed to FN for 24 hours, the number of 
cells displaying apoptotic morphology significantly increased (Figure 3.3.8 Ai & B). 
This suggests microglia protect the neurons from 24 hours of FN exposure. However, 
this observed ‘protective’ effect must be time-dependent, because as previously shown 
(Figure 3.3.1), FN exposure for 48 hours with microglia present in the CGC cultures 
caused a significant increase in apoptotic morphology (Figure 3.3.8 Aii & B). These 
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findings suggest that microglia are able to efficiently clear ‘acute’ (<24 h) FN exposure, 
but not ‘chronic’ (>24 h) exposure, possibly due to FN-mediated microglial toxicity 
which indirectly causes neuronal death. 
3.3.3. Differential expression of ED-1 is observed in CGC cultures after FG or FN 
treatment 
To support the hypothesis that FN induces microglial death in the CGC cultures, ED-1 
expression in the cultures was assayed. FN increased ED-1 expression after 2 h. This 
was followed a slow decline until 24 h when a significant decrease was observed at 48 
h (Figure 3.3.9 Ai & B), supporting the suggestion that FN is directly toxic to microglia. 
Interestingly, FG induced a bi-phasic expression of ED-1 in the CGC cultures, with 
decreases being observed after 4 h and 48 h (Figure 3.3.9 Aii & B). 
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Figure 3.3.4. Initial characterisation of LME treatment of CGCs 
A. Representative images from ICC experiments performed on CGC cultures after 
treatment with 1-10 mM LME for 24 hours. ICC was performed with DAPI (blue) for 
quantification of total cell number and those displaying apoptotic morphology, and 
IB4 (green) for microglial identification and quantification. Scale bar = 30 µm. B. 
Quantification of cells displaying apoptotic morphology (% of total cell number in 
the field) and microglial number, as a percentage of control levels. Paired two-
tailed Student’s t-tests were performed between controls and specific treatments. 
Levels of significance were: non significant p>0.05, *** p<0.001. N = 3.  
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Figure 3.3.5. Secondary characterisation of LME treatment of CGCs 
A. Representative images from ICC experiments performed on CGC cultures after 
treatment with 25-75 mM LME for 1 hour, followed by wash-off. ICC was 
performed with DAPI (blue) for quantification of total cell number and those 
displaying apoptotic morphology, and IB4 (green) for microglial identification and 
quantification. Scale bar = 30 µm. B. Quantification of cells displaying apoptotic 
morphology (% of total cell number in the field) and microglial number, as a 
percentage of control levels. Paired two-tailed Student’s t-tests were performed 
between controls and specific treatments. Levels of significance were: non 
significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. N = 3. 
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Figure 3.3.6. Characterisation of the effects of 25 mM LME treatment on 
neurons and astrocytes in CGC cultures 
Panel of representative images from ICC experiments performed on CGC cultures 
after treatment with LPS (1 µg/ml; 48 hours), FG (2.5 mg/ml; 24 hours) or FN (1 
mg/ml; 48 hours) and pre-treatment with 25 mM LME for 1 hour. No observable 
changes to astrocyte and neuronal density and morphology were recorded with 
respect to each main treatment group. Importantly, no significant change in 
neuronal or astrocytic morphology were observed when cultures were treated with 
LME alone, supporting a microglial-specific action of the compound. ICC was 
performed with DAPI (blue), anti-β-III-tubulin (green) for identification of changes in 
neuronal density and anti-GFAP (red) for identification of changes in astrocytic 
density and morphology. Scale bar = 30 µm.  
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Figure 3.3.7. Further characterisation of the effectiveness of 25 mM LME 
treatment in the removal of microglia from astrocytic cultures 
A. Panel of representative images from ICC experiments performed on primary 
astrocyte cultures after pre-treatment with 25 mM LME for 1 hour showing no 
observable changes in astrocyte density and morphology, but an observable loss 
of contaminating microglia. ICC was performed with DAPI (blue), anti-GFAP (red) 
for identification of changes in astrocytic density and morphology, and anti-ED1 
(green) for identification of microglial number. B. Representative images from ICC 
experiments performed on primary astrocyte cultures after treatment with LPS (1 
µg/ml) for 24 hours following pre-treatment with 25 mM LME for 1 hour. ICC was 
performed as described in A but with anti-GFAP (green) and anti-iNOS (red) to 
identify activated microglia. As in A no changes in astrocyte density and 
morphology were observed, however a loss in contaminating microglial 
number/reactivity was identified. Scale bar = 30 µm. 
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Figure 3.3.8. FG- and FN-mediated neuronal death is differentially dependent 
on microglia 
A. Panel of representative images from fixed cell staining experiments in CGC 
cultures, in some cases, treated with leucine-methyl-ester (LME; 25 mM) to deplete 
microglia, prior to treatment with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) for 
24 hours (Ai) or 48 hours (Aii). Cell staining was performed using Hoechst-33342 
for nuclear morphology analysis. Original magnification: x40, scale bar: 20 µm. B. 
Quantification of apoptotic morphology in the CGC cultures in the presence and 
absence of microglia. Data are presented as the percentage of the total population 
displaying apoptotic morphology. Treatments were in triplicate and data were 
analysed from 3 independent experiments. To compare between control levels and 
treatments, a one way ANOVA was performed with Dunnett’s post-test. For direct 
comparison between treatment in the presence and absence of microglia, paired 
two-tailed Student’s t-tests were performed. Levels of significance were: non-
significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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  Figure 3.3.9. FG and FN induce differential, time-dependent expression of 
ED1 in CGC cultures 
A. Representative Western blots for ED1 and β-actin expression in CGC cultures 
after timecourse treatment with FG (2.5 mg/ml; Ai) or FN (1 mg/ml; Aii). B. 
Quantification of ED1 expression (log scale) with respect to protein-loading control, 
β-actin. Western blots were repeated once (n = 2).  
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3.3.4. Fibrinogen is cleaved to fibrin in culture and is responsible for late 
neuronal death   
If FG is cleaved to FN in culture and this reaction mediates the ‘direct’, non-microglial 
neurotoxicity, the serine protease thrombin that is responsible for the cleavage reaction 
(Möller et al. 2006) would have to be present in the culture. To identify whether 
prothrombin was expressed in the CGC cultures used here and whether FG treatment 
increased or modulated this expression, RNA was extracted from CGCs, which had 
been time-dependently exposed to FG, and reverse transcribed to cDNA. Polymerase 
chain reaction (PCR) was performed and constitutive expression of prothrombin in the 
CGC cultures was not observed, however a significant increase in prothrombin gene 
expression was seen after 48 hours exposure with FG (Figure 3.3.10 A), suggesting 
that the chronic (>24 h) presence of FG can induce expression of the enzyme required 
for conversion of the protein to FN. These data do not confirm that FG is converted to 
FN but do suggest and further support the idea that FG could be converted to FN and 
induce direct neurotoxicity.  
To further elucidate whether FG is converted to FN in the CGC cultures, which in turn 
induces direct or non-microglial mediated neurotoxicity, a thrombin activity inhibitor, 
hirudin (Hi) was administered to the cultures prior to 24 or 48 hours of FG exposure, in 
the presence or absence of microglia (Figure 3.3.10 B). Inhibition of thrombin activity 
had no effect on FG-mediated increases in apoptotic morphology after either 24 or 48 
hours of treatment, when microglia were present. However, if microglia were depleted 
from the cultures prior to thrombin inhibition, ‘FG’-mediated neuronal toxicity after 48 
hours was significantly inhibited (Figure 3.3.10 Bii), which strongly suggests that FG is 
indeed cleaved in culture to FN which in turn is responsible for the late neuronal 
toxicity.    
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185 
 
  
Figure 3.3.10. ‘Chronic’ FG treatment induces prothrombin gene expression 
in CGCs leading to cleavage of FG to FN 
Ai. A representative PCR gel identifying prothrombin gene expression in CGC 
cultures after FG (2.5 mg/ml) timecourse treatment. Aii. Quantification of thrombin 
gene expression in CGC cultures with respect to expression of the house-keeper 
gene, GAPDH. Bi. Panel of representative images from fixed cell staining 
experiments in CGC cultures treated with FG (2.5 mg/ml), Hirudin (Hi; 50 U/ml) or 
in combination, after LME-treatment (25 mM) for 48 hours. Cell staining was 
performed using Hoechst-33342 to assess nuclear morphology. Original 
magnification: x40, scale bar: 20 µm. Bii. Quantification of apoptotic morphology in 
the CGC cultures after administration of treatments stated in Bi after 24 or 48 
hours incubation. The PCR experiment quantification is presented as the relative 
thrombin gene expression with respect to GAPDH expression. The fixed cell 
staining data were presented as the percentage of nuclei in the total population 
displaying apoptotic morphology. Treatments were in triplicate and data were 
analysed from 3 independent experiments. To compare between control levels and 
treatments, one way ANOVA were performed with Dunnett’s post-test. For direct 
comparison between treatments in the presence and absence of microglia after 48 
hours, a paired two-tailed Student’s t-test was performed. Levels of significance 
were: non-significant p>0.05, ** p<0.01, *** p<0.001.  
186 
 
3.3.5. Differential induction of Map Kinase pathways after fibrinogen and fibrin 
treatment of CGCs  
The p38-MAPKs, of which there are four, were first defined trying to identify drugs to 
inhibit TNFα-mediated inflammatory responses (Lee et al. 1994), and have been shown 
to be activated when cells are under stress by a vast array of stimuli (Johnson & 
Lapadat 2002). Furthermore, persistent activation of the p38-MAPK signalling pathway 
has been suggested to mediate neuronal apoptosis in AD, PD, and ALS (Kim & Choi 
2010). Therefore, to identify whether activation of this stress pathway was induced in 
CGCs after FG or FN treatment, Western blotting for expression of the phosphorylated 
form of p38 was performed.  
Expression of phospho-p38-MAPK after FG treatment was time dependent, increasing 
over time until 24 hours of exposure, with significant expression compared with control 
being reached after 4 hours (Figure 3.3.11 A). A slight decrease in phosphor-p38-
MAPK was observed after 48 hours of treatment when compared with that seen at 24 
hours, however this was not significant. Treatment with FN did not induce a similar 
profile to that observed after FG exposure, with an earlier significant expression of 
phospho-p38-MAPK, after 2 hours exposure (Figure 3.3.11 B). However, expression of 
phospho-p38-MAPK at later time-points did not reach significance when compared with 
non-treated control levels, suggesting an earlier role for the p38-MAPK pathway in FN-
mediated stress, when compared with FG-mediated induction of the pathway. 
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Figure 3.3.11. FG and FN induce differential, time-dependent expression of 
phosphorylated p38-MAPK in CGC cultures 
Ai. Representative Western blots for phosphorylated p38-MAPK and total p38-
MAPK expression in CGC cultures after timecourse treatment with FG (2.5 mg/ml), 
presented with the molecular weight marker allowing identification of the specific 
phosphorylated p38-MAPK band. Aii. Densitometric quantification of 
phosphorylated p38-MAPK expression in CGC cultures after timecourse treatment 
with FG, with respect to background intensity. Bi. Representative Western blots for 
phosphorylated p38-MAPK and total p38-MAPK expression in CGC cultures after 
timecourse treatment with FN (1 mg/ml). Bii. Densitometric quantification of 
phosphorylated p38-MAPK expression in CGC cultures after timecourse treatment 
with FN, with respect to background intensity. Blots are representative of n = 3 
experiments. To compare between control levels and all treatment time-points, one 
way ANOVAs were performed with Dunnett’s post-test. Levels of significance 
were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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3.3.6. Fibrinogen and fibrin treatment of CGCs induces TNFα release, dependent 
on microglia 
As previously shown with primary microglial cultures (Figure 3.2.3), TNFα release is a 
prominent feature when cells are exposed to FG or FN. Therefore, similar experiments 
were performed in the CGCs, known to have microglia present, to identify whether 
these cells behaved in a similar manner in a more physiological setting.  
Initially a time-course was performed to observe whether the treatment of the CGCs 
following a similar pattern to that seen in primary microglial cultures (Figure 3.3.12 A). 
LPS treatment as a positive control, significantly increased TNFα release from as early 
as 4 hours. Treatment of CGCs with LPS saw a significant drop in release, at 8 hours, 
compared with release at 6 hours. Finally, LPS treatment saw a significant rise in TNFα 
release, after 8 hours, which peaked at 24 hours before dropping significantly at 48 
hours (Figure 3.3.12 A).  
TNFα release due to FN treatment did not reach significance until 24 hours. Similar to 
LPS treatment, a significant drop at 48 hours was observed in the FN-treated cultures 
when compared with 24 hour release levels (Figure 3.3.12 A). Treatment with FG saw 
further stunted TNFα release profile in comparison to LPS-mediated release, however 
significant release was observed at 24 hours with a significant drop in release at 48 
hours when compared with 24 hour release levels (Figure 3.3.12 A). 
To identify whether the microglia present in the cultures were responsible for the 
observed TNFα release, LME depletion of the cells was performed prior to treatment 
with FG, FN or LPS (Figure 3.3.12 B). As expected, LPS-mediated TNFα release after 
24 hours was significantly reduced in cultures where microglia had been depleted 
(Figure 3.3.12 Bi). Co-treatment of cultures with LPS and Interferon-γ (IFNγ) did not 
significantly enhance TNFα release, when compared with sole treatment with LPS. 
Treatment with the two highest concentrations of FG tested significantly induced TNFα 
release that was dependent on microglia present. The same observation was also 
made with the two highest concentrations of FN administered (Figure 3.3.12 Bi). The 
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depletion of microglia had a similar effect on LPS-mediated TNFα release after 48 
hours of treatment. The same was true for TNFα release mediated by the top two FG 
concentrations administered and also the two highest concentrations of FN 
administered (Figure 3.3.12 Bii).   
Cultures were also co-treated with LPS and FG or FN to identify whether the same 
pathways were being induced. Co-treatment of cultures with FG and LPS significantly 
enhanced TNFα release when compared with treatment of FG only. Similarly, 
treatment of cultures with FN and LPS significantly enhanced TNFα release when 
compared with treatment of FN only (Figure 3.3.13). These data suggest that the 
pathways and mechanisms by which FN and FG mediate their TNFα release differ from 
those utilised by LPS. 
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Figure 3.3.12. FG and FN induce significant TNFα release in CGC cultures, 
dependent on microglia  
A. Timecourse analysis of TNFα release using an ELISA system after treatment of 
CGC cultures with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml). B. Analysis of 
TNFα release in CGC cultures after treatment for 24 hours (Bi) and 48 hours (Bii) 
with FG (0.1-2.5 mg/ml), FN (0.05-1 mg/ml), LPS (1 µg/ml) or LPS and IFNγ 
(100U/ml), in the presence (-LME) or absence (+LME) of microglia. Treatments 
were in duplicate in each experiment and data were analysed from 3 independent 
experiments. Paired two-tailed Student’s t-tests were performed for direct 
comparisons between time-points (as in Figure 3.2.3) or for comparison of 
treatments in the presence and absence of microglia. In concentration dependent 
studies a one-way ANOVA was performed with Dunnett’s post-test. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.    
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Figure 3.3.13. FG and FN induce significant TNFα release in CGC cultures via 
a different mechanism to LPS  
Analysis of TNFα release in CGC cultures using an ELISA system after treatment 
for 24 hours with LPS (1 µg/ml), FG (2.5 mg/ml), FN (1 mg/ml), or FG and FN in 
combination with LPS. Treatments were in duplicate in each experiment and data 
were analysed from 3 independent experiments. For comparisons between control 
levels and all treatments a one way ANOVA was performed with Dunnett’s post-
test. Paired two-tailed Student’s t-tests were performed for direct comparisons 
between treatments alone or in combination with LPS. Levels of significance were: 
non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.    
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3.3.7. Fibrin- but not fibrinogen-mediated responses are regulated by CD11b and 
scavenger receptor-A  
To further attempt to elucidate the signalling pathways contributing to FN- and FG-
mediated neuronal toxicity, antibody block of the CD11b (Mac-1) integrin receptor was 
performed prior to treatment with FN and FG for 24 hours and ELISA analyses of TNFα 
release. Antibody block of CD11b prior to LPS treatment did not significantly modulate 
TNFα release. Also, FG-mediated TNFα release was not attenuated by antibody block 
of the receptor (Figure 3.3.14 A). However FN-mediated TNFα release was 
significantly reduced in the presence of CD11b blocking antibody (Figure 3.3.14 A), 
suggesting differential receptor binding affinity for soluble fibrinogen and its insoluble 
cleavage product fibrin. 
Following on from these data suggesting contributions from other receptors, 
pharmacological inhibition of scavenger receptor A (SRA) was performed. Roles for 
SRA in microglial-mediated responses have been published on numerous occasions 
(Husemann et al. 2002; Hooper et al. 2009a; Yang et al. 2011b), so it was therefore 
deemed a reasonable target to pursue with respect to FG- and FN-mediated cellular 
interactions. Western blotting for iNOS expression in CGCs was performed after LPS, 
FG, or FN treatment for 24 hours in the presence or absence of the SRA inhibitor, 
fucoidan (Hooper et al. 2009a). As shown previously, in serum-containing conditions, 
FG failed to induce significant iNOS (Figure 3.3.14 Bii). However FN induced iNOS 
expression to a level similar to that observed after LPS treatment. Furthermore this FN-
mediated induction of iNOS could be significantly attenuated if cultures were pre-
treated with fucoidan, suggesting a possible role for this receptor. LPS-induced 
expression of iNOS was not modulated significantly by fucoidan pre-treatment (Figure 
3.3.14 Bii). 
As FG-treatment failed to induce iNOS expression in the serum-containing conditions 
used for CGC culturing, TNFα release was performed on supernatants collected from 
cultures pre-treated with fucoidan (Figure 3.3.14 C
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modulation of TNFα release occurred after any of the treatments, including FN-treated 
cultures, suggesting TNFα release after LPS, FN, or FG treatment is not dependent on 
ligand-SR-A binding (Figure 3.3.14 C). 
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Figure 3.3.14. FN- but not FG-mediated responses are regulated by CD11b 
and scavenger receptor class A  
A. Analysis of TNFα release in CGC cultures using an ELISA system after 
treatment for 24 hours with LPS (1 µg/ml), FG (2.5 mg/ml), FN (1 mg/ml), or LPS, 
FG and FN in combination with CD11b blocking antibody (10 µg/ml) or rat IgG as a 
serotype control (10 µg/ml). B. Western blot analysis of iNOS expression in CGC 
cultures after treatment for 24 hours with LPS (1 µg/ml), FG (2.5 mg/ml), FN (0.05-
1 mg/ml) alone or in combination with Fucoidan (Fu; 100 µg/ml). A representative 
blot is shown in Bi and quantification of 3 independent experiments in Bii. C. 
Analysis of TNFα release in CGC cultures using an ELISA system after treatment 
for 24 hours as outlined in B. For each ELISA experiment, treatments were 
assayed in duplicate and data were analysed from 3 independent experiments. For 
comparisons between control levels and all other treatments, a one way ANOVA 
was performed with Dunnett’s post-test. Paired two-tailed Student’s t-tests were 
performed for direct comparisons between treatments alone or in combination 
inhibitors or serotype controls. Levels of significance were: non-significant p>0.05, 
* p<0.05, ** p<0.01, *** p<0.001.    
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3.3.8. Fibrinogen and fibrin treatment induces microglial superoxide production 
in CGCs, dependent on NADPH oxidase 
To further characterise the microglia present in these CGC cultures, live cell staining 
for superoxide production was performed. Cultures were co-stained with isolectin-B4 
(IB4) and dihydroethidium (DHE) which stain microglia and produced superoxide, 
respectively (Streit 1990; Park & Jin 2008). Superoxide-positive microglia were 
identified by obvious red staining of the cell nucleus, and quantified.  
Treatment of cultures with the positive control PMA, induced superoxide production in 
microglia, which could be significantly attenuated if cultures were pre-treated with 
apocynin (APO), an inhibitor of NADPH oxidase activity (Park & Jin 2008). Only the top 
concentration of FG significantly increased superoxide production in microglia, which 
could be attenuated by pre-treatment with APO (Figure 3.3.15 A). Treatment with 
lower concentrations of FG also induced significant superoxide production in the 
microglia present when compared with control levels, however pre-treatment with APO 
did not inhibit the superoxide production. Pre-treatment with APO caused significant 
attenuation of the superoxide produced by the highest concentration or FN (Figure 
3.3.15 A).         
This observed superoxide production was not involved in the FG- or FN-mediated 
TNFα release, as treatment of the CGCs with APO prior to FG or FN treatment for 24 
hours did not significantly modulate release of the cytokine (Figure 3.3.15 B). 
Interestingly treatment with PMA for 24 hours significantly increased TNFα release in 
these cultures, and this also could not be attenuated by APO (Figure 3.3.15 B), 
suggesting NADPH oxidase-independent effects of PMA were responsible or the 
concentration used wasn’t sufficient to attenuate the release. Finally, Hoechst-33342 
staining on fixed CGC cultures to identify nuclear morphology was performed. Cultures 
treated with PMA for 24 hours showed no significant increase in cells displaying 
apoptotic morphology, when compared with control levels. Also, pre-treatment with 
APO did not induce any PMA-mediated effects. In line with previous findings, treatment 
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with FG for 24 hours induced a significant increase in apoptotic morphology, when 
compared with control levels, however pre-treatment with APO did not modulate this 
effect. Similarly, LPS administration for 48 hours caused a significant increase in 
apoptotic morphology when compared with control levels, with pre-treatment of cultures 
with APO having no significant effect (Figure 3.3.15 C). However, treatment with FN in 
the presence of APO caused a significant increase in cells displaying apoptotic 
morphology, suggesting some protective effects are mediated via NADPH oxidase 
activity (Figure 3.3.15 C). 
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  Figure 3.3.15. FG and FN induce superoxide production, but it is not involved 
in TNFα release or apoptosis 
Ai.  Representative images of live cell staining experiments performed on CGC 
cultures after treatment with PMA (10 ng/ml), FG (2.5 mg/ml), FN (1 mg/ml) or LPS 
(1 µg/ml), in the absence or presence of apocynin (APO; 10 µM), for 24 hours. Cell 
staining was performed with Hoechst-33342 for total cell number quantification, 
dihydroethidium (DHE; 5 µM) for the presence of superoxide (red), and IB4 for the 
identification of microglia (green). Inset shows enlarged DHE+ cell nuclei with 
arrowheads identifying other positively stained microglia. Original magnification: 
x40, scale bar: 20 µm. Aii. Specific quantification of the superoxide-positive 
microglia present in the CGC cultures with data presented as a percentage of total 
microglia displaying nuclear DHE staining. Treatments were in triplicate and data 
were analysed from 3 independent experiments. B. Analysis of TNFα release in 
CGC cultures using an ELISA system after treatment as outlined in Ai. C. 
Quantification of cells displaying apoptotic morphology after treatment as outlined 
in Ai. To compare between control levels and treatments, one way ANOVA tests 
were performed with Dunnett’s post-test. For direct comparison between 
treatments in the absence and presence of inhibitors, paired two-tailed Student’s t-
tests were performed. Levels of significance were: non-significant p>0.05, * 
p<0.05, ** p<0.01, *** p<0.001.  
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3.3.9. The presence of serum causes differential release of pro-inflammatory 
cytokines 
Interleukin-6 (IL-6) is another pro-inflammatory cytokine released from activated 
microglia (Horvath et al. 2008). Therefore, CGC cultures were assayed for IL-6 release 
by ELISA to identify whether this cytokine is released after treatment with FG and FN. 
Some cultures were pre-treated with LME to remove microglia, a CD11b blocking 
antibody, or rat IgG as an isotype control. Cultures were then treated with LPS, FG or 
FN for 24 hours and supernatants were assayed for IL-6 release. LPS treatment 
significantly induced IL-6 release after 24 hours, compared with control levels. Pre-
treatment of cultures with LME, significantly attenuated the LPS-mediated release of IL-
6, suggesting microglia are required for IL-6 release (Figure 3.3.16). Interestingly, FG 
treatment did not significantly induce IL-6 release, when compared with control levels. 
However, FN-treatment caused a significant induction in IL-6 release, which was 
significantly attenuated if microglia were depleted from the cultures prior to treatment 
(Figure 3.3.16). Also, in line with TNFα release data, CD11b block, caused significant 
attenuation of FN-mediated IL-6 release, however, as with TNFα release, no significant 
block was observed in LPS-treated cultures (Figure 3.3.16). 
To identify if the lack of IL-6 release after FG treatment was due to the presence of 
serum in the cultures as previously suggested with respect to iNOS expression (Figure 
3.2.6 & 3.2.7), a serum-free CGC culture medium was developed (Section 2.3.3.1). In 
serum-free conditions FG-treatment induced significant IL-6 release after 24 hours, 
when compared with control levels (Figure 3.3.17 A). Also pre-treatment of cultures 
with LME significantly attenuated the observed FG-mediated IL-6 release, supporting 
the requirement of microglia for IL-6 secretion in these cultures. Interestingly, LPS-
induced IL-6 release in serum-free conditions (SF) is not significantly different from 
LPS-mediated release in serum-containing conditions (SC). However FN-mediated 
release in SF conditions is significantly lower than release observed in SC conditions. 
These data show differential effects of serum in all treatment groups.     
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Serum-free conditions were then subsequently tested in a TNFα release ELISA (Figure 
3.3.17 B). Interestingly only a small insignificant increase in release was observed in 
FG treatment cultures when compared with release in conditions containing serum. 
Again, no significant modulation was seen in LPS-induced release. However, FN-
mediated TNFα release was again significantly decreased in SF conditions compared 
with SC conditions (Figure 3.3.17 B). 
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Figure 3.3.16. FN but not FG induces IL-6 release in serum-containing CGC 
cultures, dependent on microglia  
Quantification of IL-6 release from CGC cultures after treatment with FG (2.5 
mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) alone or in combination with anti-CD11b 
blocking antibody (10 µg/ml) or rat IgG, as a serotype control (10 µg/ml), for 24 
hours. In some instances, LME pre-treatment was performed to deplete microglia 
(LME). Treatments were in duplicate in each experiment and data were analysed 
from 3 independent experiments. A one-way ANOVA was performed with 
Dunnett’s post-test to compare control levels with all treatments. Paired two-tailed 
Student’s t-tests were performed for direct comparisons between treatments in the 
absence or presence of inhibitors or microglia. Levels of significance were: non-
significant p>0.05, * p<0.05, *** p<0.001.    
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Figure 3.3.17. FG and FN induce IL-6 and TNFα release in serum-free CGC 
cultures, dependent on microglia  
A. Quantification of IL-6 release using an ELISA system after treatment of serum-
free CGC cultures with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml), +/- LME 
pre-treatment to deplete microglia (LME). B. Quantification of TNFα release using 
an ELISA system after treatment of serum-free CGC cultures as stated in A. 
Treatments were in duplicate in each experiment and data were analysed from 3 
independent experiments. A one-way ANOVA was performed with Dunnett’s post-
test to compare control levels with all treatments. Paired two-tailed Student’s t-
tests were performed for direct comparisons between specific treatments in the 
absence or presence of microglia. Levels of significance were: non-significant 
p>0.05, ** p<0.01, *** p<0.001.    
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3.3.10. Expression of inducible, but not constitutive nitric oxide synthase is 
modulated by fibrin treatment of CGCs with dependence on TNFα synthesis 
Changes in neuronal NOS (nNOS, bNOS, or NOS1), the constitutively expressed 
isoform, after treatment was initially characterised due to studies suggesting 
constitutive NOS isoforms can contribute to the activation of apoptotic pathways in the 
brain during inflammation (Czapski et al. 2007). Cultures were treated for 24 hours with 
FG, FN or LPS and ICC was performed (Figure 3.3.18). No obvious increase in nNOS 
expression was observed, suggesting a limited role for nNOS at 24 hours of treatment. 
However, these data are preliminary. 
The inducible form of NOS (iNOS or NOS2) is a common marker for rodent microglial 
activation (Ferretti et al. 2011). Treatment for 24 hours with LPS or FN increased the 
number of microglia in culture expressing iNOS (Figure 3.3.19). FG caused the lowest 
increase in iNOS positive microglia, supporting earlier studies in primary microglial 
cultures (Figure 3.2.7). To further support these findings, Western blotting for iNOS 
expression was performed on the cultures. Some cultures were pre-treated with LME 
or AMT-HCl, a specific iNOS activity inhibitor (Combs et al. 2001). In support of the ICC 
data, significant iNOS expression was observed in LPS- and FN-treated cultures with 
no significant expression in FG-treated cultures (Figure 3.3.19 B). LME pre-treatment 
of cultures showed that the observed LPS- and FN-mediated iNOS expression 
depended on the presence of microglia due to the near complete attenuation of 
expression. Pre-treatment with AMT-HCl had no significant effect on expression 
(Figure 3.3.19 B).  
Finally, to identify whether there is a convergence of iNOS and TNFα pathways after 
FN treatment, Western blotting for iNOS expression in cultures pre-treated with 
thalidomide was performed. Treatment with FG again showed no modulation of iNOS 
expression. Treatment with LPS and FN showed increased levels of iNOS expression 
which was down-regulated in the cultures pre-treated with thalidomide (Figure 3.3.20). 
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These data suggest LPS- and FN-mediated iNOS expression is dependent on TNFα 
synthesis. However, these data are preliminary. 
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Figure 3.3.18. FG or FN treatment does not modulate nNOS expression in 
CGC cultures 
A. Representative images of CGC cultures after 24 hours of treatment with FG (2.5 
mg/ml), FN (1 mg/ml) or LPS (1 µg/ml). Cultures were co-stained with DAPI for 
quantification of cell number and probed with anti-nNOS (green), except in 
negative control cultures, where the primary antibody was omitted. Original 
magnification: x40, scale bar: 20 µm. N = 1. 
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Figure 3.3.19. FN but not FG treatment increases microglial-associated iNOS 
expression in CGC cultures 
A. Representative images of CGC cultures after treatment with FG (2.5 mg/ml; 24 
hours), FN (1 mg/ml; 48 hours) or LPS (1 µg/ml; 48 hours). Cultures were co-
stained with DAPI for quantification of cell number, IB4 for microglial identification 
(green) and probed with anti-iNOS (red), except in negative control cultures, where 
IB4 and anti-iNOS were omitted. Original magnification: x40, scale bar: 20 µm. Bi. 
Representative Western blots for iNOS and β-actin expression in CGC cultures 
after treatment as stated in A, alone or in combination with AMT-HCl (AMT; 150 
nM), +/- LME depletion of microglia (LME). Bii. Quantification of iNOS expression 
with respect to protein-loading control, β-actin. For ICC experiments, treatments 
were in duplicate in each experiment and data were analysed from 2 independent 
experiments. For Western blotting experiments treatments were repeated in 3 
independent experiments. One way ANOVA with Dunnett’s post-test was 
performed to compare control levels with all other treatments. For specific 
comparisons paired two-tailed Student’s t tests were performed. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
B  
Bii. 
211 
 
 
Thal Thal Thal ThalStd
FGCTR LPS FN
iNOS
β-actin
Ai.
Figure 3.3.20. FN-mediated iNOS expression in CGC cultures is attenuated by 
thalidomide pre-treatment 
Representative Western blots for iNOS and β-actin expression in CGC cultures 
treated with FG (2.5 mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or LPS (1 µg/ml; 48 
hours) alone or in combination with Thalidomide (Thal; 10 µg/ml). N = 1. 
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3.4. The effects of modulating microglial function on fibrinogen- and 
fibrin-induced cerebellar granule cell toxicity 
Polymyxin B (PMX) does not inhibit FG- or FN-mediated responses in microglia 
(Figure 3.2.4 & 3.2.6). To further support this hypothesis, Hoechst-33342 fixed cell 
staining was performed on cultures after treatment with PMX prior to exposure to FG or 
FN for 24 and 48 hours, respectively, and apoptotic morphology was quantified. As 
expected, 48 hours of LPS treatment induced significant apoptotic morphology, which 
could be significantly inhibited by pre-treating cultures with PMX (Figure 3.4.1). Also, in 
support of previous findings, FG-induced a significant increase in apoptotic 
morphology, when compared with control, which could not be inhibited by pre-
treatment of cultures with PMX. Similarly, FN induced a significant increase in apoptotic 
morphology compared with control levels, which could not be significantly inhibited by 
pre-treatment with PMX (Figure 3.4.1). 
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Figure 3.4.1. FG- and FN-mediated neuronal death is not due to endotoxin 
contamination 
Ai. Panel of representative images of fixed cell staining experiments in CGC 
cultures after treatment with FG (2.5 mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or 
LPS (1 µg/ml; 48 hours) alone or in combination with PMX (100 nM). Cell staining 
was performed with Hoechst-33342 for nuclear morphology analysis. Original 
magnification: x40, scale bar: 20 µm. Aii. Quantification of apoptotic morphology in 
CGC cultures treated as stated in Ai. Data are presented as a percentage of the 
total population displaying apoptotic nuclear morphology. Treatments were in 
triplicate and data were analysed from 3 independent experiments. To compare 
between control levels and treatments, a one way ANOVA was performed with 
Dunnett’s post-test. For direct comparison between specific treatments, paired two-
tailed Student’s t-tests were performed. Levels of significance were: non-significant 
p>0.05, *** p<0.001.  
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3.4.1. Pharmacological inhibition of TNFα synthesis, but not iNOS activity 
protects against fibrinogen- and fibrin-mediated toxicity  
TNFα release was a prominent feature of both FG- and FN-treated cultures, suggesting 
a role for this cytokine in observed neuronal toxicity. Therefore, CGC cultures were 
treated with TNFα synthesis inhibitor, thalidomide prior to FG treatment for 24 hours or 
FN treatment for 48 hours. Pre-treatment was also performed with AMT-HCl (Figure 
3.4.2). 
Inhibition of TNFα synthesis, caused a significant reduction in observed apoptotic 
morphology in LPS-treated, however cells displaying apoptotic morphology was still 
significantly above control levels. Similarly, pre-treatment of LPS-treated cultures with 
AMT-HCl, significantly reduced apoptotic morphology, however, as with thalidomide 
pre-treatment, levels of apoptotic morphology were still significantly above that 
observed in control cultures (Figure 3.4.2). Pre-treatment with thalidomide also caused 
significant attenuation of FG-induced increases in apoptotic morphology, however, 
AMT-HCl pre-treatment had no significant effect. Following a similar profile, FN-
induced increases in apoptotic morphology could be significantly attenuated by 
thalidomide pre-treatment, with AMT-HCl pre-treatment having no effect (Figure 3.4.2). 
Pre-treatment with thalidomide did not completely attenuate FN-mediated death. 
Finally, as expected, depletion of microglia prior to treatments caused an attenuation of 
the protective effect mediated by thalidomide pre-treatment in cultures exposed to FN, 
further supporting the prominent role for microglia in the TNFα-dependent death. 
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Figure 3.4.2. FG- and FN-mediated neuronal death involves TNFα synthesis, 
but not iNOS activity 
Quantification of fixed cell staining experiments in CGC cultures after direct 
treatment with FG (2.5 mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or LPS (1 µg/ml; 
48 hours) alone or in combination with AMT (150 nM) or Thal (10 µg/ml), +/- LME 
depletion of microglia. Cell staining was performed with Hoechst-33342 for nuclear 
morphology analysis. Treatments were in duplicate and data were analysed from 3 
independent experiments. Data are presented as the percentage of the total 
population displaying apoptotic nuclear morphology. To compare between control 
levels and all other treatments, a one way ANOVA was performed with Dunnett’s 
post-test. For direct comparison between specific treatments, paired two-tailed 
Student’s t-tests were performed. Levels of significance were: non-significant 
p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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3.4.2. Microglia are responsible for the release of neurotoxic factors after 
fibrinogen and fibrin treatment   
To support the role for microglia in mediating the observed neuronal toxicity, 
experiments were performed using microglial-conditioned medium (MGCM). Primary 
microglial cultures were treated with thalidomide or AMT-HCl prior to exposure to LPS, 
FG, or FN for 24 hours. The MGCM was collected from these cultures and 
administered to CGCs that had been depleted of microglia and incubated for a further 
24 hours (Figure 3.4.3). Exposure of the CGCs to MGCM from LPS-treated microglia 
induced a significant increase in apoptotic morphology, compared with cultures 
exposed to non-treated control MGCM. Furthermore, exposure of CGCs to MGCM 
from LPS-treated cultures pre-treated with thalidomide or AMT-HCl, significantly 
reduced the LPS-mediated increase in apoptotic morphology (Figure 3.4.3). Again, in 
line with the direct treatment of neuronal cultures, exposure of CGCs to MGCM from 
FG-treated microglia induced a significant increase in cells displaying apoptotic 
morphology. Exposure of CGCs to MGCM from FG-treated cultures pre-treated with 
thalidomide, significantly reduced the FG-mediated increase in apoptotic morphology, 
however, MGCM from FG-treated cultures pre-treated with AMT-HCl could not 
significantly reduce FG-mediated increases in apoptotic morphology (Figure 3.4.3). 
Similarly, exposure of the neuronal cultures to MGCM from FN-treated microglia 
induced a significant increase in apoptotic morphology with MGCM pre-treated with 
thalidomide attenuating the FN-induced effect and AMT-HCl pre-treatment having no 
effect. 
  
217 
 
 
CTR AMT Thal AMT Thal AMT Thal AMT Thal
0
10
20
LPS FNFG
*** **
**
***
***
*** *
**
%
 
Ce
lls
 
di
sp
la
yi
n
g
ap
o
pt
o
tic
 
m
o
rp
ho
lo
gy
Figure 3.4.3. FG and FN mediate neuronal death via microglia, with 
significant dependence on TNFα synthesis 
Quantification of fixed cell staining experiments on CGC cultures after exposure to 
microglial condition medium (MGCM) from primary cultures treated with FG (2.5 
mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) alone or in combination with AMT (150 nM) 
or Thal (10 µg/ml), for 24 hours. Cell staining was performed using Hoechst-33342 
for nuclear morphology analysis. Treatments were in duplicate and data were 
analysed from 3 independent experiments. Data are presented as the percentage 
of the total population displaying apoptotic nuclear morphology. To compare 
between control levels and all other treatments, a one way ANOVA was performed 
with Dunnett’s post-test. For direct comparison between specific treatments, paired 
two-tailed Student’s t-tests were performed. Levels of significance were: non-
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3.4.3. Inhibition of caspase-3 activation in microglia attenuates fibrin- and 
fibrinogen-mediated neurotoxicity 
Due to the observation in primary microglial cultures, that cleavage of caspase-3 was 
significantly induced after FG and FN treatment for 24 hours with little or no significant 
death, MGCM assays using the pan-caspase inhibitor, z-VAD-FMK, were performed. 
As in the thalidomide and AMT-HCl MGCM assays, primary microglial cultures were 
treated with z-VAD-FMK prior to treatment with LPS, FG or FN for 24 hours. The 
MGCM was then administered to CGCs depleted of microglia and incubated for a 
further 24 hours (Figure 3.4.4). As shown previously, CGCs exposed to MGCM from 
LPS-, FG- and FN-treated cultures have a significantly higher number of cells 
displaying apoptotic morphology, when compared with control cultures. Furthermore, 
MGCM from LPS-, FG-, or FN-treated cultures pre-treated with z-VAD-FMK 
significantly attenuated the increases in apoptotic morphology when compared with 
relevant treatment groups (Figure 3.4.4 Aii). Finally to be noted, CGCs treated with 
MGCM from FN + z-VAD-FMK cultures still had a significant number of cells displaying 
apoptotic morphology compared with control levels (Figure 3.4.4 Aii), suggesting a 
caspase-3 independent mechanism for some FN-mediated neurotoxicity or possible 
transfer of FN in the medium. 
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Figure 3.4.4. FG- and FN-mediated neuronal death via microglia can be 
attenuated by microglial-specific caspase inhibition 
Quantification of apoptotic morphology in CGC cultures after exposure to MGCM 
from primary cultures treated with FG (2.5 mg/ml), FN (1 mg/ml) or LPS (1 µg/ml) 
alone or in combination with z-VAD-FMK (1 µg/ml) for 24 hours. Cell staining was 
performed using Hoechst-33342 for nuclear morphology analysis. Data are 
presented as the percentage of the total population displaying apoptotic nuclear 
morphology. Treatments were in triplicate and data were analysed from 3 
independent experiments. To compare between control levels and treatments, a 
one way ANOVA with Dunnett’s post-test was performed. For direct comparison 
between specific treatments, paired two-tailed Student’s t-tests were performed. 
Levels of significance were: non-significant p>0.05, ** p<0.01, *** p<0.001.  
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3.5. Discussion 
This chapter characterises microglia and neuronal culture responses after exposure to 
FG and FN. Pharmacological manipulation of the FG and FN responses were 
characterised using either direct or indirect administration of inhibitors. Initially, toxicity 
was quantified and differential observations after FG or FN treatment were observed. 
Furthermore, expression of iNOS, ED-1 and CD11b and cytokine release were 
characterised, again with differences between the treatments being observed. 
Development of methodology, here, to deplete microglia from the cerebellar granule 
cultures supports significant differential roles for microglia in FG and FN-mediated 
neurotoxicity, in vitro, with further support from indirect conditioned medium 
experiments.     
3.5.1. FG and FN can induce microglial activation, but only FN is toxic 
It has been suggested that FN deposition contributes to pathology (Paul et al. 2007). 
Therefore the toxic effect of FN and the soluble precursor FG on primary microglial 
cultures was quantified by assessing morphological changes associated with different 
forms of death. Apoptosis or programmed cell death in a culture can be characterised 
by quantification of cells displaying classic morphological features including membrane 
blebbing and bright pyknotic nuclei, due to chromatin condensation (Kerr et al. 1972). 
Necrosis is a passive form of cell death lacking the regulatory mechanisms 
characteristic of apoptosis. Although necrotic cell death morphology is more diverse 
than apoptotic morphology, due to its unregulated nature, some characteristics are 
common. These include early membrane permeability and nuclear dilation (Ziegler & 
Groscurth 2004). Nuclear dilation is a simple morphological change to quantify, and 
was therefore used for this initial analysis of FN and FG toxicity.     
Apoptotic morphology in microglia treated with FG or FN for 24 hours was almost non-
existent unlike microglia treated with staurosporine (STS), a classic inducer of 
apoptosis (Kingham & Pocock 2000). Furthermore data presented here suggest that 
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exposure to LPS, the classic treatment to model microglia inflammatory responses 
(Block et al. 2007; Saijo et al. 2009; Burguillos et al. 2011), also failed to induce 
significant apoptotic morphology after 24 hours of treatment. Previously published 
literature, including work in our lab has shown LPS treatment of microglia can induce 
significant apoptosis (Lee et al. 2001; Taylor et al. 2003). However, recent work 
suggests LPS does not induce significant apoptosis until chronic treatment is reached 
(>48 h) (Burguillos et al. 2011). These differences in LPS-mediated effects are possibly 
due to variations in the LPS serotype used. It has been shown previously that 
prostacyclin synthesis from human endothelial cells differs depending on the LPS 
serotype administered (Watanabe & Jaffe 1993). However, differences in culture 
preparation and media composition could also contribute to this variation and 
timecourse analyses of apoptotic induction after treatment would provide a clearer 
picture. 
Cultures treated with FN, but not FG showed a significant increase in the percentage of 
cells displaying enlarged, dilated nuclei, the morphological change used here to 
quantify necrosis. No direct link between FN and microglial necrosis has previously 
been shown. However, leakage of factors from necrotic cells, due to increased 
membrane permeability, initiates or potentiates pro-inflammatory responses (Hirt & 
Leist 2003), and studies that deplete fibrin from animal models of multiple sclerosis and 
Alzheimer’s disease have shown significant attenuation of inflammation (Akassoglou et 
al. 2004; Paul et al. 2007). This suggests FN deposition in the CNS is capable of 
activating an inflammatory response, which could be due to the FN-mediated induction 
microglial death observed here.  
Previous studies have identified CD11b as a marker of microglial activation which is 
upregulated in AD brains (Akiyama & McGeer 1990). Furthermore, the receptor has 
been identified as key to FG-mediated phagocytosis by microglia, in vitro (Adams et al. 
2007a).  Therefore, changes in CD11b receptor expression were deemed a relevant 
222 
 
marker of microglial activation after FG or FN treatment. Significantly increased 
microglial surface expression of CD11b, similar to that observed after LPS treatment, 
which has been shown to rapidly increase surface expression of CD11b on monocytes 
by 2 - 3 fold (Fan & Edgington 1991) is shown after FG and FN treatment. These data 
support previous findings and suggest that FG and FN can induce an activated 
microglial phenotype. 
3.5.2. FG and FN induce TNFα release from microglia 
Further characterisation of the activated microglia phenotype was performed by 
analysis of TNFα release after treatment with FG and FN. TNFα is a well characterised 
pro-inflammatory cytokine involved in many neuroinflammatory cascades, including 
autocrine microglia activation (Kuno et al. 2005) and direct apoptosis via activation of 
extrinsic pathway-associated TNF receptors (Kaul et al. 2001; Taylor et al. 2005). It is 
shown that treatment of primary microglial cultures, but also CGC cultures, with FG or 
FN significantly induced TNFα release, with differential profiles. It is also shown, in 
CGC cultures, that FG- and FN-induced TNFα release is dependent on microglia. 
Furthermore, the concentrations released were similar or above previously published 
concentrations shown to be sufficient to induce neurotoxicity (Taylor et al. 2005). As 
previously reported (Nguyen et al. 2002), and supported here, LPS can significantly 
induce TNFα release from microglia. FN-, but not FG-mediated induction of TNFα 
release in both cultures followed a similar pattern of release to that observed after LPS 
treatment. Possible contamination of the FN preparations with endotoxin (LPS) was 
therefore suggested. Published literature states that only 40 pg/ml of LPS is required to 
induce microglial proliferation, NO production and cytokine release (Weinstein et al. 
2008). Cultures treated with polymyxin B (PMX), an antibiotic that binds to the 
biologically active portion of the LPS macromolecule known as lipid A (Morrison & 
Jacobs 1976) and potently abolishes LPS responses (Jacobs & Morrison 1977), prior 
to FG and FN exposure were still able to induce significant TNFα release comparable 
to PMX-negative cultures. Furthermore, support for the induction of differing pathways 
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in microglia after FG or FN treatment compared with LPS was found by co-treating 
CGC cultures with either FG or FN and LPS. If LPS, FG and FN are inducing TNFα 
release via the same pathway, co-treatment of cultures would not significantly enhance 
release when compared with sole-treatment of cultures. However, significant increases 
in release were observed in both FG-LPS and FN-LPS treated cultures. Additionally, 
pre-treatment with PMX did not attenuate FG- or FN-mediated neuronal apoptosis. 
These data suggest that FG- or FN-mediated responses are not due to endotoxin 
contamination and induce TNF release via differing pathways to LPS. 
3.5.3. Involvement of the p38-MAPK pathway in FG-mediated responses 
It was decided at an early stage to focus mainly on FG-mediated signalling over FN. 
This was mainly due to solubility issues with FN which prevented exact concentration 
dependent analysis, but was also because focussing on the earlier event, i.e. FG 
extravasation into the CNS parenchyma, would be more interesting and significant from 
a disease progression viewpoint. However, wherever possible FN treatment was 
performed in parallel with FG treatment. 
LPS-mediated TNFα release has been shown to be dependent on activation of the 
p38-MAPK pathway (Nakajima et al. 2004). Also the PI3K pathway has been shown to 
be involved in FG-mediated microglial phagocytosis (Adams et al. 2007a) and 
microglial-mediated neurotoxicity after amyloid-β treatment (Zhang et al. 2011). Data 
presented here suggests that pre-treatment of primary microglial cultures with 
SB203580, an inhibitor of p38-MAPK, using a previously published concentration (Kim 
et al. 2002), significantly decreased FG-mediated TNFα release after 24 hours. 
However inhibition of PI3K with the specific inhibitor wortmannin, at a previously 
published concentration (Morgan et al. 2004), could not attenuate FG-mediated TNFα 
release. In CGC cultures, p38-MAPK phosphorylation significantly increased, time-
dependently after FG treatment until 24 hours, whereas FN treatment only induced an 
early significant increase in phosphorylation. These data suggest FG-mediated TNFα 
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release is dependent on the p38-MAPK pathway, which was shown to be significantly 
phosphorylated over time. However no role for the PI3K pathway was observed in FG-
mediated TNFα release suggesting the role of other MAPKs should be investigated.  
3.5.4. FG-mediated iNOS expression was dependent on serum conditions  
The expression of iNOS is a classic marker of activated microglia (Ferretti et al. 2011). 
Previous studies in our laboratory had given differential expression of iNOS after FG 
treatment (E. East, unpublished observations; I. Sevastou, unpublished observations). 
Interestingly the FG-mediated iNOS expression in microglial cultures seemed to be 
dependent on the presence or absence of serum. In serum-free conditions both FG 
and FN treatment significantly induced expression of iNOS to a level similar to that 
observed after LPS treatment. However, in serum-containing conditions, FG-induced 
iNOS expression was non-existent, with no significant change in FN- or LPS-mediated 
expression. Interestingly, the same loss of FG-induced iNOS expression when serum 
was present was observed in CGC cultures. However in primary microglial cultures and 
CGCs treated with FG, increased expression of ED-1, a marker of phagocytic, 
activated microglia (Damoiseaux et al. 1994; Pinteaux-Jones et al. 2008), was 
observed. It is also shown that TNFα and IL-6 release is differentially induced after FG 
treatment of CGCs. These data suggest that serum can preferentially mask FG-
mediated iNOS expression and cytokine release but microglial activation still occurs. In 
a physiological situation, other serum factors are likely to extravasate from vasculature 
into the CNS parenchyma, subsequently suggesting that iNOS expression and IL-6 
release may not be important in FG-mediated toxicity. Many human studies suggest 
macrophage and microglial activation is independent of significant iNOS expression 
and NO release (Peterson et al. 1994; Denis 1994; Colton et al. 2000; Carter & Dick 
2003). Interestingly, published data have suggested both TNFα and IL-6 production 
can be induced by FG treatment of PBMCs, in vitro (Jensen et al. 2007). These studies 
however use serum-free conditions. TNFα release by LPS stimulation however, has 
been shown to be markedly enhanced in the presence of FG, in serum-containing 
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conditions (Fan & Edgington 1993), supporting a significant role for TNFα in FG-
associated inflammation. Here, it is also shown that iNOS expression after FN and LPS 
treatment is coupled to TNFα synthesis with thalidomide treatment attenuating iNOS 
expression although inhibition of iNOS activity had no significant effect on FN-mediated 
neurotoxicity. No significant modulation in the constitutively expressed NOS isoform, 
nNOS was observed, further suggesting that NOS enzymes are not significantly 
involved in FG- or FN-mediated toxicity  
Inhibition of FG binding to microglial CD11b down-regulates iNOS expression in a 
model of MS, in vivo (Adams et al. 2007a). Nitric oxide (NO), the product of an iNOS-
catalysed reaction has been shown to induce neuronal death by inhibiting the 
mitochondrial respiratory chain (Bal-Price & Brown., 2001). These findings suggest 
iNOS expression could be important in disease progression. Analyses of the FG 
structure have suggested that for FG-CD11b ligation to occur, the protein must be 
‘immobilised’. This ‘immobilisation’ un-masks a cryptic binding site in the γ-chain C 
domain of the protein (γ377-395) that allows FG-CD11b ligation (Lishko et al. 2002). 
Adams and colleagues use ‘immobilised’ fibrinogen as a model of fibrin deposition 
(Adams et al. 2007a). The main criticism of this model would be that coverslips were 
coated in FG in order to immobilise the protein prior to culturing of microglia, preventing 
any initial resting phenotype required for a baseline culture activation state. 
Interestingly, the same group that discovered γ377-395 as the cryptic binding site 
published another paper two years later identifying further binding sites in the FG 
molecule for CD11b (Lishko et al. 2004). Furthermore soluble FG has been shown to 
interact with CD11b on polymorphonuclear leukocytes, mediating phagocytosis (Rubel 
et al. 2002) and induce pro-inflammatory cytokine release from isolated peripheral 
mononuclear blood cells (Jensen et al. 2007). 
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3.5.5. Caspase involvement in FG- and FN-mediated responses 
Caspase activation is a classic hallmark of apoptotic cell death (Yuan et al. 2003; 
Danial & Korsmeyer 2004). Due to differing observations in our lab, ICC studies were 
performed on primary microglial cultures to identify whether cleaved caspase-3, the 
classic executioner caspase, was upregulated after treatment with FG and FN. As 
expected, treatment of microglial cultures with staurosporine induced significant 
expression of cleaved-caspase-3. Interestingly, caspase-3 cleavage after LPS 
treatment was significantly above that observed in control cultures however no 
significant increase in cells displaying an apoptotic nuclear morphology was observed. 
In the context of data presented here, this suggests caspase-3 cleavage can occur in 
microglia after LPS treatment as part of a non-apoptotic pathway. In support of these 
findings, Burguillos and colleagues published a paper earlier this year, providing strong 
evidence for LPS-induced, non-apoptotic induction of caspase-8 and caspase-3/7 in 
microglia that was involved purely with cellular activation (Burguillos et al. 2011). 
Caspase-3 cleavage in microglial cultures also occurred after FG- and FN-treatment. 
FN-mediated induction was associated with an increase in death, although it seemed to 
be necrotic cell death as previously described. FG-mediated caspase-3 cleavage was 
not associated with an increase in apoptotic morphology, in line with the LPS data. 
However, longer incubations may reveal that significant apoptosis does occur and 
timecourse analyses and the use of biochemical assays, such as the LDH assay would 
provide more conclusive data. Finally it is shown here that inhibition of caspase 
activation, specifically in microglia, is sufficient to attenuate FG- and FN-mediated 
neurotoxicity. However, it is possible that the pan-caspase inhibitor used to inhibit 
microglial caspase activation was transferred to the CGCs in the MGCM that was 
administered, providing direct protection rather than via microglial down-regulation. 
Protein silencing techniques specifically in microglia would remove this particular 
caveat and provide more robust data.  
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Together, these data suggest that caspase-3 cleavage in microglia can no longer 
confirm cellular apoptosis. Other markers such as Annexin V or caspase-3/7 
expression in parallel with poly(ADP-ribose) polymerase (PARP-1) expression, a 
nuclear substrate of caspase-3, that is also involved in caspase-independent apoptosis 
(Hong et al. 2004), must be performed to truly identify whether apoptosis is occurring. 
Conversely, only using apoptotic morphology as a marker, as presented here, it cannot 
be comprehensively concluded that apoptosis in microglial cultures after treatment with 
FG or LPS does not occur.  
3.5.6. Modelling FG- and FN-mediated neuronal toxicity – involvement of 
microglia 
The loss of neurons underlies cognitive decline in neurodegenerative disorders 
(Alzheimer et al. 1995; Qiang et al. 2011). Whether this is due to indirect inflammation, 
intrinsic neuronal vulnerability, or a combination of both is yet to be elucidated with 
numerous arguments for and against each paradigm (Wyss-Coray & Mucke 2002; 
Saxena & Caroni 2011). It is therefore important to understand whether extravasation 
of blood-borne proteins, including FG, into the CNS parenchyma due to blood brain 
barrier dysfunction, and the subsequent deposition of FN can directly affect neuronal 
integrity. 
Significant apoptotic morphology after FG treatment for only 24 hours in CGC cultures 
was observed here, whereas FN- and LPS-mediated toxicity was not present until 48 
hours of exposure. These data suggest an early potently toxic effect of FG in neuronal 
cultures. Previous data suggesting administration of high molecular weight proteins, 
such as FG, can produce a hypertonic ‘extracellular’ culture medium that causes cell 
shrinkage (Horie et al. 1989) led us to check the ‘apoptotic’ morphology observed. The 
use of live Annexin V-FITC, live caspase-3/7, fixed caspase-3 ICC and lactate 
dehydrogenase release here provided strong support for apoptotic pathways being 
induced by FG and FN with ICC of caspase-3 expression supporting a neuronal 
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specific induction of the caspase, with respect to the observed apoptosis. These data 
suggest a more potently neurotoxic role for FG than previously published data that 
suggests inhibition of neurite outgrowth occurs in the presence of FG, but not 
significant neuronal death (Schachtrup et al. 2007).  
As recently suggested, with respect to microglial activation (Burguillos et al. 2011), 
non-apoptotic roles for caspases have also been identified in neuronal cells, from in 
vitro drosophila neuronal models (Kuo et al. 2006), to mouse models of Alzheimer’s 
disease (D'Amelio et al. 2011). Significant non-apoptotic caspase-3 activation in long 
term depression (LTD) and long term potentiation (LTP) (Li et al. 2010; Jo et al. 2011), 
phenomena associated with learning and memory (Malenka & Bear 2004), have also 
been observed. However with the range of staining protocols, morphological changes 
and biochemical assays, data presented here strongly suggests classical apoptosis 
and neuronal toxicity is occurring after FG and FN treatment of CGC cultures   
Within the CNS, LPS induces its neurotoxicity primarily through activation of microglia, 
with a positive correlation being observed between abundance of microglia and 
sensitivity to LPS-induced neurotoxicity (Kim et al. 2000) so, it was expected that LPS 
treatment of neuronal cultures would not induce toxicity unless microglia were present. 
However, data presented here shows that after 48 hours of LPS treatment, significant 
apoptotic morphology occurs in the CGC cultures. These data suggest that either LPS 
can mediate direct neurotoxic effects, or that immune-competent cells such as 
microglia are present in the neuronal cultures, and chronic exposure (>24 h) of the 
‘contaminating’ microglia to LPS is able to induce indirect neurotoxicity.  
Manipulation of the neuronal cultures to specifically deplete ‘contaminating’ microglia 
using leucine-methyl-ester enabled us to identify the important role for microglia in 
LPS-mediated responses including TNFα release and neurotoxicity in CGC cultures. It 
also provided an opportunity to model and manipulate other responses hypothesised to 
be due to microglia. Leucine-methyl-ester (LME) as a phagocyte-specific executioner 
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has been used previously in our laboratory to deplete microglia from primary cultures 
(Morgan et al. 2004) with other groups using the compound to deplete microglia from 
astrocyte cultures (Hamby et al. 2006). Also, the compound has been used. LME is a 
lysosomotropic agent originally used to selectively destroy macrophages (Thiele et al. 
1983). Here, it is shown that LPS-mediated neurotoxicity observed after 48 hours, 
could be ablated if microglia were depleted. The observed increase in apoptotic 
morphology seen after 24 hours exposure of the CGC cultures to FG could also be 
attenuated by LME pre-treatment, suggesting this initial early toxicity is indirect via a 
microglial-dependent mechanism. This protection via microglia depletion was lost 
however, after 48 hours of exposure. These data suggested that FG has direct 
neurotoxic capabilities, or that the protein is cleaved in culture to FN, which in turn 
could have direct neurotoxic effects. Studies identifying thrombin gene expression 
coupled with pharmacological manipulation of the enzyme suggested that FG is 
cleaved to FN in the cultures and it is the presence of FN that induces the later 
neurotoxicity. 
This direct neurotoxicity was also observed if microglia were depleted prior to FN 
exposure for 24 hours, suggesting microglia were competently protecting neurons from 
FN-mediated toxicity for at least 24 hours, in vitro. However, a loss of this protection 
was observed here if FN exposure was prolonged. These observations suggest that 
microglia can cope with ‘acute’ (≤24 h) FN exposure, but not ‘chronic’ (>24 h) 
exposure, due possibly to phagocytic degradation pathways becoming saturated after 
chronic exposure, or microglia number significantly decreasing due to direct FN-
mediated toxicity. This hypothesis certainly fits with the ED-1 expression profile after 
FN treatment of CGC cultures, showing a significant drop in expression after 48 hours 
of treatment. Interestingly, FG treatment gave a bi-phasic ED-1 expression profile, with 
significant drops observed after 4 and 48 hours of exposure. These decreases in ED-1 
expression could correlate with early FG-mediated toxicity (≤ 24h) and late FG-
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mediated toxicity (>24h), with the latter due to conversion to FN. Microglial senescence 
is also a possibility (Streit 2006) with chronic activation enhancing cell loss.     
3.5.7. Preliminary ligand-receptor elucidation 
Identification of the initial protein-cellular interactions that are responsible for the 
observed cytokine release and neurotoxicity would be important findings possibly 
enabling early attenuation of these responses. Involvement of CD11b in FN-, but not 
FG-mediated TNFα and IL-6 release further supports the requirement of protein 
immobilisation prior to receptor ligation, as previously described. Further studies on the 
role of scavenger receptor A (SRA) in FG- and FN-mediated responses yielded similar 
results, with no significant change in FG-mediated TNFα release or toxicity. Scavenger 
receptors are involved in mediating cell adhesion to, and endocytosis of, various native 
and pathologically modified substances (Husemann et al. 2002), including interactions 
with fibrillar Aβ1-42 (El Khoury et al. 1996). Also, the receptor has been shown to be 
involved in chromogranin A-induced microglial stress and neurotoxicity (Hooper et al. 
2009a)  Interestingly, SRA-inhibition with fucoidan, attenuated FN-mediated iNOS 
expression but not TNFα release in CGC cultures. The inhibitory activity of fucoidan 
may reflect its capacity to mask sites on ligands, which interact with SRA, rather than 
masking the receptor itself (Husemann et al. 2002). Therefore, the observed differential 
attenuation of iNOS activity and TNFα release may in part be due to preferential 
masking of a binding motif associated with iNOS activity and not TNFα release. 
3.5.8. No role for NADPH oxidase in attenuation of FG- or FN-mediated responses 
Both FG and FN, at high concentrations, induced significant superoxide staining in 
microglia present in the CGC cultures, which was dependent on NADPH oxidase 
activity. This microglia associated increase in superoxide was comparable to data 
produced in our laboratory using BV2 microglia cells in an optimised biochemical assay 
(E. Mead, unpublished observations). Inhibition of NADPH oxidase activity did not 
affect FN- or FG-induced TNFα release or neurotoxicity. It was therefore decided that 
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this area of research would not be pursued for this thesis however, more elegant 
silencing of the NADPH oxidase enzyme using siRNA (Loane et al. 2009) or genetic 
knockouts would be an interesting avenue to pursue in future especially as the 
treatment. did significantly induce superoxide production. 
3.5.9. TNFα synthesis, but not iNOS activity is involved in FG- and FN-mediated 
toxicity 
Finally, pharmacological inhibition of factors here identified to be significantly induced 
by FG and FN treatment of cultures was performed. Here, TNFα synthesis but not 
iNOS activity was significantly associated with FG- and FN-mediated apoptosis. 
Furthermore it was shown that microglia are significantly involved in the observed 
neurotoxicity with MGCM experiments supporting these suggestions. The use of 
MGCM allowed identification of whether stable soluble factors released from microglia 
are involved in any observed toxicity. Using MGCM inhibition of TNFα release, 
specifically in microglia, is shown here to be sufficient to attenuate FG- and FN-
mediated neurotoxicity. Furthermore, concentrating the FG-MGCM and immuno-
blotting allowed us to show FG transfer in the MGCM to the CGCs was minimal and 
below levels shown to be neurotoxic. However, transfer of the inhibitors could not be 
ruled out.  
3.5.10. Conclusions 
These data provide initial characterisation of toxicity in microglial and CGC cultures 
after exposure to FG or FN, identifying a vital role for microglia in FG-mediated 
neurotoxicity, and are summarized in Figure 3.5.1. It seems FN deposition is highly 
toxic to the microglia and neurons, with data suggesting an induction of necrotic cell 
death as well as nitric oxide and TNFα release. However, inhibition of iNOS activity 
could not attenuate FN-mediated neurotoxicity in CGC cultures. FG treatment induced 
lower concentrations of TNFα with limited iNOS expression also observed. However 
exposure of microglia to FG can still induce activation and, in CGC cultures early 
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potent activation of microglia to a neurotoxic phenotype occurred. These data provide a 
platform to further identify mechanisms by which FG induces neurotoxicity and how 
microglia are involved. 
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Figure 3.5.1. Summary of results obtained in chapter 3 
A. Fibrin treatment of microglia led an increase in iNOS expression, toxicity and 
death via activation of CD11b and/or scavenger receptor A (SR-A). This led to the 
release of pro-inflmmatory cytokines, TNFα and IL-6 that, in the case of TNFα, 
participated in neuronal death via caspase-3/7 activation. Direct treatment of 
neurons with FN in the absence of microglia also induced death with dependence 
on caspase-3/7. B. Fibrinogen treatment of microglia led to an increase in iNOS 
expression in serum-free conditions but not serum-containing conditions. Caspase-
3/7 activation occurred that did not seem to induce apoptosis, rather activation, 
which was also dependent on p38 MAPK-dependent pathways. FG-mediated 
microglial activation also led to the release of pro-inflammatory cytokines, in 
particular TNFα, with FG-mediated neuronal death being highly dependent on the 
observed TNFα release from microglia, as well as possible involvement from p38-
MAPK pathways and activation of caspase-3/7.  
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4. Identifying and coupling a role for Endoplasmic Reticulum 
Stress in fibrinogen-mediated neuronal apoptosis 
4.1. Introduction 
This chapter focuses primarily on the involvement of the endoplasmic reticulum (ER) in 
FG-induced toxicity in neurons and microglia. Stressing of the ER is now widely 
accepted as an important pathological event in many diseases ranging from 
neurological disorders to cancers, diabetes, and atherosclerosis (Kim et al. 2008). Cells 
respond to ER stress by activation of the unfolded protein response (UPR), a cellular 
process that increases transcription of genes encoding ER-resident chaperones to 
facilitate protein folding and removal of mis-folded and mutant proteins (Imaizumi et al. 
2001; Benn & Woolf 2004; Szegezdi et al. 2006). However, if mis-folding of proteins or 
expression of mutant proteins become chronic events such as in many 
neurodegenerative disorders (Saxena & Caroni 2011), ER stress can induce apoptotic 
cascades and death can occur. Initially, the discovery of an ER localised caspase in 
mice, caspase-12, was a significant suggestion that this organelle could be involved in 
cellular apoptosis (Nakagawa et al. 2000). Furthermore, Nakagawa and colleagues 
suggested β-amyloid-mediated neurotoxicity was dependent on ER stress involving 
caspase-12 cleavage. 
4.1.1. ER stress in disease 
In the last decade, much research has shown involvement of ER stress in 
neurodegenerative and neuroinflammatory disorders (Lindholm et al. 2006), including 
Alzheimer’s disease (Salminen et al. 2009), Parkinson’s disease (Wang & Takahashi 
2007), amyotrophic lateral sclerosis (Kanekura et al. 2009) and multiple sclerosis 
(Mháille et al. 2008). Mutant presenilin-1 over expression as a model of Alzheimer’s 
disease has been shown to down-regulate the UPR and also hyper-sensitise neurons 
to ER stress-mediated apoptosis (Katayama et al. 1999; Terro et al. 2002). In 
Parkinson’s disease, mutant α-synuclein has been shown to induce ER stress 
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associated toxicity in neurons (Smith et al. 2005). Data recently published suggests 
parkin is involved in interorganellar crosstalk between the ER and mitochondria and 
increased expression of the protein is observed after both ER and mitochondrial stress 
(Bouman et al. 2011). Furthermore this group showed transcriptional regulation of 
parkin by ATF4, a transcription factor of the UPR. These data coupled with reports 
showing parkin-mediated suppression of UPR-mediated cell death (Imai et al. 2000), 
suggest loss of function mutants of parkin could enhance ER and mitochondrial 
stresses contributing to disease pathogenesis. 
In an attempt to link fibrinogen extravasation into the CNS to induction of ER stress in 
neurons and microglia, literature from atherosclerosis research was studied. As 
previously stated, ER stress is prominent in atherosclerosis (Kim et al. 2008) with 
fibrinogen identified as a prominent feature of proliferative atherosclerotic lesions, 
constantly deposited and lysed (Bini et al. 1989; Smith et al. 1992) and degradation of 
fibrin has been suggested to induce macrophage migration enabling plaque removal 
(Smith et al. 1992). These observations coupled with ER stress dependent 
macrophage apoptosis in atherosclerosis (Tabas et al. 2009; Hotamisligil 2010a 
Hotamisligil 2010b), it was suggested that the study of fibrinogen-mediated ER stress 
in microglia and neurons could provide some interesting results.     
4.1.2. Modelling ER stress, in vitro 
Investigating ER stress in vitro has been suggested to be dissimilar to the actual 
process in vivo, with cultured cells displaying the full UPR repertoire upon induction of 
stress (Saxena & Caroni 2011), not seen in vivo. However, this induction in vitro has 
been suggested as another function of the UPR, independent of protein mis-folding 
induction, involved in regulating basal cellular homeostasis (Rutkowski & Hegde 2010). 
Here live cell staining, ICC and Western blotting were used to show FG and FN 
treatment of neurons and microglia can increase expression of ER stress markers, and 
inhibition of ER stress can attenuate observed toxicity. It is also shown that FG-
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mediated induction of ER stress-related markers is dependent on microglia, supporting 
an indirect mechanism of toxicity with further elucidation of the pathway.    
4.2. Exposure of CGC cultures to fibrinogen or fibrin induces 
expression of endoplasmic reticulum stress markers 
Initially CGC cultures were treated with either thapsigargin or tunicamycin, time-
dependently, as positive controls for caspase-12 cleavage, which occurs in cells 
undergoing ER stress (Nakagawa et al. 2000). Thapsigargin initiates ER stress by 
inhibiting the sarco-ER calcium-ATPase (SERCA), causing calcium dyshomeostasis, 
and tunicamycin can induce ER stress by inhibiting protein N-glycosylation (Takano et 
al. 2007). Treatment of CGCs with thapsigargin (Th) induced a significant increase in 
cleaved caspase-12 expression over time (Figure 4.2.1 A). Tunicamycin (Tu) 
treatment also induced a significant increase in cleaved caspase-12 expression, but 
only after 24 hours exposure with more variability being observed at the earlier time 
points (Figure 4.2.1 B). Therefore, thapsigargin was chosen as the main positive 
control for ER stress responses, however, where possible tunicamycin treatment was 
also performed.  
4.2.1. Differential induction of caspase-12 activation is observed after fibrinogen 
and fibrin treatment 
To identify if FG or FN exposure could induce significant caspase-12 cleavage, 
Western blotting was performed. Treatment of CGCs with FG induced significant 
cleavage of caspase-12 when compared with control levels, after 12 hours (Figure 
4.2.2 A). Furthermore, significant time-dependent increases in the caspase-12 
cleavage product were observed in FG-treated cultures at all time points tested post 12 
hours of exposure. Conversely, FN treatment of CGC cultures did not give the same 
time-dependent increases in caspase-12 cleavage. Only 48 hours of exposure gave an 
observable increase in expression of the 36 kDa active form (Figure 4.2.2 B), 
suggesting any ER stress due to FN exposure is not the initial mediator of the observed 
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cell toxicity. Finally, administration of other treatments to CGCs gave variable 
responses. Treatment for 48 hours with LPS caused significant cleavage of caspase-12 
compared with control levels (Figure 4.2.3).  Treatment with staurosporine for 4 hours, 
the positive control used in previous experiments for induction of the classic intrinsic 
apoptotic pathway, did not significantly induce caspase-12 cleavage, as previously 
shown (Nakagawa et al. 2000) (Figure 4.2.3). 
To further support these Western blotting data, live cell staining was performed on 
CGC cultures with a fluorescently tagged peptide that covalently binds to the active 
form of caspase-12 (Figure 4.2.4 A). The fluorescence intensity after treatment was 
quantified and compared with non-treated control cultures (Figure 4.2.4 B). Treatment 
with either thapsigargin or tunicamycin for 24 hours significantly increased the 
fluorescence intensity when compared with non-treated controls. These increases in 
fluorescence could be attributed to caspase activation as pre-treatment with the pan-
caspase inhibitor, z-VAD-FMK, significantly attenuated fluorescence intensity (Figure 
4.2.4 B). 
Live cell staining on cultures that had been treated with FG or FN for 48 hours also 
showed a significant increase in fluorescence intensity compared with control. 
Comparable with the positive control-mediated induction, the increase in fluorescence 
due to FG treatment was dependent on caspase activation as pre-treatment with z-
VAD-FMK attenuated the observed fluorescence intensity (Figure 4.2.4 B). Cultures 
were also exposed to FG for 24 hours and these data also show significant increases 
in fluorescence intensity that was dependent on caspase activation. The FN-mediated 
increase in fluorescence intensity could not be significantly attenuated by z-VAD-FMK 
pre-treatment. The high variability in the FN cultures could explain this observation and 
will be discussed further. Finally, in support of the Western blotting data, treatment of 
cultures with staurosporine for 8 hours did not induce a significant increase in 
fluorescence intensity although significant PI staining was observed, supporting the 
toxic effect of the compound in an ER-stress-independent manner (Figure 4.2.4). To 
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further support the significant impact of z-VAD-FMK pre-treatment, cleaved caspase-12 
expression in lysates from cultures exposed to FG, FN, or thapsigargin after z-VAD-
FMK treatment were compared with thapsigargin-mediated expression. Cultures with z-
VAD-FMK pre-treatment showed significantly less cleaved caspase-12 expression 
when compared with thapsigargin treatment (Figure 4.2.5). Interestingly, FN-mediated 
expression was completely attenuated with z-VAD-FMK pre-treatment, suggesting a 
caveat in the live cell staining methodology, which will be discussed further. 
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Figure 4.2.1. Thapsigargin and tunicamycin induce cleavage of caspase-12 in 
CGCs 
Ai. Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with thapsigargin (Th; 2 µM) for 4-24 hours. Aii. 
Quantification of the time-dependent cleavage of caspase-12 expression by 
thapsigargin, with respect to β-actin expression as represented in Ai.  Bi. 
Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with tunicamycin (Tu; 1 µg/ml) for 4-24 hours. Bii. 
Quantification of the time dependent cleavage of caspase-12 expression by 
tunicamycin, with respect to β-actin expression as represented in Bi. Experiments 
were repeated on 3 independent occasions. One way ANOVA with Dunnett’s post-
test was performed to compare control levels with each time-point. Levels of 
significance were: non-significant p>0.05, * p<0.05. 
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Figure 4.2.2. FG and FN induce time-dependent cleavage of caspase-12 in 
CGCs 
Ai. Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with fibrinogen (FG; 2.5 mg/ml) for 2-48 hours. Aii. 
Quantification of the time-dependent cleavage of caspase-12 expression by FG, 
with respect to β-actin expression as represented in Ai.  Bi. Representative 
Western blots for caspase-12 and β-actin expression in CGC cultures after 
treatment with fibrin (FN; 1 mg/ml) for 2-48 hours. Bii. Quantification of the time 
dependent cleavage of caspase-12 expression by FN, with respect to β-actin 
expression as represented in Bi. FG Western blotting was repeated on 3 
independent occasions, and FN Western blotting was repeated on 2 independent 
occasions. One way ANOVA with Dunnett’s post-test was performed to compare 
control levels with each time-point in the FG treatment studies. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4.2.3. LPS but not Staurosporine induces cleavage of caspase-12 in 
CGCs 
Ai. Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with thapsigargin (Th; 2 µM; 24 hours), staurosporine 
(STS; 0.5 µM; 8 hours), LPS (1 µg/ml; 48 hours), FG (2.5 mg/ml; 24 hours), FN (1 
mg/ml; 48 hours) or tunicamycin (Tu; 1 µg/ml; 24 hours). Aii. Quantification of 
cleaved caspase-12 expression, with respect to β-actin expression, after 
treatments as outlined in Ai. Experiments were repeated on 3 independent 
occasions. One way ANOVA with Dunnett’s post-test was performed to compare 
control levels with each treatment. Levels of significance were: non-significant 
p>0.05, * p<0.05, ** p<0.01. 
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Figure 4.2.4. FG induces an increase in activated caspase-12-associated 
fluorescence, dependent on caspase activation 
A. Panel of representative images of live cell staining experiments in CGC cultures 
after treatment with Th (2 µM; 24 hours), Tu (1 µg/ml; 24 hours), FG (2.5 mg/ml; 24 
hours), FN (1 mg/ml; 48 hours) or STS (0.5 µM; 8 hours), alone or in combination 
with z-VAD-FMK (1 µg/ml). Live cell staining was performed with Hoechst-33342 
for nucleus identification, propidium iodide (PI; red) for total cell death, and FITC-
ATAD-FMK (green) for active caspase-12. Original magnification: x40, scale bar: 
40 µm. B. Quantification of the relative active caspase-12 fluorescence 
intensity/cell in CGC cultures after administration of treatments stated in A. Data 
are presented in arbitrary fluorescence units (AFU). Treatments were in triplicate 
and data were analysed from 3 independent experiments. To compare AFU of 
control levels and treatments, a one way ANOVA was performed with Dunnett’s 
post-test. To compare specific treatments with caspase inhibition, paired two-tailed 
Student’s t-tests were performed.  Levels of significance were: non-significant 
p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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Figure 4.2.5. FG- and FN-mediated caspase-12 cleavage is dependent on 
caspase activation 
A. Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after co-treatment with FG (2.5 mg/ml; 24 hours) or FN (1 mg/ml; 48 
hours) with z-VAD-FMK (1 µg/ml), or treatment with thapsigargin (Th; 2 µM; 24 
hours) alone or in combination with z-VAD-FMK. B. Quantification of cleaved 
caspase-12 expression, with respect to β-actin expression, after treatments 
outlined in A. The experiment was repeated on 3 independent occasions. Paired 
two-tailed Student’s t-tests were performed to compare Th-mediated expression 
levels with each ‘inhibited’ treatment. Levels of significance were: non-significant 
p>0.05, ** p<0.01. 
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4.2.2. Fibrinogen- but not fibrin-mediated caspase-12 expression is dependent on 
the presence of microglia in CGC cultures 
Following on from the earlier studies that identified a significant role for microglia in FG- 
and FN-mediated responses, CGC cultures were pre-treated with LME and live cell 
staining for the active form of caspase-12 were performed. Treatment of cultures for 24 
hours with thapsigargin or tunicamycin significantly induced caspase-12 cleavage, 
which was not attenuated by microglial depletion. However, FG treatment induced 
significant expression of active caspase-12 after 24 hours and this could be prevented 
if microglia were depleted from the cultures (Figure 4.2.6). In line with the earlier 
observations suggesting FN and LPS did not induce significant toxicity after 24 hours, 
no significant increase in caspase-12 activation was seen in either treatment groups at 
this time point (Figure 4.2.6). However, if FN-treated cultures were depleted of 
microglia, significant increases in caspase-12 activation were observed, following a 
similar pattern to the increase in toxicity staining with PI. Following on from these data, 
caspase-12 cleavage was quantified in cultures after 48 hours of treatment, again 
using fluorescence intensity. As expected, thapsigargin and tunicamycin induced 
significant increases in caspase-12 cleavage which was independent of microglia 
(Figure 4.2.7). FG treatment for 48 hours induced significant induction of caspase-12 
cleavage to a level similar to that seen in positive control treated cultures. Depletion of 
microglia from these cultures prior to FG treatment caused a drop in caspase-12 
cleavage, however, this was not a significant decrease and cell toxicity staining was 
still significantly increased above control levels (Figure 4.2.7), in line with earlier 
observations (Figure 3.3.1). FN treatment for 48 hours also induced significant 
increases in the active form of caspase-12 and as predicted, microglial depletion did 
not inhibit this induction. Finally, LPS treatment for 48 hours induced significant 
caspase-12 induction with depletion of microglia causing a drop in cleavage close to 
significance (Figure 4.2.7). 
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Western blotting was performed on lysates from cultures pre-treated with LME to 
support the live cell staining data. Thapsigargin treatment for 24 hours increased the 
expression of the cleaved fragment of caspase-12 (36 kDa) and in support of the live 
cell staining data, depletion of microglia did not attenuate the expression (Figure 
4.2.8). Also in line with the live staining data, FG treatment for 24 hours induced 
cleaved caspase-12 expression that seemed to be inhibited in cultures depleted of 
microglia. Finally, FN treatment for 48 hours increased expression of the cleaved form 
of caspase-12. However, no obvious modulation in FN-mediated caspase-12 cleavage 
was observed after pre-treatment with LME (Figure 4.2.8). 
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Figure 4.2.6. FG induces an increase in activated caspase-12-associated 
fluorescence in CGC cultures, dependent on the presence of microglia 
A. Panel of representative images from live cell staining experiments in CGC 
cultures after treatment with Th (2 µM), Tu (1 µg/ml), FG (2.5 mg/ml), FN (1 mg/ml) 
or LPS (1 µg/ml) for 24 hours, +/- LME pre-treatment for the depletion of microglia 
(LME). Live cell staining was performed using Hoechst-33342 for nucleus 
identification, propidium iodide (PI; red) for total cell death, and FITC-ATAD-FMK 
(green) for active caspase-12. Original magnification: x40, scale bar: 40 µm. B. 
Quantification of the relative active caspase-12 fluorescence intensity/cell in CGC 
cultures after administration of treatments outlined in A. Data are presented in 
arbitrary fluorescence units (AFU). Treatments were in triplicate and data were 
analysed from 3 independent experiments. To compare the AFU of control levels 
and treatments, a one way ANOVA was performed with Dunnett’s post-test. To 
compare specific treatments on cultures where microglia were present or removed, 
paired two-tailed Student’s t-tests were performed.  Levels of significance were: 
non-significant p>0.05, * p<0.05.  
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Figure 4.2.7. Microglial-associated dependence of FG-mediated caspase-12 
cleavage in CGC cultures is time-dependent 
A. Panel of representative images from live cell staining experiments in CGC 
cultures after treatment with Th (2 µM), Tu (1 µg/ml), FG (2.5 mg/ml), FN (1 mg/ml) 
or LPS (1 µg/ml) for 48 hours, +/- LME pre-treatment for the depletion of microglia 
(LME). Live cell staining was performed using Hoechst-33342 for nucleus 
identification, propidium iodide (PI; red) for total cell death, and FITC-ATAD-FMK 
(green) for active caspase-12. Original magnification: x40, scale bar: 40 µm. B. 
Quantification of the relative active caspase-12 fluorescence intensity/cell in CGC 
cultures after administration of treatments outlined in A. Data are presented in 
arbitrary fluorescence units (AFU). Treatments were in triplicate and data were 
analysed from 3 independent experiments. To compare the AFU of control levels 
and treatments, a one way ANOVA was performed with Dunnett’s post-test. Levels 
of significance were: non-significant p>0.05, * p<0.05.  
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Figure 4.2.8. FG-mediated expression of the cleaved form of caspase-12 in 
CGC cultures seems to be dependent on the presence of microglia 
Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with FG (2.5 mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or 
Th (2 µM; 24 hours) +/- LME depletion of microglia (LME). The experiment was 
repeated on 2 independent occasions.  
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4.2.3. Fluorescence associated with fibrinogen- and thapsigargin-induced 
activated caspase-12 in microglia, present in CGC cultures, was not due to 
phagocytosis of the dye 
It was observed that some of the caspase-12 staining appeared most intense in the 
microglia present in the cultures. Microglia are the phagocytes of the brain (Kreutzberg 
1996). It could therefore be hypothesised that these significant increases in microglia 
expression of caspase-12 were partly due to the fluorescently-tagged peptide being 
recognised as a foreign pathogen and the microglia phagocytosing the dye creating a 
false positive increase in expression. Previously published studies have run control 
experiments at decreased temperatures to inhibit the mechanism of phagocytosis or 
internalisation (Tosello-Trampont et al. 2001; Gronski et al. 2009), therefore cultures 
treated with either thapsigargin or FG were incubated with the fluorescent caspase-12 
tag at 4°C for 30 minutes to observe whether the FI TC-ATAD-FMK expression in the 
microglia was in fact due to phagocytosis and not microglial ER stress. Microglia were 
identified by morphology and quantified as being caspase-12 positive or negative.  
A large number of the microglia in the CGC cultures displayed FITC-ATAD-FMK 
fluorescence after 24 hours of thapsigargin treatment at 37°C and probe incubation at 
4°C, when compared with control cultures ( Figure 4.2.9). Similarly, FG treatment for 24 
hours at 37°C induced increased fluorescence above control levels after probe 
incubation at 4°C, with a larger numbers of microgl ia displaying FITC-ATAD-FMK 
fluorescence when compared with control cultures. Therefore, these data suggest the 
fluorescence observed in the microglia is due to binding to active caspase-12 and not 
due to internalisation/phagocytosis (Figure 4.2.9). 
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  Figure 4.2.9. The observed fluorescence induction after treatments is not due 
to phagocytosis of FITC-ATAD-FMK 
Panel of representative images from live cell staining experiments in CGC cultures 
after treatment with Th (2 µM) or FG (2.5 mg/ml) for 24 hours, followed by FITC-
ATAD-FMK  (green) dye incubation at 4°C for 20 minu tes. Hoechst-33342 (blue) 
staining was also performed. Original magnification: x40, scale bar: 40 µm.  
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4.2.4. Fibrinogen and fibrin significantly increase expression of CHOP in primary 
microglial cultures 
Caspase-12 has been shown to be activated by ER stress in rodents (Nakagawa et al. 
2000). However, the argumentation cannot be reversed and an assumption made that 
caspase-12 activation implies ER stress. Therefore, to support the caspase-12 data, 
expression of CHOP/GADD153, the major pro-apoptotic transcription factor induced by 
ER stress (Salminen et al. 2009) was targeted. 
Following on from the observations that caspase-12 activation is present in microglia in 
the CGC cultures, immunocytochemistry was performed on primary microglial cultures 
for expression of CHOP. Treatment of cultures with thapsigargin or tunicamycin for 24 
hours increased the number of microglia staining positive for CHOP expression when 
compared with control cultures. Furthermore, FG or FN treatment of the microglial 
cultures for 24 hours also increased the number of cells displaying CHOP expression 
when compared with control levels (Figure 4.2.10). 
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Figure 4.2.10. FG and FN induce expression of CHOP in primary microglial 
cultures 
Representative images from primary microglial cultures after treatment with Th (2 
µM), Tu (1 µg/ml), FG (2.5 mg/ml) or FN (1 mg/ml) for 24 hours. Cultures were 
stained with DAPI for quantification of cell number and probed with anti-Calnexin-
TRITC (red) for staining of cellular ER and anti-CHOP (green), except in negative 
control cultures, where primary antibodies were omitted. Original magnification: 
x40, scale bar: 40 µm. 
256 
 
4.2.5. Fibrinogen-mediated responses can be attenuated through inhibition of an 
ER stress pathway  
It was hypothesised that caspase-12 activation by FG or FN treatment would be 
downstream of any unfolded protein response (UPR) induced in the presence of these 
protein preparations. Therefore, inhibiting pathways activated during the UPR could 
prevent significant cleavage of caspase-12 and possibly increase cytoprotection. The 
compound salubrinal (Sal) has been shown to protect cultures from ER stress 
mediated by tunicamycin and other inducers by inhibiting the dephosphorylation of 
eukaryotic initiation factor 2α (eIF2α) (Boyce et al. 2005). The PKR-like endoplasmic 
reticulum kinase (PERK) is an eIF2α kinase that is activated during the UPR. The 
kinase phosphorylates eIF2α to attenuate mRNA translation, reducing the burden of 
protein substrate for the ER-folding and -degradation machinery (Yan et al. 2002). Pre-
treatment of salubrinal therefore increases the expression of the phosphorylated form 
of eIF2α by inhibiting dephosphorylation, providing a more robust, prolonged protection 
against ER stress inducers. 
The CGC cultures were treated with salubrinal prior to thapsigargin, FG, or FN 
treatment and cleaved caspase-12 expression was compared with cultures with no 
salubrinal pre-treatment by Western blotting. Salubrinal treatment alone did not 
modulate caspase-12 expression (Figure 4.2.11). However, the FG-mediated 
expression of cleaved caspase-12 after 24 hours of exposure was observably 
attenuated with salubrinal pre-treatment. Cleavage above the control was still observed 
in these cultures, suggesting the involvement of other pathways. Interestingly, FN-
mediated cleaved caspase-12 expression after 48 hours of treatment was not 
attenuated by salubrinal pre-treatment, suggesting other pathways may be involved in 
FN-mediated caspase-12 expression, or as previously suggested, the observed 
caspase-12 expression is secondary and FN-mediated toxicity is due primarily to other 
stress pathways. However, these data are preliminary and require further clarification. 
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To further support a role for ER stress in FG-mediated microglial activation, live cell 
staining for cleaved caspase-3/7 was performed on primary microglial cultures in the 
presence or absence of salubrinal pre-treatment. This experiment was performed in 
line with recent studies suggesting significant non-apoptotic roles for caspase-3/7 in 
microglial activation. Obviously it wouldn’t be possible to rule out with 100% certainty, 
the classical apoptotic roles of caspase-3/7; however quantification of morphological 
changes attributed to cells undergoing apoptosis provided a strong indicator of whether 
any observed increase in fluorescence associated with caspase-3/7 cleavage is 
apoptosis-dependent or –independent. 
Treatment of the cultures with staurosporine (STS) for 4 hours induced significant 
active caspase-3/7 associated fluorescence, as expected (Figure 4.2.12). Also it was 
likely this activation of caspase-3/7 was primarily apoptotic-dependent with a significant 
increase cells displaying apoptotic morphology when compared with control cultures 
(Figure 4.2.12 Aiii). Similarly, treatment of cultures with FG for 24 hours induced a 
significant increase in active caspase-3/7 associated fluorescence. However, the 
observed cellular morphology in FG-treated cultures seemed healthy with little or no 
significant apoptotic morphology when compared with control cultures, in line with 
previous observations (Figure 3.2.8), suggesting these observed increases in 
caspase-3/7 could be apoptosis-independent (Figure 4.2.12 Aiii). Furthermore, 
treatment of cultures with salubrinal prior to FG exposure completely ablated the said 
caspase-3/7 expression, suggesting ER stress via the PERK-eIF2α axis is involved in 
the downstream cleavage of caspase-3/7 in microglia after FG treatment. FN-treatment 
of the microglial cultures for 24 hours was also able to induce significant caspase-3/7 
activation (Figure 4.2.12 Aii); however salubrinal pre-treatment could not significantly 
attenuate the activation, although there was a trend towards attenuation. This suggests 
the observed expression could be due to both apoptosis-dependent and -independent 
cleavage of the caspases. In line with the apoptotic-mediated activation, the 
percentage of cells displaying apoptotic morphology in the FN-treated cultures was 
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significantly higher than in non-treated control cultures (Figure 4.2.12 Aiii). Finally, 
LPS treatment was analysed for its ability to induce caspase-3/7 activation in the 
microglia. As shown previously (Figure 3.2.8), LPS significantly induced active 
caspase-3/7 expression after 24 hours. Pre-treatment with salubrinal did attenuate the 
caspase-3/7 expression, however, not significantly, suggesting that either the caspase-
3/7 expression was apoptotic or induced in a non-apoptotic fashion independent of ER 
stress pathways. The percentage of cells displaying apoptotic morphology in LPS 
treated cultures was not significantly different to control cultures suggesting a non-
apoptotic role for caspase-3/7 that was independent of ER stress induction. 
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Figure 4.2.11. FG-mediated expression of the cleaved form of caspase-12 in 
CGC cultures can be inhibited with salubrinal treatment 
Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with Th (2 µM; 24 hours), FG (2.5 mg/ml; 24 hours), or FN 
(1 mg/ml; 48 hours) alone or in combination with salubrinal (Sal; 100 nM). The 
experiment was repeated on 2 independent occasions. 
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  Figure 4.2.12. FG-mediated caspase-3/7 cleavage in microglia can be 
attenuated by inhibition of an ER stress-associated pathway 
Ai. Panel of representative images from live cell staining experiments in primary 
microglial cultures after treatment with STS (0.5 µM; 8 hours), FG (2.5 mg/ml), FN 
(1 mg/ml) or LPS (1 µg/ml), for 24 hours. Live cell staining was performed using 
Hoechst-33342 for nucleus identification and FAM-DEVD-FMK (green) for active 
caspase-3/7. Original magnification: x40, scale bar: 40 µm. Aii. Quantification of 
the relative active caspase-3/7 fluorescence intensity/cell in microglial cultures 
after administration of treatments as outlined in Ai. Data are present in arbitrary 
fluorescence units (AFU) Aiii. Quantification of the percentage of microglia present 
that displayed classical apoptotic morphology after administration of treatments as 
outlined in Ai. Treatments were in duplicate and data were analysed from 3 
experiments. One-way ANOVA was performed to compare control levels of AFU or 
apoptotic morphology to each treatment. Paired two-tailed Student’s t-tests were 
performed to compare specific treatments in the absence and presence of 
inhibition. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01.  
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Turning the focus to the caspase-12 cleavage observed in the cerebellar granule 
neurons and to attempt to identify pathways involved in said cleavage, MGCM 
experiments were performed. Primary microglia were treated with thapsigargin or FG in 
the absence or presence of a range of pathway inhibitors for 24 hours, the medium was 
removed and administered to the CGC cultures depleted of microglia and caspase-12 
expression was assayed by Western blotting. Administration of media from 
thapsigargin-treated microglial cultures to CGC cultures induced an increase in 
expression of the active, cleaved form of caspase-12 (36 kDa) (Figure 4.2.13), 
suggesting ER stress in microglia can induce extracellular signalling that can lead to 
neuronal vulnerability also with an ER stress component. Administration of media from 
FG-treated microglial cultures to the microglia-depleted CGC cultures also induced 
significant expression of the cleaved caspase-12, to a level similar to that seen with Th-
MGCM (Figure 4.2.13) again suggesting microglial dysfunction or activation can lead 
to ER stress pathway activation in the neurons.  
Previous data from ELISAs showed activation of the p38-MAPK pathway in FG-
mediated TNFα release (Figure 3.2.5). Therefore, in an attempt to further elucidate the 
pathways in microglia responsible for the FG-mediated caspase-12 activation in the 
neurons, pathway inhibitors were administered to the microglial cultures prior to FG 
exposure for 24 hours. Pre-treatment of microglia with the specific inhibitor of p38-
MAPK, SB203580 (SB) markedly decreased FG-MGCM-mediated caspase-12 
cleavage in the neuronal cultures (Figure 4.2.13). This again suggests a role for this 
MAPK pathway in FG-mediated responses. Interestingly and conversely to the TNFα 
release data, pre-treatment of the microglial cultures with the phosphoinositide 3-
kinase (PI3K) pathway inhibitor, wortmannin (Wort), also markedly attenuated the FG-
mediated caspase-12 cleavage in the neuronal cultures. No observable modulation of 
caspase-12 cleavage occurred in the neuronal cultures after pre-treatment of the 
microglial cultures with the ERK1/2 specific inhibitor, PD98059 (PD) or the CD11b 
blocking antibody (CD11b). Finally, pre-treatment of the microglial cultures with 
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salubrinal did not attenuate the FG-MGCM-mediated caspase-12 cleavage observed in 
the neuronal cultures (Figure 4.2.13). This suggests FG-mediated microglial activation 
independent of the PERK-eIF2α axis of ER stress is sufficient to induce ER stress in 
neurons. These data however require clarification as the experiment was only 
performed on one occasion and the quality is poor. 
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Figure 4.2.13. Expression of the cleaved form of caspase-12 in CGC cultures 
can be induced by FG-treated MGCM with involvement from MAPK pathways 
Western blots for caspase-12 and β-actin expression in CGC cultures after 
treatment with MGCM from  FG-treated microglial cultures alone or in combination 
with anti-CD11b blocking antibody (10 µg/ml), wortmannin (Wort; 100 nM), 
SB203580 (SB; 10 µM), PD98059 (PD; 10 µM) or salubrinal (Sal; 100 nM) for 24 
hours. The experiment was performed on 1 occasion.  
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4.3. TNFα synthesis is involved in fibrinogen- and fibrin-mediated 
induction of endoplasmic reticulum stress marker activation in 
microglia and neuronal cultures 
It was hypothesised from previous observations that soluble factors released from 
microglia could be responsible for the observed caspase-12 cleavage and subsequent 
cellular stress in the neurons, and therefore, pharmacological inhibition of iNOS activity 
or TNFα synthesis was performed. Addition of either AMT-HCl (iNOS activity inhibitor) 
or thalidomide (TNFα synthesis inhibitor) had no significant effect on fluorescence 
intensity attributed to caspase-12 activity, when compared with control levels (Figure 
4.3.1). Similarly, pre-treatment of cultures with either AMT-HCl or thalidomide had no 
significant effect on caspase-12 activity induced by thapsigargin or tunicamycin 
treatment for 24 hours, as expected. FG-mediated induction of caspase-12 cleavage 
after 24 hours could not be attenuated by pre-treatment with AMT-HCl, in line with 
previous findings (Figure 3.4.2 & 3.4.3). However, exposure of the cultures to 
thalidomide prior to FG treatment for 24 hours significantly attenuated the fluorescence 
intensity attributed to caspase-12 activity (Figure 4.3.1). Modulation of the FN-
mediated caspase-12 activity after 48 hours of treatment yielded similar, yet 
insignificant inhibition in the case of thalidomide pre-treatment, to that observed in FG 
treated cultures. Also, similarly to the FG-treated cultures, pre-treatment with AMT-HCl 
failed to attenuate FN-mediated caspase-12 activity (Figure 4.3.1). The presence of 
auto-fluorescent insoluble aggregates of FN in the cultures have been touched on 
previously, and could be manipulating, in a false-positive fashion, the fluorescence 
intensity data producing high variability between quantified fields and repetitions. To 
clarify these fluorescence findings, Western blotting was performed. In support of the 
thapsigargin-mediated induction of caspase-12 activity after 24 hours observed in the 
live cell staining experiments, significant expression of the cleaved form of caspase-12 
(36 kDa), when compared with control levels, was observed (Figure 4.3.2). 
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Furthermore, pre-treatment with thalidomide failed to inhibit this significant cleavage. 
Again, in line with the fluorescence intensity analysis of the live cell staining, FG 
induced significant cleavage of caspase-12 after 24 hours, which could be significantly 
inhibited by thalidomide pre-treatment (Figure 4.3.2). Finally, FN-mediated induction of 
caspase-12 cleavage could not be inhibited by thalidomide pre-treatment, suggesting 
the quantified fluorescence intensity attributed to caspase-12 activity was correct. 
Interestingly, previous observations suggested treatment of cultures with thalidomide 
prior to FN for 48 hours protected the cultures from toxicity. This observation seemed 
to be supported in the caspase-12 live cell staining experiment by a significantly lower 
percentage of cells staining for propidium iodide (PI), further supporting the hypothesis 
that caspase-12 activity is not primarily required for FN-mediated toxicity. 
These findings could also be replicated in primary microglial cultures, with FN 
treatment for 24 hours inducing cleavage that could not be inhibited after a pre-
treatment of cultures with thalidomide (Figure 4.3.3). Furthermore, significant caspase-
12 cleavage induced by FG treatment for 24 hours could be inhibited by thalidomide 
treatment. 
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270 
 
  
CTR AMT Thal AMT Thal AMT Thal AMT Thal AMT Thal AMT Thal
0
7
14
21
28
35
***
*****
***
**
***
*** *
**
**
**
*
ns
ns
Th Tu FG FN LPS
**
AF
U
B.
Figure 4.3.1. FG-induced caspase-12-associated fluorescence in CGC 
cultures is attenuated by inhibition of TNFα synthesis 
A. Panel of representative images from live cell staining experiments in CGC 
cultures after treatment with Th (2 µM; 24 hours), Tu (1 µg/ml; 24 hours), FG (2.5 
mg/ml; 24 hours), FN (1 mg/ml; 48 hours) or LPS (1 µg/ml; 48 hours) alone or in 
combination with AMT-HCl (AMT; 150 nM) or thalidomide (Thal; 10 µg/ml). Live 
cell staining was performed using Hoechst-33342 for nucleus identification, 
propidium iodide (PI; red) for total cell death, and FITC-ATAD-FMK (green) for 
active caspase-12. Original magnification: x40, scale bar: 40 µm. B. Quantification 
of the relative active caspase-12 fluorescence intensity/cell in CGC cultures after 
administration of treatments outlined in A. Data are presented in arbitrary 
fluorescence units (AFU). Treatments were in duplicate and data were analysed 
from 3 independent experiments. To compare the AFU of control levels to all other 
treatments, a one way ANOVA was performed with Dunnett’s post-test. To 
compare specific treatments with treatments + inhibitors, paired two-tailed 
Student’s t-tests were performed.  Levels of significance were: non-significant 
p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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Figure 4.3.2. FG-mediated expression of the cleaved form of caspase-12 in 
CGC cultures is dependent on TNFα synthesis 
A. Representative Western blots for caspase-12 and β-actin expression in CGC 
cultures after treatment with Th (2 µM; 24 hours), FG (2.5 mg/ml; 24 hours) or FN 
(1 mg/ml; 48 hours) alone or in combination with Thal (10 µg/ml). B. Quantification 
of cleaved caspase-12 expression, with respect to β-actin expression, after 
treatments as outlined in A. Experiments were repeated on 3 independent 
occasions. One-way ANOVA with Dunnett’s post test was performed to compare 
control levels with each treatment and paired two-tailed Student’s t-tests were 
performed to compare specific treatments with microglia present or absent. Levels 
of significance were: non-significant p>0.05, * p<0.05. 
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Figure 4.3.3. FG-mediated expression of the cleaved form of caspase-12 in 
CGC cultures seems to be dependent on TNFα synthesis 
Representative Western blots for caspase-12 and β-actin expression in primary 
microglial cultures after treatment with FG (2.5 mg/ml) or FN (1 mg/ml) alone or in 
combination with Thal (10 µg/ml) for 24 hours. The FG treatment was performed 
on 2 independent occasions and FN treatment was performed on 1 occasions. 
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4.3.1. Fibrinogen- and fibrin-mediated CHOP expression in microglia is 
dependent on TNFα synthesis and fibrinogen-mediated TNFα release is 
dependent on ER stress induction  
As explained previously, caspase-12 activation alone cannot confirm ER stress. 
Therefore, further support of the ER stress hypothesis, and involvement of TNFα 
signalling, was achieved by immunocytochemistry for CHOP expression in microglial 
cultures after treatment with FG and FN in the presence or absence of inhibition of 
TNFα signalling. Treatment with AMT-HCl or thalidomide alone did not induce an 
increase in CHOP-positive microglia, when compared with control cultures (Figure 
4.3.4). As expected, treatment with thapsigargin for 24 hours induced an increase in 
the percentage of CHOP-positive microglia, when compared with control cultures. In 
line with previous observations, FG treatment for 24 hours also increased the 
percentage of CHOP-positive microglia, when compared with control cultures (Figure 
4.3.4). AMT-HCl had no effect on FG-mediated CHOP expression however thalidomide 
pre-treatment markedly decreased the percentage of CHOP-positive microglia in FG-
treated cultures. Exposure of cultures to FN for 24 hours increased the percentage of 
CHOP-positive cells, when compared with controls, in line with previous observations 
(Figure 4.2.10). Treatment of cultures with AMT-HCl prior to FN exposure for 24 hours 
did not modulate the percentage of CHOP-positive microglia. However, unlike the 
caspase-12 expression profile, thalidomide pre-treatment did decrease the number of 
CHOP-positive microglia in FN-treated cultures (Figure 4.3.4). Finally, FG-mediated 
TNFα release could be significantly attenuated by co-treatment with salubrinal, 
although significant TNFα release was still observed, when compared to control levels 
suggesting partial ER stress-dependent induction of TNFα release from microglia 
(Figure 4.3.5). 
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  Figure 4.3.4. FG- and FN-mediated induction of CHOP expression in 
microglia is attenuated by TNFα synthesis inhibition 
Representative images from primary microglial cultures after treatment with Th (2 
µM, FG (2.5 mg/ml) or FN (1 mg/ml) alone or in combination with AMT (150 nM) or 
Thal (10 µg/ml), for 24 hours. Cultures were stained with DAPI for quantification of 
cell number and probed with anti-Calnexin-TRITC (red) for staining of cellular ER 
and anti-CHOP (green), except in negative control cultures, where primary 
antibodies were omitted. Original magnification: x40, scale bar: 40 µm. Treatments 
were in triplicate, n = 1.    
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Figure 4.3.5. FG- mediated TNFα release from microglia is partially 
attenuated by ER stress inhibition 
ELISA analysis of TNFα release from primary microglia cultures after treatment 
with FG (2.5 mg/ml) alone or in combination with salubrinal (100 nM) for 24 hours. 
Treatments were in duplicate in each experiment and data were analysed from 3 
independent experiments. To compare multiple treatments to non-treated control 
levels an ANOVA with Dunnett’s post-test was performed. Paired two-tailed 
Student’s t-tests were performed between specific treatments.  Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001 
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4.4. Fibrinogen treatment causes calcium dyshomeostasis in 
microglia 
Due to the more interesting and robust findings, it was decided the majority of 
subsequent ER stress related data would focus on FG-mediated responses. Alteration 
in calcium homeostasis is a contributing factor in ER stress (Lindholm et al. 2006). 
Therefore, it was hypothesised that suppressing any FG-mediated alterations in 
microglial calcium concentration would allow us to identify whether FG exposure 
modulated calcium homeostasis, in turn inducing ER stress pathways.  
4.4.1. High concentrations of BAPTA-AM induce microglial apoptosis 
Initially, previously published concentrations (50 µm; Hoffmann et al. 2003) of the well 
characterised calcium chelator, BAPTA-AM were tested, however almost total death 
was observed in the microglial cultures. Therefore a concentration titration was 
performed on the cultures and the percentage of apoptotic and amoeboid morphology 
was quantified. BAPTA-AM (5-10,000 nM) was incubated with microglial cultures for 24 
hours to mimic the duration required for FG-treatment. Only the top concentration 
(10,000 nM) was able to induce observable levels of apoptotic morphology when 
compared with control levels (Figure 4.4.1). With previously published effective 
concentrations ranging from 10-50 µM, it was decided to use the highest concentration 
that did not induce an increase in apoptotic and amoeboid morphology, 
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  Figure 4.4.1. BAPTA-AM titration on primary microglial cultures – analysis of 
activated and apoptotic morphology 
A. Panel of representative images from live cell staining experiments in primary 
microglial cultures after treatment with BAPTA-AM (5 – 10,000 nM). Live cell 
staining was performed using Hoechst-33342 for identification of nuclear apoptotic 
morphology and isolectin-B4 (IB4; green) for microglial identification and used for 
the quantification of amoeboid morphology. Original magnification: x20. B. 
Quantification of morphological changes in microglia (apoptotic and amoeboid after 
treatment as outlined in A. Data are presented as a percentage of the total number 
in each field analysed. Treatments were in triplicate, n = 1.  
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4.4.2. Co-treatment of microglia with fibrinogen and BAPTA induces significant 
apoptosis 
Live cell staining was performed on microglial cultures to identify whether FG-mediated 
caspase-12 activation was modulated if free calcium was chelated. Treatment with 
BAPTA-AM alone for 24 hours did not induce caspase-12 activation or significant cell 
death. As previously shown, FG treatment for 24 hours significantly increased 
fluorescence intensity attributed to caspase-12 activation when compared with control 
intensity, and also in line with previous findings, the cultures did not show a significant 
percentage of cells staining positive for PI, when compared with control cultures 
(Figure 4.4.2). BAPTA-AM co-treatment with FG for 24 hours inhibited the FG-
mediated increase in caspase-12 activity (Figure 4.4.2), however the cultures showed 
a significant increase in cells staining positive for PI, when compared with control 
cultures, suggesting strong toxicity of co-treatment is responsible for the lack of 
caspase-12 activity rather than an inhibitory effect mediated by BAPTA-AM. These 
findings support a vital role for calcium in FG-mediated caspase-12 activation in 
microglia.  
Live cell staining for caspase-3/7 activation was performed on the microglial cultures 
after treatment with FG in the absence and presence of BAPTA-AM. Interestingly, 
BAPTA-AM treatment alone for 24 hours did not induce a significant increase in 
fluorescence intensity attributed to caspase-3/7 activity (Figure 4.4.3), further 
supporting a non-toxic induction of caspase-12 cleavage. Also, in line with previous 
experiments, no significant increase in death was observed, when compared with 
control cultures. FG treatment alone for 24 hours induced a significant in fluorescence, 
but no significant increase in death, when compared with control cultures (Figure 
4.4.3). Finally, BAPTA-AM treatment prior to FG exposure for 24 hours induced 
significant death, when compared with control cultures and these data were further 
supported by a significant increase in caspase-3/7 attributed fluorescence (Figure 
4.4.3). 
281 
 
 
  
CTR
BAPTA
FG
FG + BAPTA
Hoechst FITC-ATAD-FMK PI Merged
B.
A.
0
25
50
75
100
0
25
50
*
*
CTR
AFU
% Death
FG
BAPTA BAPTA
%
 
De
at
h A
FU
Figure 4.4.2. Co-treatment of microglia with FG and BAPTA-AM attenuates 
caspase-12 activation, but enhances cell death 
A. Panel of representative images from live cell staining experiments in primary 
microglial cultures after treatment with BAPTA-AM (BAPTA; 1 µM) or FG (2.5 
mg/ml), alone or in combination for 24 hours. Live cell staining was performed 
using Hoechst-33342 for nucleus identification, propidium iodide (PI; red) for total 
cell death, and FITC-ATAD-FMK (green) for active caspase-12. Original 
magnification: x40, scale bar: 40 µm. B. Quantification of cell death presented as a 
percentage of cells staining positive for PI (black bars) and quantification of the 
relative active caspase-12 fluorescence intensity/cell in microglial cultures (grey 
bars) after administration of treatments as outlined in A. Data are presented in 
arbitrary fluorescence units (AFU). Treatments were in triplicate and data were 
analysed from 3 independent experiments. To compare the % cell death and AFU 
of control levels and treatments, a one way ANOVA was performed with Dunnett’s 
post-test. Levels of significance were: non-significant p>0.05, ** p<0.01, *** 
p<0.001.  
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Figure 4.4.3. Co-treatment of microglia with FG and BAPTA-AM induces 
apoptotic cell death 
A. Panel of representative images from live cell staining experiments in primary 
microglial cultures after treatment with BAPTA-AM (BAPTA; 1 µM) or FG (2.5 
mg/ml), alone or in combination. Live cell staining was performed using Hoechst-
33342 for nucleus identification, propidium iodide (PI; red) for total cell death, and 
FAM-DEVD-FMK (green) for active caspase-3/7. Original magnification: x40, scale 
bar: 40 µm. B. Quantification of cell death presented as a percentage of cells 
staining positive for PI (black bars) and quantification of the relative active 
caspase-3/7 fluorescence intensity/cell in microglial cultures (grey bars) after 
administration of treatments as outlined in A. Data are presented in arbitrary 
fluorescence units (AFU). Treatments were in triplicate and data were analysed 
from 3 independent experiments. To compare the % cell death and AFU of control 
levels and treatments, a one way ANOVA was performed with Dunnett’s post-test. 
Levels of significance were: non-significant p>0.05, ** p<0.01, *** p<0.001.  
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4.4.3. Fibrinogen mediates early calpain activity in a microglial cell line 
To further study the role of calcium in FG-mediated responses, calpain activity was 
analysed. Calpains are calcium activated cysteine proteases. To date, there are 6 
members, divided into subfamilies by ubiquitous or tissue-specific expression. Two 
ubiquitously expressed members are the most comprehensively characterised, known 
as µ-calpain and m-calpain (Saido et al. 1994; Nakagawa & Yuan 2000). These 
calpains are distinguishable from each other by their differential in vitro calcium 
concentration requirement for activation, with µ-calpain dependent on micromolar 
calcium and m-calpain on millimolar (Nakagawa & Yuan 2000), hence the respective 
names. Furthermore it has been suggested that m-calpain may be responsible for 
procaspase-12 cleavage to the active form and that disturbances in intracellular 
calcium storage as a result of amyloid-β peptide cytotoxicity may induce apoptosis 
through calpain-mediated caspase-12 activation (Nakagawa & Yuan 2000). Therefore, 
it was decided, due to lack of calcium imaging facilities that characterisation of the 
activity of this protease family could allow us to further support a significant role for 
calcium in FG-mediated responses. 
Initial optimisation and characterisation of the calpain activity assay adapted from 
D’Amelio et al., 2011, is shown in Figure 4.4.4 and described in methodology Section 
2.9. After optimisation was completed, a timecourse of FG-mediated calpain activity in 
the BV2 microglia cell line was performed as it was hypothesised that due to previous 
findings (Nakagawa & Yuan 2000), the calpain activity/activation would occur prior to 
any significant caspase-12 cleavage had occurred (i.e. < 12 hours; Figure 4.2.2). 
Ionomycin treatment for 30 minutes significantly increased calpain activity, when 
compared with control, and this increase could be inhibited by calpastatin pre-treatment 
(Figure 4.4.5). Longer exposure (1 hour) to ionomycin did not significantly increase 
calpain activity when compared with control. There was a highly significant increase in 
FG-mediated calpain activity after only 1 hour, when compared with control activity that 
was significantly attenuated by calpastatin pre-treatment. However, after 2-4 hours, 
284 
 
variability was observed and any significant increase of calpain activity was not 
inhibited by calpastatin pre-treatment, in fact at 2 hours, pre-treatment with calpastatin 
actually enhanced FG-mediated calpain activity (Figure 4.4.5). At 8 hours of FG 
treatment however, a highly significant increase in calpain activity was observed that 
could be inhibited by calpastatin pre-treatment (Figure 4.4.5). The signal window when 
compared with control activity was the largest observed, therefore 8 hours of FG 
treatment was used in subsequent calpain activity assays. Finally, it was noted that no 
significant increase in calpain activity was observed after 12 hours of treatment. This 
supports the idea that activity of this protease occurs primarily before significant 
caspase-12 cleavage. 
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Figure 4.4.4. Calpain activity assay optimisation 
A. Titration of calpastatin-mediated inhibition of calpain activity identified 1 µM 
calpastatin as the optimum concentration to be used in subsequent experiments. B. 
Optimisation of Ionomycin (Ion; 2 µM) incubation period shows 30 minutes provides 
the largest increase in calpain activity when compared with control and will therefore 
be used in subsequent experiments. C. Optimisation of the dye incubation period 
and fluorescence readout position shows 16 hours with the readout performed from 
the bottom of the well is the most effective. 
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Figure 4.4.5. FG treatment of BV2 microglia induces a significant increase in 
calpain activity 
Calpain activity assay performed on BV2 microglia lysates treated with ionomycin 
(2 µM) for 0.5 – 1 hours or FG (2.5 mg/ml) for 1 – 48 hours, alone or in 
combination with calpastatin (Cal; 1 µM). Data are presented as the percentage of 
calpain activity in relation to control levels. Treatments were in triplicate and data 
were analysed from 3 independent experiments. To compare calpain activity 
between control and all treatments, a one way ANOVA was performed with 
Dunnett’s post-test. Paired two-tailed Student’s t-tests were performed for 
comparisons between treatments with and without calpastatin ‘inhibition’. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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4.4.4. Fibrinogen-mediated calpain activity has dependence on iNOS activity   
It was hypothesised that inhibiting TNFα would not affect FG-mediated calpain activity 
after 8 hours. This was due to TNFα release data from FG-treated microglia (Figure 
3.2.3 A) that identified the concentration of TNFα that is released after 8 hours of FG 
treatment to be significantly lower than the concentrations shown previously to be 
effective (Taylor et al. 2005). It was also suggested that iNOS activity would not be 
involved in any FG-mediated calpain responses due to lack of data supporting a role 
for the enzyme in any of the previously observed FG responses. As expected, 
treatment of cultures with ionomycin for 30 minutes significantly increased calpain 
activity, when compared with control (Figure 4.4.6). This increase in activity was 
significantly inhibited by pre-treatment of cultures with calpastatin. Also, treatment with 
either AMT-HCl or thalidomide alone for 8 hours did not significantly modulate calpain 
activity. In agreement with the first hypothesis, pre-treatment of cultures with 
thalidomide did not induce significant modulation of FG-mediated calpain responses 
after 8 hours. Interestingly however, treatment of cultures with AMT-HCl prior to FG 
exposure for 8 hours did significantly inhibit FG-mediated activity (Figure 4.4.6), 
suggesting an early role for iNOS activity in FG-mediated responses. Finally, in line 
with previous observations, treatment of cultures with calpastatin prior to FG exposure 
for 8 hours significantly inhibited calpain activity. 
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Figure 4.4.6. FG-mediated calpain activity in BV2 microglia is partially 
dependent on iNOS activity 
Calpain activity assay performed on BV2 microglia lysates treated with ionomycin 
(2 µM) for 0.5 hours or FG (2.5 mg/ml) for 8 hours, alone or in combination with 
AMT-HCl (AMT; 150 nM), thalidomide (Thal; 10 µg/ml) or calpastatin (Cal; 1 µM). 
Data are presented as the percentage of calpain activity in relation to control 
levels. Treatments were in triplicate and data were analysed from 3 independent 
experiments. To compare calpain activity between control and all treatments, a one 
way ANOVA was performed with Dunnett’s post-test. Paired two-tailed Student’s t-
tests were performed for comparisons between treatments with and without 
inhibitors. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01, 
*** p<0.001.  
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The involvement of calpain activity in FG-mediated cleavage of caspase-12 and TNFα 
expression was then assayed as these events have been shown to occur 
chronologically later than the significant calpain activity. Western blotting for caspase-
12 and TNFα expression was performed in BV2 lysates after treatment with calpastatin 
prior to FG exposure for 24 hours (Figure 4.4.7). Treatment of cultures with 
thapsigargin for 24 hours significantly increased cleaved caspase-12 expression and 
TNFα expression. Also in line with previous experiments, treatment of cultures with FG 
induced significant cleaved caspase-12 and TNFα expression, and these increases in 
expression could be inhibited by calpastatin pre-treatment (Figure 4.4.7), suggesting 
calpain activity is upstream of FG-mediated caspase-12 cleavage and TNFα 
expression, which have been shown to be involved in subsequent neuronal toxicity. 
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Figure 4.4.7. FG-mediated expression of the cleaved form of caspase-12 and 
TNFα in BV2 microglia is dependent on calpain activity 
A. Representative Western blots for caspase-12, TNFα and β-actin expression in 
BV2 microglia lysates after treatment with Thapsigargin (2 µM) or FG (2.5 mg/ml) 
for 24 hours, alone or in combination with calpastatin (Cal; 1 µM). B. Quantification 
of cleaved caspase-12 expression (Bi) and TNFα expression (Bii), with respect to 
β-actin expression, after treatments as stated in A. Experiments were repeated on 
3 independent occasions. One-way ANOVA with Dunnett’s post test was 
performed to compare control levels with each treatment and paired two-tailed 
Student’s t-tests were performed to compare FG with and without calpastatin 
inhibition. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01. 
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4.5. Pharmacological manipulation of ER stress-associated 
pathways significantly reduces fibrinogen-mediated apoptosis 
Following on from these experiments showing a range of ER- and calcium-dependent 
responses, it was hypothesised that manipulation of these pathways could protect 
against microglial-mediated neurotoxicity. Initially, CGC cultures were treated with z-
ATAD-FMK, a caspase-12 specific inhibitor, prior to FG or FN exposure for 24 or 48 
hours, respectively. Staurosporine (STS) was used as a positive control for significant 
apoptosis but via a caspase-12 independent pathway, and tunicamycin and 
thapsigargin were used as positive controls for significant apoptosis via caspase-12 
dependent pathways. As expected, STS treatment for 8 hours induced a significant 
increase in apoptotic morphology when compared with control levels, and this 
significant increase could not be inhibited by pre-treatment with z-ATAD-FMK (Figure 
4.5.1). Both tunicamycin and thapsigargin administration for 24 hours induced 
significant increases in apoptotic morphology, when compared with control cultures. 
Interestingly however, pre-treatment with z-ATAD-FMK could only significantly inhibit 
tunicamycin-mediated apoptosis and not thapsigargin induction (Figure 4.5.1), 
suggesting caspase-12 independent pathways are involved in thapsigargin-mediated 
cellular toxicity or the thapsigargin concentration used was too high for effective 
inhibition by z-ATAD-FMK. FG treatment induced a significant increase in apoptotic 
morphology, as previously shown, which could be significantly inhibited by z-ATAD-
FMK pre-treatment. However, the significant FN-mediated increase in apoptotic 
morphology could not be significantly inhibited by z-ATAD-FMK pre-treatment, further 
supporting the idea that caspase-12 is not primarily involved in FN-mediated cellular 
toxicity. 
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Figure 4.5.1. Inhibition of caspase-12 activation attenuates FG-mediated 
neuronal death, but not FN-mediated neuronal death 
Quantification of apoptotic morphology in CGC cultures after direct treatment with 
STS (0.5 µM; 8 hours), Tunicamycin (Tu; 1 µg/ml; 24 hours), Thapsigargin (Th; 2 
µM; 24 hours), FG (2.5 mg/ml; 24 hours) or FN (1 mg/ml; 48 hours), alone or in 
combination with z-ATAD-FMK (ATAD: 1 µg/ml). Cell staining was performed using 
Hoechst-33342 for nuclear morphology analysis. Treatments were in duplicate and 
data were analysed from 3 independent experiments. To compare between control 
levels and all other treatments, a one way ANOVA was performed with Dunnett’s 
post-test. For direct comparison treatments with and without caspase-12 inhibition, 
paired two-tailed Student’s t-tests were performed. Levels of significance were: 
non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001.  
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4.5.1. Microglial specific ER stress is involved in fibrinogen-mediated 
neurotoxicity 
To identify if microglial-specific ER stress induced by FG was involved in subsequent 
neuronal toxicity, primary microglial cultures were treated with salubrinal prior to FG or 
FN treatment for 24 hours. Microglial conditioned medium (MGCM) from these cultures 
was then administered to neuronal cultures depleted of microglia and Hoechst-33342 
staining was employed to quantify apoptotic morphology (Figure 4.5.2). Treatment of 
CGCs with thapsigargin-MGCM induced a significant increase in apoptotic morphology, 
when compared with cultures treated with non-treated control-MGCM. FG-MGCM 
administered to CGCs also significantly increased the percentage of cells displaying 
apoptotic morphology when compared with control-MGCM treatment. MGCM from 
cultures treated with salubrinal prior to FG treatment induced significantly less 
apoptosis, however the percentage of apoptotic morphology in FG + Sal-MGCM-
treated cultures was still significant above control levels (Figure 4.5.2). Finally, FN-
MGCM administered to CGC cultures significantly increased the percentage of cells 
displaying apoptotic characteristics. However, pre-treatment of microglia with salubrinal 
did not significantly inhibit the FN-mediated increase in apoptotic morphology (Figure 
4.5.2). 
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Figure 4.5.2. Inhibition of FG-mediated ER stress in microglia attenuates FG-
mediated neurotoxicity 
Quantification of apoptotic morphology in CGC cultures after exposure to microglial 
condition medium (MGCM) from cultures treated with Th (2 µM), FG (2.5 mg/ml) or 
FN (1 mg/ml), alone or in combination with Salubrinal (Sal; 100 nM), for 24 hours. 
Cell staining was performed using Hoechst-33342 for nuclear morphology analysis. 
Treatments were in duplicate and data were analysed from 3 independent 
experiments. To compare between control levels and all other treatments, a one 
way ANOVA was performed with Dunnett’s post-test. For direct comparison 
between treatments with or without salubrinal inhibition, paired two-tailed Student’s 
t-tests were performed. Levels of significance were: non-significant p>0.05, * 
p<0.05, *** p<0.001.  
295 
 
4.5.2. Inhibition of calpain activity in neurons and microglia can attenuate 
fibrinogen-mediated neurotoxicity 
Previous data has suggested a significant role for calpain activity in FG-mediated 
responses (Figure 4.4.4 – 4.4.6). To identify if the inhibition of calpain activity could 
attenuate FG-mediated neurotoxicity, experiments with MGCM were performed (Figure 
4.5.3). As previously described, CGC cultures were depleted of microglia prior to the 
addition of MGCM. As expected, administration of FG-MGCM significantly increased 
neuronal apoptosis. Interestingly, this observed increase in toxicity could be 
significantly attenuated if CGCs were pre-treated directly with calpastatin, when 
compared with FG-MGCM alone, suggesting a prominent role for neuronal calpain 
activity in FG-mediated neurotoxicity via microglia (Figure 4.5.3). Finally, the 
administration of MGCM from FG and calpastatin-treated cultures also attenuated 
neurotoxicity, when compared with FG-MGCM alone. This further suggests a 
significant role for microglial calpain activity in the release of neurotoxic factors. 
  
296 
 
  
Basal CTR Cal  Cal
0.0
2.5
5.0
7.5
10.0
12.5 **
**
**
FG MGCM
FG + Cal
MGCM
Cal
MGCMMGCM
%
 
A
po
pt
o
tic
m
o
rp
ho
lo
gy
Figure 4.5.3. Inhibition of calpain activity in neurons and microglia can 
attenuate FG-mediated neurotoxicity 
Quantification of apoptotic morphology in CGC cultures after exposure for 24 hours 
to microglial condition medium (MGCM) from cultures treated with FG (2.5 mg/ml) 
alone or in combination with calpastatin (Cal; 1 µM) for 24 hours. Some neuronal 
cultures were treated directly with calpastatin in the presence or absence of FG-
MGCM. Cell staining was performed using Hoechst-33342 for nuclear morphology 
analysis. Treatments were in duplicate and data were analysed from 3 
independent experiments. To compare between control levels and all other 
treatments, a one way ANOVA was performed with Dunnett’s post-test. For direct 
comparison between treatments with or without salubrinal inhibition, paired two-
tailed Student’s t-tests were performed. Levels of significance were: non-significant 
p>0.05, ** p<0.01.  
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4.6. Discussion 
This chapter focuses on the role of endoplasmic reticulum stress in the observed FG- 
and FN-mediated neurotoxicity. Here, significant induction of ER stress in both 
microglia and neurons after treatment was observed, with FG-mediated induction in 
neuronal cultures being dependent on microglia. Furthermore, data present here 
suggests up-stream involvement of a calcium dependent enzyme in FG-mediated 
induction of caspase-12 and TNFα expression and subsequent neuronal apoptosis, 
with contributions from other ER stress related pathways also being observed. 
4.6.1. Caspase-12 involvement in fibrinogen-mediated neuronal death 
Caspase-12 has been identified in rodents as an ER-residing caspase responsible for 
ER-stress-induced apoptosis (Nakagawa et al. 2000). Furthermore, Nakagawa and 
colleagues show amyloid-β induces neurotoxicity with dependence on ER stress and 
caspase-12. Therefore studies were undertaken to identify if FG or FN-mediated 
neurotoxicity was also dependent on caspase-12. Initial studies to identify if caspase-
12 cleavage occurred in CGC cultures after treatment with known ER stress inducers 
were performed and both thapsigargin and tunicamycin induced caspase-12 cleavage 
differentially. Thapsigargin induces ER stress by inhibiting the sarco-ER calcium-
ATPase (SERCA), causing calcium dyshomeostasis, whereas tunicamycin induces ER 
stress by inhibiting protein N-glycosylation (Takano et al. 2007). These differences in 
induction of ER stress may support the observed differential cleavage of caspase-12.    
It was found that FG and FN could induce expression of the cleaved/active form of 
caspase-12 in the CGCs. Interestingly, FN-mediated induction occurred only after 48 
hours of treatment whereas FG induced significant time-dependent caspase-12 
cleavage from 12 hours of treatment. Given the lack of FN-mediated toxicity until 48 
hours of exposure, if microglia were present in CGC cultures (Section 3.3.2), this late 
significant increase in caspase-12 cleavage suggests it is not primarily involved in the 
previously observed toxicity. However significant cleavage after 12 hours in FG-treated 
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cultures does suggest potential involvement in the previously observed toxicity 
(Section 3.3.1 – 3.3.2). These expression data were supported by live cell staining of 
CGCs, however, only FG-, and not FN-mediated increases in active caspase-12 
fluorescence could be inhibited by pre-treatment of cultures with the pan-caspase 
inhibitor z-VAD-FMK suggesting that the fluorescence observed in FN-treated cultures 
was not due to caspase activation. However, with the use of Western blotting, it is 
shown that both FG and FN-mediated caspase-12 cleavage was due to caspase 
activation. Therefore, this anomaly in the fluorescence intensity experiments is most 
probably due to the auto-fluorescence of insoluble aggregates of FN present in the 
cultures contributing to the overall fluorescence intensity reading, making this 
experiment in this particular instance, unreliable. 
To identify if microglia present in CGC cultures were important in FG-mediated 
caspase-12, LME depletion experiments were performed. It is shown that FG-mediated 
caspase-12 cleavage is dependent on the presence of microglia in the CGC cultures. It 
was suggested that this significant drop in active caspase-12 could have been due to 
the loss of microglia-specific caspase-12 activation, decreasing the fluorescence 
intensity. However, scrutiny of the fluorescent images shows neuronal/neurite 
expression of caspase-12 is lost when microglia are depleted. This suggests a 
requirement for microglia in neuronal-specific caspase-12 cleavage after FG treatment. 
Furthermore, Western blotting shows significant attenuation of caspase-12 cleavage 
after microglia are depleted. Finally, in support of a significant role for caspase-12 
activation in FG-mediated neurotoxicity, it is shown here that inhibition of caspase-12 
can significantly attenuate FG-induced death.  
Briefly, in support of a protective role for microglia after FN exposure, cultures depleted 
of microglia had a significant increase in caspase-12 cleavage after 24 hours. However 
scrutiny of the images shows almost complete co-localisation of active caspase-12 
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staining with PI, potentially suggesting false-positive fluorescence due to channel 
cross-over and not an actual induction of caspase-12 cleavage.     
4.6.2. CHOP up-regulation and cross-talk with caspase-12 activation strengthens 
a role for ER stress after fibrinogen treatment 
Because caspase-12 cleavage has been shown to be occur after treatment with known 
ER stressors in rodents (Nakagawa et al. 2000), it has been assumed to this point that 
caspase-12 cleavage implies ER stress has occurred. However this assumption 
requires further support as caspase-12 activation alone does not imply ER stress. 
Furthermore it has been suggested, although data presented here disagrees, that pan-
caspase inhibitors do not protect against ER stress-mediated apoptosis (Sanges & 
Marigo 2006), suggesting caspase-12 activation may not be wholly responsible for the 
observed neuronal toxicity. Therefore, to support a role for ER stress in toxicity after 
FG treatment in particular, expression of CHOP/GADD153 (CHOP) was analysed in 
microglia. CHOP has been identified as a major pro-apoptotic transcription factor that is 
induced by ER stress (Salminen et al. 2009). Furthermore, whereas caspase-12 
activation is part of the m-calpain-caspase-12-caspase-3/7 axis of ER stress-mediated 
apoptosis, CHOP is part of the PERK-eIF2α-CHOP axis that down-regulates Bcl-2 and 
induces apoptosis (Lai et al. 2007), thus providing strong, dual pathway evidence of the 
induction of ER stress.  
Here it is shown that both FG and FN treatment of microglia induced significant CHOP 
expression, comparable to thapsigargin or tunicamycin treatment, providing further 
support for ER stress induction. Furthermore, data presented here suggests that 
inhibition of the PERK-eIF2α-CHOP axis by salubrinal, a compound that inhibits 
dephosphorylation of eIF2α (Boyce et al. 2005), significantly inhibited caspase-12 
cleavage CGC cultures after FG treatment, suggesting cross-talk between the two ER 
stress pathways under investigation. In support of this observation, caspase-12 
cleavage has previously been inhibited by salubrinal treatment during identification of 
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ER stress involvement in excitotoxicity (Sokka et al. 2007). Interestingly, significant 
cleavage above control was still observed in FG-treated CGCs pre-treated with 
salubrinal suggesting salubrinal only partially inhibits caspase-12 cleavage. Salubrinal 
is also shown to inhibit FG-mediated TNFα release and caspase-3/7 activation in 
primary microglial cultures with no significant increase in apoptotic morphology. These 
data suggest that FG-mediated induction of inflammation, characterised by TNFα 
release, is dependent on ER stress supporting previously published literature (Hu et al. 
2006; Martinon et al. 2010) that identifies novel roles for UPR and ER stress 
associated factors in macrophage inflammatory activation. Furthermore, if caspase-3/7 
cleavage in microglia mediates cellular activation rather than apoptosis (Burguillos et 
al. 2011), these data also suggest ER stress is occurring up-stream of this activation. 
It was hypothesised that if this observed down-regulation of caspase-3/7-associated 
activation in microglia by salubrinal is important in FG-mediated neurotoxicity, then 
medium from these microglial cultures (FG+Sal-MGCM) would attenuate stress marker 
expression in neuronal cultures, when compared with FG-MGCM. However it is shown 
here that FG+Sal-MGCM could not attenuate caspase-12 cleavage, when compared 
with FG-MGCM. These data suggest that inhibition of the PERK-eIF2α-CHOP axis of 
ER stress induced by FG in the microglial cultures is not sufficient to prevent the 
release of stable soluble factors that can induce neuronal caspase-12 cleavage, further 
supporting the involvement of other pathways in FG-mediated neurotoxicity. However, 
these data are of poor quality and require clarification through repetition. Interestingly, 
FG-MGCM-mediated neuronal apoptosis could be inhibited if microglial cultures were 
co-treated with salubrinal, suggesting caspase-12 activation is not solely responsible 
for FG-mediated neurotoxicity. In further support of this, significant levels of apoptosis 
were still observed.  
Finally, inhibition of p38 MAPK and PI3K pathways in microglia attenuated indirect FG-
mediated caspase-12 cleavage in neurons, supporting a significant role of p38 MAPK 
in FG-mediated responses via microglia. Again, these data are of poor quality and 
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require clarification through repetition, but coupled with previous data (Figure 3.2.5) 
showing inhibition of p38-MAPK attenuated FG-mediated TNFα release, a role for 
TNFα release in FG-mediated caspase-12 cleavage can be initially proposed.   
4.6.3. TNFα synthesis is involved in fibrinogen-mediated ER stress induction 
Following on from these preliminary MGCM data, live cell staining, Western blotting 
and ICC support a significant role for TNFα in FG-mediated ER stress in CGC and 
primary microglial cultures. It is shown here that FG-induced caspase-12 activation was 
down-regulated after pre-treatment with thalidomide. Furthermore, FG induction of 
CHOP expression in microglia was down-regulated if cultures were pre-treated with 
thalidomide. Conversely, it is shown that FN-induced caspase-12 activation in CGC 
and microglial cultures could not be inhibited by thalidomide pre-treatment however PI-
positive nuclei in CGC cultures were significantly decreased, further supporting a 
primary role for TNFα, but a secondary role for caspase-12 activation in FN-mediated 
toxicity. Interestingly FN-mediated CHOP expression could be down-regulated by 
thalidomide suggesting an ER stress pathway independent of caspase-12 could be 
involved in FN-mediated responses. No significant involvement of iNOS activity was 
observed in any of these responses. Published literature shows ER stress can lead to 
expression of TNFα (Hu et al. 2006). Together these data suggest microglial ER stress 
can induce TNFα release leading to either autocrine activation or neuronal toxicity.  
4.6.4. Calcium and iNOS involvement in early fibrinogen-mediated responses 
Calcium dyshomeostasis is a contributing factor in ER stress (Lindholm et al. 2006). 
Therefore, it was hypothesised that suppressing any FG-mediated induction of calcium 
dyshomeostasis would further support a significant role for ER stress in the observed 
toxicity. BAPTA-AM, the well documented fast calcium chelator (Hoffmann et al. 2003; 
Hooper et al. 2005), was optimised for use on the microglial cultures and co-treated 
with FG to identify whether caspase-12 and -3/7 induction was dependent on calcium. 
It was found that co-treatment of microglia with FG and BAPTA-AM induced significant 
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death with a loss of caspase-12 activation, probably due to apoptosis. This was 
supported by significant caspase-3/7 induction associated with PI staining. Therefore 
ablation of free calcium by BAPTA-AM prevents microglial activation due to FG 
treatment leading to death. The use of BAPTA-AM as a tool in culture is ideal for acute 
ablation of free calcium, i.e. during calcium imaging protocols. However a chronic 
incubation, such as here, provides an extreme un-physiological environment meaning 
no great insights can be concluded from these data furthermore, this particular finding 
brings previously published data under scrutiny (Hoffmann et al. 2003). Future 
experiments should utilise calcium chelators with slower binding kinetics which may 
prevent the massive increase in death induced by the acute nature of BAPTA-AM-
mediated calcium chelation. It was therefore decided that investigation into calpain 
activity would provide more valuable data into the involvement of calcium in FG-
mediated responses.  
Calpains are calcium activated cysteine proteases and it has been suggested that m-
calpain may be responsible for procaspase-12 cleavage to the active form and that 
disturbances in intracellular calcium storage as a result of amyloid-β peptide 
cytotoxicity may induce apoptosis through calpain-mediated caspase-12 activation 
(Nakagawa & Yuan 2000). Furthermore, calpastatin over-expression in neurons 
significantly decreased Aβ-associated toxicity in neuronal-like PC12 cells (Vaisid et al. 
2008), with further support for the regulation of  Aβ-induced neurotoxicity by calpains 
being observed in primary cultured neurons (Wei et al. 2008).  
To model calcium-mediated calpain activation and subsequent ER stress, the 
ionophore, Ionomycin that depletes intracellular calcium stores, increasing the 
availability of cytoplasmic calcium (Pocock & Nicholls 1992) was utilised. A significant 
induction in FG-mediated calpain activity was observed after only 1 hour suggesting 
calcium involvement in any FG-mediated response is early and up-stream of caspase-
12 activation and TNFα release. Furthermore, the lack of any further significant calpain 
activity after 12 hours of FG treatment further supports the idea that the event is early 
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and up-stream of other responses observed so far. In line with this hypothesis pre-
treatment of cultures with thalidomide could not attenuate FG-mediated calpain activity 
after 8 hours. However, iNOS activity inhibition could significantly attenuate calpain 
activity. Inhibitors of calpains have been shown to inhibit the induction of iNOS in 
macrophages (Griscavage et al. 1996) however no studies have been published that 
suggest inhibition of iNOS activity can attenuate calpain activity. It is possible that the 
observed attenuation of calpain activity by AMT-HCl is a non-specific action of the 
compound and the use of other iNOS activity inhibitors or protein silencing experiments 
would potentially provide more conclusive data for this perceived mechanism of action.  
Calpain activity was also shown to be involved in upstream events including FG-
mediated expression of cleaved caspase-12 and TNFα. This data led us to investigate 
the role of calpain activity in FG-mediated neurotoxicity. It is shown that inhibition of 
calpain activity in neurons provided protection form FG-MGCM, suggesting calpain 
activity in neurons plays an important role in FG-mediated neurotoxicity induced via 
activation of microglia. Recent studies suggest microglial cytokine release can induce 
calpain activation in neurons (McDowell et al. 2011) Furthermore, if calpain activity was 
inhibited in microglia treated with FG, significant neuronal protection was also observed 
suggesting calpain activity in microglia is responsible for FG-mediated release of 
neurotoxic factors. Previous studies identify an increase in calpain expression in the 
microglia in an inflammatory model (Shields et al. 1998). Together these data suggest 
that regulation of this family of enzymes may provide significant attenuation of neuronal 
loss due to microglial dependent and independent mechanisms of neurotoxicity.     
4.6.5. Conclusions   
Here, a significant role for ER stress in FG-mediated neuronal toxicity has been 
identified. Data presented here, summarized in Figure 4.6.1, suggest that FG can 
induce significant ER stress in both microglia and neurons. However, the significance 
and complete mechanisms require further elucidation. It seems that FG induces ER 
stress in microglia via calpain-associated pathways leading to TNFα release, which in 
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turn can induce further microglial activation in an autocrine fashion. Interestingly 
caspase-12 has been identified as having a prominent role in inflammation, with 
caspase-12 deficient mice showing enhanced bacterial clearance and sepsis 
resistance (Saleh et al. 2006), suggesting FG exposure could induce an inflammatory 
response in microglia leading to TNFα release which subsequently induces ER stress 
and toxicity in neurons via calpain activity.  
Another important point that must be raised is that caspase-12 has been shown to 
have acquired deleterious mutations including the presence of a frameshift mutation 
that results in premature stop codons in the gene, suggesting the lack of a functional 
caspase (Fischer et al. 2002). However, active caspases generally undergo post-
translational modifications (Earnshaw et al. 1999) and caspase-12 has been shown to 
mediate ER-stress associated neuronal death in human variant Creutzfeldt-Jakob 
disease (vCJD), a prion protein-associated neurodegenerative disease (Hetz et al. 
2003) and human AD (Lee et al. 2010), suggesting a functional caspase-12 protein can 
occur in humans that mediates similar functions. Other studies have proposed that 
human caspase-4, which is homologous to mouse caspase-12, is performing the ER 
stress functions of caspase-12 in humans (Hitomi et al. 2004). It was shown that 
caspase-4 cleavage is specifically induced by ER stress but not by other apoptotic 
signals, and knockdown of caspase-4 decreases ER stress-induced apoptosis.  
The suggestion that ER stress occurs in both microglia and neurons after FG treatment 
has been significantly strengthened by data here that shows significant CHOP 
expression in microglia but also pharmacological inhibition of the PERK-eIF2α-CHOP 
axis in CGC cultures, which significantly modulated FG-mediated responses. 
Furthermore, the early involvement of calpains in the FG-mediated activation of 
microglia proposes that calcium dyshomeostasis occurs upstream of the microglial-
associated ER stress that is involved in TNFα release and subsequent neurotoxicity. 
Finally, calpain activity in neurons has also been implicated in the FG-mediated toxicity 
cascade.  
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Figure 4.6.1. Summary of results obtained in chapter 4 
A. Fibrin treatment of microglia led to an increase in CHOP expression suggesting 
some involvement of ER stress mechanisms in the earlier observations of toxicity. 
Treatment of neuronal cultures with FN caused a significant increase in caspase-
12 activation, again suggesting a possible role for ER stress in the observed 
neurotoxicity. However, this involvement seemed to be minimal and potentially 
post-induction of significant toxicity via other pathways. B. Fibrinogen treatment of 
microglia led to an increase in the calpain activity suggesting modulation of 
calcium, with dependence on iNOS activity. Furthermore, CHOP and caspase-12 
expression were increased with regulation from TNFα and calpain activity. FG-
mediated microglial activation also led to an increase in neuronal caspase-12 and 
calpain activity, both of which were involved in the observed neuronal death. 
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5. Characterisation of mGluR agonist-mediated 
neuroprotection from fibrinogen-mediated toxicity 
5.1. Introduction 
In this chapter, experiments were performed to determine whether activation of 
particular metabotropic glutamate receptors (mGluRs) could provide neuroprotection 
from FG- and FN-induced neurotoxicity, with a particular focus on microglial-mediated 
toxicity.  Activation of mGluRs on microglia can induce both neurotoxic and 
neuroprotective phenotypes, depending on the group or receptor activated (Pocock & 
Kettenmann 2007). Previous studies in our laboratory have attributed protective and 
toxic effects to the activation of specific group II and III mGluRs (Taylor et al. 2002; 
Taylor et al. 2003; Taylor et al. 2005). However, limited research has been performed 
on the role of group I mGluRs (mGluR1/5) on microglia. 
5.1.1. Blood-borne proteins and mGluRs 
A review of the published literature suggests little or no research has been performed 
on the relationship, if any, between fibrinogen and mGluRs. Interestingly however, 
thrombin, the proteolytic enzyme for fibrinogen immobilisation has been shown to 
down-regulate astrocytic mGluR5 (Miller et al. 1996).  
5.1.2. The roles of mGluRs in disease 
The diversity and heterogeneous distribution of mGluR subtypes throughout the CNS 
provides opportunities for selective targeting of particular subtypes in particular regions 
making them, as a group, an attractive therapeutic target. Furthermore, a vast array of 
pre-clinical studies suggests that ligands targeted at specific mGluR subtypes could 
provide potential treatments in numerous CNS disorders, some of which are listed 
below: 
• Antagonism of mGluR2/3 and/or 5 in depression (Pilc et al. 2008) 
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• Agonism of mGluR2/3 and antagonism of mGluR5 in anxiety and stress 
disorders (Swanson et al. 2005) 
• Agonism of mGluR2/3 or 5 in Schizophrenia (Moghaddam 2004) 
• Antagonism of mGluR2 in Epilepsy (Alexander & Godwin 2006) 
• Agonism of group II and III mGluRs in Alzheimer’s disease (Lee et al. 
2004b) 
• Antagonism of mGluR5 in Parkinson’s disease (Conn et al. 2005) 
Allosteric modulation of mGluRs is an intense new area of research for the 
development of efficacious compounds for the treatment of a wide range of CNS 
disorders. This class of compound has been shown to provide high selectivity and 
novel modes of efficacy, which are desirable characteristics for compounds targeted at 
the CNS (Conn et al. 2009). Negative allosteric modulation of mGluR5 has been 
implicated as a promising therapeutic in fragile X syndrome, chronic pain and 
depression, with positive allosteric modulation of mGluR5 identified as a potent anti-
psychotic with possible therapeutic benefits in other disorders that involve impaired 
cognitive function (Niswender & Conn 2010). 
Data presented here suggests that positive allosteric modulation of mGluR5 can 
protect against FG-mediated neurotoxicity. Furthermore, it is shown that by specifically 
targeting microglial mGluR5, FG-mediated neurotoxicity can be attenuated.  
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5.2. Effects of mGluR agonists on fibrinogen-induced microglial 
reactivity 
5.2.1. Fibrinogen-induced iNOS expression and TNFα expression and release can 
be attenuated by mGluR agonist treatment 
To identify whether activation of mGluRs can modulate the FG-induced activated 
microglial phenotype, ICC, ELISA and live cell staining was performed. As previously 
shown in serum-free conditions, FG treatment induced iNOS expression in primary 
microglia (Figure 5.2.1). Therefore, as a measure of microglial reactivity, iNOS and 
ED-1 expression ICC was performed on primary microglial cultures after treatment with 
LPS or FG, in the absence or presence of mGluR agonists. Treatment with the group I 
agonist (S)-3,5-Dihydroxyphenylglycine (DHPG) at a previously published 
concentration (Macek et al. 1996) or the specific mGluR5 agonist 3-Cyano-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB) at the published EC50 value (Stauffer 
2011) did not significantly increase iNOS expression, when compared with control. 
However, a significant increase in ED-1 expression was observed (Figure 5.2.1 A & 
B). In line with previously published data (Taylor et al. 2005), treatment with the group 
II agonist (2S,2'R,3'R)-2-(2',3'-Dicarboxycyclopropyl)glycine (DCGIV) or the specific 
mGluR3 agonist N-acetyl-L-aspartyl-L-glutamate (NAAG) did not significantly increase 
expression of iNOS in primary microglial cultures. However, treatment with NAAG, but 
not DCGIV induced a significant increase in ED-1 expression (Figure 5.2.1 A &B). 
Furthermore, in line with previously published data (Taylor et al. 2003; Taylor et al. 
2005), treatment with the group III (mGluR4/5/6/7) agonist (L)-2-amino-4-phosphono-
butyric acid (L-AP4) did not significantly modulate iNOS or ED-1 expression, compared 
with relevant control levels (Figure 5.2.1 A &B). 
LPS treatment of primary microglia induced a strong significant increase in iNOS and 
ED-1 expression levels, when compared with control levels (Figure 5.2.1 A & B). Co-
treatment of cultures with any of the mGluR agonists tested could not down-regulate 
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the LPS-mediated increases in iNOS and ED-1 expression. Conversely, FG-induced 
increases in iNOS and ED-1 expression could be significantly attenuated by co-
treatment with CDPPB, suggesting a role for mGluR5 in this activated microglial 
phenotype (Figure 5.2.1 A & B). Furthermore, only DCGIV treatment induced a 
significant increase in cells displaying apoptotic morphology, suggesting the CDPPB-
associated attenuation of iNOS and ED-1 was not due to toxicity (Figure 5.2.1 C). 
LPS or FG treatment of microglia can induce significant release of TNFα (Section 
3.2.1). Therefore expression and release of the pro-inflammatory cytokine was 
assessed by Western blotting and ELISA analysis after FG or LPS treatment in the 
absence and presence of mGluR agonists. In line with the iNOS/ED-1 data, co-
treatment with mGluR agonists could not attenuate LPS-mediated TNFα expression in 
BV2 microglia (Figure 5.2.2 A). FG-mediated TNFα expression in BV2 microglia could 
be attenuated by co-treatment with CDPPB. Furthermore, co-treatment with DHPG 
could also significantly attenuate TNFα expression (Figure 5.2.2 B). Expression of 
TNFα suggests functionality however release of the cytokine provides stronger 
evidence for involvement in downstream cascades, therefore a TNFα ELISA system 
was used. Treatment with DCGIV induced significant TNFα release from primary 
microglial cultures, when compared with non-treated controls as previously described 
(Taylor et al. 2005) (Figure 5.2.2 C). Similarly, LPS induced a significant increase in 
TNFα release from primary microglial cultures, when compared with non-treated 
controls, as previously shown (Section 3.2.1). In line with the expression data, LPS-
induced TNFα release could not be attenuated by co-treatment with mGluR agonists 
(p>0.05; Figure 5.2.2 C). However, significant FG-induced TNFα release could be 
attenuated by co-treatment with either DHPG or CDPPB (Figure 5.2.2 C), further 
suggesting a role for group I mGluRs in down-regulating FG-mediated microglial 
activation 
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  Figure 5.2.1. FG-induced microglial iNOS expression in serum-free conditions 
can be attenuated by co-treatment with CDPPB 
A. Representative images of serum-free primary microglial cultures after 24 hours of 
treatment with FG (2.5 mg/ml) or LPS (1 µg/ml), and co-treatment with DHPG (100 
µM), CDPPB (100 nM), DCGIV (500 nM), NAAG (50 µM) or L-AP4 (100 µM). 
Cultures were co-stained with DAPI for quantification of cell number and probed with 
anti-ED1 (green) for identification of activated microglia and anti-iNOS (red), except 
in negative control cultures, where primary antibodies were omitted. Original 
magnification: x40, scale bar: 10 µm. B. Quantification of ED-1+ and iNOS+ microglia 
after administration of treatments stated in A. C. Quantification of cells displaying 
apoptotic morphology after administration of treatments stated in A. Data in B and C 
is presented as a percentage of total microglial number. Treatments were in 
duplicate in each experiment and data were analysed from 3 independent 
experiments. To compare the expression of ED-1 or iNOS in multiple treatment 
groups to control levels a one way ANOVA was performed with Dunnett’s post-test. 
Direct comparison of specific treatments was analysed using paired two-tailed 
Student’s t-tests. Levels of significance were: non-significant p>0.05, * p<0.05, ** 
p<0.01, *** p<0.001. 
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Figure 5.2.2. FG-induced microglial TNFα expression and release in serum-free 
conditions can be attenuated by co-treatment with DHPG or CDPPB 
A and B. Representative Western blots for TNFα and β-actin expression in BV2-
microglial cultures after treatment with LPS (1 µg/ml) (Ai) or FG (2.5 mg/ml) (Bi), and 
co-treatment with DHPG (100 µM), CDPPB (100 nM), DCGIV (500 nM), NAAG (50 
µM) or L-AP4 (100 µM) for 24 hours. Quantification of TNFα expression was 
performed with respect to the β-actin loading control for LPS (Aii) and FG (Bii), 
respectively. C. ELISA quantification of TNFα release after treatments as outlined in 
A, except for L-AP4 co-treatment, which was omitted. For the ELISA system, 
treatments were in duplicate in each experiment and data were analysed from 3 
independent experiments. Western blotting was also performed on 3 independent 
occasions. To compare TNFα expression or release in multiple treatment groups to 
control levels a one way ANOVA was performed with Dunnett’s post-test. Direct 
comparison of specific treatments was analysed using paired two-tailed Student’s t-
tests. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** 
p<0.001. 
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5.2.2. Fibrinogen-mediated caspase activity can be attenuated by mGluR agonist 
treatment 
To identify whether mGluR agonist treatment could modulate FG-induced caspase 
activation in microglia, live cell staining was performed. Treatment of primary microglia 
with FG for 24 hours induced significant caspase-12 activation with no significant 
induction of cell death (Figure 5.2.3 A, B & E). Co-treatment of cultures with CDPPB or 
NAAG significantly attenuated FG-mediated caspase-12 activation (Figure 5.2.3 A & 
B), with no significant modulation of cell death (Figure 5.2.3 E). Co-treatment with 
DCGIV however did not attenuate caspase-12 activity, but did induce significant cell 
death, compared with control levels. Treatment with mGluR agonists alone did not 
induce significant caspase-12 activation, however, as expected, DCGIV treatment 
significantly increased cell death (Figure 5.2.3 E).  FG induced a significant increase in 
caspase-3/7 induction. In line with the caspase-12 data, co-treatment with CDPPB or 
NAAG significantly attenuated the FG-mediated increase in caspase-3/7 induction 
(Figure 5.2.3 C & D). Furthermore, in line with previously published data (Taylor et al. 
2005), treatment of primary microglial cultures with DCGIV significantly increased 
caspase-3/7 expression, whereas NAAG or CDPPB treatment had no effect (Figure 
5.2.3 C & D). 
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Figure 5.2.3. FG-induced caspase-12 and -3/7 activation in microglia can be 
attenuated by co-treatment with CDPPB or NAAG 
A. Representative images from live cell staining experiments to identify caspase-12 
activation in primary microglial cultures after treatment with FG (2.5 mg/ml), CDPPB 
(100 nM), DCGIV (500 nM) or NAAG (50 µM) alone or in combination for 24 hours. 
Live cell staining was performed using Hoechst-33342 for nucleus identification, 
propidium iodide (PI; red) for total cell death, and FITC-ATAD-FMK (green) for active 
caspase-12. Original magnification: x40. B. Quantification of the relative active 
caspase-12 fluorescence intensity/cell in primary microglial cultures after 
administration of treatments outlined in A. C. Representative images from live cell 
staining experiments to identify caspase-3/7 activation in primary microglial cultures 
after treatment as outlined in A. D. Quantification of the relative active caspase-3/7 
fluorescence intensity/cell in primary microglial cultures after administration of 
treatments outlined in A. Data in B and D is presented in arbitrary fluorescence units 
(AFU). E. Quantification of PI+ cells to identify levels of cell death after treatment 
outlined in A. Treatments were in duplicate in each experiment and data were 
analysed from 3 independent experiments. To compare caspase-12 or -3/7 
expression or PI+ nuclei in multiple treatment groups to control levels one way 
ANOVA were performed with Dunnett’s post-test. Direct comparison of specific 
treatments was analysed using paired two-tailed Student’s t-tests. Levels of 
significance were: non-significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
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5.2.3. Fibrinogen- and fibrin-mediated neurotoxicity can be attenuated by mGluR 
agonist treatment – dependence on microglia 
The role of microglia in the CGC cultures with respect to mGluR agonist modulation of 
FG- and FN-mediated responses was investigated. Initially, apoptotic morphology in 
CGC cultures was quantified both in the presence and absence of microglia using the 
LME pre-treatment protocol (Section 2.5.2). With respect to the mGluR agonists, only 
DCGIV treatment alone induced significant neuronal apoptosis, which was dependent 
on microglia (Figure 5.2.4 A), similar to previously published data (Taylor et al. 2005). 
FN induced a significant increase in apoptosis after 48 hours of treatment, when 
compared with control levels (Figure 5.2.4 B). Depletion of microglia had no significant 
effect on the observed toxicity, as previously shown (Figure 3.3.4). Co-treatment of 
cultures with DHPG, CDPPB, or NAAG significantly attenuated FN-mediated apoptosis 
(Figure 5.2.4 B) however, depletion of microglia prior to these treatments prevented 
the observed attenuation, suggesting significant involvement of microglia in the 
observed neuroprotection. Co-treatment of CGCs with FN and DCGIV or L-AP4 had no 
significant effect on the observed toxicity (Figure 5.2.4 B). 
FG treatment for 24 hours significantly increased apoptosis in the CGC cultures, when 
compared with control levels. This significant increase was dependent on the presence 
of microglia (Figure 5.2.4 C) as previously shown (Figure 3.3.4). In the presence of 
microglia co-treatment of cultures with CDPPB significantly attenuated FG-mediated 
apoptosis. A significant attenuation was also observed if microglia were depleted, 
suggesting a microglial-independent neuroprotective role for mGluR5 allosteric 
modulation. Interestingly, co-treatment with DHPG could not attenuate FG-mediated 
apoptosis, with no significant modulation observed in cultures depleted of microglia. 
Furthermore, no significant modulation of FG-mediated apoptosis was observed if 
cultures were co-treated with DCGIV, however co-treatment with NAAG significantly 
attenuated the observed toxicity in the presence and absence of microglia (Figure 
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5.2.4 C). Interestingly, the previously published protective role of L-AP4 was not 
reciprocated here (Taylor et al. 2003), however culture conditions differed.  
  
323 
 
  
CTR LME LME LME LME LME LME LME
0
10
20
30
**
**
*
**
*
***
*
**
*
CDPPB DCGIV L-AP4NAAGDHPG
FN
%
 
Ce
lls
 
di
sp
la
yi
n
g
ap
o
pt
o
tic
 
m
o
rp
ho
lo
gy
CTR LME LME LME LME LME LME LME
0
5
10
15
20
25 *
**
**
CDPPBDHPG DCGIV L-AP4NAAG
FG
*
**
**
ns*
*
%
 
Ce
lls
 
di
sp
la
yi
n
g
ap
o
pt
o
tic
 
m
o
rp
ho
lo
gy
CTR LME LME LME LME LME LME
0
10
20
CDPPB DCGIV L-AP4NAAGDHPG
*
*
%
 
Ce
lls
 
di
sp
la
yi
n
g
ap
o
pt
o
tic
 
m
o
rp
ho
lo
gy
B.
C.
A.
Figure 5.2.4. FN-mediated neurotoxicity can be down-regulated by a range of 
mGluR agonists in the presence of microglia, whereas attenuation of FG-
induced neurotoxicity only occurs after CDPPB treatment in the presence of 
microglia 
Hoechst-33342 staining of fixed CGC cultures for the quantification of apoptotic 
nuclear morphology. Some cultures were depleted of microglia prior to treatment 
with LME. Cultures were treated with DHPG (100 µM), CDPPB (100 nM), DCGIV 
(500 nM), NAAG (50 µM) or L-AP4 (100 µM) for 24 hours (A), FN alone and in 
combination with the stated mGluR agonists for 48 hours (B) or FG alone and in 
combination with the stated mGluR agonists for 24 hours (C). Treatments were in 
triplicate in each experiment and data were analysed from 3 independent 
experiments. To compare the percentage of apoptotic morphology in multiple 
treatment groups to control levels one way ANOVA were performed with Dunnett’s 
post-test. Direct comparison of specific treatments was analysed using paired two-
tailed Student’s t-tests. Levels of significance were: non-significant p>0.05, * 
p<0.05, ** p<0.01. 
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5.2.4. Activation of mGluRs modulates fibrinogen-mediated ERK1/2 
phosphorylation 
The phosphorylation of p42/44 MAPK (ERK1/2) is generally associated with pro-
survival pathways (Cheung & Slack 2004), although studies have been published 
suggesting neuronal ERK1/2 phosphorylation is detrimental to neurons after oxidative 
injury (Chu et al. 2004), with chronic activation playing a role in neurodegeneration 
(Colucci-D’Amato et al. 2003). Furthermore, phosphorylation of ERK1/2 has been 
shown to be involved in microglial activation (Kim et al. 2004; Hooper & Pocock 2007). 
To observe changes in ERK1/2 phosphorylation after FG and mGluR agonist 
treatment, Western blotting of CGC culture lysates was performed with microglia 
present or depleted. Treatment of CGCs with DCGIV significantly enhanced expression 
of phospho-ERK1/2 independent of the presence of microglia (Figure 5.2.5 Ai). FG 
also induced significant expression of phospho-ERK1/2 independent of the presence of 
microglia. In the presence of microglia, co-treatment of CGC cultures with FG and 
DCGIV also significantly induced phospho-ERK1/2 expression when compared with 
control, however if microglia were depleted prior to this co-treatment phospho-ERK1/2 
expression was significantly attenuated (Figure 5.2.5 Ai). 
Treatment of CGC cultures with CDPPB alone did not induce significant expression of 
phospho-ERK1/2 above control levels whether microglia were present or not. However, 
FG-mediated induction of phospho-ERK1/2 expression could be significantly 
attenuated by co-treatment of cultures with CDPPB, if microglia were present (Figure 
5.2.5 Aii), further suggesting specific positive allosteric modulation of microglial 
mGluR5 is associated with down-regulation of FG-mediated responses. 
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Figure 5.2.5. FG-induced phosphorylation of ERK1/2 can be down-regulated by 
CDPPB co-treatment if microglia are present  
Representative Western blots and quantification of pERK1/2 and total ERK1/2 
expression in CGC cultures in the presence or absence (denoted ‘+’ on blots or ‘LME’ 
on quantification) of microglia after treatment with FG (2.5 mg/ml) and DCGIV (500 
nM), alone or in combination (Ai), or FG and CDPPB (100 nM), alone or in 
combination (Aii) for 24 hours. Quantification of pERK1/2 expression was performed 
with respect to background intensity. Western blotting was also performed on 3 
independent occasions. To compare pERK1/2 expression in multiple treatment groups 
to control levels a one way ANOVA was performed with Dunnett’s post-test. Direct 
comparison of specific treatments was analysed using paired two-tailed Student’s t-
tests. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01. 
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5.2.5. Fibrinogen-mediated caspase-3 cleavage in neuronal cultures is attenuated 
by activation of group I mGluRs 
Cleaved caspase-3 expression by Western blotting was performed after FG treatment 
of CGCs with co-treatment from mGluR agonists. FG induced significant expression of 
cleaved caspase-3, when compared with control levels, as previously shown (Figure 
3.3.2). Interestingly, whether microglia were present or depleted, co-treatment of 
cultures with DHPG or CDPPB significantly attenuated FG-mediated caspase-3 
cleavage (Figure 5.2.6 A). No significant attenuation was observed if cultures were co-
treated with either NAAG or DCGIV, suggesting a limited role for group II in FG-
mediated caspase-3 activity. Further support for neuronal caspase-3 cleavage being 
attenuated in the CGC cultures was provided by ICC. Caspase-3 cleavage after FG 
treatment was observed in CGC cultures in association with NeuN expression, 
suggesting neuronal caspase-3 activation is occurring (Figure 5.2.6 B). In line with the 
Western blotting data, expression of caspase-3 seems to be down regulated in the 
CDPPB co-treated cultures. However unlike the Western blotting data complete 
attenuation of FG-mediated caspase-3 activity was not observed in cultures co-treated 
with DHPG (Figure 5.2.6 B). 
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Figure 5.2.6. FG-mediated caspase-3 cleavage can be attenuated by group I 
mGluR agonists  
Ai. Representative Western blots of cleaved caspase-3 and β-actin expression in 
CGC cultures in the presence or absence (LME) of microglia after treatment with 
FG (2.5 mg/ml) alone or in combination with DHPG (100 µM), CDPPB (100 nM), 
DCGIV (500 nM) or NAAG (50 µM) for 24 hours. Quantification of cleaved 
caspase-3 expression was performed with respect to β-actin loading control 
expression (Aii).  Localisation of caspase-3 expression in CGC cultures was 
performed using ICC (B). After treatment as outlined in Ai, cultures were fixed 
and probed with anti-NeuN (green) for neuronal identification and anti-cleaved 
caspase-3 (red). Western blotting was performed on 3 independent occasions. To 
compare cleaved caspase-3 expression in multiple treatment groups to control 
levels a one way ANOVA was performed with Dunnett’s post-test. Direct 
comparison of specific treatments was analysed using paired two-tailed Student’s 
t-tests. Levels of significance were: non-significant p>0.05, * p<0.05, ** p<0.01. 
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5.2.6. Microglial mGluR5 activation attenuates fibrinogen-mediated neurotoxicity  
Finally, to investigate the role of microglia in the observed neuroprotection by group I 
mGluR agonists, MGCM experiments were performed on CGC cultures initially 
depleted of contaminating microglia. In addition to agonist treatment, administration of 
the selective mGluR5 allosteric antagonist 3-((2-Methyl-4-thiazolyl)ethynyl)pyridine 
(MTEP) was performed in certain treatment groups. MGCM from cultures treated with 
DCGIV significantly increased apoptotic morphology in the CGC cultures when 
compared with non-treated controls (Figure 5.2.7 A), as previously described (Taylor 
et al. 2005). None of the other mGluR agonists or MTEP induced significant apoptosis 
(p>0.05) when administered alone. 
As previously shown (Figure 3.4.3), FN-MGCM induced significant apoptosis in CGC 
cultures, when compared with control (Figure 5.2.7 B). MGCM from cultures co-treated 
with FN and mGluR agonists did not significantly modulate FN-mediated apoptosis 
(Figure 5.2.7 Bii). Interestingly antagonism of mGluR5 significantly enhanced FN-
mediated toxicity, further suggesting an important role for mGluR5 in microglial 
reactivity. 
FG-MGCM induced significant apoptosis in CGC cultures, when compared with control 
levels (Figure 5.2.7 C), similar to data previously reported (Figure 3.4.3). MGCM from 
cultures co-treated with FG and CDPPB or DHPG did not significantly induce CGC 
culture apoptosis (Figure 5.2.7 Cii) suggesting significant protective roles for group I 
mGluRs on microglia. Furthermore, if MGCM from cultures treated with FG, CDPPB 
and MTEP was applied to CGC cultures, significant apoptosis was observed when 
compared with control levels (Figure 5.2.7 Cii) supporting specific activation of 
microglial mGluR5 in the observed neuroprotection. Significant toxicity was observed if 
CGCs were treated with FG-DCGIV or FG-NAAG MGCM. However, as previously 
reported, L-AP4 activation of microglial group III mGluRs induced neuroprotection 
(Taylor et al. 2003) from FG-mediated toxicity (Figure 5.2.7 Cii). 
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In support of the microglial mGluR5-mediated protection, ICC was performed on CGC 
cultures after treatment with MGCM. FG-MGCM induced an increase in neuronal-
associated caspase-3 cleavage, which was not present in CGC cultures treated with 
FG-CDPPB-MGCM. In line with the apoptotic morphology quantification, caspase-3 
cleavage was observed after administration of MGCM from cultures co-treated with FG, 
CDPPB and MTEP (Figure 5.2.7 D). 
To identify whether it was purely microglial mGluR5 activation that could modulate FG-
mediated neurotoxicity, apoptosis was quantified in CGCs depleted of microglia and 
directly treated with mGluR agonists in the presence of FG-MGCM. As expected, FG-
MGCM alone induced significant apoptosis, when compared with CTR-MGCM 
induction. Direct treatment of cultures with CDPPB but not DHPG significantly 
attenuated FG-mediated toxicity, supporting the ability of microglial independent 
activation mGluR5 to mediate protection (Figure 5.2.8). Direct treatment of CGCs with 
DCGIV and NAAG could not attenuate FG-MGCM induced neurotoxicity, suggesting 
any neuroprotective effect observed with NAAG treatment depends on activation of 
microglial mGluR3 rather neuronal or astrocytic receptors (Figure 5.2.8). These data 
are in contrast to data shown in Figure 5.2.4 C, suggesting microglia are not required 
for NAAG-mediated protection from toxicity induced by direct FG treatment.      
To support the apoptotic morphology quantification and caspase-3 expression data, 
LDH assays were performed on CGC cultures treated with MGCM.  As expected, 
DCGIV-MGCM treatment significantly increased LDH release above control levels 
(Figure 5.2.9). FG-MGCM treatment also significantly increased LDH release above 
control levels. Furthermore, in line with the apoptotic morphology quantification, LDH 
release was significantly attenuated in cultures treated with FG+DHPG-MGCM or 
FG+CDPPB-MGCM, with co-administration of MTEP significantly inhibiting DHPG- and 
CDPPB-mediated attenuation (Figure 5.2.9). No significant modulation of FG-MGCM-
mediated LDH release was observed after co-treatment with group II agonists. 
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  Figure 5.2.7. FG-MGCM induced neurotoxicity was attenuated by activation of 
microglial group I and III mGluRs 
Ai. Representative images from Hoechst-33342 staining experiments on fixed CGC 
cultures for quantification of apoptotic morphology after treatment for 24 hours with 
MGCM from cultures treated with DHPG (100 µM), CDPPB (100 nM) MTEP (100 
µM), DCGIV (500 nM), NAAG (50 µM) or L-AP4 (100 µM) for 24 hours. Bi. 
Representative images from Hoechst-33342 staining of CGC cultures after treatment 
with FN and mGluR compound MGCM for 24 hours. Ci. Representative images from 
Hoechst-33342 staining of CGC cultures after treatment with FG and mGluR 
compound MGCM for 24 hours as detailed in A. Quantification of apoptotic 
morphology was performed for each treatment group, i.e. mGluR compounds alone 
(Aii), FN and mGluR compounds (Bii) and FG and mGluR compounds (Cii). D. 
Expression and localisation of caspase-3 expression in CGC cultures treated with FG 
and mGluR5 compound MGCM was performed using ICC. After treatment with 
MGCM from FG-, FG + CDPPB- or FG + CDPPB + MTEP-treated microglial cultures, 
CGC cultures were fixed and incubated with anti-NeuN (green) for neuronal 
identification and anti-cleaved caspase-3 (red). Scale bars = 10 µm. All experiments 
were performed on 3 independent occasions. To compare the levels of apoptotic 
morphology in multiple treatment groups to control levels one way ANOVA were 
performed with Dunnett’s post-test. Direct comparison of specific treatments was 
analysed using paired two-tailed Student’s t-tests. Levels of significance were: non-
significant p>0.05, * p<0.05, ** p<0.01, *** p<0.001. 
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Figure 5.2.8. FG-MGCM-induced neurotoxicity could be prevented by direct 
treatment of neuronal cultures with CDPPB  
Quantification of apoptotic morphology using Hoechst-33342 staining in fixed CGC 
cultures after treatment for 24 hours with FG-MGCM in the absence or presence of 
direct DHPG (100 µM), CDPPB (100 nM) MTEP (100 µM), DCGIV (500 nM), or 
NAAG (50 µM) treatment of neuronal cultures. Treatments were in duplicate and 
experiments were performed on 3 independent occasions. To compare the levels of 
apoptotic morphology in multiple treatment groups to control levels a one way 
ANOVA was performed with Dunnett’s post-test. Direct comparison of specific 
treatments was analysed using paired two-tailed Student’s t-tests. Levels of 
significance were: non-significant p>0.05, ** p<0.01. 
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Figure 5.2.9. FG-MGCM-induced LDH release could be attenuated by activation 
of microglial mGluR5  
Quantification of LDH release from CGC cultures after 24 hours of treatment with 
MGCM from cultures treated for 24 hours with DHPG (100 µM), CDPPB (100 nM) 
MTEP (100 µM), DCGIV (500 nM), or NAAG (50 µM), in the absence or presence of 
FG (2.5 mg/ml) treatment. Treatments were in triplicate and experiments were 
performed on 3 independent occasions. To compare the levels of LDH release in 
multiple treatment groups to control levels a one way ANOVA was performed with 
Dunnett’s post-test. Direct comparison of specific treatments was analysed using 
paired two-tailed Student’s t-tests. Levels of significance were: non-significant 
p>0.05, ** p<0.01. 
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5.3. Discussion 
This chapter provides data suggesting neuroprotection from FG can be afforded by 
activating group I mGluRs present on microglia or by activating neuronal or astrocytic 
mGluR3 & 5. Furthermore, it is shown that FN-mediated toxicity in CGC cultures can 
be attenuated by activation of group I mGluRs or mGluR3. However, specific activation 
of these particular receptors on microglia does not protect against microglial-associated 
FN-induced neurotoxicity.  
It is shown that positive allosteric modulation of microglial mGluR5 can provide strong 
neuroprotection from FG-induced toxicity. It is also important to note that microglial-
independent mGluR3-dependent neuroprotection from FG was observed suggesting 
that protection from FG-mediated toxicity could be provided by activation of allosteric 
modulation of microglial mGluR5 and orthosteric agonism of neuronal mGluR3. 
5.3.1. Classical microglial activation markers are down-regulated by mGluR 
agonist treatment 
Treatment with the group I agonist DHPG (mGluR1 and 5) and the mGluR5 positive 
allosteric modulator CDPPB induced significant microglial activation shown by an 
increase in ED-1 expression, but not iNOS expression. Previous studies using DHPG 
treatment alone show little or no change in microglial morphology using OX-42 
(CD11b) (Farso et al. 2009), another marker of microglial activation (Figure 3.2.2). 
Little research has been performed on the role of positive allosteric modulation of 
microglial mGluR5, however orthosteric agonism of microglial mGluR5 with (RS)-2-
chloro-5-hydroxyphenylglycine (CHPG)  does not significantly increase reactive oxygen 
species (ROS) or nitric oxide (NO) levels in microglia (Byrnes et al. 2009a; Loane et al. 
2009), providing lose support for the lack of iNOS activity we observe here.  
Treatment with group II agonists (DCGIV or NAAG) did not significantly increase iNOS 
expression, supporting previously published work from the laboratory (Taylor et al. 
2005). However, treatment with mGluR3 specific agonist NAAG significantly increased 
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ED-1 expression, which does not concur with previously published data (Taylor et al. 
2005; Pinteaux-Jones et al. 2008). This observed variability could be due to differences 
in the serum content of culture medium. Both Taylor et al (2005) and Pinteaux-Jones et 
al (2008) used serum-containing conditions, whereas here, serum-free conditions were 
used allowing FG-mediated iNOS expression to be used as a marker of activation. 
Therefore, higher microglial sensitivity in serum-free conditions could lower the 
activation threshold. However, no significant increase in ED-1 or iNOS expression was 
observed after treatment with the group III agonist, L-AP4, similar to the previously 
published data (Taylor et al. 2003; Taylor et al. 2005), suggesting mGluR3 but not 
group III activation is more sensitive to iNOS activity in serum-free conditions. 
Orthosteric agonism of mGluR5 has been shown to reduce LPS-mediated microglia 
activation, identified by reductions in nitric oxide, reactive oxygen species, and TNFα 
production (Byrnes et al. 2009a; Loane et al. 2009). Findings presented here show no 
attenuation of LPS-induced iNOS and ED-1 expression and TNFα expression and 
release when co-treated with mGluR5 positive allosteric modulator, CDPPB. These 
data suggest allosteric modulation is less effective than orthosteric agonism in down-
regulating LPS-mediated microglial activation. Further scrutiny of Byrnes et al (2009a) 
and Loane et al (2009), reveals the use of lower LPS concentrations (in both cases, 10 
times lower), which could simply suggest that the concentration utilised here is 
insurmountable in terms of mGluR5 allosteric modulation. In contrast to LPS, the 
potency of positive allosteric mGluR5 modulation on reducing FG-evoked responses 
suggests that mGluR5 coupling to this pathway is highly robust. This further supports 
the suggestion that differential pathways are induced after LPS and FG treatments. 
Interestingly, co-treatment of microglia with DHPG could also significantly attenuate 
FG-mediated TNFα expression and release, suggesting important down-regulatory 
roles for both group I agonists in TNFα-associated responses. However, further reading 
provides data suggesting microglia only express mGluR5 and not mGluR1 (Biber et al. 
1999). This in turn suggests that here, classical orthosteric agonism of mGluR5 is able 
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to down-regulate FG-mediated TNFα responses as well as positive allosteric 
modulation of the receptor.  
5.3.2. Modulation of ER-associated caspase-12 and caspase-3/7 activation with 
mGluR agonists 
Due to limited availability of the caspase-12 and -3/7 fluorescently tagged peptides, 
only a small number of treatments were analysed. Co-treatment of cultures with 
CDPPB or NAAG significantly attenuated FG-mediated caspase-12 and -3/7 activation. 
Involvement of mGluR3 or mGluR5 activation in down-regulation of ER stress is a 
novel idea and one which has received little or no attention. These data suggest FG-
mediated caspase-12 expression due to ER stress can be prevented if cultures are co-
treated with CDPPB or NAAG. MGluR5 is predominantly coupled to Gq/G11 proteins 
leading to activation of phospholipase Cβ, which results in calcium mobilisation 
(Niswender & Conn 2010). The role of calcium dyshomeostasis in FG-mediated 
microglial activation has already been alluded to (Section 4.4) and these data coupled 
with the mGluR5 activation data here allow one to hypothesise that mGluR5 activation 
can regulate calcium levels possibly returning cellular homeostasis after FG-mediated 
dyshomeostasis has occurred. Western blotting for caspase-12 and/or caspase-3 
activation would enable further clarification of these data.  
NAAG treatment has been shown to down-regulate caspase-3 activation in neurons in 
excitotoxic conditions (Spillson & Russell 2003), however this microglial caspase-3/7 
activation is not associated with enhanced cellular toxicity, suggestive on non-apoptotic 
caspase activation (Burguillos et al. 2011). These data therefore suggest that mGluR3 
agonism can down-regulate FG-mediated microglial activation, which is at odds with 
the iNOS and ED-1 expression data and the TNFα expression and release data, 
implying differential pathways for iNOS, ED-1 and TNFα induction and caspase-3/7 
activation, although this is at odds with Burguillos et al (2011), who show in BV2 
microglia that inhibition of caspase-3/7 attenuates LPS-induced morphological changes 
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and iNOS expression, further confusing the data collected here associated with 
mGluR3 activation. Therefore, much greater, in depth studies with NAAG are required 
to understand the compounds’ mechanism of action with respect to down-regulation of 
caspase activity in microglia. Microglial cultures treated with CDPPB down-regulated 
the FG-induced caspase-3/7 ‘activation’ supporting the iNOS and ED-1 expression 
data and the TNFα expression and release data. 
5.3.3. Modulation of neurotoxicity induced after direct treatment with fibrinogen 
or fibrin by mGluR agonists 
The roles of specific mGluR activation in FG- and FN-mediated neuronal apoptosis 
were investigated. Initially, support for previously published data (Taylor et al. 2005) 
suggesting DCGIV treatment alone can induce death that is dependent on microglia is 
shown. No other mGluR agonists tested induced significant death when administered 
alone. Co-treatment of cultures with DHPG, CDPPB, or NAAG significantly attenuated 
FN-mediated apoptosis if microglia were present. However, prior depletion of microglia 
prevented the observed attenuation. These data suggest that the presence of microglia 
are required and potentially involved in group I and mGluR3-mediated neuroprotection 
from FN, further supporting a protective role for NAAG although later MGCM studies 
suggested otherwise. 
FG-mediated neurotoxicity could be attenuated by CDPPB co-treatment but not DHPG, 
although co-treatment with DHPG could significantly inhibit caspase-3 cleavage in 
CGC cultures. Removal of microglia had no effect on the mGluR5-associated 
attenuation of the FG-induced apoptosis however we propose this is not due to 
neuronal specific modulation of mGluR5 but due to the previous observations made in 
section 3.3.2, that suggest that FG induces its neurotoxic effects via a microglial 
dependent mechanism. This is supported by cleaved caspase-3 expression in CGCs in 
the presence and absence of microglia. Previously published studies have shown that 
activation of group I mGluRs can significantly attenuate neuronal apoptosis induced by 
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staurosporine but in turn increase necrotic cell death (Allen et al. 2000). These data 
support the lack of significant attenuation of FG-mediated neuronal toxicity by DHPG 
co-treatment, which could be due to quantification of apoptotic-like necrotic cell death, 
further supported by the significant inhibition of caspase-3 cleavage. No significant 
modulation of FG-mediated apoptosis by co-treating with DCGIV was observed unless 
microglia were removed. However, co-treatment with NAAG significantly attenuated the 
observed FG-mediated toxicity in the presence of microglia. These data support 
previously published data from our laboratory identifying differential roles for the 
microglial group II mGluRs (Taylor et al. 2005). Caspase-3 cleavage data however 
suggests no significant modulation occurs in cultures where microglia were depleted, 
although, in the case of NAAG co-treatment in particular, the expression of caspase-3 
cleavage is trending towards an attenuation and further repetitions would ascertain 
whether this treatment does in fact inhibit FG-mediated caspase-3 cleavage. In 
conclusion these data suggest varying mechanisms of cell death induced by particular 
treatments that would have otherwise been missed had these experiments been 
performed independently on homogenous cultures. 
5.3.4. MAPK pathway modulation by mGluR agonists 
Phosphorylation of p42/44 MAPK (ERK1/2) is generally associated with pro-survival 
pathways (Cheung & Slack 2004), although studies have been published suggesting 
neuronal ERK1/2 phosphorylation is detrimental to neurons after oxidative injury (Chu 
et al. 2004), with chronic activation playing a role in neurodegeneration (Colucci-
D’Amato et al. 2003). Furthermore, phosphorylation of ERK1/2 has been shown to be 
involved in microglial activation (Kim et al. 2004; Hooper & Pocock 2007). Data 
presented here suggests that treatment of CGCs with DCGIV significantly enhanced 
expression of phospho-ERK1/2, independent of the presence of microglia, suggesting 
group II mGluR activation in neurons and astrocytes involves ERK1/2-associated 
pathways, which has recently been observed in striatal lysates using a different 
mGluR2/3 agonist (LY379268) (Di Liberto et al. 2011). We also show significant 
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expression of phospho-ERK1/2 independent of the presence of microglia after FG 
treatment suggesting FG is able to signal via other cells present in the cultures as 
shown previously (Schachtrup et al. 2007; Schachtrup et al. 2010). In the presence of 
microglia it is shown that co-treatment of CGC cultures with FG and DCGIV 
significantly induced phospho-ERK1/2 expression, however, if microglia were depleted 
prior to this co-treatment phospho-ERK1/2 expression was significantly attenuated, 
suggesting microglial involvement in this induction of phospho-ERK1/2.  
Positive allosteric modulation of mGluR5 alone did not induce significant 
phosphorylation of ERK1/2 unless microglia were depleted. However FG-mediated 
induction of phospho-ERK1/2 expression could be significantly attenuated by co-
treatment of cultures with CDPPB, if microglia were present. FG has been shown to 
suppress apoptosis in neutrophils during inflammation via activation of Akt and ERK1/2 
pathways, which prolongs the inflammatory response (Pluskota et al. 2008). These 
published data coupled with observations here suggest mGluR5 modulation can down-
regulate the FG-mediated prolongation of activation. However, due to the vast 
signalling capabilities of ERK1/2, at this stage it is impossible to know for certain. What 
is important is that CDPPB can down-regulate the FG-mediated phosphorylation of 
ERK1/2, with dependence on microglia, suggesting significant modulatory capabilities 
of the compound with respect to FG-induced responses. 
5.3.5. Modulation of fibrinogen-induced microglial-mediated neurotoxicity by 
mGluR5 
To further strengthen the notion of microglial dependence in mediating both FG toxicity 
and protection, MGCM studies were undertaken. Data presented here provides 
significant support for positive allosteric modulation of mGluR5 on microglia as a 
protective mechanism against FG-mediated neurotoxicity. Initially it is shown that only 
DCGIV treatment of microglia can induce neurotoxicity, supporting the microglial 
depletion data and previously published data (Taylor et al. 2005). Similarly to Taylor et 
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al (2005), no other mGluR agonist tested induced neurotoxicity via microglial-
dependent release of soluble factors. In direct treatment studies it was shown that the 
presence of microglia in the CGCs was a requirement for group I- and mGluR3-
mediated neuroprotection from FN. However, down-regulation of the activated 
microglial phenotype with DHPG, CDPPB and NAAG could not prevent microglial-
mediated FN-induced neurotoxicity. These data suggest that FN is still able to induce 
the release of neurotoxic factors from microglia at a concentration high enough to 
induce neurotoxicity, which is feasible when reviewing the extent of TNFα release from 
microglia (Figure 3.2.3), compared with LPS or FG, where FG-mediated release is 
much lower. Alternatively, significant transfer of FN in the MGCM could have occurred 
that is able to induce direct neurotoxicity. This is a significant caveat to these 
experiments and is difficult to test in a similar manner to FG (Section 2.4.2) due to the 
insolubility of FN. 
In the case of protection from FG-mediated neurotoxicity, activation of group I mGluRs 
and group III mGluRs afforded protection from FG. These data suggest it is not only 
mGluR5 on microglia that is able to protect against FG-mediated neurotoxicity. Group 
III mGluRs comprises of mGluR4/6/7/8, but rat microglia only express mRNA and 
receptor protein for mGluR4, mGluR6, and mGluR8, not mGluR7 (Taylor et al. 2003). 
Previously, activation of this group of receptors has been shown to mediate protection 
from LPS, chromogranin A, Aβ25-35 (Taylor et al. 2003), myelin (Pinteaux-Jones et al. 
2008) and excitotoxicity in neurons (Lafon-Cazal et al. 1999), suggesting the group is a 
promising target for pharmaceutical development. However, further investigation needs 
to be performed to identify if a particular receptor is specifically responsible for 
mediating this neuroprotection. This will enable the development of more specific 
agonists avoiding non-specific interactions with other group members. 
As previously suggested, DHPG treatment of microglia will only agonise mGluR5 due 
to the lack of functional mGluR1 on microglia (Biber et al. 1999). Here it is shown that 
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DHPG treatment significantly attenuated FG-mediated neurotoxicity as assessed by 
quantification of apoptotic morphology as well as LDH release assays. Furthermore, 
co-administration of MTEP, the mGluR5 negative allosteric modulator, significantly 
inhibited the DHPG-mediated attenuation of FG-mediated LDH release, supporting 
mGluR5 specific activation by DHPG on microglia. This MTEP inhibition was also 
observed in CDPPB-treated microglia, with further data presented here showing an 
inhibition of CDPPB-mediated downregulation of cleaved caspase-3 in CGC cultures 
treated with MGCM. Finally, when cultures were directly treated with CDPPB then 
exposed to FG-MGCM, significant attenuation was again observed, which could not be 
reciprocated by DHPG direct treatment, supporting published data identifying 
differential toxicity profiles for the group I receptors present on neurons (Allen et al. 
2000). These data also suggest that specific allosteric modulation of mGluR5 both on 
microglia and other cell types including neurons and astrocytes could provide 
protection against FG-induced toxicity.   
5.3.6. Conclusions  
Together these data provide evidence for a prominent role for the activation of specific 
mGluRs in mediating neuroprotection from FG and possibly FN, as summarized in 
Figure 5.3.1. The significant attenuation of FG-MGCM-mediated neurotoxicity by co-
administering CDPPB direct to the CGCs provides strong support, in a more 
physiologically viable model, for a prominent role for mGluR5 in neuroprotection, as 
previously suggested in Alzheimer’s disease and spinal cord injury models (Movsesyan 
et al. 2004; Byrnes et al. 2009b). Finally, these data provide support for the hypothesis 
that combating early FG extravasation before FN deposition will attenuate the 
accelerated neuronal loss observed in neurodegenerative disorders. 
  
344 
 
 
FG
Caspase-12
Neuronal
Death
ERK1/2
phosphorylation
Microglial
activation
Caspase-3/7
mGluR5
mGluR5
CDPPB
CDPPB
A.
B.
FN
Inflammation
Caspase-12
Neuronal
Death
Caspase-3/7
mGluR5
CDPPB
-
Group I mGluR3
Activation
mGluR3
Microglial death
(Caspase3 cleavage)
Caspase-3/7
activation
Figure 5.3.1. Summary of results obtained in chapter 5 
A. Co-treatment of microglia with FN and either group I mGluR agonists or an 
mGluR3 agonist provided significant protection from FN-mediated neurotoxicity. 
Furthermore, specific activation of mGluR5 on neurons also provided protection 
from FN-mediated neurotoxicity. B. Fibrinogen-mediated microglial activation and 
subsequent neurotoxicity could be attenuated by co-treatment of microglial cultures 
with an mGluR5 agonist. Direct treatment of neuronal cultures with either an 
mGluR3 or mGluR5 agonist provided neuroprotection from FG mediated toxicity 
via microglial activation. 
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6. Initial translation of findings using a human model of 
phagocytes, in vitro 
6.1. Introduction 
To identify whether the significant microglial findings described in chapters 3-5 would 
translate to a human model, the in vitro monocyte-derived macrophage model (MDM or 
hMΦ) was selected. To date hMΦ are the closest culture available to model human 
pre-mortem microglial signalling in vitro, if human foetal microglia are discounted due to 
ethical and lawful reasons limiting their use. One of the most important aspects of the 
hMΦ cultures is how they are prepared in vitro. By isolating pure monocytes from the 
blood and differentiating them to macrophages in culture the desired cell type is not 
wrestled from its homeostatic environment, rather the macrophages are differentiated 
in the cell culture system, the only environment they are ever exposed to. 
Early studies identified that the hMΦ share similar morphological and immunological 
features with microglia, such as the ruffled cell membrane and the expression of 
surface antigens including MHC class II and complement receptor 3 (CR3; MAC-1, 
CD11b) (Bauer et al. 1991). More recent studies using hMΦ in tandem with human 
foetal microglia showed that fibrillary Aβ can induce ROS and H2O2 to a similar extent 
in both models (Coraci et al. 2002). 
Limited studies have been performed to characterise the hMΦ with respect to rodent 
microglia, studies which would provide invaluable data and hopefully support for the 
use of these cells. The identification of a subset of monocyte-derived microglia in 
rodent models (Bechmann et al. 2005; Mildner et al. 2007) suggests that studies to 
identify particular transcription regulators and the relevant extrinsic support factors that 
enable this differentiation in vivo could allow refinement of the hMΦ model to further 
mimic microglia however, species differences could create some difficulties. Some 
limited microarray studies have been performed which have identified some correlation 
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between the genes upregulated upon activation of the hMΦ and rodent microglia. 
Albright and colleagues (2004) compared the upregulation of genes in hMΦ to those in 
rat-derived mixed glial cultures (containing ~ 60% microglia) and found 180 genes were 
commonly upregulated, equating to approximately 24% of the total hMΦ genes and 
20% of the total mixed glial genes that were upregulated. The obvious and rather large 
caveat in these experimental procedures is the use of mixed glia containing 40% non-
microglial cells rather than using purified cultures with a purity of 90-99%. These non-
microglial cells could be responsible for the greater number of genes that were shown 
to upregulated in the mixed glia cultures when compared with the hMΦ cultures (747 in 
hMΦ and 914 in mixed glia) (Albright & González-Scarano 2004). Furthermore, non-
cell autonomous communication could be manipulating the gene expression in the 
microglia present in these cultures. 
Here, using gene and protein expression techniques support is provided for studies 
suggesting a limited role for iNOS activity in human macrophages after activation and 
also significant support for the identification of pro-inflammatory cytokine induction 
upon FG treatment with regulation by ER stress. 
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6.2. Fibrinogen or fibrin treatment of hMΦ induces expression of 
TNFα, but only fibrinogen treatment is associated with ER 
stress 
To ascertain whether FG and FN treatment of human macrophages (hMΦ) induced a 
similar profile to that seen in rat microglia studies, gene expression analysis for 
previously used markers was performed. Interestingly, no treatment tested induced 
significant iNOS gene expression in the hMΦ cultures, a result that supports previous 
suggestions that human macrophages lack the high output iNOS-mediated NO release 
that is observed in rodent cells (Peterson et al. 1994), although later studies disagree 
(Ding et al. 1997) (Figure 6.2.1A & Bi). However all treatments tested, apart from 
thapsigargin, induced significant increases in TNFα gene expression, suggesting 
strong activation of these cells also occurs after FG and FN treatment with little or no 
involvement from iNOS-dependent pathways (Figure 6.2.1A & Bii). Finally, to identify 
if ER stress pathways were being induced, CHOP gene expression was analysed after 
the same treatments. FG but not FN treatment significantly induced CHOP expression 
above that seen in control cultures (Figure 6.2.1A & Biii). 
Live cell staining studies with the hMΦ cultures supported an induction of ER stress 
pathways after FG treatment for 24 hours with significant enhancement of caspase-12 
cleavage that was not dependent on cell death (Figure 6.2.2). The positive control for 
ER stress induction, thapsigargin, also significantly enhanced caspase-12 cleavage in 
the hMΦ cultures after 24 hours. However, a significant increase in cell death was also 
observed. 
Inhibition of the PERK-eIF2α-ATF4 axis of ER stress with salubrinal completely 
attenuated FG-mediated caspase-12 cleavage (Figure 6.2.2), supporting an ER stress-
dependent cleavage of caspase-12. Interestingly however, salubrinal treatment could 
not significantly attenuate thapsigargin-induced caspase-12 cleavage, although a 
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significant attenuation of thapsigargin-mediated cell death was observed, when 
compared with thapsigargin treatment alone; Figure 6.2.2). 
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Figure 6.2.1. FG and FN treatment of human macrophages induces TNFα 
gene expression but only FG can induce CHOP gene expression 
A. Representative PCR blots for iNOS (70 bp), TNFα (123 bp), CHOP (95 bp) and 
GAPDH (66 bp) gene expression after Thapsigargin (Th; 2 µM), FG (2.5 mg/ml), 
FN (1 mg/ml), LPS (1 µg/ml) or LPS + IFNγ (100 U/ml) treatment of hMΦ for 24 
hours. Arrow indicates non-specific bands. Quantification of iNOS (Bi), TNFα (Bii) 
and CHOP (Biii) gene expression in hMΦ cultures with respect to gene expression 
of GAPDH. Quantified data were analysed from 3 independent experiments. To 
compare between control levels and multiple treatments, one way ANOVA were 
performed with Dunnett’s post-test. Levels of significance were: non-significant, 
p>0.05, * p<0.05.  
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Figure 6.2.2. FG induces an increase in activated caspase-12-associated 
fluorescence in hMΦ cultures that is dependent on ER stress 
A. Panel of representative images of live cell staining experiments in hMΦ cultures 
after treatment with Th (2 µM) or FG (2.5 mg/ml) alone or in combination with Sal 
(100 nM). Live cell staining was performed with Hoechst-33342 for nucleus 
identification, propidium iodide (PI; red) for total cell death, and FITC-ATAD-FMK 
(green) for active caspase-12. Original magnification: x40, scale bar: 30 µm. B. 
Quantification of the relative active caspase-12 fluorescence intensity/cell and % 
death in the population (by quantification of PI-positive cells) in hMΦ cultures after 
administration of the treatments outlined in A. Caspase-12 fluorescence data are 
presented in arbitrary fluorescence units (AFU). Treatments were in triplicate and 
data were analysed from 3 independent experiments. To compare multiple 
treatments to control levels, one way ANOVA were performed with Dunnett’s post-
test. To compare specific treatments with ER stress inhibited treatments, paired 
two-tailed Student’s t-tests were performed.  Levels of significance were: non-
significant p>0.05, * p<0.05, ** p<0.01.  
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6.3. Inhibition of an ER stress pathway attenuates fibrinogen-
mediated upregulation of TNFα gene expression and caspase-3 
cleavage 
To identify whether the observed induction of ER stress in the hMΦ cultures was 
upstream or downstream of TNFα expression, PCR was performed. Initially, CHOP 
gene expression was analysed and as previously shown (Figure 6.2.1 Biii), both 
thapsigargin and FG treatment enhanced gene expression. Interestingly, co-treatment 
of cultures with salubrinal did not attenuate the observed increase in expression 
(Figure 6.3.1 A & Bi).  
As previously shown (Figure 6.2.1 Bii), thapsigargin treatment for 24 hours could not 
induce significant TNFα expression (Figure 6.3.1 A & Bii). However, FG treatment of 
the cultures for 24 hours induced significant TNFα expression that was attenuated if 
cultures had been treated with salubrinal (Figure 6.3.1 A & Bii). These data suggest 
that ER stress occurs prior to any significant induction of TNFα expression. 
Induction of caspase-3 cleavage after FG, FN or thapsigargin treatment for 24 hours 
was then quantified from ICC experiments. Thapsigargin induced significant caspase-3 
cleavage, which correlated to a significant increase in cell death characterised by 
apoptotic morphology (Figure 6.3.2. A & B). FN treatment also induced significant 
caspase-3 cleavage in parallel with a significant increase in cell death. In support of 
previous studies with rat microglia (Section 3.2.3), FG treatment significantly increased 
caspase-3 cleavage in the hMΦ cultures without a significant increase in cell death 
(Figure 6.3.2 A & B), suggesting caspase-3 involvement macrophage activation 
(Burguillos et al. 2011). Furthermore, this non-apoptotic cleavage of caspase-3 could 
be completely attenuated if cultures were co-treated with salubrinal (Figure 6.3.2 A & 
B), further suggesting ER stress as an initial mechanism in hMΦ activation. 
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Figure 6.3.1. FG-mediated TNFα gene expression in hMΦ can be attenuated 
by inhibition of ER stress 
A. Representative PCR blots for CHOP (95 bp), TNFα (123 bp) and GAPDH (66 
bp) gene expression after Thapsigargin (Th; 2 µM) or FG (2.5 mg/ml) treatment 
for 24 hours, alone or in combination with salubrinal (Sal; 100 nM). Quantification 
of CHOP (Bi) and TNFα (Bii) gene expression in hMΦ cultures with respect to 
gene expression of GAPDH. Quantified data were analysed from 3 independent 
experiments. To compare between control levels and multiple treatments, one 
way ANOVA were performed with Dunnett’s post-test. Paired two-tailed Student’s 
t-tests were performed to compare specific treatments. Levels of significance 
were: non-significant p>0.05, * p<0.05, ** p<0.01. 
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Figure 6.3.2. FN and FG induce caspase-3 cleavage in hMΦ with inhibition of 
ER stress attenuating the FG-mediated cleavage 
A. Representative images of hMΦ cultures after 24 hours of treatment with Sal (100 
nM), Th (2 µM), FN (1 mg/ml), FG (2.5 mg/ml) or FG + Sal. Cultures were stained 
with DAPI for quantification of cell number and probed with anti-CD68 (green) for 
identification of hMΦ and anti-cleaved caspase-3 (red), except in negative control 
cultures, where primary antibodies were omitted. Original magnification: x40, scale 
bar: 20 µm. B. Quantification of cleaved caspase-3-positive hMΦ (grey bars) and 
death in the hMΦ population (quantified by apoptotic morphology; black bars) after 
administration of treatments outlined in A. Data are presented as percentages of 
total hMΦ number. Treatments were in duplicate in each experiment and data were 
analysed from 3 independent experiments. To compare % cleaved caspase-3 cells 
or % death in multiple treatment groups to control levels one way ANOVA were 
performed with Dunnett’s post-test. Direct comparison of specific treatments was 
analysed using paired two-tailed Student’s t-tests. Levels of significance were: non-
significant p>0.05, ** p<0.01, *** p<0.001. 
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6.4. Discussion 
This final results chapter focuses on preliminary data from translational experiments 
performed to identify whether the novel rat microglial data reported in previous 
chapters in this thesis could be replicated in a human cell culture model. The majority 
of markers utilised in the hMΦ culture model correlated with previously presented rat 
data suggesting robust and evolutionarily conserved signalling pathways are involved 
in FG-mediated activation of phagocytes. 
6.4.1. Human macrophage responses generally mimic those of rat microglia 
The only marker tested that did not correlate to the rat data was the expression of 
iNOS, which was previously shown in similar serum-free conditions to be significantly 
enhanced by FG, FN, and LPS treatment (Section 3.2.2). Furthermore, potent co-
treatment of hMΦ with LPS and IFNγ could not significantly enhance iNOS expression. 
Although studies have been published suggesting iNOS-mediated NO production does 
occur in human microglia and macrophages (Colasanti et al. 1995; Ding et al. 1997), 
data presented here are in support of the vast majority of studies published that have 
suggested human macrophage and microglial activation is independent of significant 
iNOS expression and NO release (Peterson et al. 1994; Denis 1994; Colton et al. 2000; 
Carter & Dick 2003). Furthermore, murine macrophages produce the large amounts of 
NO and L-citrulline from L-arginine via iNOS catalysis due to their capability of 
synthesising the obligatory cofactor tetrahydrobiopterin (BH4), essential for the 
stabilization and function of iNOS. However, human macrophages along with a number 
of other species are not able to synthesise BH4 and therefore have limited NOS activity 
(Schneemann & Schoeden 2007).  
A significant conclusion from the primary rat culture data presented here was that 
inhibition of iNOS activity with AMT-HCl failed to attenuate FG- or FN-mediated 
responses including caspase activation and subsequent neuronal death. These 
observations correlate with the lack of involvement of iNOS in the hMΦ signalling after 
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treatment, further supporting the idea that there is little or no involvement of this 
enzymatic pathway in the execution of FG and FN toxicity cascades. Interestingly, 
some researchers even suggest that the lack of this high output iNOS-mediated NO 
release may actually exacerbate human disorders (Colton et al. 2000).      
The expression of TNFα after FG and FN treatment in the hMΦ cultures correlated with 
the rat data suggesting significant expression and release after treatment. These data 
are in line with previous studies suggesting LPS and IFNγ can induce TNFα release 
from human retinal microglia independent of iNOS activity (Carter & Dick 2003) and 
LPS treatment of human macrophages downregulates CD4, a protein with a role in 
immune function, via an endogenous TNFα-dependent mechanism (Herbein et al. 
1995). Limited research has been performed on the identification of FG-mediated TNFα 
from human macrophages. One paper does identify a significant induction of TNFα and 
IL-6 from human peripheral blood mononuclear cells (PBMCs) (Jensen et al. 2007), the 
pre-cursors to the hMΦ used here, with earlier studies using the same cells (PBMCs) 
identifying a significant induction of IL-1β after culturing with FG gels (Perez & Roman 
1995). A significant induction of IL-6 release from human macrophages has been 
identified after exposure to FG via a TLR4-dependent mechanism and when FG was 
administered to a HEK293-CD14-MD2 cell line that expresses TLR4 significant 
induction of TNFα was also observed (Hodgkinson et al. 2008). The lack of 
thapsigargin-induced TNFα gene expression is at odds with the BV2-microlgial data 
that showed a significant increase in protein expression after treatment (Figure 4.4.6). 
However, an increase was certainly observed and a review of the raw data shows one 
assay significantly skewed the analysis suggesting further repetitions could provide 
statistical significance.  
Significant CHOP gene expression was observed after treatment of hMΦ with 
thapsigargin, FG, LPS, and LPS and IFNγ, but not FN. These data were again broadly 
in line with the rat primary microglial data. However, rat data showed FN treatment of 
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primary microglia could induce a significant increase in CHOP protein expression 
(Figure 4.2.10) suggesting discrepancies between the two models with respect to FN-
induced pathways. Further time-dependent studies must be undertaken however, as 
FN treatment induced significant toxicity in rat primary microglia after 24 hours, the 
same incubation period used in these hMΦ experiments, suggesting CHOP expression 
levels may be significantly induced at earlier time-points.  
Interestingly, although a significant induction of CHOP gene expression was observed 
after FG treatment of hMΦ, no significant increase in death was observed. Previous 
studies have shown LPS treatment can induce non-apoptotic CHOP gene expression 
in a macrophage cell line (Nakayama et al. 2010), whereas recent protein expression 
studies suggest that LPS treatment of macrophages decreases CHOP protein levels 
(Woo et al. 2009; Martinon et al. 2010), a mechanism that may induce a significant 
increase in CHOP gene expression. However, further studies are required to unravel 
this complicated mechanism, again with timecourse analyses potentially providing 
clearer data.    
6.4.2. ER stress pathways are mobilised in hMΦ in response to fibrinogen – 
regulation of cellular activation 
The rest of the chapter focused on ER stress pathways in hMΦ cultures after FG 
treatment in particular. Live cell staining studies supported an induction of ER stress 
pathways after FG treatment with significant enhancement of caspase-12 cleavage 
being observed, with limited cell death. Furthermore, in support of ER stress-
associated caspase-12 cleavage, an intensely debated topic in human disease 
progression, pre-treatment of hMΦ cultures with salubrinal, an inhibitor of the PERK-
eIF2α-ATF4 axis of ER stress completely attenuated FG-mediated caspase-12 
cleavage. These data support caspase-12 association with ER stress in humans (Hetz 
et al. 2003; Mandic et al. 2003; Lee et al. 2010) and further support the notion that FG 
can induce ER stress in phagocytes. Interestingly, thapsigargin-mediated caspase-12 
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cleavage could not be significantly attenuated by salubrinal pre-treatment even though 
a significant attenuation of cell death was observed. Furthermore, thapsigargin- and 
FG-mediated CHOP gene expression could not be attenuated by salubrinal pre-
treatment. These data follow a similar pattern to recently published work suggesting 
salubrinal can significantly attenuate ER stress-mediated apoptosis but does not down-
regulate pro-apoptotic factors, including CHOP, associated with ER stress after 
induction by thapsigargin (Kitamura et al. 2011).   
In my view the most interesting data in this chapter identifies a potential role for ER 
stress in the regulation of macrophage activation. As previously described, FG 
treatment of the hMΦ cultures induced significant TNFα gene expression. However, 
expression could be attenuated if cultures were pre-treated with salubrinal. 
Furthermore, FG treatment could induce significant caspase-3 cleavage in the hMΦ, 
independent of apoptosis at the time-point tested, which could also be attenuated by 
pre-treatment of the cultures with salubrinal. Taken together with the assumption that 
the non-apoptotic caspase-3 cleavage observed was associated with activation as 
previously described (Burguillos et al. 2011; Venero et al. 2011), these data suggest 
that FG association with hMΦ induces ER stress-dependent pathways that in turn 
regulate activation via the release of TNFα. Recent elegant studies have suggested 
that TLR signalling specifically activates the ER stress sensor kinase IRE1α and the 
downstream transcription factor, XBP1 which is required for optimal production of pro-
inflammatory cytokines including TNFα in macrophages (Martinon et al. 2010). These 
data support the hypothesis that the UPR has prominent roles in regulating cellular 
homeostasis as well as its classical role in protein quality control (Rutkowski & Hegde 
2010).  
6.4.3. Conclusions  
Continuing research to couple ER stress pathways to macrophage and microglial 
activation cascades in general would potentially provide mechanisms that could be 
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manipulated for therapeutic benefit. Furthermore, complete elucidation of FG-mediated 
interaction with macrophages and microglia is likely to accelerate our understanding of 
how this protein is inducing the observed responses. 
The data presented in this chapter, although preliminary, provide novel signalling 
pathways with respect to FG that require further elucidation. What is also promising is 
the relative consistency of the data produced in these hMΦ cultures with respect to the 
primary rat microglial data and further characterisation of the hMΦ cultures coupled 
with the use of human microglial cell lines and human tissue samples as well as the 
rapid development of pluripotent stem cell technology, could render rodent cultures 
obsolete.   
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7. Final Discussion 
Blood brain barrier dysfunction leads to extravasation of fibrinogen into the CNS 
parenchyma followed by enhanced inflammation and cognitive decline in animal 
models of neurodegenerative diseases (Paul et al. 2007; Cortes-Canteli & Strickland 
2009; Cortes-Canteli et al. 2010), as well as being a hallmark of human AD pathology 
(Fiala et al. 2007; Ryu & McLarnon 2009). In addition to exacerbating Aβ load in animal 
models of AD, fibrinogen has been shown to bind to microglia inducing a phagocytic 
phenotype with significant involvement in EAE disease progression (Adams et al. 
2007a; Cortes-Canteli et al. 2010). Research into microglial involvement in 
neurodegeneration suggests these cells are intrinsically coupled to disease 
progression through chronic inflammation leading to an acceleration of degeneration in 
a self-perpetuating loop (Block et al. 2007; Glass et al. 2010). This thesis aimed to 
further elucidate the signalling capabilities of fibrinogen, and the cleavage product 
fibrin, through microglia. 
The first aim of the study was to characterise microglial responses to FG and FN and 
how these responses manifested with respect to neuronal integrity and viability. It was 
hypothesised that FG and FN would induce inflammation and toxicity in microglial 
cultures due to previous observations in the laboratory (E. East, I. Sevastou, and J.M. 
Pocock, unpublished observations). Although both treatments induced significant 
responses associated with inflammation, only treatment with FN induced significant 
morphological changes that were associated with toxicity at the time points tested. In 
neuronal cultures, it was initially shown that direct FG treatment induced neurotoxicity 
after 48 hours of exposure. However, PCR analysis coupled with pharmacological 
manipulation of thrombin suggested that intra-culture conversion of FG to FN was 
responsible for the direct neurotoxicity at this time-point.  
Interestingly, the identification of caspase-3 cleavage in microglial cultures after FG 
treatment initially suggested apoptosis. However, a non-significant increase in 
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apoptotic nuclear morphology was observed and recent studies have identified non-
apoptotic cleavage of caspase-8, -3 and -7 is involved in microglial activation rather 
than apoptosis, with RNAi studies that targeted the implicated caspases causing a 
down-regulation of microglial-mediated inflammatory responses after TLR signalling 
(Burguillos et al. 2011; Venero et al. 2011). Data presented here suggest that FG-
mediated microglial activation also involved non-apoptotic cleavage of caspases which 
therefore potentially suggests involvement of TLR signalling. Previous studies in our 
laboratory has suggested that blockage of TLR4 actually enhances FG-mediated iNOS 
expression in microglia (I. Sevastou & J.M. Pocock, unpublished observations). 
Furthermore published literature has suggested that fibrinogen can bind to TLR4 on 
macrophages and a HEK293 cell line inducing significant induction of pro-inflammatory 
cytokines (Hodgkinson et al. 2008). These data coupled with observations here 
suggesting FG does not induce pro-inflammatory cytokine release through CD11b 
suggests further investigation into the FG-TLR4-proinflammatory cytokine release 
pathway could yield some interesting and potentially useful results.        
Comparison of FG- and FN-induced inflammatory responses to those of LPS 
suggested FN induced a similar response potentially via a similar pathway. However, 
published literature has identified LPS (endotoxin) contamination in other blood borne 
protein preparations stating that only 40 pg/ml of LPS (endotoxin) is required to induce 
microglial activation (Weinstein et al. 2008). It was therefore suggested that 
contamination of FN may be responsible for the observed activation. However, studies 
here using the endotoxin inhibitor PMX strongly suggested that the FG- and FN-
mediated responses were not due to endotoxin contamination. Furthermore, co-
treatment of FG- and FN-treated cultures with LPS supported the hypothesis that 
differential pathways were initiated by the blood borne proteins when compared with 
LPS induction. Other contaminants, however, cannot be ruled out. 
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One of the most interesting initial observations was that the serum composition of the 
culture medium could be used to manipulate FG-mediated responses. In serum-free 
conditions FG could induce iNOS expression and significantly greater cytokine release 
when compared with serum-containing conditions. These observations suggest serum 
components can down-regulate the FG-mediated inflammatory response, which in 
physiological conditions could prevent acute dyshomeostasis by desensitising the 
signalling capacity of FG. However data here suggests that chronic extravasation of FG 
into the CNS parenchyma that leads to saturation of degradation pathways, coupled 
with chronic inflammation and the subsequent release of toxic factors, including 
cytokines, can overcome this serum-associated protective mechanism.  
The development and optimisation of a microglial-depletion technique for use on 
neuronal cultures provided a cell culture system in which modelling of microglial 
responses in an enriched neuronal culture could be performed. Using this technique it 
was possible to support the idea that LPS-mediated inflammatory responses and 
subsequent neurotoxicity occurs through microglia and not through astrocytes, in vitro 
(Lee et al. 1993). Furthermore, the FG-mediated neurotoxicity observed after only 24 
hours in vitro, which was initially assumed to be a direct interaction, was shown to 
depend on microglia. It also enabled the identification of an acute neuroprotective 
mechanism afforded by microglia with respect to FN exposure. Microglia in the CGC 
cultures were also shown to respond differentially to FG or FN exposure shown by the 
analysis of ED-1 expression, which suggested that FG can induce a bi-phasic 
expression of ED-1, the marker of microglial activation, whereas FN induces prolonged 
expression with an early plateau followed by a late decline, correlating to neuronal 
death. These data support a role for microglia in FG- and FN-mediated responses in 
the neuronal cultures with the bi-phasic expression observed after FG treatment 
correlating to the immobilisation and conversion of FG to FN, in culture.  
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Modelling microglial responses within the CGC cultures provided a more physiological 
environment. However, the use of microglial conditioned medium treatment of 
microglial-depleted neuronal cultures also allowed us to identify the importance of 
soluble secreted factors, in particular TNFα (Taylor et al. 2005), in subsequent 
neurotoxicity, supporting the use of differing models in the investigation of microglial-
mediated responses. The investigations here were performed in an attempt to 
characterise microglial- and neuronal-associated responses after exposure to FG or 
FN, in vitro, and how these responses were coupled. However, it is possible that other 
cells including astrocytes, which have been associated with FG signalling (Schachtrup 
et al. 2010), could be involved in the regulation of the observed responses and further 
investigations into the specific roles of other cell types should be performed.  
Broadly speaking this initial characterisation of FG- and FN-mediated responses 
suggests indirect (microglial) FN-mediated neurotoxicity is predominantly due to 
microglial death whereas indirect FG-mediated neurotoxicity is due to pro-inflammatory 
activation of microglia.     
The second section of this thesis describes the involvement of ER stress in FG- and 
FN-mediated neurotoxicity. ER stress is increasingly recognised as an integral part of 
the pathophysiology of many neurodegenerative diseases (Hetz et al. 2003; Lindholm 
et al. 2006; Unterberger et al. 2006; Mháille et al. 2008; Zhang & Kaufman 2008; Kim 
et al. 2008; Salminen et al. 2009). Research on atherosclerosis suggests an 
association between fibrinogen, a prominent feature of proliferative atherosclerotic 
lesions (Bini et al. 1989; Smith et al. 1992), and macrophage-specific ER stress (Tabas 
et al. 2009; Hotamisligil 2010a; Hotamisligil 2010b). The connections between FG, 
phagocytic cells and ER stress, and the mounting evidence for ER stress induction in 
neurodegeneration suggested that investigations into whether FG- or FN-mediated 
microglial activation and subsequent neurotoxicity involved ER stress could provide 
interesting findings.  
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Induction of ER stress, identified by caspase-12 and CHOP expression, was observed 
in microglia and neurons, preferentially after treatment with FG, particularly in the case 
of caspase-12 activation. Furthermore, a dependence on microglia with respect to FG-
mediated caspase-12 expression in neurons was observed, which was not surprising 
considering the earlier data suggesting microglial-dependent induction of neurotoxicity 
by FG. Inhibition of TNFα synthesis could downregulate the FG-mediated caspase-12 
and CHOP expression in the CGC and microglial cultures. Conversely, inhibition of ER 
stress downregulated FG-mediated TNFα release from microglial cultures. These data 
support previous work linking autocrine TNFα signalling to ER stress pathways (Hu et 
al. 2006; Martinon et al. 2010). Coupled to this observed ER stress-mediated regulation 
of TNFα signalling are further observations here that suggest FG-mediated ‘non-
apoptotic’ caspase-3/7 activation in microglia can be attenuated by salubrinal 
treatment. Taken together, with the assumption that the non-apoptotic caspase-3/7 
cleavage is associated with microglial activation (Burguillos et al. 2011; Venero et al. 
2011), these data could provide an additional upstream factor in this still novel 
signalling cascade. 
It was decided that calpain activity after treatment with FG would be investigated due to 
the suggestion that m-calpain may be responsible for procaspase-12 cleavage to the 
active form and that disturbances in intracellular calcium may induce neuronal 
apoptosis through calpain-mediated caspase-12 activation (Nakagawa & Yuan 2000). 
The assay was developed and optimised using a similar methodology to that performed 
by D’Amelio et al (2010) for the identification of caspase activity. Interestingly, FG-
mediated calpain activity was attenuated by iNOS activity inhibition. This modulation of 
the early FG-mediated induction of calpain activity by iNOS suggests expression may 
occur prior to the incubation period previously tested (i.e. < 24 hours). A timecourse 
analysis of FG-mediated iNOS expression was subsequently attempted using lysates 
from serum-containing BV2-microglia but no significant expression was observed at 
any timepoint. These data suggest a potential non-specific role for AMT-HCl in the 
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regulation of calpain activity or via inhibition of fluorescence however, further studies 
are required. Finally, pharmacological inhibition of calpain activity in microglia 
prevented FG-mediated neurotoxicity. Furthermore, inhibition of calpain activity in the 
neuronal cultures (depleted of microglia) also afforded protection from FG-mediated 
neurotoxicity (via MGCM), suggesting prominent calcium dyshomeostasis also occurs 
in the neurons after induction of intracellular signalling cascades by inflammatory 
factors released from microglia. Together, these data suggest interesting additions to 
the FG-mediated activation of microglia including possible calcium signalling that leads 
to calpain-mediated ER stress which in turn regulates TNFα release leading to the loss 
of neuronal integrity (Figure 7.1.1). 
In the past our laboratory has identified neurotoxic and neuroprotective roles for 
metabotropic glutamate receptors, dependent on the activation or inhibition of 
receptors in specific groups (Taylor et al. 2002; Taylor et al. 2003; Taylor et al. 2005; 
Pinteaux-Jones et al. 2008). However, little research has been performed on the role of 
the group I receptors in mediating neuroprotection or toxicity. Other laboratories have 
identified group I mGluR5 activation as a neuroprotective mechanism in culture models 
of microglial-mediated inflammation (Byrnes et al. 2009a; Loane et al. 2009), glutamate 
excitotoxicity (Montoliu et al. 1997), and Aβ-mediated neurotoxicity (Movsesyan et al. 
2004), as well as in vivo spinal cord injury studies (Byrnes et al. 2009b). The third 
section of my thesis relates to studies performed to identify if the FG- and FN-mediated 
neurotoxicity could be attenuated by specific mGluR activation. 
The majority of repeated studies here supported the previous work, in particular the 
observation that activation of all group II mGluRs induced significant microglial death 
as well as enhanced neuronal toxicity, but sole activation of group II mGluR3 was 
protective (Taylor et al. 2005). As previously discussed, FG-mediated iNOS expression 
could be induced if cultures were treated in serum-free conditions. Therefore, this 
manipulation of culture conditions was used to identify whether activation of mGluRs 
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could modulate the iNOS and ED-1 expression induced by FG in serum-free 
conditions. In contrast to previously published findings (Byrnes et al. 2009a; Loane et 
al. 2009), mGluR5 activation did not downregulate LPS-mediated microglial activation. 
However, this may be due to the mechanism of action of CDPPB, used here, which is a 
positive allosteric modulator of mGluR5 rather than a classic orthosteric agonist such 
as (RS)-2-chloro-5-hydroxyphenylglycine (CHPG), used in the cited studies (Byrnes et 
al. 2009a; Loane et al. 2009), although significant down-regulation was observed with 
DHPG, a group I orthosteric agonist. 
As well as identifying possible neuroprotection from FG- and FN-mediated toxicity via 
activation of mGluR3, it was shown that FG-mediated neurotoxicity could be attenuated 
by positive allosteric modulation of mGluR5. Furthermore, unlike orthosteric binding 
sites which are often highly conserved across members of a single GPCR subfamily, 
making it difficult to achieve high selectivity for specific GPCR subtypes, allosteric 
binding sites (through which CDPPB acts) are highly specific for receptor subtypes 
meaning the ligands require greater selectivity and provide novel modes of efficacy 
(Conn et al. 2009). These ligand-receptor characteristics make these compounds very 
attractive from a pharmaceutical point of view. 
What is also interesting with respect to these data is that specific positive allosteric 
modulation of microglial mGluR5 attenuated FG-mediated toxicity, suggesting that if it 
were possible to target only microglial mGluR5 sufficient neuroprotection may be 
afforded. This kind of cell-specific targeting would also decrease any non-specific 
effects of chronic mGluR5 activation on neurons and other cell types. Finally, data 
presented here provides support for previous studies that suggest microglia express 
mGluR5 but not mGluR1 of the group I receptors (Biber et al. 1999). 
Translation of animal data to human models is, in many cases, an enormous hurdle. 
Due to contrasting data from genetic and system based studies, identification of 
whether certain characteristics of FG- and FN-mediated rat microglial activation could 
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be translated to a human phagocyte model in the form of monocyte-derived 
macrophages was performed. As previously described, caspase-12-associated ER 
stress is a controversial mechanism in humans due to acquired mutations in the 
caspase-12 gene (Fischer et al. 2002). However, active caspases generally undergo 
post-translational modification (Earnshaw et al. 1999) and studies have shown 
caspase-12 mediated ER stress in human models (Hetz et al. 2003), suggesting 
functionality can occur (Hetz et al. 2003; Lee et al. 2010). Here, data suggests that 
caspase-12 activation is associated with ER stress in human macrophages. 
Furthermore, FG can induce TNFα expression and caspase-3 cleavage, which is 
shown to be regulated by ER stress, correlating with to the previously presented rat 
microglia data. Researching ER stress mechanisms in vitro has received critism due to 
culture systems, upon stress induction, inducing the full UPR repertoire (Saxena & 
Caroni 2011), which is not seen in vivo. However, this more extensive UPR induction in 
vitro has been suggested as another function of the UPR involved in regulating basal 
cellular homeostasis, independent of the classic induction via protein mis-folding 
(Rutkowski & Hegde 2010). This is supported by recent studies that identified an ER 
stress associated transcription factor was regulating TLR signalling, with genetic 
ablation attenuating LPS-mediated cytokine expression in macrophages (Woo et al. 
2009; Martinon et al. 2010). 
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  Figure 7.1.1. Summary of results 
A. Overview of the proposed mechanism by which FN deposits induce the observed 
detrimental effects. FN can induce microglial death leading to an increase in 
inflammation through an increase in iNOS activity and the release of TNFα and IL-6, 
which in turn may mediate the observed neuronal death. These effects may be 
mediated through CD11b and scavenger receptor-A ligation. Activation of microglial 
group I mGluRs and mGluR3 but also neuronal positive allosteric modulation of 
mGluR5 can mediate neuroprotection. FN also induces direct neurotoxicity in the 
absence of microglia.  
B. Overview of the proposed mechanisms by which soluble FG mediates the observed 
microglial activation and subsequent neurotoxicity. FG induced significant calpain 
activation upstream of ER stress pathway activation, identified via caspase-12 and 
CHOP induction, which in turn was found to be upstream of non-apoptotic microglial 
caspase-3/7 activation and subsequent TNFα release leading to neuronal death, with 
some dependence on MAPK pathway activation. Positive allosteric modulation of 
microglial mGluR5, but also neuronal mGluR5 and orthosteric agonism of mGluR3 
could mediate neuroprotection. Question marks are associated with specific areas of 
the pathways that gave conflicting data or that would require much greater in depth 
investigation before concluding significant involvement. 
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7.1. Future work 
The observations made here that FG-mediated induction of an activated microglial 
phenotype with regulation from ER stress are novel and require further 
characterisation. Listed below are future studies that would enable greater 
understanding of the pathways induced in microglia after FG treatment: 
• Extensive calcium imaging to identify the role of this signalling molecule in 
both FG-mediated microglial activation and the subsequent loss of neuronal 
integrity    
• Microarray studies on primary rat microglia and human macrophage cultures 
after fibrinogen treatment to allow full correlation analysis between the 
culture models with the added benefit of potentially uncovering further 
intrinsic members of the activation signalling cascades 
• Initial elucidation of the mechanisms by which soluble fibrinogen interacts 
with microglia, i.e. with respect to the induced cytokine release, does 
fibrinogen signal through the TLRs? 
• Studies focussing on the role of mitochondria in the observed signalling 
pathways 
• Development and optimisation of RNAi studies to enable functional 
knockdown of proteins of interest in microglia without the use of 
pharmacology and all its non-specific effects 
• Further characterisation of the hMΦ preparation including studies to identify 
transcription regulators and the relevant extrinsic support factors that could 
potentially allow greater refinement of the culture to further mimic human 
microglia. This could lead to studies comparing healthy human ‘microglia’ to 
diseased ‘microglia’, using simple phlebotomy allowing characterisation of 
microglia at all stages of disease rather than just end-stage, with respect to 
post-mortem cultures. 
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• Following on from the last point, research published on the conversion of 
human fibroblasts or somatic cells back to pluripotent stem cells that could 
be differentiated (Takahashi et al. 2007; Yu et al. 2007), suggests that upon 
acquiring the relevant transcription regulator and extrinsic support factor 
knowledge it could be possible to induce microglia from healthy as well as 
diseased individuals for comprehensive signalling analysis. 
7.2. Conclusions 
In conclusion, this thesis has provided, for the first time, characterisation of soluble 
fibrinogen-mediated microglial activation, a mechanism with potentially important 
consequences. Specifically it is shown here that FG- and FN-mediated toxicity is 
independent of iNOS activity, an important point with respect to the translation of these 
data to human studies. Identification of non-apoptotic caspase cleavage is also a novel 
mechanism, which was subsequently reported earlier this year (Burguillos et al. 2011; 
Venero et al. 2011). However, FG induction of non-apoptotic caspase activation is 
described here for the first time. The development of a microglial depletion technique 
for use on the CGC cultures allowed us to perform more physiologically relevant 
studies and enabled us to show the significant potency of a small population of 
microglia with respect to mediated neurotoxicity. ER stress mechanisms have also 
been identified and coupled to the FG-mediated activation of microglia, as well as 
suggestions that this stress pathway is also induced in neurons possibly after calcium 
dyshomeostasis due to non-cell autonomous factors. Furthermore, regulation of FG-
mediated cytokine expression and release has been afforded to ER stress induction in 
rat microglia which was translated in hMΦ studies. Finally data presented here shows 
for the first time that specific positive allosteric modulation of the mGluR5 receptor can 
protect neurons from microglial-dependent FG-mediated toxicity.  
It is understood that basic neuroscience does not directly or immediately offer 
therapeutic benefit to suffers of neurodegenerative disease however, it is hoped that 
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further elucidation of pathways such as those described in this thesis will lead to a 
greater understanding of neurodegenerative disease pathogenesis which in turn could 
lead to more effective and efficacious treatments for patients suffering from an array of 
diseases that encompass common pathological events.   
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9. Drug Glossary 
Drug Name Abbreviation Action 
2-Amino-5,6-dihydro-6-
methyl-4H-1,3-thiazine 
hydrochloride 
AMT-HCl or AMT iNOS activity inhibitor 
Apocynin APO NADPH oxidase inhibitor 
1,2-Bis(2-
aminophenoxy)ethane-
N,N,N',N'-tetraacetic acid 
tetrakis(acetoxymethyl ester) 
BAPTA-AM or BAPTA Ca2+ chelator 
Calpastatin Cal Calpain inhibitor 
Anti-CD11b antibody CD11b 
CD11b receptor blocking 
antibody 
3-Cyano-N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamide CDPPB 
mGluR5 positive allosteric 
modulator (agonist; group I) 
(2S,2'R,3'R)-2-(2',3'-
Dicarboxycyclopropyl)glycine DCGIV Group II mGluR agonist 
(S)-3,5-
Dihydroxyphenylglycine 
DHPG Group I mGluR agonist 
Fucoidan Fu Scavenger receptor A ligand 
Hirudin Hi Thrombin activity inhibitor 
Interferon-γ IFNγ 
Pro-inflammatory cytokine – 
activator of microglia 
Ionomycin Ion Ca2+ ionophore 
(L)-2-amino-4-phosphono-
butyric acid 
L-AP4 Group III mGluR agonist 
Leucine-methyl-ester LME 
Lysosomatropic agent 
inducing toxicity in 
phagocytes 
Lipopolysachharide  LPS 
Classical microglial 
inflammatory activator  
3-((2-Methyl-4-
thiazolyl)ethynyl)pyridine MTEP mGluR5 antagonist 
N-acetyl-L-aspartyl-L-
glutamate 
NAAG mGluR3 agonist (group II) 
PD98059 PD ERK1/2 inhibitor  
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Phorbol 12-myristate 13-
acetate 
PMA NADPH oxidase activator 
Polymyxin B  PMX LPS activity inhibitor  
Salubrinal Sal 
ER stress inhibitor via 
eIF2α-associated pathways 
SB203580 SB P38 MAPK inhibitor  
Staurosporine STS 
Inducer of the intrinsic 
pathway of apoptosis 
Thapsigargin Th 
ER stress activator via 
inhibition of Ca2+/ATPase 
Thalidomide Thal TNFα synthesis inhibitor  
Tunicamycin Tu 
ER stress activator via 
inhibition of N-glycosylation 
Wortmannin Wort PI3K inhibitor  
carbobenzoxy-Val-Ala-
Asp(OME)-
fluoromethylketone 
z-VAD-FMK or z-VAD Caspase-3/7 inhibitor 
carbobenzoxy -Ala-Thr-Ala-
Asp(OME)-
fluoromethylketone 
z-ATAD-FMK or z-
ATAD 
Caspase-12 inhibitor 
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